



(43) International Publication Date
28 April 2016 (28.04.2016)

(10) International Publication Number
WO 2016/064877 A2

- (51) International Patent Classification:
G01N 33/53 (2006.01)
- (21) International Application Number:
PCT/US2015/056462
- (22) International Filing Date:
20 October 2015 (20.10.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/066,316 20 October 2014 (20.10.2014) US
62/066,313 20 October 2014 (20.10.2014) US
62/066,310 20 October 2014 (20.10.2014) US
- (71) Applicant: **ASTUTE MEDICAL, INC.** [US/US]; Bldg 2,
R. 645, 3550 General Atomics Court, San Diego, CA
92121 (US).
- (72) Inventors: **ANDERBERG, Joseph**; 470 Delage Court,
Encinitas, CA 92024 (US). **McPHERSON, Paul**; 1449
Elva Court, Encinitas, CA 92024 (US). **GRAY, Jeff**; 417
Bay Meadows Way, Solana Beach, CA 92075 (US). **NA-
KAMURA, Kevin**; 2409 Newcastle Ave, Cardiff by the
Sea, CA 92007 (US). **KAMPF, James, Patrick**; 5882
Gablewood Way, San Diego, CA 92130 (US). **KWAN,
Thomas**; 3950 Mahaila Ave, Unit V23, San Diego, CA
92122 (US).
- (74) Agents: **WHITTAKER, Michael, A.** et al.; Acuity Law
Group, P.C., 12707 High Bluff Drive, Suite 200, San
Diego, CA 92130 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).
- Published:
— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*

(54) Title: METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

(57) Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO as diagnostic and prognostic biomarker assays in renal injuries.



WO 2016/064877 A2

**METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF
RENAL INJURY AND RENAL FAILURE**

[0001] This application claims the benefit of U.S. Provisional Application No. 62/066,310 filed October 20, 2014; and of U.S. Provisional Application No. 62/066,313 filed October 20, 2014; and of U.S. Provisional Application No. 62/066,316 filed October 20, 2014; each of which is hereby incorporated in its entirety including all tables, figures, and claims.

BACKGROUND OF THE INVENTION

[0002] The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the present invention.

[0003] The kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acid-base balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by reference in their entirety. Renal disease and/or injury may be acute or chronic. Acute and chronic kidney disease are described as follows (from Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, which are hereby incorporated by reference in their entirety): "Acute renal failure is worsening of renal function over hours to days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances is called azotemia. Chronic renal failure (chronic kidney disease) results from an abnormal loss of renal function over months to years".

[0004] Acute renal failure (ARF, also known as acute kidney injury, or AKI) is an abrupt (typically detected within about 48 hours to 1 week) reduction in glomerular filtration. This loss of filtration capacity results in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products that are normally excreted by the kidney, a reduction in urine output, or both. It is reported that ARF complicates about 5% of hospital admissions, 4-15% of cardiopulmonary bypass surgeries, and up to 30% of

intensive care admissions. ARF may be categorized as prerenal, intrinsic renal, or postrenal in causation. Intrinsic renal disease can be further divided into glomerular, tubular, interstitial, and vascular abnormalities. Major causes of ARF are described in the following table, which is adapted from the Merck Manual, 17th ed., Chapter 222, and which is hereby incorporated by reference in their entirety:

Type	Risk Factors
Prerenal	
ECF volume depletion	Excessive diuresis, hemorrhage, GI losses, loss of intravascular fluid into the extravascular space (due to ascites, peritonitis, pancreatitis, or burns), loss of skin and mucus membranes, renal salt- and water-wasting states
Low cardiac output	Cardiomyopathy, MI, cardiac tamponade, pulmonary embolism, pulmonary hypertension, positive-pressure mechanical ventilation
Low systemic vascular resistance	Septic shock, liver failure, antihypertensive drugs
Increased renal vascular resistance	NSAIDs, cyclosporines, tacrolimus, hypercalcemia, anaphylaxis, anesthetics, renal artery obstruction, renal vein thrombosis, sepsis, hepatorenal syndrome
Decreased efferent arteriolar tone (leading to decreased GFR from reduced glomerular transcapillary pressure, especially in patients with bilateral renal artery stenosis)	ACE inhibitors or angiotensin II receptor blockers
Intrinsic Renal	
Acute tubular injury	Ischemia (prolonged or severe prerenal state): surgery, hemorrhage, arterial or venous obstruction; Toxins: NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, streptozotocin
Acute glomerulonephritis	ANCA-associated: Crescentic glomerulonephritis, polyarteritis nodosa, Wegener's granulomatosis; Anti-GBM glomerulonephritis: Goodpasture's syndrome; Immune-complex: Lupus glomerulonephritis, postinfectious glomerulonephritis, cryoglobulinemic glomerulonephritis
Acute tubulointerstitial nephritis	Drug reaction (eg, β -lactams, NSAIDs, sulfonamides, ciprofloxacin, thiazide diuretics, furosemide, phenytoin, allopurinol, pyelonephritis, papillary necrosis)
Acute vascular nephropathy	Vasculitis, malignant hypertension, thrombotic microangiopathies, scleroderma, atheroembolism
Infiltrative diseases	Lymphoma, sarcoidosis, leukemia

Type	Risk Factors
Postrenal	
Tubular precipitation	Uric acid (tumor lysis), sulfonamides, triamterene, acyclovir, indinavir, methotrexate, ethylene glycol ingestion, myeloma protein, myoglobin
Ureteral obstruction	Intrinsic: Calculi, clots, sloughed renal tissue, fungus ball, edema, malignancy, congenital defects; Extrinsic: Malignancy, retroperitoneal fibrosis, ureteral trauma during surgery or high impact injury
Bladder obstruction	Mechanical: Benign prostatic hyperplasia, prostate cancer, bladder cancer, urethral strictures, phimosis, paraphimosis, urethral valves, obstructed indwelling urinary catheter; Neurogenic: Anticholinergic drugs, upper or lower motor neuron lesion

[0005] In the case of ischemic ARF, the course of the disease may be divided into four phases. During an initiation phase, which lasts hours to days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs. Renal injury can be mediated during this phase by reperfusion of the kidney. Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion. During the maintenance phase, lasting from 1 to 2 weeks, renal cell injury occurs, and glomerular filtration and urine output reaches a minimum. A recovery phase can follow in which the renal epithelium is repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%.

[0006] Acute kidney injury caused by radiocontrast agents (also called contrast media) and other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of days to about a week. Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells. CIN classically presents as an acute (onset within 24-48h) but reversible (peak 3-5 days, resolution within 1 week) rise in blood urea nitrogen and serum creatinine.

[0007] A commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 days or within a period of hospitalization) elevation of serum

creatinine. Although the use of serum creatinine elevation to define and detect AKI is well established, the magnitude of the serum creatinine elevation and the time over which it is measured to define AKI varies considerably among publications. Traditionally, relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 2 mg/dL and other definitions were used to define AKI. However, the recent trend has been towards using smaller serum creatinine rises to define AKI. The relationship between serum creatinine rise, AKI and the associated health risks are reviewed in Praught and Shlipak, *Curr Opin Nephrol Hypertens* 14:265-270, 2005 and Chertow et al, *J Am Soc Nephrol* 16: 3365-3370, 2005, which, with the references listed therein, are hereby incorporated by reference in their entirety. As described in these publications, acute worsening renal function (AKI) and increased risk of death and other detrimental outcomes are now known to be associated with very small increases in serum creatinine. These increases may be determined as a relative (percent) value or a nominal value. Relative increases in serum creatinine as small as 20% from the pre-injury value have been reported to indicate acutely worsening renal function (AKI) and increased health risk, but the more commonly reported value to define AKI and increased health risk is a relative increase of at least 25%. Nominal increases as small as 0.3 mg/dL, 0.2 mg/dL or even 0.1 mg/dL have been reported to indicate worsening renal function and increased risk of death. Various time periods for the serum creatinine to rise to these threshold values have been used to define AKI, for example, ranging from 2 days, 3 days, 7 days, or a variable period defined as the time the patient is in the hospital or intensive care unit. These studies indicate there is not a particular threshold serum creatinine rise (or time period for the rise) for worsening renal function or AKI, but rather a continuous increase in risk with increasing magnitude of serum creatinine rise.

[0008] One study (Lassnigg et al, *J Am Soc Nephrol* 15:1597-1605, 2004, hereby incorporated by reference in its entirety) investigated both increases and decreases in serum creatinine. Patients with a mild fall in serum creatinine of -0.1 to -0.3 mg/dL following heart surgery had the lowest mortality rate. Patients with a larger fall in serum creatinine (more than or equal to -0.4 mg/dL) or any increase in serum creatinine had a larger mortality rate. These findings caused the authors to conclude that even very subtle changes in renal function (as detected by small creatinine changes within 48 hours of surgery) seriously effect patient's outcomes. In an effort to reach consensus on a unified classification system for using serum creatinine to define AKI in clinical trials and in

clinical practice, Bellomo *et al.*, *Crit Care*. 8(4):R204-12, 2004, which is hereby incorporated by reference in its entirety, proposes the following classifications for stratifying AKI patients:

“Risk”: serum creatinine increased 1.5 fold from baseline OR urine production of <0.5 ml/kg body weight/hr for 6 hours;

“Injury”: serum creatinine increased 2.0 fold from baseline OR urine production <0.5 ml/kg/hr for 12 h;

“Failure”: serum creatinine increased 3.0 fold from baseline OR creatinine >355 μ mol/l (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h or anuria for at least 12 hours;

And included two clinical outcomes:

“Loss”: persistent need for renal replacement therapy for more than four weeks.

“ESRD”: end stage renal disease—the need for dialysis for more than 3 months.

These criteria are called the RIFLE criteria, which provide a useful clinical tool to classify renal status. As discussed in Kellum, *Crit. Care Med.* 36: S141-45, 2008 and Ricci *et al.*, *Kidney Int.* 73, 538-546, 2008, each hereby incorporated by reference in its entirety, the RIFLE criteria provide a uniform definition of AKI which has been validated in numerous studies.

[0009] More recently, Mehta *et al.*, *Crit. Care* 11:R31 (doi:10.1186.cc5713), 2007, hereby incorporated by reference in its entirety, proposes the following similar classifications for stratifying AKI patients, which have been modified from RIFLE:

“Stage I”: increase in serum creatinine of more than or equal to 0.3 mg/dL (≥ 26.4 μ mol/L) or increase to more than or equal to 150% (1.5-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 6 hours;

“Stage II”: increase in serum creatinine to more than 200% (> 2-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 12 hours;

“Stage III”: increase in serum creatinine to more than 300% (> 3-fold) from baseline OR serum creatinine ≥ 354 μ mol/L accompanied by an acute increase of at least 44 μ mol/L OR urine output less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours.

[0010] The CIN Consensus Working Panel (McCollough et al, Rev Cardiovasc Med. 2006;7(4):177-197, hereby incorporated by reference in its entirety) uses a serum creatinine rise of 25% to define Contrast induced nephropathy (which is a type of AKI). Although various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small changes in serum creatinine, such as 0.3 mg/dL or 25%, are sufficient to detect AKI (worsening renal function) and that the magnitude of the serum creatinine change is an indicator of the severity of the AKI and mortality risk.

[0011] Although serial measurement of serum creatinine over a period of days is an accepted method of detecting and diagnosing AKI and is considered one of the most important tools to evaluate AKI patients, serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients. The time period for serum creatinine to rise to values (e.g., a 0.3 mg/dL or 25% rise) considered diagnostic for AKI can be 48 hours or longer depending on the definition used. Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI. Furthermore, serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Some patients with AKI will recover fully, some will need dialysis (either short term or long term) and some will have other detrimental outcomes including death, major adverse cardiac events and chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited. Knowing these things can be of vital importance in managing and treating patients with AKI.

[0012] These limitations underscore the need for better methods to detect and assess AKI, particularly in the early and subclinical stages, but also in later stages when recovery and repair of the kidney can occur. Furthermore, there is a need to better identify patients who are at risk of having an AKI.

BRIEF SUMMARY OF THE INVENTION

[0013] It is an object of the invention to provide methods and compositions for evaluating renal function in a subject. As described herein, measurement of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO (collectively referred to herein as “kidney injury markers, and individually as a “kidney injury marker”) can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure (also called acute kidney injury).

[0014] These kidney injury markers may be used, individually or in panels comprising a plurality of kidney injury markers, for risk stratification (that is, to identify subjects at risk for a future injury to renal function, for future progression to reduced renal function, for future progression to ARF, for future improvement in renal function, *etc.*); for diagnosis of existing disease (that is, to identify subjects who have suffered an injury to renal function, who have progressed to reduced renal function, who have progressed to ARF, *etc.*); for monitoring for deterioration or improvement of renal function; and for predicting a future medical outcome, such as improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require renal replacement therapy (*i.e.*, hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end stage renal disease, a decreased or increased risk that a subject will progress to chronic renal failure, a decreased or increased risk that a subject will suffer rejection of a transplanted kidney, *etc.*

[0015] In a first aspect, the present invention relates to methods for evaluating renal status in a subject. These methods comprise performing an assay method that is configured to detect one or more kidney injury markers of the present invention in a body fluid sample obtained from the subject. The assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO,

is/are then correlated to the renal status of the subject. This correlation to renal status may include correlating the assay result(s) to one or more of risk stratification, diagnosis, prognosis, staging, classifying and monitoring of the subject as described herein. Thus, the present invention utilizes one or more kidney injury markers of the present invention for the evaluation of renal injury.

[0016] In certain embodiments, the methods for evaluating renal status described herein are methods for risk stratification of the subject; that is, assigning a likelihood of one or more future changes in renal status to the subject. In these embodiments, the assay result(s) is/are correlated to one or more such future changes. The following are preferred risk stratification embodiments.

[0017] In preferred risk stratification embodiments, these methods comprise determining a subject's risk for a future injury to renal function, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to a likelihood of such a future injury to renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0018] In other preferred risk stratification embodiments, these methods comprise determining a subject's risk for future reduced renal function, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to a likelihood of such reduced renal function. For example, the measured concentrations may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of suffering a future reduced renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood

of future reduced renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0019] In still other preferred risk stratification embodiments, these methods comprise determining a subject's likelihood for a future improvement in renal function, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to a likelihood of such a future improvement in renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold. For a "negative going" kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold.

[0020] In yet other preferred risk stratification embodiments, these methods comprise determining a subject's risk for progression to ARF, and the result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to a likelihood of such progression to ARF. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0021] And in other preferred risk stratification embodiments, these methods comprise determining a subject's outcome risk, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to a likelihood of the occurrence of a clinical outcome related to a

renal injury suffered by the subject. For example, the measured concentration(s) may each be compared to a threshold value. For a “positive going” kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, *etc.*, is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a “negative going” kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, *etc.*, is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.

[0022] In such risk stratification embodiments, preferably the likelihood or risk assigned is that an event of interest is more or less likely to occur within 180 days of the time at which the body fluid sample is obtained from the subject. In particularly preferred embodiments, the likelihood or risk assigned relates to an event of interest occurring within a shorter time period such as 18 months, 120 days, 90 days, 60 days, 45 days, 30 days, 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less. A risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition.

[0023] In preferred risk stratification embodiments, the subject is selected for risk stratification based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF. For example, a subject undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery; a subject having pre-existing congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, or sepsis; or a subject exposed to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin are all preferred subjects for monitoring risks according to the methods described herein. This list is not

meant to be limiting. By “pre-existence” in this context is meant that the risk factor exists at the time the body fluid sample is obtained from the subject. In particularly preferred embodiments, a subject is chosen for risk stratification based on an existing diagnosis of injury to renal function, reduced renal function, or ARF.

[0024] In other embodiments, the methods for evaluating renal status described herein are methods for diagnosing a renal injury in the subject; that is, assessing whether or not a subject has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status. The following are preferred diagnostic embodiments.

[0025] In preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of an injury to renal function, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to the occurrence or nonoccurrence of such an injury. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0026] In other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of reduced renal function, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-

protein kinase receptor UFO, is/are correlated to the occurrence or nonoccurrence of an injury causing reduced renal function. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0027] In yet other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of ARF, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to the occurrence or nonoccurrence of an injury causing ARF. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased

likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0028] In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal replacement therapy, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to a need for renal replacement therapy. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0029] In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal transplantation, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to a need for renal transplantation. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is

below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).

[0030] In still other embodiments, the methods for evaluating renal status described herein are methods for monitoring a renal injury in the subject; that is, assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to the occurrence or nonoccurrence of a change in renal status. The following are preferred monitoring embodiments.

[0031] In preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from an injury to renal function, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0032] In other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from reduced renal function, and the assay

result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0033] In yet other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from acute renal failure, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0034] In other additional preferred monitoring embodiments, these methods comprise monitoring renal status in a subject at risk of an injury to renal function due to the pre-existence of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal

function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.

[0035] In yet other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject having, or at risk of, an injury to renal function for future persistence of acute kidney injury. "Future persistence" as used herein refers to an existing acute renal injury that will continue for a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours. In certain embodiments the subject has an acute kidney injury at the time the sample is obtained. This is not meant to imply that the subject must have an acute kidney injury at the time the sample is obtained, but rather that the subject, upon onset of an acute kidney injury, suffers from an acute kidney injury that will persist. In various embodiments, the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to the future persistence of the acute kidney injury in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a future persistence of acute kidney injury may be assigned to the subject; alternatively, when the measured concentration is below the threshold, a future improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a future persistence of acute kidney injury may be assigned to the subject; alternatively, when the measured concentration is above the threshold, a future improvement of renal function may be assigned to the subject.

[0036] In still other embodiments, the methods for evaluating renal status described herein are methods for classifying a renal injury in the subject; that is, determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a

particular RIFLE stage. In these embodiments, the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to a particular class and/or subclass. The following are preferred classification embodiments.

[0037] In preferred classification embodiments, these methods comprise determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage, and the assay result(s), for example a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and/or Tyrosine-protein kinase receptor UFO, is/are correlated to the injury classification for the subject. For example, the measured concentration may be compared to a threshold value, and when the measured concentration is above the threshold, a particular classification is assigned; alternatively, when the measured concentration is below the threshold, a different classification may be assigned to the subject.

[0038] A variety of methods may be used by the skilled artisan to arrive at a desired threshold value for use in these methods. For example, the threshold value may be determined from a population of normal subjects by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such normal subjects. Alternatively, the threshold value may be determined from a “diseased” population of subjects, e.g., those suffering from an injury or having a predisposition for an injury (e.g., progression to ARF or some other clinical outcome such as death, dialysis, renal transplantation, *etc.*), by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such subjects. In another alternative, the threshold value may be determined from a prior measurement of a kidney injury marker in the same subject; that is, a temporal change in the level of a kidney injury marker in the subject may be used to assign risk to the subject.

[0039] The foregoing discussion is not meant to imply, however, that the kidney injury markers of the present invention must be compared to corresponding individual thresholds. Methods for combining assay results can comprise the use of multivariate

logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, calculating ratios of markers, *etc.* This list is not meant to be limiting. In these methods, a composite result which is determined by combining individual markers may be treated as if it is itself a marker; that is, a threshold may be determined for the composite result as described herein for individual markers, and the composite result for an individual patient compared to this threshold.

[0040] The ability of a particular test to distinguish two populations can be established using ROC analysis. For example, ROC curves established from a “first” subpopulation which is predisposed to one or more future changes in renal status, and a “second” subpopulation which is not so predisposed can be used to calculate a ROC curve, and the area under the curve provides a measure of the quality of the test. Preferably, the tests described herein provide a ROC curve area greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95.

[0041] In certain aspects, the measured concentration of one or more kidney injury markers, or a composite of such markers, may be treated as continuous variables. For example, any particular concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc. In yet another alternative, a threshold that can provide an acceptable level of specificity and sensitivity in separating a population of subjects into “bins” such as a “first” subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a “second” subpopulation which is not so predisposed. A threshold value is selected to separate this first and second population by one or more of the following measures of test accuracy: an odds ratio greater than 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a specificity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more

preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;

a sensitivity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding specificity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;

at least about 75% sensitivity, combined with at least about 75% specificity;

a positive likelihood ratio (calculated as $\text{sensitivity}/(1-\text{specificity})$) of greater than 1, at least about 2, more preferably at least about 3, still more preferably at least about 5, and most preferably at least about 10; or

a negative likelihood ratio (calculated as $(1-\text{sensitivity})/\text{specificity}$) of less than 1, less than or equal to about 0.5, more preferably less than or equal to about 0.3, and most preferably less than or equal to about 0.1.

The term “about” in the context of any of the above measurements refers to $\pm 5\%$ of a given measurement.

[0042] Multiple thresholds may also be used to assess renal status in a subject. For example, a “first” subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., and a “second” subpopulation which is not so predisposed can be combined into a single group. This group is then subdivided into three or more equal parts (known as tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1. The second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile. The third tertile is also assigned an odds ratio that is relative to that first tertile.

[0043] In certain embodiments, the assay method is an immunoassay. Antibodies for use in such assays will specifically bind a full length kidney injury marker of interest, and may also bind one or more polypeptides that are “related” thereto, as that term is defined hereinafter. Numerous immunoassay formats are known to those of skill in the art. Preferred body fluid samples are selected from the group consisting of urine, blood, serum, saliva, tears, and plasma.

[0044] The foregoing method steps should not be interpreted to mean that the kidney injury marker assay result(s) is/are used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, a risk stratification, diagnostic, classification, monitoring, etc. method may combine the assay result(s) with one or more variables measured for the subject selected from the group consisting of demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatinine ratio, a renal failure index calculated as $\text{urine sodium} / (\text{urine creatinine} / \text{plasma creatinine})$, a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concentration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration. Other measures of renal function which may be combined with one or more kidney injury marker assay result(s) are described hereinafter and in Harrison’s Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, and

Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.

[0045] When more than one marker is measured, the individual markers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times. The individual markers may also be measured on the same or different body fluid samples. For example, one kidney injury marker may be measured in a serum or plasma sample and another kidney injury marker may be measured in a urine sample. In addition, assignment of a likelihood may combine an individual kidney injury marker assay result with temporal changes in one or more additional variables.

[0046] In various related aspects, the present invention also relates to devices and kits for performing the methods described herein. Suitable kits comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the described threshold comparisons.

[0047] In certain embodiments, reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit. Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support. In the case of sandwich immunoassays, such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter.

[0048] Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ecl (electrochemical luminescence) labels, metal chelates, colloidal metal particles, *etc.*) as well as molecules that may be indirectly detected by production of a detectable reaction product (*e.g.*, enzymes such as horseradish peroxidase, alkaline phosphatase, *etc.*) or through the use of a specific binding molecule which itself may be detectable (*e.g.*, a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dinitrobenzene, phenylarsenate, ssDNA, dsDNA, *etc.*).

[0049] Generation of a signal from the signal development element can be performed using various optical, acoustical, and electrochemical methods well known in

the art. Examples of detection modes include fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, *etc.* In certain of these methods, the solid phase antibody is coupled to a transducer (*e.g.*, a diffraction grating, electrochemical sensor, *etc.*) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (*e.g.*, a fluorometer that employs an excitation light source and an optical detector). This list is not meant to be limiting. Antibody-based biosensors may also be employed to determine the presence or amount of analytes that optionally eliminate the need for a labeled molecule.

DETAILED DESCRIPTION OF THE INVENTION

[0050] The present invention relates to methods and compositions for diagnosis, differential diagnosis, risk stratification, monitoring, classifying and determination of treatment regimens in subjects suffering or at risk of suffering from injury to renal function, reduced renal function and/or acute renal failure through measurement of one or more kidney injury markers. In various embodiments, a measured concentration of one or more markers selected from the group consisting of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO or one or more markers related thereto, and optionally one or more additional kidney injury markers known in the art, are correlated to the renal status of the subject.

[0051] For purposes of this document, the following definitions apply:

As used herein, an “injury to renal function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury may be identified, for example, by a decrease in glomerular filtration rate or estimated GFR, a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy, *etc.* “Improvement in Renal Function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter.

As used herein, “reduced renal function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of

greater than or equal to 0.1 mg/dL ($\geq 8.8 \mu\text{mol/L}$), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour).

As used herein, “acute renal failure” or “ARF” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl ($\geq 26.4 \mu\text{mol/l}$), a percentage increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours). This term is synonymous with “acute kidney injury” or “AKI.”

[0052] In this regard, the skilled artisan will understand that the signals obtained from an immunoassay are a direct result of complexes formed between one or more antibodies and the target biomolecule (*i.e.*, the analyte) and polypeptides containing the necessary epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such “immunoreactive” polypeptides present in the sample. Expression of biomarkers may also be determined by means other than immunoassays, including protein measurements (such as dot blots, western blots, chromatographic methods, mass spectrometry, *etc.*) and nucleic acid measurements (mRNA quantitation). This list is not meant to be limiting.

[0053] As used herein, the term “C-C motif chemokine 16” refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 16 precursor (human sequence: Swiss-Prot O15467 (SEQ ID NO: 1)):

```

MKVSEAALSL LVLILIITSA SRSQPKVPEW VNTPTCCLK YYEKVLPRL    50
VVG YRKALNC HLP AII FVTK RNREVCTNPN DDWVQEYIKD PNLPLLPTRN 100
LSTVKIITAK NGQPQLLNSQ                                     120

```

[0054] The following domains have been identified in C-C motif chemokine 16:

Residues	Length	Domain ID
1-23	23	Signal peptide
24-120	97	C-C motif chemokine 16

[0055] As used herein, the term “C-C motif chemokine 14” refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 14 precursor (human sequence: Swiss-Prot Q16627 (SEQ ID NO: 1)):

```

MKISVAAIPF FLLITIALGT KTESSSRGPY HPSECCFTYT TYKIPRQRIM    50
DYYETNSQCS KPGIVFITKR GHSVCTNPSD K WVQDYIKDM KEN          93

```

[0056] The following domains have been identified in C-C motif chemokine 14:

Residues	Length	Domain ID
1-19	19	Signal peptide
20-93	74	C-C motif chemokine 14
22-93	72	HCC-1(3-74)
23-93	71	HCC-1(4-74)
28-93	66	HCC-1(9-74)
27		R → QTGGKPKVVKIQLKLVG (SEQ ID NO: 2) in isoform 2

[0057] As used herein, the term “Tyrosine-protein kinase receptor UFO” refers to one or more polypeptides present in a biological sample that are derived from the Tyrosine-protein kinase receptor UFO precursor (human sequence: Swiss-Prot P30530 (SEQ ID NO: 1)):

```

MAWRCPRMGR VPLAWCLALC GWACMAPRGT QAEESPFVGN PGNITGARGL    50
TGTLRCQLQV QGEPPEVHWL RDGQILELAD STQTQVPLGE DEQDDWIVVS    100
QLRITSLQLS DTGQYQCLVF LGHQTFVSQP GYVGLEGLPY FLEEPEDRTV    150
AANTPFNLSC QAQGPPEPVD LLWLQDAVPL ATAPGHGPQR SLHVPGLNKT    200
SSFSCAHNA KGVTTSTRAT ITVLPQQPRN LHLVSRQPTE LEVAWTPGLS    250
GIYPLTHCTL QAVLSNDGMG IQAGEPDPPE EPLTSQASVP PHQLRLGSLH    300
PHTPYHIRVA CTSSQGPSSW THWLPVETPE GVPLGPPENI SATRNGSQAF    350
VHWQEPRAPL QGTLLGYRLA YQGQDTPEVL MDIGLRQEV LELQGDGSVS    400
NLTVCAAYT AAGDGPWSLP VPLEAWRPGQ AQPVHQLVKE PSTPAFSPWP    450
WYVLLGAVVA AACVLILALF LVHRRKKETR YGEVFEPTVE RGELVVRVYRV    500
RKSYSRRTE ATLNSLGI SE ELKEKL RDVM VDRHKVALGK TLGEGEFGAV    550
MEGQLNQDDS ILKVAVKTMK IAICTRSELE DFLSEAVCMK EFDHPNVMRL    600
IGVCFQGSER ESFPAPVVIL PFMKHGDLHS FLLYSRLGDQ PVYLP TQMLV    650
KFMADIASGM EYLSTKRFIH RDLAARNCML NENMSVCVAD FGLSKKIYNG    700

```

DYYRQGRIAK	MPVKWIAIES	LADRVYTSKS	DVWSFGVTMW	EIATRGQTPY	750
PGVENSEIYD	YLRQGNRLKQ	PADCLDGLYA	LMSRCWELNP	QDRPSFTELR	800
EDLENTLKAL	PPAQEPDEIL	YVNMDEGGGY	PEPPGAAGGA	DPPTQPDPKD	850
SCSCLTAAEV	HPAGRYVLCP	STTPSPAQPA	DRGSPAAPGQ	EDGA	894

[0058] In certain embodiments, the Tyrosine-protein kinase receptor UFO assay detects one or more soluble forms of Tyrosine-protein kinase receptor UFO. Tyrosine-protein kinase receptor UFO is a single-pass membrane protein having an extracellular domain which may be found in Tyrosine-protein kinase receptor UFO forms of Tyrosine-protein kinase receptor UFO generated by proteolysis of the membrane-bound form or by alternative splicing. In the case of an immunoassay, one or more antibodies that bind to epitopes within an extracellular domain may be used to detect these Tyrosine-protein kinase receptor UFO form(s). The following domains have been identified in Tyrosine-protein kinase receptor UFO:

Residues	Length	Domain ID
1-25	25	Signal peptide
26-894	869	Tyrosine-protein kinase receptor UFO
473-894	422	cytoplasmic domain
452-472	21	transmembrane domain
26-451	426	extracellular domain
429-437		Missing in isoform 2

[0059] As used herein, the term “relating a signal to the presence or amount” of an analyte reflects this understanding. Assay signals are typically related to the presence or amount of an analyte through the use of a standard curve calculated using known concentrations of the analyte of interest. As the term is used herein, an assay is “configured to detect” an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte. Because an antibody epitope is on the order of 8 amino acids, an immunoassay configured to detect a marker of interest will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or antibodies used in the assay.

[0060] The term “related marker” as used herein with regard to a biomarker such as one of the kidney injury markers described herein refers to one or more fragments, variants, etc., of a particular marker or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers. The term also refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, *etc.*

[0061] The term “positive going” marker as that term is used herein refer to a marker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition. The term “negative going” marker as that term is used herein refer to a marker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.

[0062] The term “subject” as used herein refers to a human or non-human organism. Thus, the methods and compositions described herein are applicable to both human and veterinary disease. Further, while a subject is preferably a living organism, the invention described herein may be used in post-mortem analysis as well. Preferred subjects are humans, and most preferably “patients,” which as used herein refers to living humans that are receiving medical care for a disease or condition. This includes persons with no defined illness who are being investigated for signs of pathology.

[0063] Preferably, an analyte is measured in a sample. Such a sample may be obtained from a subject, or may be obtained from biological materials intended to be provided to the subject. For example, a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, and an analyte measurement used to evaluate the kidney for preexisting damage. Preferred samples are body fluid samples.

[0064] The term “body fluid sample” as used herein refers to a sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing condition or the effect of a treatment regimen on a condition. Preferred body fluid samples include blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, and pleural effusions. In addition, one of skill in the art would realize that certain body fluid samples would be

more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.

[0065] The term “diagnosis” as used herein refers to methods by which the skilled artisan can estimate and/or determine the probability (“a likelihood”) of whether or not a patient is suffering from a given disease or condition. In the case of the present invention, “diagnosis” includes using the results of an assay, most preferably an immunoassay, for a kidney injury marker of the present invention, optionally together with other clinical characteristics, to arrive at a diagnosis (that is, the occurrence or nonoccurrence) of an acute renal injury or ARF for the subject from which a sample was obtained and assayed. That such a diagnosis is “determined” is not meant to imply that the diagnosis is 100% accurate. Many biomarkers are indicative of multiple conditions. The skilled clinician does not use biomarker results in an informational vacuum, but rather test results are used together with other clinical indicia to arrive at a diagnosis. Thus, a measured biomarker level on one side of a predetermined diagnostic threshold indicates a greater likelihood of the occurrence of disease in the subject relative to a measured level on the other side of the predetermined diagnostic threshold.

[0066] Similarly, a prognostic risk signals a probability (“a likelihood”) that a given course or outcome will occur. A level or a change in level of a prognostic indicator, which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being “indicative of an increased likelihood” of an adverse outcome in a patient.

[0067] Marker Assays

[0068] In general, immunoassays involve contacting a sample containing or suspected of containing a biomarker of interest with at least one antibody that specifically binds to the biomarker. A signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices are well known to the skilled artisan for the detection and analysis of biomarkers. *See, e.g.*, U.S. Patents 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, and *The Immunoassay Handbook*, David Wild, ed. Stockton Press, New

York, 1994, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims.

[0069] The assay devices and methods known in the art can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of the biomarker of interest. Suitable assay formats also include chromatographic, mass spectrographic, and protein “blotting” methods. Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. *See, e.g.*, U.S. Patents 5,631,171; and 5,955,377, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims. One skilled in the art also recognizes that robotic instrumentation including but not limited to Beckman ACCESS®, Abbott AXSYM®, Roche ELECSYS®, Dade Behring STRATUS® systems are among the immunoassay analyzers that are capable of performing immunoassays. But any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like.

[0070] Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in assays. Solid phases that may be used to immobilize specific binding members include those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include membrane filters, cellulose-based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates. An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip could then be dipped into the test sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot. Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.

[0071] Biological assays require methods for detection, and one of the most common methods for quantitation of results is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied.

Detectable labels may include molecules that are themselves detectable (*e.g.*, fluorescent moieties, electrochemical labels, metal chelates, *etc.*) as well as molecules that may be indirectly detected by production of a detectable reaction product (*e.g.*, enzymes such as horseradish peroxidase, alkaline phosphatase, *etc.*) or by a specific binding molecule which itself may be detectable (*e.g.*, biotin, digoxigenin, maltose, oligohistidine, 2,4-dinitrobenzene, phenylarsenate, ssDNA, dsDNA, *etc.*).

[0072] Preparation of solid phases and detectable label conjugates often comprise the use of chemical cross-linkers. Cross-linking reagents contain at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non-specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups. Maleimides, alkyl and aryl halides, and alpha-haloacyls react with sulfhydryls to form thiol ether bonds, while pyridyl disulfides react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. Imidoesters are also very useful for protein-protein cross-links. A variety of heterobifunctional cross-linkers, each combining different attributes for successful conjugation, are commercially available.

[0073] In certain aspects, the present invention provides kits for the analysis of the described kidney injury markers. The kit comprises reagents for the analysis of at least one test sample which comprise at least one antibody that a kidney injury marker. The kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein. Preferred kits will comprise an antibody pair for performing a sandwich assay, or a labeled species for performing a competitive assay, for the analyte. Preferably, an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker. Most preferably each of the antibodies are monoclonal antibodies. The instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use. For example, the term labeling encompasses advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits.

[0074] Antibodies

[0075] The term “antibody” as used herein refers to a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope. *See, e.g.* Fundamental Immunology, 3rd Edition, W.E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994; J. Immunol. Methods 175:267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25:85-97. The term antibody includes antigen-binding portions, i.e., “antigen binding sites,” (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term “antibody.”

[0076] Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention. The term “specifically binds” is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody “specifically binds” if its affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s). Preferably the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. In preferred embodiments, Preferred antibodies bind with affinities of at least about 10^7 M^{-1} , and preferably between about 10^8 M^{-1} to about 10^9 M^{-1} , about 10^9 M^{-1} to about 10^{10} M^{-1} , or about 10^{10} M^{-1} to about 10^{12} M^{-1} .

[0077] Affinity is calculated as $K_d = k_{\text{off}}/k_{\text{on}}$ (k_{off} is the dissociation rate constant, K_{on} is the association rate constant and K_d is the equilibrium constant). Affinity can be determined at equilibrium by measuring the fraction bound (r) of labeled ligand at various concentrations (c). The data are graphed using the Scatchard equation: $r/c = K(n-r)$: where r = moles of bound ligand/mole of receptor at equilibrium; c = free ligand concentration

at equilibrium; K = equilibrium association constant; and n = number of ligand binding sites per receptor molecule. By graphical analysis, r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot. Antibody affinity measurement by Scatchard analysis is well known in the art. *See, e.g.,* van Erp *et al.*, *J. Immunoassay* 12: 425-43, 1991; Nelson and Griswold, *Comput. Methods Programs Biomed.* 27: 65-8, 1988.

[0078] The term “epitope” refers to an antigenic determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

[0079] Numerous publications discuss the use of phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. *See, e.g.,* Cwirla *et al.*, *Proc. Natl. Acad. Sci. USA* 87, 6378-82, 1990; Devlin *et al.*, *Science* 249, 404-6, 1990; Scott and Smith, *Science* 249, 386-88, 1990; and Ladner *et al.*, U.S. Pat. No. 5,571,698. A basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide. This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide. The establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides. Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target. The identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. *See, e.g.,* U.S. Patent No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims.

[0080] The antibodies that are generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding. The screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates.

The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h. The microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present.

[0081] The antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected. In the development of immunoassays for a target protein, the purified target protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because the binding affinity of various antibodies may differ; certain antibody pairs (*e.g.*, in sandwich assays) may interfere with one another sterically, *etc.*, assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody.

[0082] Assay Correlations

[0083] The term “correlating” as used herein in reference to the use of biomarkers refers to comparing the presence or amount of the biomarker(s) in a patient to its presence or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome.

[0084] Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribution of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncertainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, cost/benefit analysis is involved in selecting a diagnostic threshold.

[0085] Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction using cardiac troponin is the 97.5th percentile of the concentration seen in a normal population. Another method may be to look at serial samples from the same patient, where a prior “baseline” result is used to monitor for temporal changes in a biomarker level.

[0086] Population studies may also be used to select a decision threshold. Receiver Operating Characteristic (“ROC”) arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold able to best distinguish a “diseased” subpopulation from a “nondiseased” subpopulation. A false positive in this case occurs when the person tests positive, but actually does not have the disease. A false negative, on the other hand, occurs when the person tests negative, suggesting they are healthy, when they actually do have the disease. To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to 1 - specificity, the ROC graph is sometimes called the sensitivity vs (1 - specificity) plot. A perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5. A threshold is selected to provide an acceptable level of specificity and sensitivity.

[0087] In this context, “diseased” is meant to refer to a population having one characteristic (the presence of a disease or condition or the occurrence of some outcome) and “nondiseased” is meant to refer to a population lacking the characteristic. While a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.

[0088] In addition to threshold comparisons, other methods for correlating assay results to a patient classification (occurrence or nonoccurrence of disease, likelihood of an outcome, *etc.*) include decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject belongs to one classification out of a plurality of classifications.

[0089] Measures of test accuracy may be obtained as described in Fischer *et al.*, *Intensive Care Med.* 29: 1043-51, 2003, and used to determine the effectiveness of a given biomarker. These measures include sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and ROC curve areas. The area under the curve (“AUC”) of a ROC plot is equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. The area under the ROC curve may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.

[0090] As discussed above, suitable tests may exhibit one or more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding specificity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; at least 75% sensitivity, combined with at least 75% specificity; a ROC curve area of greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95; an odds ratio different from 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least 2, more preferably at least 3, still more preferably at least 5, and most preferably at least 10; and or a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal

to 0.5, more preferably less than or equal to 0.3, and most preferably less than or equal to 0.1

[0091] Additional clinical indicia may be combined with the kidney injury marker assay result(s) of the present invention. These include other biomarkers related to renal status. Examples include the following, which recite the common biomarker name, followed by the Swiss-Prot entry number for that biomarker or its parent: Actin (P68133); Adenosine deaminase binding protein (DPP4, P27487); Alpha-1-acid glycoprotein 1 (P02763); Alpha-1-microglobulin (P02760); Albumin (P02768); Angiotensinogenase (Renin, P00797); Annexin A2 (P07355); Beta-glucuronidase (P08236); B-2-microglobulin (P61769); Beta-galactosidase (P16278); BMP-7 (P18075); Brain natriuretic peptide (proBNP, BNP-32, NTproBNP; P16860); Calcium-binding protein Beta (S100-beta, P04271); Carbonic anhydrase 9 (Q16790); Casein Kinase 2 (P68400); Clusterin (P10909); Complement C3 (P01024); Cysteine-rich protein (CYR61, O00622); Cytochrome C (P99999); Epidermal growth factor (EGF, P01133); Endothelin-1 (P05305); Exosomal Fetuin-A (P02765); Fatty acid-binding protein, heart (FABP3, P05413); Fatty acid-binding protein, liver (P07148); Ferritin (light chain, P02792; heavy chain P02794); Fructose-1,6-biphosphatase (P09467); GRO-alpha (CXCL1, (P09341); Growth Hormone (P01241); Hepatocyte growth factor (P14210); Insulin-like growth factor I (P05019); Immunoglobulin G; Immunoglobulin Light Chains (Kappa and Lambda); Interferon gamma (P01308); Lysozyme (P61626); Interleukin-1alpha (P01583); Interleukin-2 (P60568); Interleukin-4 (P05112); Interleukin-9 (P15248); Interleukin-12p40 (P29460); Interleukin-13 (P35225); Interleukin-16 (Q14005); L1 cell adhesion molecule (P32004); Lactate dehydrogenase (P00338); Leucine Aminopeptidase (P28838); Meprin A-alpha subunit (Q16819); Meprin A-beta subunit (Q16820); Midkine (P21741); MIP2-alpha (CXCL2, P19875); MMP-2 (P08253); MMP-9 (P14780); Netrin-1 (O95631); Neutral endopeptidase (P08473); Osteopontin (O14788); Renal papillary antigen 1 (RPA1); Renal papillary antigen 2 (RPA2); Retinol binding protein (P09455); Ribonuclease; S100 calcium-binding protein A6 (P06703); Serum Amyloid P Component (P02743); Sodium/Hydrogen exchanger isoform (NHE3, P48764); Spermidine/spermine N1-acetyltransferase (P21673); TGF-Beta1 (P01137); Transferrin (P02787); Trefoil factor 3 (TFF3, Q07654); Toll-Like protein 4 (O00206); Total protein; Tubulointerstitial nephritis antigen (Q9UJW2); Uromodulin (Tamm-Horsfall protein, P07911).

[0092] For purposes of risk stratification, Adiponectin (Q15848); Alkaline phosphatase (P05186); Aminopeptidase N (P15144); CalbindinD28k (P05937); Cystatin C (P01034); 8 subunit of F1FO ATPase (P03928); Gamma-glutamyltransferase (P19440); GSTa (alpha-glutathione-S-transferase, P08263); GSTpi (Glutathione-S-transferase P; GST class-pi; P09211); IGFBP-1 (P08833); IGFBP-2 (P18065); IGFBP-6 (P24592); Integral membrane protein 1 (Itm1, P46977); Interleukin-6 (P05231); Interleukin-8 (P10145); Interleukin-18 (Q14116); IP-10 (10 kDa interferon-gamma-induced protein, P02778); IRPR (IFRD1, O00458); Isovaleryl-CoA dehydrogenase (IVD, P26440); I-TAC/CXCL11 (O14625); Keratin 19 (P08727); Kim-1 (Hepatitis A virus cellular receptor 1, O43656); L-arginine:glycine amidinotransferase (P50440); Leptin (P41159); Lipocalin2 (NGAL, P80188); MCP-1 (P13500); MIG (Gamma-interferon-induced monokine Q07325); MIP-1a (P10147); MIP-3a (P78556); MIP-1beta (P13236); MIP-1d (Q16663); NAG (N-acetyl-beta-D-glucosaminidase, P54802); Organic ion transporter (OCT2, O15244); Osteoprotegerin (O14788); P8 protein (O60356); Plasminogen activator inhibitor 1 (PAI-1, P05121); ProANP(1-98) (P01160); Protein phosphatase 1-beta (PPI-beta, P62140); Rab GDI-beta (P50395); Renal kallikrein (P06870); RT1.B-1 (alpha) chain of the integral membrane protein (Q5Y7A8); soluble tumor necrosis factor receptor superfamily member 1A (sTNFR-I, P19438); soluble tumor necrosis factor receptor superfamily member 1B (sTNFR-II, P20333); Tissue inhibitor of metalloproteinases 3 (TIMP-3, P35625); uPAR (Q03405) may be combined with the kidney injury marker assay result(s) of the present invention.

[0093] Other clinical indicia which may be combined with the kidney injury marker assay result(s) of the present invention includes demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a urine total protein measurement, a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a renal papillary antigen 1 (RPA1)

measurement; a renal papillary antigen 2 (RPA2) measurement; a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatinine ratio, and/or a renal failure index calculated as urine sodium / (urine creatinine / plasma creatinine). Other measures of renal function which may be combined with the kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.

[0094] Combining assay results/clinical indicia in this manner can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, etc. This list is not meant to be limiting.

[0095] Diagnosis of Acute Renal Failure

[0096] As noted above, the terms “acute renal (or kidney) injury” and “acute renal (or kidney) failure” as used herein are defined in part in terms of changes in serum creatinine from a baseline value. Most definitions of ARF have common elements, including the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR. Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of ml/min:

$$GFR = \frac{\text{Urine Concentration} \times \text{Urine Flow}}{\text{Plasma Concentration}}$$

[0097] By normalizing the GFR to the body surface area, a GFR of approximately 75–100 ml/min per 1.73 m² can be assumed. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood.

[0098] There are several different techniques used to calculate or estimate the glomerular filtration rate (GFR or eGFR). In clinical practice, however, creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured.

[0099] Creatinine clearance (CCr) can be calculated if values for creatinine's urine concentration (U_{Cr}), urine flow rate (V), and creatinine's plasma concentration (P_{Cr}) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate ($U_{Cr} \times V$) divided by its plasma concentration. This is commonly represented mathematically as:

$$C_{Cr} = \frac{U_{Cr} \times V}{P_{Cr}}$$

[00100] Commonly a 24 hour urine collection is undertaken, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken:

$$C_{Cr} = \frac{U_{Cr} \times 24\text{-hour volume}}{P_{Cr} \times 24 \times 60\text{mins}}$$

[0100] To allow comparison of results between people of different sizes, the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as ml/min/1.73 m². While most adults have a BSA that approaches 1.7 (1.6-1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA:

$$C_{Cr\text{-corrected}} = \frac{C_{Cr} \times 1.73}{BSA}$$

[0101] The accuracy of a creatinine clearance measurement (even when collection is complete) is limited because as glomerular filtration rate (GFR) falls creatinine secretion

is increased, and thus the rise in serum creatinine is less. Thus, creatinine excretion is much greater than the filtered load, resulting in a potentially large overestimation of the GFR (as much as a twofold difference). However, for clinical purposes it is important to determine whether renal function is stable or getting worse or better. This is often determined by monitoring serum creatinine alone. Like creatinine clearance, the serum creatinine will not be an accurate reflection of GFR in the non-steady-state condition of ARF. Nonetheless, the degree to which serum creatinine changes from baseline will reflect the change in GFR. Serum creatinine is readily and easily measured and it is specific for renal function.

[0102] For purposes of determining urine output on a mL/kg/hr basis, hourly urine collection and measurement is adequate. In the case where, for example, only a cumulative 24-h output was available and no patient weights are provided, minor modifications of the RIFLE urine output criteria have been described. For example, Bagshaw *et al.*, *Nephrol. Dial. Transplant.* 23: 1203–1210, 2008, assumes an average patient weight of 70 kg, and patients are assigned a RIFLE classification based on the following: <35 mL/h (Risk), <21 mL/h (Injury) or <4 mL/h (Failure).

[0103] Selecting a Treatment Regimen

[0104] Once a diagnosis is obtained, the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc. The skilled artisan is aware of appropriate treatments for numerous diseases discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, NJ, 1999. In addition, since the methods and compositions described herein provide prognostic information, the markers of the present invention may be used to monitor a course of treatment. For example, improved or worsened prognostic state may indicate that a particular treatment is or is not efficacious.

[0105] One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The examples provided herein are representative of preferred

embodiments, are exemplary, and are not intended as limitations on the scope of the invention.

[0106] Example 1: Contrast-induced nephropathy sample collection

[0107] The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after receiving intravascular contrast media. Approximately 250 adults undergoing radiographic/angiographic procedures involving intravascular administration of iodinated contrast media are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:

Inclusion Criteria

males and females 18 years of age or older;

undergoing a radiographic / angiographic procedure (such as a CT scan or coronary intervention) involving the intravascular administration of contrast media;

expected to be hospitalized for at least 48 hours after contrast administration.

able and willing to provide written informed consent for study participation and to comply with all study procedures.

Exclusion Criteria

renal transplant recipients;

acutely worsening renal function prior to the contrast procedure;

already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment;

expected to undergo a major surgical procedure (such as involving cardiopulmonary bypass) or an additional imaging procedure with contrast media with significant risk for further renal insult within the 48 hrs following contrast administration;

participation in an interventional clinical study with an experimental therapy within the previous 30 days;

known infection with human immunodeficiency virus (HIV) or a hepatitis virus.

[0108] Immediately prior to the first contrast administration (and after any pre-procedure hydration), an EDTA anti-coagulated blood sample (10 mL) and a urine

sample (10 mL) are collected from each patient. Blood and urine samples are then collected at 4 (± 0.5), 8 (± 1), 24 (± 2), 48 (± 2), and 72 (± 2) hrs following the last administration of contrast media during the index contrast procedure. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, CA. The study urine samples are frozen and shipped to Astute Medical, Inc.

[0109] Serum creatinine is assessed at the site immediately prior to the first contrast administration (after any pre-procedure hydration) and at 4 (± 0.5), 8 (± 1), 24 (± 2) and 48 (± 2), and 72 (± 2) hours following the last administration of contrast (ideally at the same time as the study samples are obtained). In addition, each patient's status is evaluated through day 30 with regard to additional serum and urine creatinine measurements, a need for dialysis, hospitalization status, and adverse clinical outcomes (including mortality).

[0110] Prior to contrast administration, each patient is assigned a risk based on the following assessment: systolic blood pressure < 80 mm Hg = 5 points; intra-arterial balloon pump = 5 points; congestive heart failure (Class III-IV or history of pulmonary edema) = 5 points; age > 75 yrs = 4 points; hematocrit level $< 39\%$ for men, $< 35\%$ for women = 3 points; diabetes = 3 points; contrast media volume = 1 point for each 100 mL; serum creatinine level > 1.5 g/dL = 4 points OR estimated GFR $40-60$ mL/min/ 1.73 m² = 2 points, $20-40$ mL/min/ 1.73 m² = 4 points, < 20 mL/min/ 1.73 m² = 6 points. The risks assigned are as follows: risk for CIN and dialysis: 5 or less total points = risk of CIN - 7.5%, risk of dialysis - 0.04%; 6-10 total points = risk of CIN - 14%, risk of dialysis - 0.12%; 11-16 total points = risk of CIN - 26.1%, risk of dialysis - 1.09%; > 16 total points = risk of CIN - 57.3%, risk of dialysis - 12.8%.

[0111] Example 2: Cardiac surgery sample collection

[0112] The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after undergoing cardiovascular surgery, a procedure known to be potentially damaging to kidney function. Approximately 900 adults undergoing such surgery are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:

Inclusion Criteria

males and females 18 years of age or older;

undergoing cardiovascular surgery;

Toronto/Ottawa Predictive Risk Index for Renal Replacement risk score of at least 2 (Wijeysundera *et al.*, *JAMA* 297: 1801-9, 2007); and

able and willing to provide written informed consent for study participation and to comply with all study procedures.

Exclusion Criteria

known pregnancy;

previous renal transplantation;

acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria);

already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment;

currently enrolled in another clinical study or expected to be enrolled in another clinical study within 7 days of cardiac surgery that involves drug infusion or a therapeutic intervention for AKI;

known infection with human immunodeficiency virus (HIV) or a hepatitis virus.

[0113] Within 3 hours prior to the first incision (and after any pre-procedure hydration), an EDTA anti-coagulated blood sample (10 mL), whole blood (3 mL), and a urine sample (35 mL) are collected from each patient. Blood and urine samples are then collected at 3 (± 0.5), 6 (± 0.5), 12 (± 1), 24 (± 2) and 48 (± 2) hrs following the procedure and then daily on days 3 through 7 if the subject remains in the hospital. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are frozen and shipped to Astute Medical, Inc., San Diego, CA. The study urine samples are frozen and shipped to Astute Medical, Inc.

[0114] Example 3: Acutely ill subject sample collection

[0115] The objective of this study is to collect samples from acutely ill patients. Approximately 900 adults expected to be in the ICU for at least 48 hours will be enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:

Inclusion Criteria

males and females 18 years of age or older;

Study population 1: approximately 300 patients that have at least one of:

shock (SBP < 90 mmHg and/or need for vasopressor support to maintain MAP > 60 mmHg and/or documented drop in SBP of at least 40 mmHg); and
sepsis;

Study population 2: approximately 300 patients that have at least one of:

IV antibiotics ordered in computerized physician order entry (CPOE) within 24 hours of enrollment;

contrast media exposure within 24 hours of enrollment;

increased Intra-Abdominal Pressure with acute decompensated heart failure; and

severe trauma as the primary reason for ICU admission and likely to be hospitalized in the ICU for 48 hours after enrollment;

Study population 3: approximately 300 patients

expected to be hospitalized through acute care setting (ICU or ED) with a known risk factor for acute renal injury (*e.g.* sepsis, hypotension/shock (Shock = systolic BP < 90 mmHg and/or the need for vasopressor support to maintain a MAP > 60 mmHg and/or a documented drop in SBP > 40 mmHg), major trauma, hemorrhage, or major surgery); and/or expected to be hospitalized to the ICU for at least 24 hours after enrollment.

Exclusion Criteria

known pregnancy;

institutionalized individuals;

previous renal transplantation;

known acutely worsening renal function prior to enrollment (*e.g.*, any category of RIFLE criteria);

received dialysis (either acute or chronic) within 5 days prior to enrollment or in imminent need of dialysis at the time of enrollment;

known infection with human immunodeficiency virus (HIV) or a hepatitis virus;

meets only the SBP < 90 mmHg inclusion criterion set forth above, and does not have shock in the attending physician's or principal investigator's opinion.

[0116] After providing informed consent, an EDTA anti-coagulated blood sample (10 mL) and a urine sample (25-30 mL) are collected from each patient. Blood and urine samples are then collected at 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, CA. The study urine samples are frozen and shipped to Astute Medical, Inc.

[0117] Example 4. Immunoassay format

[00101] Analytes are measured using standard sandwich enzyme immunoassay techniques. A first antibody which binds the analyte is immobilized in wells of a 96 well polystyrene microplate. Analyte standards and test samples are pipetted into the appropriate wells and any analyte present is bound by the immobilized antibody. After washing away any unbound substances, a horseradish peroxidase-conjugated second antibody which binds the analyte is added to the wells, thereby forming sandwich complexes with the analyte (if present) and the first antibody. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution comprising tetramethylbenzidine and hydrogen peroxide is added to the wells. Color develops in proportion to the amount of analyte present in the sample. The color development is stopped and the intensity of the color is measured at 540 nm or 570 nm. An analyte concentration is assigned to the test sample by comparison to a standard curve determined from the analyte standards. Units for C-C motif chemokine 16 reported herein are ng/mL. Units for C-C motif chemokine 14 reported herein are ng/mL. Units for soluble Tyrosine-protein kinase receptor UFO reported herein are ng/mL.

[0118] Example 5. Apparently Healthy Donor and Chronic Disease Patient Samples

[0119] Human urine samples from donors with no known chronic or acute disease (“Apparently Healthy Donors”) were purchased from two vendors (Golden West Biologicals, Inc., 27625 Commerce Center Dr., Temecula, CA 92590 and Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, VA 23454). The urine samples were shipped and stored frozen at less than -20° C. The vendors supplied demographic information for the individual donors including gender, race (Black /White), smoking status and age.

[0120] Human urine samples from donors with various chronic diseases (“Chronic Disease Patients”) including congestive heart failure, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus and hypertension were purchased from Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, VA 23454. The urine samples were shipped and stored frozen at less than -20 degrees centigrade. The vendor provided a case report form for each individual donor with age, gender, race (Black/White), smoking status and alcohol use, height, weight, chronic disease(s) diagnosis, current medications and previous surgeries.

[0121] Example 6. Use of C-C motif chemokine 14 for evaluating renal status in patients admitted to the ICU: Recovery to RIFLE 0 from RIFLE I and F

[0122] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. C-C motif chemokine 14 is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0123] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output during a period starting at 12, 24, 48, or 72 hours after sample collection or at any time within 7 days after sample collection. Two cohorts are defined to represent a “recovered” and a “non-recovered” population. “Recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0). “Non-recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is risk of injury (R), injury

(I) or failure (F). If a patient dies or is placed on renal replacement therapy (RRT) within 9 days of enrollment, the patient is considered “non-recovered”.

[0124] The ability to distinguish the “recovered” and “non-recovered” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0125] Table 6.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.475	1.19	0.547	1.15	0.805	1.04
Average	0.567	2.10	0.625	2.06	0.744	2.02
Stdev	0.332	2.12	0.365	2.11	0.384	2.10
p (t-test)		6.1E-7		1.9E-5		0.0017
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	1.16	7.86	1.16	7.86	1.16	7.86
n (Patient)	8	73	6	75	4	77

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.551	1.58	0.557	1.38	0.611	1.20
Average	0.964	2.53	1.01	2.45	1.04	2.38
Stdev	0.898	2.32	0.916	2.31	0.939	2.30
p (t-test)		6.0E-5		1.7E-4		4.4E-4
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	3.52	7.86	3.52	7.86	3.52	7.86
n (Patient)	30	51	28	53	26	55

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.640	1.33	0.838	1.26	1.04	1.19
Average	1.21	2.18	1.30	2.15	1.42	2.09
Stdev	1.33	2.13	1.36	2.13	1.38	2.13
p (t-test)		0.068		0.13		0.25
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	4.74	7.86	4.74	7.86	4.74	7.86
n (Patient)	11	61	10	62	9	64

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.75	0.71	0.65	0.71	0.68	0.61	0.65	0.67	0.56

SE	0.076	0.057	0.084	0.094	0.060	0.091	0.13	0.062	0.100
p Value	8.8E-4	2.0E-4	0.076	0.024	0.0022	0.24	0.24	0.0070	0.57
nCohort Recovered	8	30	11	6	28	10	4	26	9
nCohort Non-recovered	73	51	61	75	53	62	77	55	64
Cutoff Quartile 2	0.460	0.460	0.525	0.460	0.460	0.502	0.460	0.460	0.474
Sensitivity	77%	80%	77%	75%	77%	74%	74%	78%	72%
Specificity	50%	37%	36%	33%	32%	20%	25%	35%	11%
Cutoff Quartile 3	1.04	1.04	1.15	1.04	1.04	1.15	1.04	1.04	1.15
Sensitivity	52%	57%	54%	51%	55%	53%	49%	53%	52%
Specificity	75%	63%	73%	67%	61%	70%	50%	58%	67%
Cutoff Quartile 4	2.87	2.87	2.94	2.87	2.87	2.94	2.87	2.87	2.91
Sensitivity	27%	35%	28%	27%	34%	27%	26%	33%	27%
Specificity	100%	93%	91%	100%	93%	90%	100%	92%	89%
OR Quartile 2	3.29	2.37	1.92	1.47	1.62	0.719	0.950	1.90	0.319
p Value	0.12	0.095	0.35	0.67	0.36	0.69	0.97	0.22	0.30
Lower limit of 95% CI	0.744	0.861	0.490	0.250	0.583	0.138	0.0934	0.677	0.0372
Upper limit of 95% CI	14.6	6.55	7.52	8.70	4.49	3.74	9.67	5.32	2.74
OR Quartile 3	3.26	2.28	3.14	2.05	1.87	2.66	0.974	1.52	2.13
p Value	0.16	0.082	0.11	0.42	0.19	0.18	0.98	0.38	0.31
Lower limit of 95% CI	0.616	0.901	0.760	0.355	0.736	0.628	0.131	0.594	0.489
Upper limit of 95% CI	17.2	5.75	13.0	11.9	4.74	11.2	7.27	3.90	9.26
OR Quartile 4	6.51	7.64	3.86	4.80	6.69	3.40	3.21	5.84	2.89
p Value	0.20	0.0099	0.21	0.29	0.016	0.26	0.44	0.026	0.33
Lower limit of 95% CI	0.359	1.63	0.459	0.259	1.42	0.400	0.165	1.24	0.337
Upper limit of 95% CI	118	35.8	32.5	89.1	31.4	28.9	62.2	27.5	24.9

[0126] Table 6.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.545	1.19	1.04	1.09	1.05	1.03
Average	0.882	2.14	1.06	2.07	1.17	2.05
Stdev	0.714	2.16	0.765	2.14	0.748	2.14
p (t-test)		7.0E-4		0.015		0.042
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	2.75	7.86	2.75	7.86	2.75	7.86
n (Patient)	11	69	8	72	7	73

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.556	1.60	0.651	1.48	0.651	1.48
Average	0.967	2.61	1.02	2.48	1.02	2.48
Stdev	0.884	2.34	0.914	2.32	0.914	2.32
p (t-test)		4.3E-5		1.8E-4		1.8E-4
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	3.52	7.86	3.52	7.86	3.52	7.86
n (Patient)	31	49	28	52	28	52

UO only

Recovery Period Duration (hr)	24	48	72
----------------------------------	----	----	----

	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	1.04	1.19	1.05	1.19	1.11	1.15
Average	1.34	2.16	1.42	2.12	1.51	2.05
Stdev	1.21	2.10	1.22	2.10	1.22	2.09
p (t-test)		0.073		0.13		0.26
Min	0.212	0.121	0.212	0.121	0.212	0.121
Max	4.74	6.66	4.74	6.66	4.74	6.66
n (Patient)	14	54	13	55	12	57

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.72	0.59	0.60	0.69	0.55	0.54	0.69	0.50
SE	0.080	0.057	0.083	0.10	0.060	0.087	0.11	0.060	0.092
p Value	0.036	1.5E-4	0.29	0.33	0.0019	0.58	0.71	0.0019	1.0
nCohort Recovered	11	31	14	8	28	13	7	28	12
nCohort Non-recovered	69	49	54	72	52	55	73	52	57
Cutoff Quartile 2	0.457	0.457	0.525	0.457	0.457	0.502	0.457	0.457	0.474
Sensitivity	77%	82%	76%	75%	81%	73%	74%	81%	70%
Specificity	36%	35%	29%	25%	36%	15%	14%	36%	8%
Cutoff Quartile 3	1.04	1.04	1.15	1.04	1.04	1.15	1.04	1.04	1.15
Sensitivity	52%	59%	52%	50%	56%	51%	49%	56%	49%
Specificity	64%	65%	57%	50%	61%	54%	43%	61%	50%
Cutoff Quartile 4	2.88	2.88	2.94	2.88	2.88	2.94	2.88	2.88	2.91
Sensitivity	29%	37%	30%	28%	35%	29%	27%	35%	28%
Specificity	100%	94%	93%	100%	93%	92%	100%	93%	92%
OR Quartile 2	1.89	2.44	1.26	1.00	2.33	0.485	0.474	2.33	0.214
p Value	0.35	0.089	0.73	1.0	0.11	0.38	0.50	0.11	0.15
Lower limit of 95% CI	0.491	0.871	0.338	0.185	0.828	0.0960	0.0535	0.828	0.0256
Upper limit of 95% CI	7.30	6.86	4.71	5.40	6.57	2.45	4.19	6.57	1.79
OR Quartile 3	1.91	2.64	1.44	1.00	1.95	1.21	0.730	1.95	0.966
p Value	0.34	0.041	0.55	1.0	0.16	0.76	0.69	0.16	0.96
Lower limit of 95% CI	0.512	1.04	0.439	0.232	0.765	0.360	0.152	0.765	0.278
Upper limit of 95% CI	7.12	6.69	4.70	4.31	4.96	4.06	3.49	4.96	3.35
OR Quartile 4	9.53	8.42	5.47	6.64	6.88	4.92	5.75	6.88	4.29
p Value	0.12	0.0069	0.12	0.20	0.015	0.14	0.24	0.015	0.18
Lower limit of 95% CI	0.536	1.79	0.660	0.366	1.46	0.590	0.314	1.46	0.512
Upper limit of 95% CI	169	39.5	45.4	120	32.3	41.1	105	32.3	36.0

[0127] Table 6.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	1.04	1.19	1.05	1.03	1.05	1.03
Average	1.18	2.29	1.27	2.22	1.27	2.22
Stdev	0.991	2.30	0.993	2.29	0.993	2.29
p (t-test)		0.0038		0.012		0.012
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	3.52	7.86	3.52	7.86	3.52	7.86
n (Patient)	23	57	21	59	21	59

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.653	1.58	0.640	1.48	0.640	1.48
Average	1.17	2.50	1.16	2.47	1.16	2.47
Stdev	1.27	2.32	1.29	2.30	1.29	2.30
p (t-test)		0.0020		0.0022		0.0022
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	6.43	7.86	6.43	7.86	6.43	7.86
n (Patient)	34	45	33	46	33	46

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	1.10	1.33	1.24	1.19	1.24	1.19
Average	1.47	2.48	1.58	2.32	1.58	2.32
Stdev	1.23	2.32	1.24	2.30	1.24	2.30
p (t-test)		0.036		0.12		0.12
Min	0.212	0.121	0.212	0.121	0.212	0.121
Max	4.74	6.66	4.74	6.66	4.74	6.66
n (Patient)	22	37	20	40	20	40

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.68	0.58	0.56	0.69	0.52	0.56	0.69	0.52
SE	0.067	0.060	0.076	0.072	0.059	0.079	0.072	0.059	0.079
p Value	0.099	0.0028	0.29	0.38	0.0018	0.80	0.38	0.0018	0.80
nCohort Recovered	23	34	22	21	33	20	21	33	20
nCohort Non-recovered	57	45	37	59	46	40	59	46	40
Cutoff Quartile 2	0.457	0.454	0.520	0.457	0.454	0.502	0.457	0.454	0.502
Sensitivity	75%	82%	73%	73%	83%	68%	73%	83%	68%
Specificity	26%	35%	23%	19%	36%	10%	19%	36%	10%
Cutoff Quartile 3	1.04	1.04	1.20	1.04	1.04	1.19	1.04	1.04	1.19
Sensitivity	51%	56%	51%	49%	57%	50%	49%	57%	50%
Specificity	52%	59%	55%	48%	61%	50%	48%	61%	50%
Cutoff Quartile 4	2.88	2.82	2.98	2.88	2.82	2.94	2.88	2.82	2.94
Sensitivity	32%	38%	32%	31%	37%	30%	31%	37%	30%
Specificity	91%	91%	86%	90%	91%	85%	90%	91%	85%
OR Quartile 2	1.08	2.52	0.794	0.632	2.71	0.231	0.632	2.71	0.231
p Value	0.89	0.081	0.71	0.47	0.060	0.073	0.47	0.060	0.073
Lower limit of 95% CI	0.358	0.893	0.231	0.185	0.958	0.0464	0.185	0.958	0.0464
Upper limit of 95% CI	3.29	7.13	2.73	2.17	7.69	1.15	2.17	7.69	1.15
OR Quartile 3	1.13	1.79	1.27	0.879	2.00	1.00	0.879	2.00	1.00
p Value	0.80	0.21	0.66	0.80	0.14	1.0	0.80	0.14	1.0
Lower limit of 95% CI	0.429	0.725	0.440	0.324	0.805	0.342	0.324	0.805	0.342
Upper limit of 95% CI	2.98	4.40	3.65	2.38	4.97	2.93	2.38	4.97	2.93
OR Quartile 4	4.85	6.27	3.04	4.17	5.86	2.43	4.17	5.86	2.43
p Value	0.047	0.0068	0.12	0.073	0.0091	0.21	0.073	0.0091	0.21
Lower limit of 95% CI	1.02	1.66	0.751	0.877	1.55	0.598	0.877	1.55	0.598
Upper limit of 95% CI	22.9	23.7	12.3	19.8	22.1	9.86	19.8	22.1	9.86

[0128] Table 6.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.838	1.19	1.04	1.11	1.04	1.11
Average	1.11	2.37	1.14	2.33	1.14	2.33
Stdev	0.912	2.35	0.915	2.34	0.915	2.34
p (t-test)		0.0012		0.0020		0.0020
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	3.52	7.86	3.52	7.86	3.52	7.86
n (Patient)	26	53	25	54	25	54

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.665	1.19	0.653	1.20	0.848	1.19
Average	1.36	2.33	1.25	2.40	1.31	2.31
Stdev	1.58	2.29	1.46	2.31	1.49	2.30
p (t-test)		0.034		0.010		0.025
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	6.43	7.86	6.43	7.86	6.43	7.86
n (Patient)	35	42	34	43	32	45

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	1.05	1.33	1.10	1.26	1.10	1.26
Average	1.80	2.43	1.89	2.38	1.89	2.38
Stdev	1.74	2.27	1.75	2.26	1.75	2.26
p (t-test)		0.28		0.42		0.42
Min	0.212	0.121	0.212	0.121	0.212	0.121
Max	6.26	6.66	6.26	6.66	6.26	6.66
n (Patient)	17	35	16	36	16	36

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.64	0.57	0.61	0.66	0.53	0.61	0.62	0.53
SE	0.064	0.063	0.084	0.066	0.062	0.087	0.066	0.064	0.087
p Value	0.038	0.025	0.43	0.089	0.0091	0.70	0.089	0.055	0.70
nCohort Recovered	26	35	17	25	34	16	25	32	16
nCohort Non-recovered	53	42	35	54	43	36	54	45	36
Cutoff Quartile 2	0.454	0.448	0.525	0.454	0.448	0.525	0.454	0.448	0.525
Sensitivity	77%	81%	74%	76%	81%	72%	76%	78%	72%
Specificity	31%	34%	24%	28%	35%	19%	28%	31%	19%
Cutoff Quartile 3	1.04	1.03	1.19	1.04	1.03	1.19	1.04	1.03	1.19
Sensitivity	51%	52%	54%	50%	53%	53%	50%	51%	53%
Specificity	54%	54%	59%	52%	56%	56%	52%	53%	56%
Cutoff Quartile 4	2.82	2.75	3.17	2.82	2.75	3.17	2.82	2.75	3.17
Sensitivity	34%	36%	26%	33%	37%	25%	33%	36%	25%
Specificity	92%	89%	76%	92%	91%	75%	92%	91%	75%
OR Quartile 2	1.52	2.22	0.889	1.23	2.39	0.600	1.23	1.59	0.600
p Value	0.44	0.13	0.86	0.71	0.10	0.49	0.71	0.38	0.49
Lower limit of 95% CI	0.530	0.784	0.230	0.419	0.842	0.140	0.419	0.570	0.140
Upper limit of 95% CI	4.35	6.27	3.44	3.59	6.76	2.56	3.59	4.44	2.56
OR Quartile 3	1.21	1.31	1.70	1.08	1.46	1.44	1.08	1.18	1.44
p Value	0.69	0.56	0.38	0.87	0.41	0.55	0.87	0.71	0.55
Lower limit of 95% CI	0.473	0.531	0.525	0.419	0.590	0.439	0.419	0.478	0.439

Upper limit of 95% CI	3.10	3.21	5.48	2.80	3.60	4.70	2.80	2.94	4.70
OR Quartile 4	6.17	4.31	1.12	5.75	6.12	1.00	5.75	5.33	1.00
p Value	0.021	0.019	0.86	0.027	0.0079	1.0	0.027	0.014	1.0
Lower limit of 95% CI	1.31	1.27	0.291	1.22	1.61	0.257	1.22	1.40	0.257
Upper limit of 95% CI	29.1	14.5	4.35	27.1	23.3	3.90	27.1	20.3	3.90

[0129] Table 6.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.620	1.26	0.637	1.19	0.640	1.16
Average	1.44	2.41	1.43	2.33	1.49	2.25
Stdev	1.70	2.24	1.68	2.22	1.71	2.21
p (t-test)		0.030		0.040		0.085
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	41	42	37	46	35	48

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.848	1.20	0.848	1.20	1.03	1.19
Average	1.66	2.37	1.62	2.38	1.71	2.21
Stdev	1.88	2.24	1.86	2.24	1.92	2.18
p (t-test)		0.15		0.11		0.29
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	48	33	46	35	42	39

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	1.04	1.08	1.04	1.08	1.04	1.03
Average	1.86	2.01	1.60	2.10	1.65	2.07
Stdev	2.29	2.00	1.84	2.09	1.85	2.09
p (t-test)		0.77		0.27		0.36
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	8.44	6.66	7.86	6.66	7.86	6.66
n (Patient)	31	48	31	48	30	49

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.66	0.62	0.55	0.64	0.62	0.57	0.60	0.58	0.55
SE	0.060	0.064	0.066	0.061	0.064	0.065	0.062	0.064	0.066
p Value	0.0088	0.070	0.42	0.023	0.070	0.26	0.100	0.20	0.44
nCohort Recovered	41	48	31	37	46	31	35	42	30

nCohort Non-recovered	42	33	48	46	35	48	48	39	49
Cutoff Quartile 2	0.467	0.460	0.493	0.467	0.460	0.493	0.467	0.460	0.493
Sensitivity	81%	79%	77%	80%	77%	77%	77%	77%	76%
Specificity	32%	29%	29%	32%	28%	29%	29%	29%	27%
Cutoff Quartile 3	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04
Sensitivity	57%	55%	50%	54%	54%	50%	52%	51%	49%
Specificity	59%	54%	52%	57%	54%	52%	54%	52%	50%
Cutoff Quartile 4	2.82	2.87	2.82	2.82	2.87	2.82	2.82	2.87	2.82
Sensitivity	33%	30%	27%	33%	31%	29%	31%	28%	29%
Specificity	83%	79%	77%	84%	80%	81%	83%	79%	80%
OR Quartile 2	1.97	1.53	1.38	1.97	1.33	1.38	1.35	1.33	1.12
p Value	0.19	0.42	0.54	0.18	0.58	0.54	0.56	0.57	0.83
Lower limit of 95% CI	0.717	0.540	0.493	0.724	0.481	0.493	0.497	0.490	0.397
Upper limit of 95% CI	5.43	4.33	3.84	5.38	3.68	3.84	3.64	3.63	3.17
OR Quartile 3	1.88	1.42	1.07	1.56	1.41	1.07	1.29	1.16	0.960
p Value	0.15	0.44	0.89	0.32	0.44	0.89	0.57	0.74	0.93
Lower limit of 95% CI	0.787	0.582	0.432	0.654	0.585	0.432	0.539	0.484	0.387
Upper limit of 95% CI	4.50	3.45	2.63	3.74	3.42	2.63	3.09	2.77	2.38
OR Quartile 4	2.43	1.65	1.27	2.50	1.88	1.72	2.20	1.44	1.60
p Value	0.093	0.33	0.65	0.093	0.22	0.33	0.15	0.48	0.40
Lower limit of 95% CI	0.862	0.597	0.443	0.858	0.680	0.579	0.753	0.522	0.539
Upper limit of 95% CI	6.84	4.57	3.66	7.29	5.22	5.09	6.41	3.97	4.75

[0130] Table 6.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	125	258	108	255	111	254
Average	149	277	107	275	116	272
Stdev	59.3	120	20.2	119	12.5	120
p (t-test)		2.9E-4		1.8E-10		6.9E-13
Min	73.7	89.8	73.7	89.8	105	73.7
Max	255	651	137	651	137	651
n (Patient)	8	74	5	77	4	78

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	182	285	182	283	171	283
Average	206	301	205	298	201	297
Stdev	89.8	126	92.3	125	93.2	123
p (t-test)		1.9E-4		3.3E-4		2.8E-4
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	446	651	446	651	446	651
n (Patient)	31	50	29	52	27	54

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	243	253	265	251	289	249

Average	232	278	233	277	253	273
Stdev	112	125	118	124	110	125
p (t-test)		0.28		0.35		0.66
Min	73.7	110	73.7	110	108	73.7
Max	395	651	395	651	395	651
n (Patient)	10	61	9	62	8	64

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.84	0.73	0.59	0.97	0.73	0.59	0.95	0.74	0.53
SE	0.057	0.055	0.093	0.021	0.056	0.097	0.033	0.055	0.11
p Value	2.6E-9	2.9E-5	0.31	0	4.3E-5	0.35	0	1.4E-5	0.78
nCohort Recovered	8	31	10	5	29	9	4	27	8
nCohort Non-recovered	74	50	61	77	52	62	78	54	64
Cutoff Quartile 2	172	171	174	172	171	174	172	171	175
Sensitivity	78%	86%	77%	79%	87%	77%	78%	87%	77%
Specificity	62%	45%	40%	100%	48%	44%	100%	52%	38%
Cutoff Quartile 3	249	249	253	249	249	253	249	249	251
Sensitivity	54%	62%	49%	53%	62%	48%	53%	61%	48%
Specificity	88%	71%	50%	100%	72%	44%	100%	74%	38%
Cutoff Quartile 4	331	331	339	331	331	339	331	331	337
Sensitivity	28%	34%	26%	27%	33%	26%	27%	31%	25%
Specificity	100%	90%	80%	100%	90%	78%	100%	89%	75%
OR Quartile 2	6.04	5.06	2.24	41.0	6.00	2.74	31.6	7.23	1.96
p Value	0.022	0.0029	0.26	0.013	0.0011	0.17	0.023	4.0E-4	0.39
Lower limit of 95% CI	1.30	1.74	0.553	2.16	2.04	0.648	1.62	2.42	0.419
Upper limit of 95% CI	28.0	14.7	9.07	780	17.7	11.6	616	21.6	9.18
OR Quartile 3	8.24	3.99	0.968	12.5	4.20	0.750	9.96	4.49	0.564
p Value	0.054	0.0049	0.96	0.091	0.0044	0.69	0.13	0.0039	0.46
Lower limit of 95% CI	0.964	1.52	0.254	0.668	1.56	0.184	0.519	1.62	0.124
Upper limit of 95% CI	70.3	10.4	3.69	234	11.3	3.06	191	12.5	2.56
OR Quartile 4	6.83	4.81	1.42	4.19	4.21	1.22	3.37	3.68	1.00
p Value	0.19	0.020	0.68	0.34	0.034	0.82	0.42	0.055	1.0
Lower limit of 95% CI	0.377	1.28	0.273	0.222	1.12	0.229	0.174	0.972	0.183
Upper limit of 95% CI	124	18.1	7.41	79.0	15.9	6.48	65.2	13.9	5.46

[0131] Table 6.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	179	255	132	254	132	254
Average	196	279	186	278	183	276
Stdev	90.2	121	97.7	119	88.7	120
p (t-test)		0.027		0.044		0.068
Min	73.7	103	73.7	103	108	73.7
Max	329	651	329	651	329	651
n (Patient)	10	70	8	72	6	74

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered	Non-recovered	Recovered	Non-recovered	Recovered	Non-recovered

	Cohort	Cohort	Cohort	Cohort	Cohort	Cohort
Median	204	293	193	283	187	285
Average	213	306	211	303	208	303
Stdev	88.7	126	91.4	124	90.8	123
p (t-test)		2.9E-4		4.5E-4		2.6E-4
Min	73.7	103	73.7	103	73.7	103
Max	446	651	446	651	446	651
n (Patient)	31	48	29	50	28	51

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	314	239	321	235	328	235
Average	265	275	268	273	283	270
Stdev	102	129	105	129	93.9	129
p (t-test)		0.76		0.87		0.69
Min	73.7	110	73.7	110	108	73.7
Max	395	651	395	651	395	651
n (Patient)	15	54	14	55	13	57

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.70	0.72	0.48	0.73	0.72	0.47	0.75	0.74	0.41
SE	0.079	0.057	0.084	0.081	0.057	0.086	0.088	0.056	0.085
p Value	0.013	8.0E-5	0.77	0.0046	1.0E-4	0.69	0.0051	2.4E-5	0.31
nCohort Recovered	10	31	15	8	29	14	6	28	13
nCohort Non-recovered	70	48	54	72	50	55	74	51	57
Cutoff Quartile 2	176	175	177	176	175	177	176	175	178
Sensitivity	79%	85%	74%	79%	86%	75%	78%	86%	74%
Specificity	50%	42%	27%	62%	45%	29%	67%	46%	23%
Cutoff Quartile 3	251	249	253	251	249	253	251	249	251
Sensitivity	51%	60%	44%	51%	60%	44%	51%	61%	44%
Specificity	60%	68%	33%	62%	69%	29%	67%	71%	23%
Cutoff Quartile 4	332	333	335	332	333	335	332	333	334
Sensitivity	29%	35%	26%	28%	34%	25%	27%	33%	25%
Specificity	100%	90%	80%	100%	90%	79%	100%	89%	69%
OR Quartile 2	3.67	4.23	1.04	6.33	4.99	1.17	7.25	5.45	0.840
p Value	0.062	0.0084	0.95	0.019	0.0036	0.81	0.030	0.0023	0.81
Lower limit of 95% CI	0.937	1.45	0.284	1.36	1.69	0.316	1.22	1.83	0.203
Upper limit of 95% CI	14.4	12.4	3.80	29.5	14.7	4.34	43.2	16.2	3.47
OR Quartile 3	1.59	3.21	0.400	1.76	3.33	0.310	2.11	3.88	0.234
p Value	0.50	0.016	0.13	0.46	0.015	0.072	0.40	0.0076	0.041
Lower limit of 95% CI	0.412	1.24	0.120	0.392	1.26	0.0864	0.364	1.43	0.0582
Upper limit of 95% CI	6.12	8.28	1.33	7.93	8.78	1.11	12.2	10.5	0.943
OR Quartile 4	8.52	5.12	1.40	6.64	4.46	1.25	4.89	4.17	0.733
p Value	0.15	0.016	0.64	0.20	0.028	0.76	0.29	0.036	0.64
Lower limit of 95% CI	0.477	1.35	0.344	0.366	1.18	0.305	0.263	1.10	0.195
Upper limit of 95% CI	152	19.3	5.70	120	16.9	5.15	90.8	15.8	2.75

[0132] Table 6.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	235	256	223	255	223	255
Average	233	283	237	280	237	280
Stdev	100	127	99.5	127	99.5	127
p (t-test)		0.082		0.15		0.15
Min	73.7	103	108	73.7	108	73.7
Max	446	651	446	651	446	651
n (Patient)	21	56	18	59	18	59

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	210	283	210	285	210	285
Average	220	305	217	305	217	305
Stdev	91.8	131	91.7	129	91.7	129
p (t-test)		0.0015		9.6E-4		9.6E-4
Min	73.7	103	73.7	103	73.7	103
Max	446	651	446	651	446	651
n (Patient)	32	44	31	45	31	45

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	301	231	320	227	320	227
Average	280	280	296	272	296	272
Stdev	89.4	139	77.1	138	77.1	138
p (t-test)		1.00		0.42		0.42
Min	73.7	114	108	73.7	108	73.7
Max	429	651	429	651	429	651
n (Patient)	20	37	18	40	18	40

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.69	0.41	0.59	0.70	0.35	0.59	0.70	0.35
SE	0.070	0.060	0.078	0.074	0.059	0.075	0.074	0.059	0.075
p Value	0.16	0.0015	0.28	0.24	5.7E-4	0.048	0.24	5.7E-4	0.048
nCohort Recovered	21	32	20	18	31	18	18	31	18
nCohort Non-recovered	56	44	37	59	45	40	59	45	40
Cutoff Quartile 2	174	173	185	174	173	187	174	173	187
Sensitivity	79%	86%	68%	78%	87%	68%	78%	87%	68%
Specificity	38%	41%	15%	39%	42%	11%	39%	42%	11%
Cutoff Quartile 3	249	249	257	249	249	255	249	249	255
Sensitivity	52%	61%	41%	51%	62%	40%	51%	62%	40%
Specificity	57%	66%	35%	56%	68%	28%	56%	68%	28%
Cutoff Quartile 4	335	334	335	335	334	334	335	334	334
Sensitivity	29%	34%	24%	27%	33%	22%	27%	33%	22%
Specificity	86%	88%	75%	83%	87%	67%	83%	87%	67%
OR Quartile 2	2.26	4.33	0.368	2.25	4.69	0.260	2.25	4.69	0.260
p Value	0.14	0.0098	0.16	0.16	0.0067	0.10	0.16	0.0067	0.10
Lower limit of 95% CI	0.760	1.42	0.0900	0.727	1.54	0.0518	0.727	1.54	0.0518
Upper limit of 95% CI	6.70	13.2	1.50	6.97	14.3	1.30	6.97	14.3	1.30
OR Quartile 3	1.43	3.03	0.367	1.29	3.46	0.256	1.29	3.46	0.256
p Value	0.49	0.022	0.082	0.63	0.012	0.027	0.63	0.012	0.027
Lower limit of 95% CI	0.521	1.17	0.119	0.448	1.32	0.0765	0.448	1.32	0.0765
Upper limit of 95% CI	3.94	7.83	1.14	3.73	9.07	0.860	3.73	9.07	0.860
OR Quartile 4	2.40	3.62	0.964	1.86	3.38	0.581	1.86	3.38	0.581

p Value	0.20	0.039	0.95	0.37	0.051	0.39	0.37	0.051	0.39
Lower limit of 95% CI	0.620	1.07	0.273	0.475	0.997	0.170	0.475	0.997	0.170
Upper limit of 95% CI	9.28	12.3	3.40	7.29	11.4	1.99	7.29	11.4	1.99

[0133] Table 6.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	210	267	210	267	210	267
Average	220	289	220	289	220	289
Stdev	87.3	129	87.3	129	87.3	129
p (t-test)		0.011		0.011		0.011
Min	108	73.7	108	73.7	108	73.7
Max	395	651	395	651	395	651
n (Patient)	22	52	22	52	22	52

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	221	279	211	283	211	279
Average	238	290	228	295	230	291
Stdev	119	119	112	121	115	121
p (t-test)		0.070		0.017		0.035
Min	73.7	103	73.7	103	73.7	103
Max	651	592	651	592	651	592
n (Patient)	33	40	31	42	29	44

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	308	240	308	240	308	240
Average	287	287	287	287	287	287
Stdev	72.0	142	72.0	142	72.0	142
p (t-test)		0.99		0.99		0.99
Min	140	73.7	140	73.7	140	73.7
Max	395	651	395	651	395	651
n (Patient)	14	34	14	34	14	34

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	0.64	0.41	0.65	0.67	0.41	0.65	0.66	0.41
SE	0.067	0.064	0.089	0.067	0.063	0.089	0.067	0.064	0.089
p Value	0.021	0.031	0.32	0.021	0.0055	0.32	0.021	0.014	0.32
nCohort Recovered	22	33	14	22	31	14	22	29	14
nCohort Non-recovered	52	40	34	52	42	34	52	44	34
Cutoff Quartile 2	175	174	201	175	174	201	175	174	201

Sensitivity	81%	82%	71%	81%	83%	71%	81%	82%	71%
Specificity	41%	36%	14%	41%	39%	14%	41%	38%	14%
Cutoff Quartile 3	249	249	261	249	249	261	249	249	261
Sensitivity	56%	57%	41%	56%	60%	41%	56%	57%	41%
Specificity	64%	61%	29%	64%	65%	29%	64%	62%	29%
Cutoff Quartile 4	331	329	345	331	329	345	331	329	345
Sensitivity	29%	30%	26%	29%	31%	26%	29%	30%	26%
Specificity	82%	82%	79%	82%	84%	79%	82%	83%	79%
OR Quartile 2	2.91	2.69	0.400	2.91	3.16	0.400	2.91	2.75	0.400
p Value	0.056	0.072	0.28	0.056	0.038	0.28	0.056	0.064	0.28
Lower limit of 95% CI	0.973	0.914	0.0754	0.973	1.07	0.0754	0.973	0.941	0.0754
Upper limit of 95% CI	8.69	7.94	2.12	8.69	9.36	2.12	8.69	8.03	2.12
OR Quartile 3	2.21	2.08	0.280	2.21	2.67	0.280	2.21	2.15	0.280
p Value	0.13	0.13	0.064	0.13	0.045	0.064	0.13	0.12	0.064
Lower limit of 95% CI	0.790	0.814	0.0729	0.790	1.02	0.0729	0.790	0.826	0.0729
Upper limit of 95% CI	6.16	5.32	1.08	6.16	6.98	1.08	6.16	5.61	1.08
OR Quartile 4	1.82	1.93	1.32	1.82	2.33	1.32	1.82	2.01	1.32
p Value	0.34	0.25	0.71	0.34	0.15	0.71	0.34	0.24	0.71
Lower limit of 95% CI	0.529	0.633	0.298	0.529	0.731	0.298	0.529	0.630	0.298
Upper limit of 95% CI	6.29	5.87	5.84	6.29	7.43	5.84	6.29	6.43	5.84

[0134] Table 6.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	246	255	246	255	246	252
Average	243	292	239	290	243	285
Stdev	101	141	101	137	100	138
p (t-test)		0.076		0.055		0.11
Min	73.7	89.8	73.7	89.8	103	73.7
Max	446	651	446	651	446	651
n (Patient)	44	40	40	44	38	46

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	246	249	246	249	239	255
Average	254	280	254	280	246	285
Stdev	121	124	122	122	119	123
p (t-test)		0.36		0.35		0.15
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	48	33	46	35	42	39

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	273	238	265	231	273	227

Average	266	274	259	274	265	270
Stdev	105	140	90.5	142	85.3	143
p (t-test)		0.77		0.56		0.84
Min	73.7	105	73.7	105	108	73.7
Max	559	651	429	651	429	651
n (Patient)	30	48	31	47	30	48

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.56	0.47	0.59	0.56	0.48	0.57	0.59	0.45
SE	0.063	0.066	0.067	0.062	0.065	0.067	0.063	0.063	0.067
p Value	0.21	0.39	0.69	0.14	0.35	0.76	0.27	0.14	0.48
nCohort Recovered	44	48	30	40	46	31	38	42	30
nCohort Non-recovered	40	33	48	44	35	47	46	39	48
Cutoff Quartile 2	169	171	172	169	171	172	169	171	172
Sensitivity	80%	82%	73%	82%	83%	72%	80%	85%	71%
Specificity	30%	31%	23%	32%	33%	23%	32%	36%	20%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	52%	52%	46%	52%	51%	45%	52%	54%	44%
Specificity	52%	52%	43%	52%	52%	42%	53%	55%	40%
Cutoff Quartile 4	332	331	334	332	331	334	332	331	334
Sensitivity	28%	24%	27%	30%	26%	28%	28%	28%	27%
Specificity	77%	75%	77%	80%	76%	77%	79%	79%	77%
OR Quartile 2	1.68	2.05	0.819	2.17	2.34	0.763	1.90	3.06	0.607
p Value	0.32	0.19	0.71	0.13	0.12	0.62	0.21	0.042	0.37
Lower limit of 95% CI	0.611	0.698	0.284	0.787	0.799	0.265	0.699	1.04	0.204
Upper limit of 95% CI	4.60	5.99	2.36	5.96	6.84	2.20	5.15	8.95	1.81
OR Quartile 3	1.21	1.15	0.647	1.21	1.16	0.583	1.21	1.41	0.519
p Value	0.66	0.75	0.35	0.66	0.75	0.25	0.66	0.44	0.16
Lower limit of 95% CI	0.514	0.476	0.258	0.514	0.479	0.233	0.513	0.589	0.205
Upper limit of 95% CI	2.85	2.80	1.62	2.85	2.78	1.46	2.87	3.39	1.31
OR Quartile 4	1.29	0.960	1.22	1.68	1.10	1.31	1.48	1.44	1.22
p Value	0.61	0.94	0.71	0.32	0.85	0.62	0.45	0.48	0.71
Lower limit of 95% CI	0.480	0.343	0.423	0.611	0.398	0.456	0.538	0.522	0.423
Upper limit of 95% CI	3.47	2.69	3.52	4.60	3.04	3.77	4.06	3.97	3.52

[0135] Example 7. Use of C-C motif chemokine 14 for evaluating renal status in patients admitted to the ICU: Recovery to RIFLE 0 and R from RIFLE I and F

[0136] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. C-C motif chemokine 14 is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0137] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output during a period starting at 12, 24, 48, or 72 hours after sample collection or at any time within 7 days after sample collection. Two cohorts are defined to represent a “recovered” and a “non-recovered” population.

“Recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0) or risk of injury (R). “Non-recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is injury (I) or failure (F). If a patient dies or is placed on renal replacement therapy (RRT) within 9 days of enrollment, the patient is considered “non-recovered”.

[0138] The ability to distinguish the “recovered” and “non-recovered” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0139] Table 7.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.474	1.33	0.506	1.33	0.537	1.26
Average	1.07	2.22	1.11	2.19	1.15	2.17
Stdev	1.70	2.09	1.74	2.09	1.78	2.08
p (t-test)		0.023		0.038		0.060
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	19	62	18	63	17	64

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.640	2.07	0.640	1.78	0.640	1.78
Average	1.44	2.67	1.48	2.55	1.48	2.55
Stdev	1.75	2.25	1.77	2.24	1.77	2.24
p (t-test)		0.011		0.024		0.024
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	47	34	45	36	45	36

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.589	1.33	0.537	1.33	0.589	1.33
Average	1.53	2.23	1.48	2.26	1.52	2.19
Stdev	1.89	2.09	1.86	2.10	1.90	2.09
p (t-test)		0.19		0.14		0.21
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	20	52	21	51	20	53

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.72	0.69	0.64	0.71	0.66	0.65	0.70	0.66	0.64
SE	0.061	0.061	0.070	0.063	0.061	0.068	0.065	0.061	0.070
p Value	2.4E-4	0.0022	0.047	0.0010	0.0080	0.026	0.0023	0.0080	0.051
nCohort Recovered	19	47	20	18	45	21	17	45	20
nCohort Non-recovered	62	34	52	63	36	51	64	36	53
Cutoff Quartile 2	0.460	0.460	0.525	0.460	0.460	0.502	0.460	0.460	0.474
Sensitivity	81%	82%	83%	79%	81%	82%	80%	81%	79%
Specificity	47%	32%	45%	44%	31%	43%	47%	31%	40%
Cutoff Quartile 3	1.04	1.04	1.15	1.04	1.04	1.15	1.04	1.04	1.15
Sensitivity	56%	62%	56%	56%	58%	57%	55%	58%	55%
Specificity	74%	60%	65%	72%	58%	67%	71%	58%	65%
Cutoff Quartile 4	2.87	2.87	2.94	2.87	2.87	2.94	2.87	2.87	2.91
Sensitivity	31%	38%	29%	30%	36%	29%	30%	36%	28%
Specificity	95%	85%	85%	94%	84%	86%	94%	84%	85%
OR Quartile 2	3.75	2.19	3.91	3.08	1.87	3.50	3.49	1.87	2.55
p Value	0.018	0.15	0.019	0.048	0.24	0.029	0.030	0.24	0.10
Lower limit of 95% CI	1.25	0.747	1.25	1.01	0.662	1.14	1.13	0.662	0.836
Upper limit of 95% CI	11.3	6.40	12.2	9.36	5.29	10.8	10.8	5.29	7.75
OR Quartile 3	3.63	2.38	2.34	3.25	1.92	2.64	2.90	1.92	2.24
p Value	0.026	0.060	0.12	0.044	0.15	0.074	0.071	0.15	0.14
Lower limit of 95% CI	1.16	0.964	0.804	1.03	0.788	0.911	0.914	0.788	0.773
Upper limit of 95% CI	11.3	5.88	6.82	10.2	4.66	7.63	9.18	4.66	6.52
OR Quartile 4	7.95	3.54	2.30	7.34	3.07	2.50	6.76	3.07	2.24
p Value	0.051	0.019	0.23	0.061	0.037	0.19	0.073	0.037	0.25
Lower limit of 95% CI	0.989	1.23	0.586	0.910	1.07	0.640	0.835	1.07	0.571
Upper limit of 95% CI	64.0	10.2	9.01	59.2	8.81	9.77	54.6	8.81	8.76

[0140] Table 7.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.541	1.33	0.545	1.33	0.551	1.26
Average	1.12	2.33	1.16	2.30	1.19	2.27
Stdev	1.57	2.15	1.60	2.15	1.62	2.14
p (t-test)		0.0076		0.013		0.021
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	24	56	23	57	22	58

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.640	1.99	0.653	1.78	0.640	1.99
Average	1.47	2.61	1.50	2.55	1.46	2.56
Stdev	1.78	2.24	1.79	2.24	1.79	2.21
p (t-test)		0.018		0.027		0.019
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	45	35	44	36	43	37

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.598	1.33	0.556	1.33	0.598	1.33
Average	1.20	2.36	1.16	2.40	1.19	2.32
Stdev	1.17	2.16	1.16	2.17	1.18	2.16
p (t-test)		0.0063		0.0037		0.0078
Min	0.212	0.121	0.212	0.121	0.212	0.121
Max	4.74	6.66	4.74	6.66	4.74	6.66
n (Patient)	22	46	23	45	22	47

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.70	0.68	0.67	0.69	0.66	0.68	0.68	0.67	0.66
SE	0.060	0.061	0.067	0.062	0.062	0.066	0.063	0.061	0.067
p Value	6.9E-4	0.0036	0.013	0.0023	0.0095	0.0065	0.0047	0.0043	0.017
nCohort Recovered	24	45	22	23	44	23	22	43	22
nCohort Non-recovered	56	35	46	57	36	45	58	37	47
Cutoff Quartile 2	0.457	0.457	0.525	0.457	0.457	0.502	0.457	0.457	0.474
Sensitivity	82%	86%	83%	81%	83%	82%	81%	84%	79%
Specificity	42%	33%	41%	39%	32%	39%	41%	33%	36%
Cutoff Quartile 3	1.04	1.04	1.15	1.04	1.04	1.15	1.04	1.04	1.15
Sensitivity	57%	60%	57%	56%	58%	58%	55%	59%	55%
Specificity	67%	58%	64%	65%	57%	65%	64%	58%	64%
Cutoff Quartile 4	2.88	2.88	2.94	2.88	2.88	2.94	2.88	2.88	2.91
Sensitivity	34%	37%	33%	33%	36%	33%	33%	38%	32%
Specificity	96%	84%	91%	96%	84%	91%	95%	86%	91%
OR Quartile 2	3.29	3.00	3.29	2.69	2.33	2.97	2.96	2.49	2.11
p Value	0.028	0.057	0.041	0.069	0.12	0.060	0.048	0.098	0.19
Lower limit of 95% CI	1.14	0.968	1.05	0.927	0.791	0.957	1.01	0.845	0.694
Upper limit of 95% CI	9.50	9.30	10.3	7.80	6.88	9.24	8.66	7.36	6.45
OR Quartile 3	2.67	2.05	2.28	2.40	1.84	2.57	2.15	2.04	2.17
p Value	0.055	0.12	0.12	0.088	0.18	0.076	0.14	0.12	0.15
Lower limit of 95% CI	0.981	0.836	0.799	0.879	0.755	0.905	0.784	0.834	0.764
Upper limit of 95% CI	7.25	5.04	6.48	6.56	4.49	7.28	5.92	4.98	6.14
OR Quartile 4	11.8	3.21	4.84	11.0	2.99	5.25	10.2	3.75	4.69
p Value	0.020	0.031	0.050	0.024	0.042	0.039	0.028	0.017	0.055
Lower limit of 95% CI	1.48	1.11	0.998	1.38	1.04	1.08	1.28	1.26	0.968
Upper limit of 95% CI	94.3	9.24	23.5	87.9	8.59	25.4	81.9	11.2	22.7

[0141] Table 7.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.653	1.29	0.838	1.19	1.04	1.19
Average	1.34	2.54	1.42	2.38	1.45	2.33
Stdev	1.52	2.33	1.58	2.29	1.59	2.28
p (t-test)		0.0085		0.032		0.048
Min	0.208	0.121	0.208	0.121	0.208	0.121

Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	38	42	34	46	33	47

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	1.03	1.19	0.848	1.20	0.848	1.20
Average	1.60	2.41	1.57	2.43	1.57	2.43
Stdev	1.80	2.27	1.81	2.24	1.81	2.24
p (t-test)		0.10		0.077		0.077
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	47	32	46	33	46	33

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	1.04	2.07	1.05	1.33	1.10	1.26
Average	1.44	2.74	1.56	2.44	1.61	2.38
Stdev	1.46	2.31	1.54	2.27	1.55	2.26
p (t-test)		0.015		0.085		0.13
Min	0.212	0.121	0.212	0.121	0.212	0.121
Max	6.26	6.66	6.26	6.66	6.26	6.66
n (Patient)	29	30	25	35	24	36

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	0.62	0.65	0.61	0.63	0.60	0.60	0.63	0.57
SE	0.062	0.065	0.071	0.063	0.064	0.074	0.064	0.064	0.075
p Value	0.021	0.075	0.031	0.072	0.043	0.20	0.13	0.043	0.33
nCohort Recovered	38	47	29	34	46	25	33	46	24
nCohort Non-recovered	42	32	30	46	33	35	47	33	36
Cutoff Quartile 2	0.457	0.454	0.520	0.457	0.454	0.502	0.457	0.454	0.502
Sensitivity	79%	81%	80%	78%	82%	74%	77%	82%	72%
Specificity	29%	30%	31%	29%	30%	24%	27%	30%	21%
Cutoff Quartile 3	1.04	1.04	1.20	1.04	1.04	1.19	1.04	1.04	1.19
Sensitivity	55%	53%	57%	52%	55%	54%	51%	55%	53%
Specificity	55%	53%	59%	53%	54%	56%	52%	54%	54%
Cutoff Quartile 4	2.88	2.82	2.98	2.88	2.82	2.94	2.88	2.82	2.94
Sensitivity	36%	34%	37%	33%	36%	31%	32%	36%	31%
Specificity	87%	81%	86%	85%	83%	84%	85%	83%	83%
OR Quartile 2	1.49	1.84	1.80	1.50	1.97	0.912	1.23	1.97	0.684
p Value	0.44	0.27	0.33	0.43	0.22	0.88	0.69	0.22	0.54
Lower limit of 95% CI	0.540	0.621	0.547	0.542	0.665	0.277	0.442	0.665	0.201
Upper limit of 95% CI	4.13	5.44	5.92	4.15	5.83	3.00	3.41	5.83	2.33
OR Quartile 3	1.50	1.29	1.85	1.23	1.43	1.51	1.11	1.43	1.32
p Value	0.37	0.58	0.24	0.65	0.44	0.43	0.82	0.44	0.60
Lower limit of 95% CI	0.619	0.524	0.659	0.505	0.582	0.538	0.455	0.582	0.469
Upper limit of 95% CI	3.61	3.17	5.21	2.98	3.51	4.24	2.70	3.51	3.72
OR Quartile 4	3.67	2.21	3.62	2.81	2.71	2.41	2.62	2.71	2.20
p Value	0.025	0.13	0.051	0.074	0.060	0.18	0.095	0.060	0.23
Lower limit of 95% CI	1.18	0.790	0.996	0.905	0.958	0.665	0.846	0.958	0.608
Upper limit of 95% CI	11.4	6.19	13.2	8.70	7.69	8.70	8.14	7.69	7.97

[0142] Table 7.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at

72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.629	1.33	0.637	1.26	0.637	1.26
Average	1.31	2.55	1.33	2.50	1.33	2.50
Stdev	1.52	2.33	1.53	2.33	1.53	2.33
p (t-test)		0.0069		0.011		0.011
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	38	41	37	42	37	42

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.653	1.20	0.653	1.20	0.653	1.20
Average	1.51	2.46	1.51	2.46	1.51	2.46
Stdev	1.80	2.28	1.80	2.28	1.80	2.28
p (t-test)		0.062		0.062		0.062
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	46	31	46	31	46	31

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.838	1.68	1.04	1.38	1.04	1.38
Average	1.57	2.64	1.63	2.57	1.63	2.57
Stdev	1.69	2.27	1.71	2.27	1.71	2.27
p (t-test)		0.064		0.11		0.11
Min	0.212	0.121	0.212	0.121	0.212	0.121
Max	6.26	6.66	6.26	6.66	6.26	6.66
n (Patient)	20	32	19	33	19	33

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.64	0.66	0.65	0.64	0.63	0.65	0.64	0.63
SE	0.060	0.065	0.076	0.061	0.065	0.078	0.061	0.065	0.078
p Value	0.0045	0.034	0.036	0.012	0.034	0.089	0.012	0.034	0.089
nCohort Recovered	38	46	20	37	46	19	37	46	19
nCohort Non-recovered	41	31	32	42	31	33	42	31	33
Cutoff Quartile 2	0.454	0.448	0.525	0.454	0.448	0.525	0.454	0.448	0.525
Sensitivity	83%	81%	81%	81%	81%	79%	81%	81%	79%
Specificity	34%	30%	35%	32%	30%	32%	32%	30%	32%
Cutoff Quartile 3	1.04	1.03	1.19	1.04	1.03	1.19	1.04	1.03	1.19
Sensitivity	56%	55%	59%	55%	55%	58%	55%	55%	58%
Specificity	58%	54%	65%	57%	54%	63%	57%	54%	63%
Cutoff Quartile 4	2.82	2.75	3.17	2.82	2.75	3.17	2.82	2.75	3.17
Sensitivity	37%	39%	28%	36%	39%	27%	36%	39%	27%
Specificity	87%	85%	80%	86%	85%	79%	86%	85%	79%
OR Quartile 2	2.53	1.82	2.33	2.04	1.82	1.71	2.04	1.82	1.71

p Value	0.085	0.28	0.19	0.18	0.28	0.41	0.18	0.28	0.41
Lower limit of 95% CI	0.880	0.613	0.650	0.726	0.613	0.478	0.726	0.613	0.478
Upper limit of 95% CI	7.25	5.42	8.37	5.73	5.42	6.15	5.73	5.42	6.15
OR Quartile 3	1.76	1.45	2.71	1.59	1.45	2.33	1.59	1.45	2.33
p Value	0.22	0.43	0.091	0.31	0.43	0.15	0.31	0.43	0.15
Lower limit of 95% CI	0.720	0.579	0.852	0.652	0.579	0.729	0.652	0.579	0.729
Upper limit of 95% CI	4.29	3.61	8.64	3.87	3.61	7.42	3.87	3.61	7.42
OR Quartile 4	3.81	3.52	1.57	3.56	3.52	1.41	3.56	3.52	1.41
p Value	0.021	0.023	0.51	0.028	0.023	0.62	0.028	0.023	0.62
Lower limit of 95% CI	1.22	1.19	0.410	1.14	1.19	0.367	1.14	1.19	0.367
Upper limit of 95% CI	11.8	10.4	5.97	11.1	10.4	5.39	11.1	10.4	5.39

[0143] Table 7.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.665	1.68	0.639	1.38	0.639	1.38
Average	1.54	2.54	1.47	2.55	1.47	2.55
Stdev	1.85	2.19	1.76	2.24	1.76	2.24
p (t-test)		0.038		0.022		0.022
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	51	32	48	35	48	35

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.911	1.20	0.911	1.20	0.911	1.20
Average	1.74	2.48	1.72	2.47	1.72	2.47
Stdev	1.89	2.36	1.90	2.31	1.90	2.31
p (t-test)		0.20		0.17		0.17
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	58	23	56	25	56	25

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.727	1.19	0.665	1.29	0.653	1.20
Average	1.69	2.23	1.43	2.43	1.44	2.38
Stdev	2.09	2.11	1.68	2.20	1.70	2.19
p (t-test)		0.27		0.029		0.039
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	8.44	6.66	7.86	6.66	7.86	6.66
n (Patient)	40	39	41	38	40	39

Recovery Period Duration (hr)	24	48	72
----------------------------------	----	----	----

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.66	0.59	0.59	0.67	0.60	0.64	0.67	0.60	0.64
SE	0.063	0.072	0.064	0.061	0.070	0.063	0.061	0.070	0.062
p Value	0.014	0.22	0.16	0.0064	0.15	0.026	0.0064	0.15	0.026
nCohort Recovered	51	58	40	48	56	41	48	56	40
nCohort Non-recovered	32	23	39	35	25	38	35	25	39
Cutoff Quartile 2	0.467	0.460	0.493	0.467	0.460	0.493	0.467	0.460	0.493
Sensitivity	81%	74%	79%	83%	76%	82%	83%	76%	82%
Specificity	29%	26%	30%	31%	27%	32%	31%	27%	32%
Cutoff Quartile 3	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04
Sensitivity	62%	57%	54%	60%	56%	58%	60%	56%	56%
Specificity	59%	53%	55%	58%	54%	59%	58%	54%	57%
Cutoff Quartile 4	2.82	2.87	2.82	2.82	2.87	2.82	2.82	2.87	2.82
Sensitivity	38%	30%	31%	37%	32%	34%	37%	32%	33%
Specificity	82%	78%	80%	83%	79%	83%	83%	79%	82%
OR Quartile 2	1.81	0.988	1.66	2.20	1.16	2.06	2.20	1.16	2.20
p Value	0.28	0.98	0.33	0.15	0.79	0.18	0.15	0.79	0.14
Lower limit of 95% CI	0.618	0.329	0.593	0.753	0.389	0.719	0.753	0.389	0.769
Upper limit of 95% CI	5.28	2.97	4.65	6.41	3.45	5.88	6.41	3.45	6.30
OR Quartile 3	2.38	1.49	1.43	2.10	1.47	1.94	2.10	1.47	1.75
p Value	0.061	0.42	0.43	0.10	0.43	0.15	0.10	0.43	0.22
Lower limit of 95% CI	0.961	0.564	0.588	0.865	0.569	0.793	0.865	0.569	0.718
Upper limit of 95% CI	5.90	3.95	3.46	5.10	3.79	4.75	5.10	3.79	4.27
OR Quartile 4	2.80	1.51	1.78	2.95	1.73	2.53	2.95	1.73	2.36
p Value	0.047	0.45	0.27	0.038	0.31	0.085	0.038	0.31	0.11
Lower limit of 95% CI	1.01	0.513	0.634	1.06	0.601	0.880	1.06	0.601	0.823
Upper limit of 95% CI	7.73	4.47	4.98	8.22	4.96	7.25	8.22	4.96	6.76

[0144] Table 7.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	207	268	211	260	216	258
Average	205	284	207	282	207	281
Stdev	82.7	126	84.7	126	87.0	125
p (t-test)		0.0028		0.0050		0.0076
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	360	651	360	651	360	651
n (Patient)	20	62	19	63	18	64

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	239	281	239	276	239	276
Average	240	297	241	294	241	294
Stdev	108	133	110	131	110	131
p (t-test)		0.044		0.057		0.057
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	46	35	44	37	44	37

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	221	258	216	260	249	257
Average	237	286	234	288	239	284
Stdev	106	128	104	129	106	128
p (t-test)		0.10		0.073		0.13
Min	73.7	110	73.7	110	73.7	110
Max	421	651	421	651	421	651
n (Patient)	21	50	22	49	21	51

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.68	0.62	0.60	0.67	0.61	0.62	0.67	0.61	0.59
SE	0.064	0.063	0.071	0.066	0.063	0.070	0.067	0.063	0.072
p Value	0.0044	0.055	0.15	0.0080	0.072	0.098	0.011	0.072	0.20
nCohort Recovered	20	46	21	19	44	22	18	44	21
nCohort Non-recovered	62	35	50	63	37	49	64	37	51
Cutoff Quartile 2	172	171	174	172	171	174	172	171	175
Sensitivity	79%	83%	80%	79%	84%	80%	80%	84%	80%
Specificity	40%	33%	38%	42%	34%	36%	44%	34%	38%
Cutoff Quartile 3	249	249	253	249	249	253	249	249	251
Sensitivity	55%	54%	52%	54%	54%	53%	53%	54%	51%
Specificity	65%	54%	57%	63%	55%	59%	61%	55%	52%
Cutoff Quartile 4	331	331	339	331	331	339	331	331	337
Sensitivity	29%	34%	28%	29%	32%	29%	28%	32%	27%
Specificity	85%	83%	81%	84%	82%	82%	83%	82%	81%
OR Quartile 2	2.51	2.34	2.46	2.80	2.67	2.23	3.14	2.67	2.52
p Value	0.096	0.12	0.12	0.066	0.073	0.16	0.044	0.073	0.11
Lower limit of 95% CI	0.850	0.799	0.803	0.935	0.913	0.733	1.03	0.913	0.824
Upper limit of 95% CI	7.43	6.84	7.55	8.37	7.82	6.78	9.54	7.82	7.73
OR Quartile 3	2.26	1.41	1.44	2.01	1.41	1.63	1.78	1.41	1.14
p Value	0.13	0.44	0.48	0.19	0.44	0.35	0.29	0.44	0.80
Lower limit of 95% CI	0.792	0.585	0.517	0.699	0.587	0.590	0.613	0.587	0.414
Upper limit of 95% CI	6.42	3.42	4.03	5.78	3.40	4.52	5.18	3.40	3.16
OR Quartile 4	2.32	2.48	1.65	2.13	2.16	1.80	1.96	2.16	1.61
p Value	0.22	0.085	0.43	0.27	0.14	0.36	0.33	0.14	0.46
Lower limit of 95% CI	0.604	0.882	0.473	0.554	0.771	0.517	0.505	0.771	0.460
Upper limit of 95% CI	8.89	6.97	5.78	8.22	6.05	6.27	7.58	6.05	5.62

[0145] Table 7.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	216	277	221	260	235	258
Average	217	294	221	288	221	287
Stdev	84.9	127	88.3	126	90.2	126
p (t-test)		0.0023		0.0095		0.014
Min	73.7	110	73.7	110	73.7	110
Max	360	651	360	651	360	651
n (Patient)	26	54	23	57	22	58

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	239	281	243	279	239	281
Average	245	302	247	299	245	299
Stdev	115	122	116	122	117	120
p (t-test)		0.042		0.061		0.053
Min	73.7	123	73.7	123	73.7	123
Max	651	592	651	592	651	592
n (Patient)	46	33	45	34	44	35

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	243	258	237	257	253	249
Average	241	291	242	288	247	284
Stdev	99.6	133	100	133	101	131
p (t-test)		0.088		0.12		0.21
Min	73.7	110	73.7	110	73.7	110
Max	421	651	421	651	421	651
n (Patient)	25	44	24	45	23	47

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.64	0.59	0.65	0.62	0.58	0.64	0.63	0.56
SE	0.061	0.064	0.070	0.065	0.064	0.071	0.066	0.064	0.072
p Value	0.0047	0.032	0.19	0.025	0.052	0.25	0.035	0.039	0.43
nCohort Recovered	26	46	25	23	45	24	22	44	23
nCohort Non-recovered	54	33	44	57	34	45	58	35	47
Cutoff Quartile 2	176	175	177	176	175	177	176	175	178
Sensitivity	81%	85%	80%	81%	85%	78%	81%	86%	79%
Specificity	38%	33%	36%	39%	33%	33%	41%	34%	35%
Cutoff Quartile 3	251	249	253	251	249	253	251	249	251
Sensitivity	56%	55%	52%	53%	53%	51%	52%	54%	49%
Specificity	62%	54%	56%	57%	53%	54%	55%	55%	48%
Cutoff Quartile 4	332	333	335	332	333	335	332	333	334
Sensitivity	31%	33%	30%	30%	32%	29%	29%	31%	28%
Specificity	88%	80%	84%	87%	80%	83%	86%	80%	78%
OR Quartile 2	2.75	2.71	2.19	2.69	2.90	1.75	2.96	3.10	1.97
p Value	0.058	0.085	0.16	0.069	0.066	0.32	0.048	0.050	0.23
Lower limit of 95% CI	0.965	0.872	0.730	0.927	0.933	0.581	1.01	0.999	0.653
Upper limit of 95% CI	7.83	8.42	6.55	7.80	9.01	5.27	8.66	9.64	5.97
OR Quartile 3	2.00	1.43	1.39	1.44	1.29	1.24	1.29	1.42	0.878
p Value	0.15	0.44	0.51	0.46	0.58	0.68	0.62	0.44	0.80
Lower limit of 95% CI	0.769	0.582	0.520	0.545	0.527	0.458	0.480	0.584	0.324
Upper limit of 95% CI	5.20	3.51	3.74	3.83	3.14	3.34	3.44	3.47	2.38
OR Quartile 4	3.52	2.06	2.20	2.83	1.91	2.03	2.63	1.78	1.38
p Value	0.064	0.17	0.22	0.13	0.21	0.27	0.16	0.27	0.60
Lower limit of 95% CI	0.929	0.736	0.631	0.742	0.687	0.581	0.686	0.641	0.423
Upper limit of 95% CI	13.4	5.74	7.69	10.8	5.33	7.11	10.1	4.96	4.48

[0146] Table 7.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	242	257	251	249	253	248
Average	243	293	244	288	248	285
Stdev	99.5	136	100	133	100	134
p (t-test)		0.072		0.11		0.18
Min	73.7	114	73.7	114	73.7	114
Max	446	651	446	651	446	651
n (Patient)	36	41	32	45	31	46

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	246	263	243	276	243	276
Average	251	297	250	297	250	297
Stdev	117	127	118	125	118	125
p (t-test)		0.12		0.11		0.11
Min	73.7	123	73.7	123	73.7	123
Max	651	592	651	592	651	592
n (Patient)	46	30	45	31	45	31

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	281	246	288	231	295	227
Average	266	293	275	283	281	279
Stdev	90.7	146	87.4	141	85.0	141
p (t-test)		0.41		0.79		0.96
Min	73.7	114	73.7	114	73.7	114
Max	429	651	429	651	429	651
n (Patient)	27	30	23	35	22	36

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	0.60	0.49	0.57	0.61	0.43	0.55	0.61	0.40
SE	0.065	0.067	0.077	0.066	0.067	0.077	0.067	0.067	0.076
p Value	0.18	0.13	0.92	0.29	0.11	0.39	0.44	0.11	0.20
nCohort Recovered	36	46	27	32	45	23	31	45	22
nCohort Non-recovered	41	30	30	45	31	35	46	31	36
Cutoff Quartile 2	174	173	185	174	173	187	174	173	187
Sensitivity	80%	87%	70%	80%	87%	69%	78%	87%	67%
Specificity	33%	33%	22%	34%	33%	17%	32%	33%	14%
Cutoff Quartile 3	249	249	257	249	249	255	249	249	255
Sensitivity	51%	53%	43%	49%	55%	43%	48%	55%	42%
Specificity	53%	52%	44%	50%	53%	39%	48%	53%	36%
Cutoff Quartile 4	335	334	335	335	334	334	335	334	334
Sensitivity	27%	30%	27%	27%	29%	26%	26%	29%	25%
Specificity	78%	78%	78%	78%	78%	74%	77%	78%	73%
OR Quartile 2	2.06	3.15	0.667	2.10	3.38	0.459	1.71	3.38	0.316
p Value	0.17	0.066	0.51	0.16	0.051	0.24	0.30	0.051	0.11
Lower limit of 95% CI	0.731	0.929	0.201	0.746	0.997	0.126	0.613	0.997	0.0778
Upper limit of 95% CI	5.82	10.7	2.21	5.88	11.4	1.67	4.79	11.4	1.28
OR Quartile 3	1.17	1.25	0.612	0.957	1.39	0.482	0.859	1.39	0.408
p Value	0.73	0.64	0.36	0.92	0.48	0.18	0.74	0.48	0.11

Lower limit of 95% CI	0.479	0.496	0.215	0.386	0.554	0.165	0.345	0.554	0.137
Upper limit of 95% CI	2.88	3.13	1.74	2.37	3.48	1.41	2.14	3.48	1.22
OR Quartile 4	1.28	1.54	1.27	1.30	1.43	0.981	1.21	1.43	0.889
p Value	0.64	0.42	0.70	0.63	0.50	0.97	0.73	0.50	0.85
Lower limit of 95% CI	0.451	0.540	0.377	0.447	0.503	0.295	0.416	0.503	0.267
Upper limit of 95% CI	3.65	4.41	4.29	3.78	4.08	3.26	3.52	4.08	2.96

[0147] Table 7.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	239	267	243	257	243	257
Average	235	300	237	296	237	296
Stdev	95.7	135	95.9	135	95.9	135
p (t-test)		0.020		0.034		0.034
Min	73.7	123	73.7	123	73.7	123
Max	421	651	421	651	421	651
n (Patient)	36	38	35	39	35	39

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	246	249	246	249	246	249
Average	249	293	249	293	249	293
Stdev	115	127	115	127	115	127
p (t-test)		0.15		0.15		0.15
Min	73.7	123	73.7	123	73.7	123
Max	651	592	651	592	651	592
n (Patient)	44	29	44	29	44	29

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	273	253	281	249	281	249
Average	262	302	269	297	269	297
Stdev	85.6	143	83.3	143	83.3	143
p (t-test)		0.24		0.39		0.39
Min	73.7	149	73.7	148	73.7	148
Max	395	651	395	651	395	651
n (Patient)	18	30	17	31	17	31

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.59	0.52	0.61	0.59	0.48	0.61	0.59	0.48
SE	0.065	0.069	0.087	0.065	0.069	0.088	0.065	0.069	0.088
p Value	0.048	0.17	0.80	0.096	0.17	0.84	0.096	0.17	0.84

nCohort Recovered	36	44	18	35	44	17	35	44	17
nCohort Non-recovered	38	29	30	39	29	31	39	29	31
Cutoff Quartile 2	175	174	201	175	174	201	175	174	201
Sensitivity	84%	83%	73%	82%	83%	71%	82%	83%	71%
Specificity	36%	32%	22%	34%	32%	18%	34%	32%	18%
Cutoff Quartile 3	249	249	261	249	249	261	249	249	261
Sensitivity	55%	52%	47%	54%	52%	45%	54%	52%	45%
Specificity	56%	52%	44%	54%	52%	41%	54%	52%	41%
Cutoff Quartile 4	331	329	345	331	329	345	331	329	345
Sensitivity	29%	28%	30%	28%	28%	29%	28%	28%	29%
Specificity	78%	77%	83%	77%	77%	82%	77%	77%	82%
OR Quartile 2	3.01	2.24	0.786	2.39	2.24	0.524	2.39	2.24	0.524
p Value	0.050	0.17	0.73	0.11	0.17	0.39	0.11	0.17	0.39
Lower limit of 95% CI	0.998	0.707	0.199	0.814	0.707	0.121	0.814	0.707	0.121
Upper limit of 95% CI	9.11	7.10	3.11	6.99	7.10	2.27	6.99	7.10	2.27
OR Quartile 3	1.54	1.17	0.700	1.39	1.17	0.576	1.39	1.17	0.576
p Value	0.35	0.74	0.55	0.49	0.74	0.37	0.49	0.74	0.37
Lower limit of 95% CI	0.617	0.459	0.216	0.554	0.459	0.174	0.554	0.459	0.174
Upper limit of 95% CI	3.86	3.00	2.26	3.46	3.00	1.91	3.46	3.00	1.91
OR Quartile 4	1.43	1.30	2.14	1.33	1.30	1.91	1.33	1.30	1.91
p Value	0.51	0.64	0.31	0.60	0.64	0.39	0.60	0.64	0.39
Lower limit of 95% CI	0.497	0.441	0.495	0.463	0.441	0.440	0.463	0.441	0.440
Upper limit of 95% CI	4.09	3.80	9.27	3.80	3.80	8.29	3.80	3.80	8.29

[0148] Table 7.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	247	255	246	255	246	255
Average	249	296	249	294	249	294
Stdev	108	144	110	140	110	140
p (t-test)		0.14		0.14		0.14
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	592	651	592	651	592	651
n (Patient)	54	30	52	32	52	32

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	255	221	256	224	256	224
Average	263	271	263	270	263	270
Stdev	120	129	121	127	121	127
p (t-test)		0.81		0.84		0.84
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	590	651	590	651	590
n (Patient)	59	22	58	23	58	23

UO only

Recovery Period Duration (hr)	24	48	72
----------------------------------	----	----	----

	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	248	249	248	249	249	249
Average	253	290	247	293	248	291
Stdev	107	145	94.9	147	95.4	146
p (t-test)		0.21		0.11		0.14
Min	73.7	105	73.7	105	73.7	105
Max	559	651	429	651	429	651
n (Patient)	40	38	42	36	41	37

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.50	0.55	0.58	0.50	0.56	0.58	0.50	0.56
SE	0.066	0.073	0.065	0.065	0.072	0.066	0.065	0.072	0.065
p Value	0.25	0.96	0.43	0.24	0.97	0.33	0.24	0.97	0.38
nCohort Recovered	54	59	40	52	58	42	52	58	41
nCohort Non-recovered	30	22	38	32	23	36	32	23	37
Cutoff Quartile 2	169	171	172	169	171	172	169	171	172
Sensitivity	80%	77%	79%	81%	78%	78%	81%	78%	78%
Specificity	28%	27%	30%	29%	28%	29%	29%	28%	29%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	53%	41%	50%	53%	39%	50%	53%	39%	51%
Specificity	52%	47%	50%	52%	47%	50%	52%	47%	51%
Cutoff Quartile 4	332	331	334	332	331	334	332	331	334
Sensitivity	30%	27%	29%	28%	26%	31%	28%	26%	30%
Specificity	78%	76%	78%	77%	76%	79%	77%	76%	78%
OR Quartile 2	1.54	1.27	1.61	1.76	1.37	1.40	1.76	1.37	1.50
p Value	0.43	0.69	0.37	0.30	0.59	0.52	0.30	0.59	0.44
Lower limit of 95% CI	0.525	0.400	0.572	0.602	0.436	0.499	0.602	0.436	0.534
Upper limit of 95% CI	4.51	4.00	4.51	5.13	4.31	3.93	5.13	4.31	4.21
OR Quartile 3	1.23	0.625	1.00	1.22	0.560	1.00	1.22	0.560	1.11
p Value	0.65	0.35	1.0	0.65	0.25	1.0	0.65	0.25	0.82
Lower limit of 95% CI	0.503	0.232	0.411	0.507	0.209	0.411	0.507	0.209	0.456
Upper limit of 95% CI	3.01	1.69	2.43	2.96	1.50	2.44	2.96	1.50	2.70
OR Quartile 4	1.50	1.21	1.40	1.30	1.11	1.61	1.30	1.11	1.50
p Value	0.43	0.74	0.52	0.60	0.85	0.36	0.60	0.85	0.43
Lower limit of 95% CI	0.546	0.396	0.506	0.477	0.366	0.580	0.477	0.366	0.542
Upper limit of 95% CI	4.12	3.67	3.90	3.56	3.36	4.49	3.56	3.36	4.18

[0149] Example 8. Use of C-C motif chemokine 16 for evaluating renal status in patients admitted to the ICU: Recovery to RIFLE 0 from RIFLE I and F

[0150] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. C-C motif chemokine 16 is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0151] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output during a period starting at 12, 24, 48, or 72 hours after sample collection or at any time within 7 days after sample collection. Two

cohorts are defined to represent a “recovered” and a “non-recovered” population.

“Recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0). “Non-recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is risk of injury (R), injury (I) or failure (F). If a patient dies or is placed on renal replacement therapy (RRT) within 9 days of enrollment, the patient is considered “non-recovered”.

[0152] The ability to distinguish the “recovered” and “non-recovered” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0153] Table 8.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.00821	0.0173	0.0120	0.0157	0.0120	0.0157
Average	0.0135	0.0735	0.0153	0.0717	0.0167	0.0702
Stdev	0.0140	0.346	0.0158	0.342	0.0171	0.338
p (t-test)		0.15		0.17		0.18
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	7.74E-6	4.13E-6
Max	0.0427	2.98	0.0427	2.98	0.0427	2.98
n (Patient)	8	73	6	75	4	77

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.00821	0.0225	0.00715	0.0208	0.0122	0.0182
Average	0.0157	0.0981	0.0162	0.0947	0.0173	0.0913
Stdev	0.0223	0.412	0.0230	0.404	0.0236	0.397
p (t-test)		0.16		0.17		0.18
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.106	2.98	0.106	2.98	0.106	2.98
n (Patient)	30	51	28	53	26	55

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0213	0.0181	0.0231	0.0177	0.0213	0.0177
Average	0.0368	0.0809	0.0405	0.0797	0.0422	0.0776
Stdev	0.0475	0.378	0.0483	0.375	0.0506	0.369
p (t-test)		0.39		0.44		0.48
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98

n (Patient)	11		61	10		62	9		64
Recovery Period Duration (hr)									
	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.68	0.49	0.59	0.67	0.45	0.56	0.64	0.44
SE	0.098	0.060	0.095	0.11	0.061	0.096	0.14	0.064	0.100
p Value	0.26	0.0033	0.94	0.41	0.0067	0.57	0.70	0.030	0.57
nCohort Recovered	8	30	11	6	28	10	4	26	9
nCohort Non-recovered	73	51	61	75	53	62	77	55	64
Cutoff Quartile 2	0.00202	0.00202	0.00161	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202
Sensitivity	71%	78%	74%	72%	79%	71%	71%	78%	70%
Specificity	25%	40%	18%	33%	43%	10%	25%	42%	11%
Cutoff Quartile 3	0.0157	0.0157	0.0193	0.0157	0.0157	0.0193	0.0157	0.0157	0.0181
Sensitivity	51%	59%	49%	49%	57%	48%	49%	55%	48%
Specificity	62%	67%	45%	50%	64%	40%	50%	62%	44%
Cutoff Quartile 4	0.0427	0.0427	0.0464	0.0427	0.0427	0.0464	0.0427	0.0427	0.0460
Sensitivity	27%	35%	26%	27%	34%	26%	26%	33%	25%
Specificity	100%	93%	82%	100%	93%	80%	100%	92%	78%
OR Quartile 2	0.825	2.42	0.625	1.29	2.86	0.272	0.833	2.63	0.296
p Value	0.82	0.079	0.57	0.78	0.039	0.23	0.88	0.060	0.27
Lower limit of 95% CI	0.154	0.901	0.122	0.219	1.05	0.0320	0.0822	0.960	0.0346
Upper limit of 95% CI	4.42	6.52	3.21	7.55	7.79	2.30	8.45	7.20	2.53
OR Quartile 3	1.71	2.86	0.806	0.974	2.35	0.625	0.974	1.92	0.752
p Value	0.48	0.029	0.74	0.97	0.077	0.50	0.98	0.18	0.69
Lower limit of 95% CI	0.381	1.11	0.222	0.185	0.913	0.160	0.131	0.741	0.185
Upper limit of 95% CI	7.70	7.33	2.93	5.14	6.04	2.43	7.27	4.97	3.06
OR Quartile 4	6.51	7.64	1.60	4.80	6.69	1.39	3.21	5.84	1.17
p Value	0.20	0.0099	0.57	0.29	0.016	0.69	0.44	0.026	0.86
Lower limit of 95% CI	0.359	1.63	0.312	0.259	1.42	0.267	0.165	1.24	0.220
Upper limit of 95% CI	118	35.8	8.21	89.1	31.4	7.25	62.2	27.5	6.20

[0154] Table 8.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0151	0.0173	0.0209	0.0155	0.0206	0.0157
Average	0.0159	0.0768	0.0207	0.0737	0.0201	0.0730
Stdev	0.0128	0.356	0.0115	0.349	0.0122	0.347
p (t-test)		0.16		0.21		0.20
Min	6.68E-6	4.13E-6	0.00279	4.13E-6	0.00279	4.13E-6
Max	0.0427	2.98	0.0427	2.98	0.0427	2.98
n (Patient)	11	69	8	72	7	73

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.00908	0.0225	0.0122	0.0195	0.0122	0.0195

Average	0.0159	0.102	0.0171	0.0960	0.0171	0.0960
Stdev	0.0222	0.420	0.0231	0.408	0.0231	0.408
p (t-test)		0.16		0.17		0.17
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.106	2.98	0.106	2.98	0.106	2.98
n (Patient)	31	49	28	52	28	52

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0209	0.0190	0.0213	0.0173	0.0209	0.0173
Average	0.0366	0.0881	0.0395	0.0866	0.0407	0.0840
Stdev	0.0417	0.401	0.0419	0.398	0.0434	0.391
p (t-test)		0.36		0.40		0.42
Min	6.68E-6	4.13E-6	0.00856	4.13E-6	0.00856	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	14	54	13	55	12	57

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.69	0.44	0.47	0.65	0.40	0.48	0.65	0.39
SE	0.090	0.059	0.084	0.11	0.062	0.084	0.11	0.062	0.085
p Value	0.40	0.0016	0.49	0.76	0.013	0.23	0.85	0.013	0.20
nCohort Recovered	11	31	14	8	28	13	7	28	12
nCohort Non-recovered	69	49	54	72	52	55	73	52	57
Cutoff Quartile 2	0.00202	0.00202	0.00161	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202
Sensitivity	71%	82%	70%	69%	81%	67%	70%	81%	67%
Specificity	18%	42%	7%	0%	43%	0%	0%	43%	0%
Cutoff Quartile 3	0.0165	0.0165	0.0207	0.0165	0.0165	0.0207	0.0165	0.0165	0.0206
Sensitivity	51%	59%	50%	49%	56%	49%	49%	56%	49%
Specificity	55%	65%	50%	38%	61%	46%	43%	61%	50%
Cutoff Quartile 4	0.0435	0.0435	0.0464	0.0435	0.0435	0.0464	0.0435	0.0435	0.0460
Sensitivity	29%	37%	26%	28%	35%	25%	27%	35%	25%
Specificity	100%	94%	79%	100%	93%	77%	100%	93%	75%
OR Quartile 2	0.544	3.21	0.183	0.132	3.15	0.0751	0.153	3.15	0.0790
p Value	0.46	0.024	0.12	0.17	0.027	0.078	0.20	0.027	0.084
Lower limit of 95% CI	0.108	1.16	0.0220	0.00730	1.14	0.00423	0.00835	1.14	0.00444
Upper limit of 95% CI	2.75	8.86	1.52	2.39	8.72	1.33	2.79	8.72	1.41
OR Quartile 3	1.24	2.64	1.00	0.568	1.95	0.827	0.730	1.95	0.966
p Value	0.75	0.041	1.0	0.46	0.16	0.76	0.69	0.16	0.96
Lower limit of 95% CI	0.344	1.04	0.309	0.126	0.765	0.246	0.152	0.765	0.278
Upper limit of 95% CI	4.43	6.69	3.24	2.55	4.96	2.78	3.49	4.96	3.35
OR Quartile 4	9.53	8.42	1.28	6.64	6.88	1.14	5.75	6.88	0.977
p Value	0.12	0.0069	0.73	0.20	0.015	0.86	0.24	0.015	0.97
Lower limit of 95% CI	0.536	1.79	0.312	0.366	1.46	0.274	0.314	1.46	0.232
Upper limit of 95% CI	169	39.5	5.28	120	32.3	4.74	105	32.3	4.12

[0155] Table 8.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0157	0.0173	0.0157	0.0173	0.0157	0.0173
Average	0.0210	0.0875	0.0218	0.0850	0.0218	0.0850
Stdev	0.0231	0.391	0.0237	0.384	0.0237	0.384
p (t-test)		0.21		0.22		0.22
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.106	2.98	0.106	2.98	0.106	2.98
n (Patient)	23	57	21	59	21	59

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0146	0.0208	0.0142	0.0217	0.0142	0.0217
Average	0.0183	0.106	0.0174	0.105	0.0174	0.105
Stdev	0.0227	0.438	0.0224	0.433	0.0224	0.433
p (t-test)		0.19		0.18		0.18
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.106	2.98	0.106	2.98	0.106	2.98
n (Patient)	34	45	33	46	33	46

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0227	0.0208	0.0227	0.0190	0.0227	0.0190
Average	0.0348	0.116	0.0368	0.108	0.0368	0.108
Stdev	0.0385	0.481	0.0397	0.464	0.0397	0.464
p (t-test)		0.32		0.34		0.34
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	22	37	20	40	20	40

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.54	0.63	0.46	0.52	0.65	0.43	0.52	0.65	0.43
SE	0.071	0.062	0.078	0.073	0.062	0.078	0.073	0.062	0.078
p Value	0.58	0.032	0.60	0.77	0.016	0.38	0.77	0.016	0.38
nCohort Recovered	23	34	22	21	33	20	21	33	20
nCohort Non-recovered	57	45	37	59	46	40	59	46	40
Cutoff Quartile 2	0.00202	0.00202	0.00393	0.00202	0.00202	0.00260	0.00202	0.00202	0.00260
Sensitivity	70%	80%	65%	69%	80%	68%	69%	80%	68%
Specificity	22%	38%	9%	19%	39%	10%	19%	39%	10%
Cutoff Quartile 3	0.0165	0.0157	0.0208	0.0165	0.0157	0.0207	0.0165	0.0157	0.0207
Sensitivity	51%	56%	49%	51%	57%	50%	51%	57%	50%
Specificity	52%	59%	50%	52%	61%	50%	52%	61%	50%
Cutoff Quartile 4	0.0435	0.0427	0.0467	0.0435	0.0427	0.0464	0.0435	0.0427	0.0464
Sensitivity	32%	33%	27%	31%	35%	25%	31%	35%	25%
Specificity	91%	88%	77%	90%	91%	75%	90%	91%	75%
OR Quartile 2	0.654	2.48	0.185	0.536	2.67	0.231	0.536	2.67	0.231
p Value	0.47	0.077	0.039	0.32	0.056	0.073	0.32	0.056	0.073
Lower limit of 95% CI	0.209	0.906	0.0372	0.158	0.974	0.0464	0.158	0.974	0.0464
Upper limit of 95% CI	2.05	6.77	0.917	1.82	7.33	1.15	1.82	7.33	1.15
OR Quartile 3	1.13	1.79	0.947	1.14	2.00	1.00	1.14	2.00	1.00
p Value	0.80	0.21	0.92	0.80	0.14	1.0	0.80	0.14	1.0
Lower limit of 95% CI	0.429	0.725	0.330	0.420	0.805	0.342	0.420	0.805	0.342

Upper limit of 95% CI	2.98	4.40	2.72	3.08	4.97	2.93	3.08	4.97	2.93
OR Quartile 4	4.85	3.75	1.26	4.17	5.33	1.00	4.17	5.33	1.00
p Value	0.047	0.033	0.71	0.073	0.014	1.0	0.073	0.014	1.0
Lower limit of 95% CI	1.02	1.11	0.367	0.877	1.41	0.289	0.877	1.41	0.289
Upper limit of 95% CI	22.9	12.6	4.32	19.8	20.2	3.45	19.8	20.2	3.45

[0156] Table 8.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0152	0.0182	0.0153	0.0177	0.0153	0.0177
Average	0.0216	0.0915	0.0225	0.0898	0.0225	0.0898
Stdev	0.0287	0.405	0.0290	0.401	0.0290	0.401
p (t-test)		0.22		0.23		0.23
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.113	2.98	0.113	2.98	0.113	2.98
n (Patient)	26	53	25	54	25	54

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0151	0.0177	0.0146	0.0182	0.0152	0.0173
Average	0.0191	0.108	0.0179	0.107	0.0190	0.102
Stdev	0.0229	0.453	0.0220	0.448	0.0222	0.438
p (t-test)		0.22		0.20		0.21
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.106	2.98	0.106	2.98	0.106	2.98
n (Patient)	35	42	34	43	32	45

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0293	0.0225	0.0296	0.0217	0.0296	0.0217
Average	0.0427	0.122	0.0453	0.118	0.0453	0.118
Stdev	0.0434	0.494	0.0434	0.488	0.0434	0.488
p (t-test)		0.36		0.39		0.39
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	17	35	16	36	16	36

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.60	0.45	0.56	0.62	0.41	0.56	0.58	0.41
SE	0.067	0.064	0.085	0.069	0.064	0.084	0.069	0.066	0.084
p Value	0.21	0.11	0.55	0.37	0.056	0.29	0.37	0.23	0.29
nCohort Recovered	26	35	17	25	34	16	25	32	16

nCohort Non-recovered	53	42	35	54	43	36	54	45	36
Cutoff Quartile 2	0.00202	0.00202	0.00449	0.00202	0.00202	0.00449	0.00202	0.00202	0.00449
Sensitivity	74%	79%	71%	72%	79%	69%	72%	76%	69%
Specificity	31%	37%	18%	28%	38%	12%	28%	34%	12%
Cutoff Quartile 3	0.0157	0.0153	0.0237	0.0157	0.0153	0.0237	0.0157	0.0153	0.0237
Sensitivity	53%	52%	49%	52%	53%	47%	52%	51%	47%
Specificity	58%	54%	47%	56%	56%	44%	56%	53%	44%
Cutoff Quartile 4	0.0427	0.0411	0.0494	0.0427	0.0411	0.0494	0.0427	0.0411	0.0494
Sensitivity	30%	31%	23%	30%	33%	22%	30%	31%	22%
Specificity	88%	83%	71%	88%	85%	69%	88%	84%	69%
OR Quartile 2	1.24	2.17	0.536	1.01	2.34	0.325	1.01	1.62	0.325
p Value	0.69	0.13	0.40	0.98	0.099	0.18	0.98	0.34	0.18
Lower limit of 95% CI	0.441	0.792	0.126	0.351	0.853	0.0628	0.351	0.597	0.0628
Upper limit of 95% CI	3.48	5.93	2.28	2.91	6.42	1.68	2.91	4.39	1.68
OR Quartile 3	1.53	1.31	0.840	1.37	1.46	0.696	1.37	1.18	0.696
p Value	0.38	0.56	0.77	0.52	0.41	0.55	0.52	0.71	0.55
Lower limit of 95% CI	0.593	0.531	0.263	0.528	0.590	0.213	0.528	0.478	0.213
Upper limit of 95% CI	3.94	3.21	2.68	3.56	3.60	2.28	3.56	2.94	2.28
OR Quartile 4	3.32	2.17	0.711	3.09	2.80	0.629	3.09	2.44	0.629
p Value	0.079	0.17	0.61	0.099	0.078	0.49	0.099	0.13	0.49
Lower limit of 95% CI	0.869	0.724	0.192	0.808	0.892	0.168	0.808	0.777	0.168
Upper limit of 95% CI	12.6	6.48	2.63	11.8	8.79	2.35	11.8	7.66	2.35

[0157] Table 8.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0151	0.0177	0.0153	0.0171	0.0153	0.0171
Average	0.0265	0.105	0.0250	0.0996	0.0254	0.0961
Stdev	0.0352	0.453	0.0302	0.434	0.0309	0.425
p (t-test)		0.27		0.26		0.26
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.113	2.98	0.113	2.98
n (Patient)	41	42	37	46	35	48

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0152	0.0182	0.0152	0.0182	0.0155	0.0173
Average	0.0268	0.127	0.0245	0.124	0.0254	0.113
Stdev	0.0341	0.509	0.0294	0.494	0.0301	0.469
p (t-test)		0.27		0.25		0.26
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.113	2.98	0.113	2.98
n (Patient)	48	33	46	35	42	39

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0206	0.0150	0.0181	0.0150	0.0169	0.0151
Average	0.0322	0.0925	0.0297	0.0933	0.0299	0.0919
Stdev	0.0413	0.425	0.0365	0.425	0.0371	0.421
p (t-test)		0.34		0.31		0.31
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.191	2.98	0.151	2.98	0.151	2.98
n (Patient)	31	48	31	48	30	49

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	0.57	0.47	0.55	0.58	0.49	0.55	0.56	0.50
SE	0.063	0.066	0.067	0.063	0.065	0.067	0.064	0.064	0.067
p Value	0.27	0.31	0.67	0.39	0.21	0.88	0.39	0.37	0.94
nCohort Recovered	41	48	31	37	46	31	35	42	30
nCohort Non-recovered	42	33	48	46	35	48	48	39	49
Cutoff Quartile 2	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202
Sensitivity	76%	79%	69%	76%	80%	69%	77%	79%	69%
Specificity	32%	33%	23%	32%	35%	23%	34%	36%	23%
Cutoff Quartile 3	0.0157	0.0157	0.0157	0.0157	0.0157	0.0157	0.0157	0.0157	0.0157
Sensitivity	55%	55%	46%	52%	54%	48%	52%	51%	49%
Specificity	56%	54%	45%	54%	54%	48%	54%	52%	50%
Cutoff Quartile 4	0.0427	0.0427	0.0427	0.0427	0.0427	0.0427	0.0427	0.0427	0.0427
Sensitivity	26%	27%	23%	26%	29%	25%	25%	28%	24%
Specificity	78%	77%	74%	78%	78%	77%	77%	79%	77%
OR Quartile 2	1.49	1.86	0.642	1.53	2.13	0.642	1.75	2.15	0.690
p Value	0.42	0.24	0.40	0.39	0.15	0.40	0.26	0.13	0.48
Lower limit of 95% CI	0.564	0.664	0.227	0.581	0.764	0.227	0.666	0.791	0.243
Upper limit of 95% CI	3.91	5.19	1.82	4.01	5.96	1.82	4.63	5.86	1.95
OR Quartile 3	1.55	1.42	0.697	1.28	1.41	0.862	1.29	1.16	0.960
p Value	0.32	0.44	0.44	0.57	0.44	0.75	0.57	0.74	0.93
Lower limit of 95% CI	0.651	0.582	0.281	0.539	0.585	0.349	0.539	0.484	0.387
Upper limit of 95% CI	3.68	3.45	1.73	3.06	3.42	2.13	3.09	2.77	2.38
OR Quartile 4	1.26	1.26	0.855	1.28	1.44	1.14	1.12	1.44	1.07
p Value	0.65	0.66	0.77	0.64	0.48	0.81	0.82	0.48	0.91
Lower limit of 95% CI	0.460	0.455	0.299	0.460	0.522	0.394	0.404	0.522	0.366
Upper limit of 95% CI	3.46	3.50	2.44	3.56	3.97	3.32	3.13	3.97	3.10

[0158] Table 8.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.48	9.96	8.41	10.0	8.48	9.96
Average	8.83	12.4	6.73	12.4	8.01	12.3
Stdev	4.38	8.96	2.95	8.82	1.64	8.85
p (t-test)		0.090		0.012		0.0088
Min	1.62	1.32	1.62	1.32	5.31	1.32

Max	15.9	38.9	9.75	38.9	9.75	38.9
n (Patient)	8	74	5	77	4	78

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.90	10.6	7.72	10.9	7.90	10.6
Average	9.48	13.8	9.08	13.8	9.33	13.5
Stdev	5.27	9.94	5.22	9.75	5.29	9.70
p (t-test)		0.014		0.0061		0.015
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	22.8	38.9	22.8	38.9	22.8	38.9
n (Patient)	31	50	29	52	27	54

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.48	9.53	8.56	9.28	10.8	8.94
Average	12.3	11.8	12.9	11.8	14.3	11.6
Stdev	8.63	8.65	8.87	8.62	8.41	8.59
p (t-test)		0.88		0.75		0.43
Min	1.62	1.32	1.62	1.32	5.31	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	10	61	9	62	8	64

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.62	0.48	0.69	0.64	0.46	0.61	0.62	0.38
SE	0.10	0.063	0.098	0.11	0.062	0.10	0.13	0.064	0.098
p Value	0.40	0.065	0.83	0.074	0.020	0.66	0.40	0.057	0.22
nCohort Recovered	8	31	10	5	29	9	4	27	8
nCohort Non-recovered	74	50	61	77	52	62	78	54	64
Cutoff Quartile 2	6.18	6.19	6.19	6.18	6.19	6.19	6.18	6.19	6.19
Sensitivity	74%	78%	74%	75%	79%	74%	74%	78%	73%
Specificity	25%	32%	20%	40%	34%	22%	25%	33%	12%
Cutoff Quartile 3	9.66	9.75	9.00	9.66	9.75	9.00	9.66	9.75	8.94
Sensitivity	51%	58%	51%	52%	60%	50%	51%	57%	50%
Specificity	62%	65%	60%	80%	69%	56%	75%	67%	50%
Cutoff Quartile 4	15.6	15.9	14.3	15.6	15.9	14.6	15.6	15.9	14.6
Sensitivity	27%	32%	25%	27%	31%	24%	27%	30%	23%
Specificity	88%	87%	70%	100%	86%	67%	100%	85%	62%
OR Quartile 2	0.965	1.69	0.703	2.04	1.96	0.821	0.967	1.75	0.395
p Value	0.97	0.31	0.68	0.45	0.19	0.82	0.98	0.28	0.40
Lower limit of 95% CI	0.179	0.617	0.135	0.316	0.711	0.154	0.0950	0.628	0.0452
Upper limit of 95% CI	5.19	4.62	3.67	13.1	5.41	4.37	9.83	4.88	3.45
OR Quartile 3	1.76	2.51	1.55	4.32	3.28	1.25	3.16	2.70	1.00
p Value	0.46	0.051	0.53	0.20	0.016	0.76	0.33	0.044	1.0
Lower limit of 95% CI	0.392	0.995	0.397	0.462	1.25	0.306	0.315	1.03	0.230
Upper limit of 95% CI	7.90	6.34	6.05	40.5	8.59	5.10	31.7	7.08	4.35
OR Quartile 4	2.59	3.18	0.761	4.19	2.78	0.638	3.37	2.42	0.510
p Value	0.39	0.060	0.72	0.34	0.098	0.56	0.42	0.15	0.39
Lower limit of 95% CI	0.300	0.950	0.174	0.222	0.829	0.142	0.174	0.721	0.109
Upper limit of 95% CI	22.4	10.6	3.32	79.0	9.30	2.87	65.2	8.13	2.39

[0159] Table 8.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts

at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	6.35	10.2	5.75	10.2	7.30	9.96
Average	9.04	12.5	8.67	12.5	10.7	12.2
Stdev	7.82	8.84	8.47	8.74	8.89	8.77
p (t-test)		0.24		0.29		0.72
Min	1.62	1.32	1.62	1.32	5.31	1.32
Max	30.3	38.9	30.3	38.9	30.3	38.9
n (Patient)	10	70	8	72	6	74

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.72	10.9	7.38	10.9	7.64	10.7
Average	9.80	13.7	9.71	13.6	9.92	13.4
Stdev	6.40	9.78	6.54	9.62	6.56	9.62
p (t-test)		0.037		0.038		0.064
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.3	38.9	30.3	38.9	30.3	38.9
n (Patient)	31	48	29	50	28	51

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.94	9.74	8.17	9.91	8.41	9.56
Average	10.2	12.4	10.4	12.4	11.1	12.1
Stdev	7.79	8.93	8.00	8.89	7.91	8.87
p (t-test)		0.36		0.44		0.69
Min	1.62	1.32	1.62	1.32	3.20	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	15	54	14	55	13	57

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	0.62	0.59	0.69	0.63	0.58	0.59	0.61	0.53
SE	0.085	0.063	0.081	0.088	0.063	0.083	0.11	0.065	0.088
p Value	0.076	0.053	0.28	0.031	0.038	0.36	0.42	0.082	0.72
nCohort Recovered	10	31	15	8	29	14	6	28	13
nCohort Non-recovered	70	48	54	72	50	55	74	51	57
Cutoff Quartile 2	6.16	6.19	6.18	6.16	6.19	6.18	6.16	6.19	6.19
Sensitivity	77%	79%	76%	78%	80%	76%	76%	78%	75%
Specificity	40%	32%	33%	50%	34%	36%	33%	32%	31%
Cutoff Quartile 3	9.28	9.56	9.00	9.28	9.56	9.00	9.28	9.56	8.94
Sensitivity	54%	58%	54%	54%	58%	53%	53%	57%	53%
Specificity	80%	65%	67%	88%	66%	64%	83%	64%	62%
Cutoff Quartile 4	16.0	16.1	14.5	16.0	16.1	14.7	16.0	16.1	14.7
Sensitivity	27%	31%	26%	26%	30%	25%	26%	29%	26%
Specificity	90%	84%	80%	88%	83%	79%	83%	82%	77%
OR Quartile 2	2.25	1.81	1.58	3.50	2.11	1.79	1.56	1.72	1.37

p Value	0.25	0.26	0.47	0.10	0.16	0.36	0.63	0.30	0.64
Lower limit of 95% CI	0.565	0.649	0.456	0.786	0.750	0.510	0.263	0.611	0.363
Upper limit of 95% CI	8.97	5.05	5.46	15.6	5.91	6.31	9.21	4.86	5.13
OR Quartile 3	4.75	2.55	2.32	8.27	2.62	2.01	5.57	2.37	1.78
p Value	0.059	0.050	0.17	0.054	0.046	0.26	0.13	0.075	0.36
Lower limit of 95% CI	0.941	1.00	0.699	0.968	1.02	0.596	0.620	0.917	0.518
Upper limit of 95% CI	24.0	6.47	7.70	70.7	6.78	6.76	50.0	6.14	6.10
OR Quartile 4	3.35	2.36	1.40	2.51	2.06	1.25	1.73	1.92	1.19
p Value	0.27	0.14	0.64	0.40	0.21	0.76	0.63	0.26	0.81
Lower limit of 95% CI	0.398	0.760	0.344	0.289	0.659	0.305	0.190	0.613	0.288
Upper limit of 95% CI	28.3	7.35	5.70	21.8	6.42	5.15	15.7	5.99	4.92

[0160] Table 8.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.11	10.6	8.15	10.3	8.15	10.3
Average	9.28	13.1	10.1	12.7	10.1	12.7
Stdev	6.82	8.98	6.94	8.98	6.94	8.98
p (t-test)		0.055		0.23		0.23
Min	1.62	1.32	3.20	1.32	3.20	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	21	56	18	59	18	59

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.25	11.5	7.38	11.0	7.38	11.0
Average	8.89	14.0	9.06	13.7	9.06	13.7
Stdev	5.17	9.57	5.16	9.58	5.16	9.58
p (t-test)		0.0046		0.0085		0.0085
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	22.8	38.9	22.8	38.9	22.8	38.9
n (Patient)	32	44	31	45	31	45

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.41	10.0	9.39	9.74	9.39	9.74
Average	11.6	13.0	12.4	12.4	12.4	12.4
Stdev	7.66	9.86	7.63	9.71	7.63	9.71
p (t-test)		0.57		0.99		0.99
Min	1.62	1.32	3.20	1.32	3.20	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	20	37	18	40	18	40

Recovery Period Duration (hr)	24	48	72
----------------------------------	----	----	----

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	0.67	0.52	0.59	0.65	0.47	0.59	0.65	0.47
SE	0.067	0.062	0.080	0.074	0.063	0.082	0.074	0.063	0.082
p Value	0.023	0.0061	0.78	0.21	0.017	0.73	0.21	0.017	0.73
nCohort Recovered	21	32	20	18	31	18	18	31	18
nCohort Non-recovered	56	44	37	59	45	40	59	45	40
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.29	6.19	6.19	6.29
Sensitivity	80%	82%	76%	78%	80%	75%	78%	80%	75%
Specificity	43%	34%	30%	39%	32%	28%	39%	32%	28%
Cutoff Quartile 3	9.56	9.28	9.91	9.56	9.28	9.74	9.56	9.28	9.74
Sensitivity	57%	61%	51%	54%	60%	50%	54%	60%	50%
Specificity	71%	66%	55%	67%	65%	50%	67%	65%	50%
Cutoff Quartile 4	15.9	15.0	15.9	15.9	15.0	15.6	15.9	15.0	15.6
Sensitivity	29%	34%	24%	27%	33%	25%	27%	33%	25%
Specificity	86%	88%	75%	83%	87%	72%	83%	87%	72%
OR Quartile 2	3.07	2.36	1.33	2.25	1.90	1.15	2.25	1.90	1.15
p Value	0.043	0.11	0.64	0.16	0.23	0.82	0.16	0.23	0.82
Lower limit of 95% CI	1.03	0.818	0.395	0.727	0.667	0.329	0.727	0.667	0.329
Upper limit of 95% CI	9.10	6.79	4.50	6.97	5.44	4.05	6.97	5.44	4.05
OR Quartile 3	3.33	3.03	1.29	2.37	2.73	1.00	2.37	2.73	1.00
p Value	0.030	0.022	0.65	0.13	0.038	1.0	0.13	0.038	1.0
Lower limit of 95% CI	1.13	1.17	0.433	0.784	1.06	0.329	0.784	1.06	0.329
Upper limit of 95% CI	9.86	7.83	3.84	7.16	7.03	3.04	7.16	7.03	3.04
OR Quartile 4	2.40	3.62	0.964	1.86	3.38	0.867	1.86	3.38	0.867
p Value	0.20	0.039	0.95	0.37	0.051	0.82	0.37	0.051	0.82
Lower limit of 95% CI	0.620	1.07	0.273	0.475	0.997	0.247	0.475	0.997	0.247
Upper limit of 95% CI	9.28	12.3	3.40	7.29	11.4	3.04	7.29	11.4	3.04

[0161] Table 8.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.17	10.6	8.17	10.6	8.17	10.6
Average	9.65	12.8	9.65	12.8	9.65	12.8
Stdev	5.94	9.17	5.94	9.17	5.94	9.17
p (t-test)		0.094		0.094		0.094
Min	3.20	1.32	3.20	1.32	3.20	1.32
Max	24.1	38.9	24.1	38.9	24.1	38.9
n (Patient)	22	52	22	52	22	52

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.90	10.9	7.90	10.9	7.94	10.6
Average	10.4	12.7	9.67	13.1	9.84	12.9
Stdev	8.00	8.57	6.69	9.18	6.88	9.05
p (t-test)		0.26		0.071		0.12
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	36.8	38.9	34.6	38.9	34.6	38.9
n (Patient)	33	40	31	42	29	44

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	10.2	9.46	10.2	9.46	10.2	9.46
Average	11.9	12.8	11.9	12.8	11.9	12.8
Stdev	5.52	10.2	5.52	10.2	5.52	10.2
p (t-test)		0.69		0.69		0.69
Min	5.31	1.32	5.31	1.32	5.31	1.32
Max	24.1	38.9	24.1	38.9	24.1	38.9
n (Patient)	14	34	14	34	14	34

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.60	0.45	0.60	0.63	0.45	0.60	0.61	0.45
SE	0.070	0.066	0.091	0.070	0.065	0.091	0.070	0.066	0.091
p Value	0.16	0.12	0.58	0.16	0.055	0.58	0.16	0.10	0.58
nCohort Recovered	22	33	14	22	31	14	22	29	14
nCohort Non-recovered	52	40	34	52	42	34	52	44	34
Cutoff Quartile 2	6.19	6.18	6.96	6.19	6.18	6.96	6.19	6.18	6.96
Sensitivity	79%	78%	71%	79%	79%	71%	79%	80%	71%
Specificity	36%	30%	14%	36%	32%	14%	36%	34%	14%
Cutoff Quartile 3	9.28	9.00	9.96	9.28	9.00	9.96	9.28	9.00	9.96
Sensitivity	56%	60%	47%	56%	60%	47%	56%	57%	47%
Specificity	64%	64%	43%	64%	65%	43%	64%	62%	43%
Cutoff Quartile 4	14.7	14.6	14.9	14.7	14.6	14.9	14.7	14.6	14.9
Sensitivity	31%	32%	26%	31%	33%	26%	31%	32%	26%
Specificity	86%	85%	79%	86%	87%	79%	86%	86%	79%
OR Quartile 2	2.13	1.50	0.400	2.13	1.75	0.400	2.13	2.05	0.400
p Value	0.18	0.45	0.28	0.18	0.30	0.28	0.18	0.19	0.28
Lower limit of 95% CI	0.713	0.524	0.0754	0.713	0.609	0.0754	0.713	0.709	0.0754
Upper limit of 95% CI	6.36	4.28	2.12	6.36	5.01	2.12	6.36	5.91	2.12
OR Quartile 3	2.21	2.62	0.667	2.21	2.67	0.667	2.21	2.15	0.667
p Value	0.13	0.047	0.53	0.13	0.045	0.53	0.13	0.12	0.53
Lower limit of 95% CI	0.790	1.01	0.190	0.790	1.02	0.190	0.790	0.826	0.190
Upper limit of 95% CI	6.16	6.79	2.34	6.16	6.98	2.34	6.16	5.61	2.34
OR Quartile 4	2.81	2.70	1.32	2.81	3.38	1.32	2.81	2.92	1.32
p Value	0.13	0.093	0.71	0.13	0.053	0.71	0.13	0.088	0.71
Lower limit of 95% CI	0.728	0.846	0.298	0.728	0.986	0.298	0.728	0.851	0.298
Upper limit of 95% CI	10.9	8.59	5.84	10.9	11.6	5.84	10.9	9.99	5.84

[0162] Table 8.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	9.06	10.2	8.48	10.5	8.48	10.5
Average	11.3	12.9	11.1	13.0	11.2	12.8
Stdev	7.16	9.92	7.39	9.52	7.40	9.46
p (t-test)		0.41		0.32		0.42
Min	1.62	1.32	1.62	1.32	3.20	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9

n (Patient)	44	40	40	44	38	46
-------------	----	----	----	----	----	----

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.48	10.4	8.41	10.5	8.41	10.5
Average	11.6	12.9	11.4	13.1	11.4	12.9
Stdev	7.97	9.65	8.08	9.40	8.39	8.99
p (t-test)		0.54		0.41		0.46
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	36.8	38.9	36.8	38.9	36.8	38.9
n (Patient)	48	33	46	35	42	39

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.48	10.2	8.41	10.4	8.48	10.2
Average	11.1	13.1	10.4	13.2	10.7	13.0
Stdev	7.72	9.28	6.57	9.30	6.48	9.36
p (t-test)		0.33		0.12		0.21
Min	1.62	1.32	1.62	1.32	3.20	1.32
Max	33.3	38.9	30.8	38.9	30.8	38.9
n (Patient)	30	48	31	47	30	48

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	0.53	0.55	0.56	0.55	0.58	0.54	0.56	0.55
SE	0.063	0.066	0.067	0.063	0.065	0.066	0.063	0.064	0.067
p Value	0.69	0.65	0.44	0.38	0.40	0.24	0.49	0.31	0.43
nCohort Recovered	44	48	30	40	46	31	38	42	30
nCohort Non-recovered	40	33	48	44	35	47	46	39	48
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	75%	76%	75%	77%	77%	77%	76%	79%	75%
Specificity	25%	27%	30%	28%	28%	32%	26%	31%	30%
Cutoff Quartile 3	9.66	9.75	9.66	9.66	9.75	9.66	9.66	9.75	9.66
Sensitivity	52%	55%	54%	55%	57%	55%	54%	56%	54%
Specificity	52%	54%	57%	55%	57%	58%	55%	57%	57%
Cutoff Quartile 4	16.0	15.9	15.6	16.0	15.9	15.6	16.0	15.9	15.6
Sensitivity	30%	30%	31%	30%	31%	32%	28%	28%	31%
Specificity	80%	79%	83%	80%	80%	84%	79%	79%	83%
OR Quartile 2	1.00	1.16	1.29	1.29	1.33	1.56	1.14	1.74	1.29
p Value	1.0	0.77	0.63	0.61	0.58	0.39	0.80	0.29	0.63
Lower limit of 95% CI	0.372	0.419	0.464	0.480	0.481	0.567	0.422	0.629	0.464
Upper limit of 95% CI	2.69	3.22	3.56	3.47	3.68	4.29	3.06	4.80	3.56
OR Quartile 3	1.21	1.42	1.55	1.47	1.73	1.71	1.47	1.73	1.55
p Value	0.66	0.44	0.35	0.38	0.22	0.25	0.38	0.22	0.35
Lower limit of 95% CI	0.514	0.582	0.617	0.620	0.713	0.686	0.620	0.716	0.617
Upper limit of 95% CI	2.85	3.45	3.87	3.47	4.21	4.29	3.49	4.16	3.87
OR Quartile 4	1.67	1.65	2.27	1.68	1.88	2.44	1.48	1.44	2.27
p Value	0.32	0.33	0.16	0.32	0.22	0.12	0.45	0.48	0.16
Lower limit of 95% CI	0.615	0.597	0.728	0.611	0.680	0.782	0.538	0.522	0.728
Upper limit of 95% CI	4.52	4.57	7.09	4.60	5.22	7.60	4.06	3.97	7.09

[0163] Example 9. Use of C-C motif chemokine 16 for evaluating renal status in patients admitted to the ICU: Recovery to RIFLE 0 and R from RIFLE I and F

[0164] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. C-C motif chemokine 16 is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0165] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output during a period starting at 12, 24, 48, or 72 hours after sample collection or at any time within 7 days after sample collection. Two cohorts are defined to represent a “recovered” and a “non-recovered” population.

“Recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0) or risk of injury (R). “Non-recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is injury (I) or failure (F). If a patient dies or is placed on renal replacement therapy (RRT) within 9 days of enrollment, the patient is considered “non-recovered”.

[0166] The ability to distinguish the “recovered” and “non-recovered” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0167] Table 9.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.00734	0.0207	0.00738	0.0206	0.00908	0.0194
Average	0.0126	0.0844	0.0129	0.0832	0.0134	0.0819
Stdev	0.0148	0.375	0.0151	0.372	0.0154	0.369
p (t-test)		0.14		0.14		0.15
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.0518	2.98	0.0518	2.98	0.0518	2.98
n (Patient)	19	62	18	63	17	64

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0108	0.0262	0.0142	0.0217	0.0142	0.0217
Average	0.0190	0.135	0.0197	0.127	0.0197	0.127
Stdev	0.0228	0.500	0.0230	0.487	0.0230	0.487
p (t-test)		0.19		0.20		0.20
Min	4.13E-6	6.68E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.106	2.98	0.106	2.98	0.106	2.98
n (Patient)	47	34	45	36	45	36

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0125	0.0217	0.0108	0.0225	0.0125	0.0208
Average	0.0293	0.0914	0.0282	0.0932	0.0290	0.0899
Stdev	0.0407	0.408	0.0400	0.412	0.0409	0.405
p (t-test)		0.29		0.28		0.29
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	20	52	21	51	20	53

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.68	0.55	0.67	0.64	0.57	0.66	0.64	0.56
SE	0.066	0.061	0.075	0.068	0.062	0.073	0.069	0.062	0.074
p Value	0.0095	0.0039	0.48	0.014	0.023	0.37	0.021	0.023	0.40
nCohort Recovered	19	47	20	18	45	21	17	45	20
nCohort Non-recovered	62	34	52	63	36	51	64	36	53
Cutoff Quartile 2	0.00202	0.00202	0.00161	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202
Sensitivity	73%	82%	73%	73%	81%	73%	73%	81%	74%
Specificity	32%	36%	20%	33%	36%	24%	35%	36%	30%
Cutoff Quartile 3	0.0157	0.0157	0.0193	0.0157	0.0157	0.0193	0.0157	0.0157	0.0181
Sensitivity	56%	62%	54%	56%	58%	55%	55%	58%	53%
Specificity	74%	60%	60%	72%	58%	62%	71%	58%	60%
Cutoff Quartile 4	0.0427	0.0427	0.0464	0.0427	0.0427	0.0464	0.0427	0.0427	0.0460
Sensitivity	31%	38%	27%	30%	36%	27%	30%	36%	26%
Specificity	95%	85%	80%	94%	84%	81%	94%	84%	80%
OR Quartile 2	1.22	2.64	0.679	1.35	2.29	0.826	1.51	2.29	1.19
p Value	0.73	0.073	0.54	0.60	0.11	0.75	0.48	0.11	0.76
Lower limit of 95% CI	0.400	0.913	0.193	0.438	0.819	0.254	0.483	0.819	0.384
Upper limit of 95% CI	3.73	7.66	2.38	4.18	6.38	2.68	4.71	6.38	3.71
OR Quartile 3	3.63	2.38	1.75	3.25	1.92	1.98	2.90	1.92	1.68
p Value	0.026	0.060	0.30	0.044	0.15	0.20	0.071	0.15	0.33
Lower limit of 95% CI	1.16	0.964	0.614	1.03	0.788	0.700	0.914	0.788	0.591
Upper limit of 95% CI	11.3	5.88	4.99	10.2	4.66	5.59	9.18	4.66	4.78
OR Quartile 4	7.95	3.54	1.47	7.34	3.07	1.61	6.76	3.07	1.44
p Value	0.051	0.019	0.54	0.061	0.037	0.46	0.073	0.037	0.57
Lower limit of 95% CI	0.989	1.23	0.420	0.910	1.07	0.460	0.835	1.07	0.410
Upper limit of 95% CI	64.0	10.2	5.17	59.2	8.81	5.62	54.6	8.81	5.03

[0168] Table 9.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0125	0.0217	0.0142	0.0208	0.0146	0.0195
Average	0.0158	0.0909	0.0162	0.0895	0.0167	0.0880
Stdev	0.0150	0.394	0.0152	0.390	0.0154	0.387
p (t-test)		0.16		0.17		0.17
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.0518	2.98	0.0518	2.98	0.0518	2.98
n (Patient)	24	56	23	57	22	58

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0142	0.0225	0.0146	0.0217	0.0142	0.0225
Average	0.0199	0.131	0.0202	0.127	0.0197	0.125
Stdev	0.0229	0.493	0.0231	0.487	0.0231	0.480
p (t-test)		0.20		0.20		0.20
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.106	2.98	0.106	2.98	0.106	2.98
n (Patient)	45	35	44	36	43	37

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0167	0.0237	0.0153	0.0249	0.0167	0.0225
Average	0.0298	0.100	0.0288	0.103	0.0296	0.0985
Stdev	0.0382	0.433	0.0376	0.438	0.0384	0.429
p (t-test)		0.28		0.27		0.29
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	22	46	23	45	22	47

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.65	0.52	0.61	0.64	0.54	0.60	0.65	0.53
SE	0.066	0.063	0.075	0.068	0.063	0.074	0.069	0.062	0.074
p Value	0.086	0.021	0.76	0.11	0.030	0.61	0.16	0.018	0.69
nCohort Recovered	24	45	22	23	44	23	22	43	22
nCohort Non-recovered	56	35	46	57	36	45	58	37	47
Cutoff Quartile 2	0.00202	0.00202	0.00161	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202
Sensitivity	70%	80%	70%	70%	81%	69%	71%	81%	70%
Specificity	21%	33%	14%	22%	34%	17%	23%	35%	23%
Cutoff Quartile 3	0.0165	0.0165	0.0207	0.0165	0.0165	0.0207	0.0165	0.0165	0.0206
Sensitivity	55%	60%	54%	54%	58%	56%	53%	59%	53%
Specificity	62%	58%	59%	61%	57%	61%	59%	58%	59%
Cutoff Quartile 4	0.0435	0.0435	0.0464	0.0435	0.0435	0.0464	0.0435	0.0435	0.0460
Sensitivity	32%	37%	28%	32%	36%	29%	31%	35%	28%
Specificity	92%	84%	82%	91%	84%	83%	91%	84%	82%
OR Quartile 2	0.604	2.00	0.361	0.654	2.14	0.466	0.709	2.30	0.693
p Value	0.38	0.19	0.14	0.47	0.15	0.23	0.56	0.12	0.54
Lower limit of 95% CI	0.193	0.711	0.0917	0.209	0.762	0.134	0.225	0.816	0.214
Upper limit of 95% CI	1.88	5.63	1.42	2.05	6.03	1.63	2.23	6.46	2.25
OR Quartile 3	2.07	2.05	1.72	1.85	1.84	1.94	1.66	2.04	1.64

p Value	0.15	0.12	0.30	0.22	0.18	0.20	0.32	0.12	0.34
Lower limit of 95% CI	0.776	0.836	0.614	0.692	0.755	0.699	0.614	0.834	0.589
Upper limit of 95% CI	5.51	5.04	4.81	4.97	4.49	5.41	4.48	4.98	4.57
OR Quartile 4	5.21	3.21	1.77	4.85	2.99	1.93	4.50	2.79	1.72
p Value	0.037	0.031	0.37	0.047	0.042	0.31	0.058	0.057	0.40
Lower limit of 95% CI	1.10	1.11	0.503	1.02	1.04	0.549	0.949	0.971	0.489
Upper limit of 95% CI	24.6	9.24	6.25	22.9	8.59	6.78	21.3	7.99	6.05

[0169] Table 9.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0129	0.0262	0.0152	0.0195	0.0153	0.0182
Average	0.0232	0.109	0.0257	0.0999	0.0265	0.0978
Stdev	0.0336	0.452	0.0347	0.433	0.0349	0.429
p (t-test)		0.23		0.26		0.27
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	38	42	34	46	33	47

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0151	0.0195	0.0146	0.0208	0.0146	0.0208
Average	0.0248	0.132	0.0244	0.129	0.0244	0.129
Stdev	0.0321	0.516	0.0323	0.508	0.0323	0.508
p (t-test)		0.26		0.25		0.25
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	47	32	46	33	46	33

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0157	0.0315	0.0206	0.0208	0.0227	0.0190
Average	0.0295	0.141	0.0336	0.121	0.0350	0.118
Stdev	0.0373	0.532	0.0386	0.495	0.0388	0.488
p (t-test)		0.27		0.31		0.33
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	29	30	25	35	24	36

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.58	0.57	0.56	0.60	0.49	0.54	0.60	0.46

SE	0.063	0.066	0.075	0.065	0.065	0.076	0.065	0.065	0.076
p Value	0.079	0.20	0.37	0.35	0.14	0.92	0.55	0.14	0.64
nCohort Recovered	38	47	29	34	46	25	33	46	24
nCohort Non-recovered	42	32	30	46	33	35	47	33	36
Cutoff Quartile 2	0.00202	0.00202	0.00393	0.00202	0.00202	0.00260	0.00202	0.00202	0.00260
Sensitivity	76%	78%	73%	72%	79%	71%	70%	79%	69%
Specificity	32%	32%	24%	26%	33%	20%	24%	33%	17%
Cutoff Quartile 3	0.0165	0.0157	0.0208	0.0165	0.0157	0.0207	0.0165	0.0157	0.0207
Sensitivity	60%	56%	57%	54%	58%	51%	53%	58%	50%
Specificity	61%	55%	59%	56%	57%	52%	55%	57%	50%
Cutoff Quartile 4	0.0435	0.0427	0.0467	0.0435	0.0427	0.0464	0.0435	0.0427	0.0464
Sensitivity	33%	31%	30%	30%	30%	26%	30%	30%	25%
Specificity	84%	81%	79%	82%	80%	76%	82%	80%	75%
OR Quartile 2	1.48	1.67	0.875	0.914	1.80	0.625	0.754	1.80	0.455
p Value	0.44	0.33	0.82	0.86	0.27	0.45	0.59	0.27	0.23
Lower limit of 95% CI	0.551	0.593	0.270	0.337	0.637	0.184	0.274	0.637	0.126
Upper limit of 95% CI	3.96	4.73	2.83	2.47	5.07	2.13	2.08	5.07	1.65
OR Quartile 3	2.25	1.59	1.85	1.51	1.76	1.15	1.36	1.76	1.00
p Value	0.075	0.31	0.24	0.37	0.22	0.79	0.50	0.22	1.0
Lower limit of 95% CI	0.920	0.644	0.659	0.618	0.715	0.411	0.558	0.715	0.356
Upper limit of 95% CI	5.52	3.93	5.21	3.68	4.35	3.20	3.33	4.35	2.81
OR Quartile 4	2.67	1.92	1.64	2.04	1.79	1.10	1.91	1.79	1.00
p Value	0.076	0.22	0.41	0.20	0.27	0.88	0.24	0.27	1.0
Lower limit of 95% CI	0.903	0.677	0.500	0.692	0.632	0.333	0.646	0.632	0.303
Upper limit of 95% CI	7.87	5.44	5.40	6.03	5.06	3.60	5.64	5.06	3.30

[0170] Table 9.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0146	0.0208	0.0151	0.0195	0.0151	0.0195
Average	0.0251	0.109	0.0258	0.106	0.0258	0.106
Stdev	0.0349	0.458	0.0351	0.453	0.0351	0.453
p (t-test)		0.26		0.26		0.26
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	38	41	37	42	37	42

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0146	0.0182	0.0146	0.0182	0.0146	0.0182
Average	0.0237	0.133	0.0237	0.133	0.0237	0.133
Stdev	0.0308	0.524	0.0308	0.524	0.0308	0.524
p (t-test)		0.26		0.26		0.26
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	46	31	46	31	46	31

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0227	0.0265	0.0249	0.0225	0.0249	0.0225
Average	0.0375	0.132	0.0395	0.128	0.0395	0.128
Stdev	0.0421	0.516	0.0423	0.508	0.0423	0.508
p (t-test)		0.32		0.33		0.33
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	20	32	19	33	19	33

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	0.58	0.52	0.57	0.58	0.49	0.57	0.58	0.49
SE	0.064	0.067	0.083	0.064	0.067	0.084	0.064	0.067	0.084
p Value	0.14	0.25	0.81	0.25	0.25	0.86	0.25	0.25	0.86
nCohort Recovered	38	46	20	37	46	19	37	46	19
nCohort Non-recovered	41	31	32	42	31	33	42	31	33
Cutoff Quartile 2	0.00202	0.00202	0.00449	0.00202	0.00202	0.00449	0.00202	0.00202	0.00449
Sensitivity	76%	77%	75%	74%	77%	73%	74%	77%	73%
Specificity	32%	33%	25%	30%	33%	21%	30%	33%	21%
Cutoff Quartile 3	0.0157	0.0153	0.0237	0.0157	0.0153	0.0237	0.0157	0.0153	0.0237
Sensitivity	56%	55%	50%	55%	55%	48%	55%	55%	48%
Specificity	58%	54%	50%	57%	54%	47%	57%	54%	47%
Cutoff Quartile 4	0.0427	0.0411	0.0494	0.0427	0.0411	0.0494	0.0427	0.0411	0.0494
Sensitivity	29%	26%	25%	29%	26%	24%	29%	26%	24%
Specificity	82%	76%	75%	81%	76%	74%	81%	76%	74%
OR Quartile 2	1.43	1.66	1.00	1.19	1.66	0.711	1.19	1.66	0.711
p Value	0.48	0.34	1.0	0.73	0.34	0.62	0.73	0.34	0.62
Lower limit of 95% CI	0.533	0.584	0.275	0.445	0.584	0.186	0.445	0.584	0.186
Upper limit of 95% CI	3.84	4.71	3.63	3.19	4.71	2.72	3.19	4.71	2.72
OR Quartile 3	1.76	1.45	1.00	1.59	1.45	0.847	1.59	1.45	0.847
p Value	0.22	0.43	1.0	0.31	0.43	0.77	0.31	0.43	0.77
Lower limit of 95% CI	0.720	0.579	0.327	0.652	0.579	0.274	0.652	0.579	0.274
Upper limit of 95% CI	4.29	3.61	3.06	3.87	3.61	2.62	3.87	3.61	2.62
OR Quartile 4	1.83	1.11	1.00	1.71	1.11	0.896	1.71	1.11	0.896
p Value	0.26	0.85	1.0	0.32	0.85	0.87	0.32	0.85	0.87
Lower limit of 95% CI	0.634	0.387	0.275	0.594	0.387	0.245	0.594	0.387	0.245
Upper limit of 95% CI	5.29	3.17	3.63	4.95	3.17	3.27	4.95	3.17	3.27

[0171] Table 9.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0108	0.0262	0.0112	0.0225	0.0112	0.0225
Average	0.0243	0.133	0.0245	0.124	0.0245	0.124
Stdev	0.0335	0.515	0.0340	0.494	0.0340	0.494
p (t-test)		0.25		0.25		0.25
Min	4.13E-6	6.68E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6

Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	51	32	48	35	48	35

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0152	0.0182	0.0152	0.0182	0.0152	0.0182
Average	0.0265	0.171	0.0267	0.159	0.0267	0.159
Stdev	0.0323	0.604	0.0328	0.581	0.0328	0.581
p (t-test)		0.27		0.28		0.28
Min	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	58	23	56	25	56	25

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.0155	0.0170	0.0142	0.0190	0.0147	0.0173
Average	0.0285	0.110	0.0257	0.114	0.0262	0.112
Stdev	0.0391	0.470	0.0349	0.475	0.0352	0.469
p (t-test)		0.29		0.26		0.27
Min	6.68E-6	4.13E-6	4.13E-6	6.68E-6	6.68E-6	4.13E-6
Max	0.191	2.98	0.151	2.98	0.151	2.98
n (Patient)	40	39	41	38	40	39

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.64	0.57	0.53	0.63	0.57	0.58	0.63	0.57	0.56
SE	0.064	0.072	0.065	0.063	0.070	0.065	0.063	0.070	0.065
p Value	0.023	0.33	0.68	0.044	0.31	0.23	0.044	0.31	0.32
nCohort Recovered	51	58	40	48	56	41	48	56	40
nCohort Non-recovered	32	23	39	35	25	38	35	25	39
Cutoff Quartile 2	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202	0.00202
Sensitivity	84%	78%	74%	83%	80%	76%	83%	80%	77%
Specificity	35%	31%	30%	35%	32%	32%	35%	32%	32%
Cutoff Quartile 3	0.0157	0.0157	0.0157	0.0157	0.0157	0.0157	0.0157	0.0157	0.0157
Sensitivity	66%	57%	51%	63%	56%	55%	63%	56%	54%
Specificity	61%	53%	52%	60%	54%	56%	60%	54%	55%
Cutoff Quartile 4	0.0427	0.0427	0.0427	0.0427	0.0427	0.0427	0.0427	0.0427	0.0427
Sensitivity	28%	30%	26%	29%	28%	29%	29%	28%	28%
Specificity	78%	78%	78%	79%	77%	80%	79%	77%	80%
OR Quartile 2	2.95	1.62	1.24	2.65	1.89	1.50	2.65	1.89	1.60
p Value	0.057	0.41	0.67	0.071	0.27	0.43	0.071	0.27	0.35
Lower limit of 95% CI	0.967	0.520	0.463	0.919	0.613	0.553	0.919	0.613	0.593
Upper limit of 95% CI	8.97	5.05	3.33	7.65	5.86	4.05	7.65	5.86	4.35
OR Quartile 3	2.96	1.49	1.16	2.58	1.47	1.58	2.58	1.47	1.43
p Value	0.021	0.42	0.74	0.038	0.43	0.31	0.038	0.43	0.43
Lower limit of 95% CI	1.18	0.564	0.481	1.05	0.569	0.649	1.05	0.569	0.588
Upper limit of 95% CI	7.43	3.95	2.81	6.33	3.79	3.84	6.33	3.79	3.46
OR Quartile 4	1.42	1.51	1.19	1.52	1.29	1.68	1.52	1.29	1.57
p Value	0.50	0.45	0.74	0.42	0.64	0.33	0.42	0.64	0.40
Lower limit of 95% CI	0.513	0.513	0.423	0.553	0.441	0.592	0.553	0.441	0.554
Upper limit of 95% CI	3.94	4.47	3.34	4.18	3.75	4.77	4.18	3.75	4.46

[0172] Table 9.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.55	10.4	7.38	10.4	7.25	10.4
Average	9.81	12.8	9.49	12.8	9.59	12.7
Stdev	7.72	8.86	7.79	8.80	7.99	8.75
p (t-test)		0.17		0.13		0.17
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	20	62	19	63	18	64

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.41	10.5	8.41	10.5	8.41	10.5
Average	11.8	12.6	11.9	12.4	11.9	12.4
Stdev	9.26	7.92	9.35	7.89	9.35	7.89
p (t-test)		0.70		0.81		0.81
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	46	35	44	37	44	37

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.72	10.2	7.83	10.3	7.56	10.3
Average	9.64	12.8	9.93	12.8	9.61	12.8
Stdev	6.85	9.15	6.82	9.23	6.86	9.08
p (t-test)		0.13		0.15		0.12
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	21	50	22	49	21	51

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.56	0.61	0.64	0.55	0.59	0.64	0.55	0.61
SE	0.069	0.065	0.071	0.068	0.065	0.071	0.070	0.065	0.071
p Value	0.080	0.33	0.13	0.038	0.41	0.21	0.044	0.41	0.12
nCohort Recovered	20	46	21	19	44	22	18	44	21
nCohort Non-recovered	62	35	50	63	37	49	64	37	51
Cutoff Quartile 2	6.18	6.19	6.19	6.18	6.19	6.19	6.18	6.19	6.19
Sensitivity	76%	80%	76%	76%	78%	76%	77%	78%	76%
Specificity	30%	30%	29%	32%	30%	27%	33%	30%	29%
Cutoff Quartile 3	9.66	9.75	9.00	9.66	9.75	9.00	9.66	9.75	8.94
Sensitivity	56%	57%	58%	57%	57%	57%	56%	57%	59%
Specificity	70%	57%	71%	74%	57%	68%	72%	57%	71%

Cutoff Quartile 4	15.6	15.9	14.3	15.6	15.9	14.6	15.6	15.9	14.6
Sensitivity	29%	31%	30%	30%	30%	29%	30%	30%	29%
Specificity	85%	80%	86%	89%	80%	82%	89%	80%	86%
OR Quartile 2	1.34	1.75	1.27	1.48	1.52	1.16	1.63	1.52	1.30
p Value	0.61	0.29	0.69	0.50	0.42	0.80	0.40	0.42	0.65
Lower limit of 95% CI	0.439	0.619	0.402	0.478	0.550	0.369	0.523	0.550	0.413
Upper limit of 95% CI	4.11	4.95	3.99	4.56	4.20	3.62	5.10	4.20	4.09
OR Quartile 3	3.02	1.73	3.45	3.73	1.73	2.86	3.34	1.73	3.57
p Value	0.045	0.22	0.027	0.023	0.22	0.052	0.039	0.22	0.023
Lower limit of 95% CI	1.03	0.713	1.15	1.20	0.714	0.989	1.07	0.714	1.19
Upper limit of 95% CI	8.91	4.21	10.4	11.6	4.17	8.25	10.5	4.17	10.7
OR Quartile 4	2.32	1.88	2.57	3.67	1.65	1.80	3.38	1.65	2.50
p Value	0.22	0.22	0.17	0.10	0.34	0.36	0.13	0.34	0.19
Lower limit of 95% CI	0.604	0.680	0.658	0.771	0.595	0.517	0.706	0.595	0.640
Upper limit of 95% CI	8.89	5.22	10.1	17.5	4.55	6.27	16.2	4.55	9.77

[0173] Table 9.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.55	10.6	7.11	10.6	6.81	10.5
Average	9.74	13.2	9.43	13.2	9.51	13.1
Stdev	7.47	9.15	7.83	8.93	8.00	8.88
p (t-test)		0.078		0.074		0.097
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	26	54	23	57	22	58

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.17	10.7	7.94	11.4	7.92	12.0
Average	11.8	12.7	11.7	12.8	11.1	13.6
Stdev	9.25	8.16	9.33	8.05	8.47	9.05
p (t-test)		0.65		0.58		0.23
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	38.9	37.2	38.9	37.2	36.8	38.9
n (Patient)	46	33	45	34	44	35

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.94	10.2	7.83	10.3	7.56	10.3
Average	9.91	13.1	10.1	13.0	9.86	13.0
Stdev	6.93	9.44	7.17	9.34	7.23	9.18
p (t-test)		0.12		0.16		0.13
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	25	44	24	45	23	47

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.56	0.60	0.66	0.58	0.60	0.66	0.60	0.62
SE	0.064	0.066	0.070	0.064	0.066	0.070	0.065	0.065	0.069
p Value	0.042	0.33	0.14	0.013	0.24	0.16	0.015	0.12	0.088
nCohort Recovered	26	46	25	23	45	24	22	44	23
nCohort Non-recovered	54	33	44	57	34	45	58	35	47
Cutoff Quartile 2	6.16	6.19	6.18	6.16	6.19	6.18	6.16	6.19	6.19
Sensitivity	80%	79%	77%	81%	79%	78%	81%	80%	79%
Specificity	35%	28%	32%	39%	29%	33%	41%	30%	35%
Cutoff Quartile 3	9.28	9.56	9.00	9.28	9.56	9.00	9.28	9.56	8.94
Sensitivity	57%	58%	57%	60%	59%	58%	59%	60%	60%
Specificity	65%	57%	64%	74%	58%	67%	73%	59%	70%
Cutoff Quartile 4	16.0	16.1	14.5	16.0	16.1	14.7	16.0	16.1	14.7
Sensitivity	31%	33%	30%	30%	32%	27%	29%	34%	30%
Specificity	88%	80%	84%	87%	80%	79%	86%	82%	83%
OR Quartile 2	2.07	1.46	1.60	2.69	1.57	1.75	2.96	1.68	1.97
p Value	0.17	0.48	0.40	0.069	0.40	0.32	0.048	0.33	0.23
Lower limit of 95% CI	0.728	0.511	0.534	0.927	0.547	0.581	1.01	0.586	0.653
Upper limit of 95% CI	5.88	4.19	4.79	7.80	4.49	5.27	8.66	4.80	5.97
OR Quartile 3	2.55	1.76	2.34	4.19	1.95	2.74	3.78	2.17	3.37
p Value	0.059	0.22	0.100	0.0087	0.15	0.056	0.015	0.094	0.025
Lower limit of 95% CI	0.964	0.715	0.851	1.44	0.792	0.973	1.29	0.877	1.16
Upper limit of 95% CI	6.73	4.35	6.43	12.2	4.83	7.70	11.1	5.35	9.74
OR Quartile 4	3.52	2.06	2.20	2.83	1.91	1.38	2.63	2.35	2.02
p Value	0.064	0.17	0.22	0.13	0.21	0.59	0.16	0.11	0.27
Lower limit of 95% CI	0.929	0.736	0.631	0.742	0.687	0.422	0.686	0.833	0.579
Upper limit of 95% CI	13.4	5.74	7.69	10.8	5.33	4.52	10.1	6.62	7.01

[0174] Table 9.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.81	10.7	7.92	10.4	7.94	10.4
Average	9.91	14.0	10.2	13.4	10.3	13.3
Stdev	6.55	9.69	6.86	9.44	6.95	9.38
p (t-test)		0.035		0.089		0.11
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	36	41	32	45	31	46

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.17	10.6	7.94	10.7	7.94	10.7
Average	11.5	12.4	10.9	13.2	10.9	13.2
Stdev	8.68	7.90	7.74	9.08	7.74	9.08
p (t-test)		0.64		0.24		0.24
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	38.9	37.2	36.8	38.9	36.8	38.9
n (Patient)	46	30	45	31	45	31

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.41	10.4	8.41	10.3	8.41	10.2
Average	10.9	13.9	11.1	13.3	11.3	13.1
Stdev	6.91	10.6	7.29	10.0	7.41	9.95
p (t-test)		0.21		0.35		0.43
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	27	30	23	35	22	36

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.57	0.56	0.61	0.59	0.55	0.60	0.59	0.54
SE	0.063	0.068	0.076	0.065	0.067	0.077	0.065	0.067	0.078
p Value	0.041	0.34	0.43	0.099	0.17	0.51	0.13	0.17	0.61
nCohort Recovered	36	46	27	32	45	23	31	45	22
nCohort Non-recovered	41	30	30	45	31	35	46	31	36
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.29	6.19	6.19	6.29
Sensitivity	80%	80%	77%	80%	81%	74%	80%	81%	75%
Specificity	33%	28%	30%	34%	29%	26%	35%	29%	27%
Cutoff Quartile 3	9.56	9.28	9.91	9.56	9.28	9.74	9.56	9.28	9.74
Sensitivity	61%	60%	57%	58%	61%	57%	57%	61%	56%
Specificity	64%	57%	59%	62%	58%	61%	61%	58%	59%
Cutoff Quartile 4	15.9	15.0	15.9	15.9	15.0	15.6	15.9	15.0	15.6
Sensitivity	32%	30%	30%	29%	32%	29%	28%	32%	28%
Specificity	83%	78%	81%	81%	80%	78%	81%	80%	77%
OR Quartile 2	2.06	1.58	1.38	2.10	1.69	1.02	2.26	1.69	1.12
p Value	0.17	0.42	0.59	0.16	0.35	0.97	0.12	0.35	0.85
Lower limit of 95% CI	0.731	0.524	0.424	0.746	0.564	0.307	0.803	0.564	0.338
Upper limit of 95% CI	5.82	4.74	4.51	5.88	5.08	3.39	6.37	5.08	3.75
OR Quartile 3	2.76	1.95	1.90	2.28	2.17	2.07	2.06	2.17	1.81
p Value	0.031	0.16	0.23	0.082	0.10	0.18	0.13	0.10	0.28
Lower limit of 95% CI	1.10	0.766	0.663	0.901	0.851	0.710	0.813	0.851	0.617
Upper limit of 95% CI	6.97	4.96	5.46	5.77	5.51	6.06	5.21	5.51	5.29
OR Quartile 4	2.32	1.54	1.89	1.76	1.90	1.44	1.64	1.90	1.31
p Value	0.13	0.42	0.32	0.31	0.23	0.56	0.38	0.23	0.67
Lower limit of 95% CI	0.776	0.540	0.542	0.588	0.667	0.420	0.547	0.667	0.380
Upper limit of 95% CI	6.95	4.41	6.56	5.27	5.44	4.94	4.92	5.44	4.50

[0175] Table 9.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.17	10.6	8.41	10.4	8.41	10.4
Average	9.99	13.6	10.1	13.4	10.1	13.4
Stdev	6.20	9.83	6.28	9.75	6.28	9.75
p (t-test)		0.068		0.086		0.086
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	24.1	38.9	24.1	38.9	24.1	38.9

n (Patient)	36	38	35	39	35	39
-------------	----	----	----	----	----	----

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.17	10.4	8.17	10.4	8.17	10.4
Average	10.8	12.9	10.8	12.9	10.8	12.9
Stdev	7.69	9.22	7.69	9.22	7.69	9.22
p (t-test)		0.33		0.33		0.33
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	36.8	38.9	36.8	38.9	36.8	38.9
n (Patient)	44	29	44	29	44	29

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.99	10.6	9.56	10.4	9.56	10.4
Average	10.5	13.8	10.7	13.5	10.7	13.5
Stdev	5.62	10.4	5.73	10.3	5.73	10.3
p (t-test)		0.17		0.23		0.23
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	24.1	38.9	24.1	38.9	24.1	38.9
n (Patient)	18	30	17	31	17	31

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.57	0.56	0.60	0.57	0.54	0.60	0.57	0.54
SE	0.066	0.069	0.085	0.066	0.069	0.087	0.066	0.069	0.087
p Value	0.11	0.29	0.49	0.15	0.29	0.62	0.15	0.29	0.62
nCohort Recovered	36	44	18	35	44	17	35	44	17
nCohort Non-recovered	38	29	30	39	29	31	39	29	31
Cutoff Quartile 2	6.19	6.18	6.96	6.19	6.18	6.96	6.19	6.18	6.96
Sensitivity	82%	79%	73%	82%	79%	74%	82%	79%	74%
Specificity	33%	30%	22%	34%	30%	24%	34%	30%	24%
Cutoff Quartile 3	9.28	9.00	9.96	9.28	9.00	9.96	9.28	9.00	9.96
Sensitivity	58%	59%	53%	56%	59%	52%	56%	59%	52%
Specificity	58%	57%	56%	57%	57%	53%	57%	57%	53%
Cutoff Quartile 4	14.7	14.6	14.9	14.7	14.6	14.9	14.7	14.6	14.9
Sensitivity	32%	31%	30%	31%	31%	29%	31%	31%	29%
Specificity	81%	80%	83%	80%	80%	82%	80%	80%	82%
OR Quartile 2	2.21	1.61	0.786	2.39	1.61	0.885	2.39	1.61	0.885
p Value	0.15	0.40	0.73	0.11	0.40	0.86	0.11	0.40	0.86
Lower limit of 95% CI	0.757	0.531	0.199	0.814	0.531	0.223	0.814	0.531	0.223
Upper limit of 95% CI	6.48	4.87	3.11	6.99	4.87	3.51	6.99	4.87	3.51
OR Quartile 3	1.92	1.86	1.43	1.73	1.86	1.20	1.73	1.86	1.20
p Value	0.16	0.20	0.55	0.25	0.20	0.76	0.25	0.20	0.76
Lower limit of 95% CI	0.764	0.721	0.442	0.687	0.721	0.367	0.687	0.721	0.367
Upper limit of 95% CI	4.85	4.82	4.62	4.34	4.82	3.92	4.34	4.82	3.92
OR Quartile 4	1.91	1.75	2.14	1.78	1.75	1.91	1.78	1.75	1.91
p Value	0.24	0.31	0.31	0.29	0.31	0.39	0.29	0.31	0.39
Lower limit of 95% CI	0.655	0.597	0.495	0.609	0.597	0.440	0.609	0.597	0.440
Upper limit of 95% CI	5.59	5.13	9.27	5.19	5.13	8.29	5.19	5.13	8.29

[0176] Table 9.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum

creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	9.06	10.2	9.06	10.2	9.06	10.2
Average	11.4	13.3	11.4	13.1	11.4	13.1
Stdev	7.18	10.6	7.17	10.5	7.17	10.5
p (t-test)		0.39		0.44		0.44
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	54	30	52	32	52	32

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	9.75	9.74	9.16	9.91	9.16	9.91
Average	12.6	10.8	12.5	11.1	12.5	11.1
Stdev	8.99	7.79	9.04	7.73	9.04	7.73
p (t-test)		0.38		0.47		0.47
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	59	22	58	23	58	23

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	8.48	10.6	8.48	10.6	8.41	10.7
Average	11.0	13.7	10.5	13.9	10.5	13.9
Stdev	7.48	9.75	6.64	9.84	6.58	9.82
p (t-test)		0.19		0.089		0.089
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	33.3	38.9	30.8	38.9	30.8	38.9
n (Patient)	40	38	42	36	41	37

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	0.46	0.57	0.52	0.48	0.59	0.52	0.48	0.59
SE	0.066	0.073	0.065	0.065	0.072	0.065	0.065	0.072	0.065
p Value	0.68	0.62	0.26	0.78	0.79	0.17	0.78	0.79	0.17
nCohort Recovered	54	59	40	52	58	42	52	58	41
nCohort Non-recovered	30	22	38	32	23	36	32	23	37
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	77%	77%	79%	75%	78%	81%	75%	78%	78%
Specificity	26%	27%	32%	25%	28%	33%	25%	28%	32%
Cutoff Quartile 3	9.66	9.75	9.66	9.66	9.75	9.66	9.66	9.75	9.66
Sensitivity	53%	50%	58%	53%	52%	58%	53%	52%	59%
Specificity	52%	51%	57%	52%	52%	57%	52%	52%	59%
Cutoff Quartile 4	16.0	15.9	15.6	16.0	15.9	15.6	16.0	15.9	15.6
Sensitivity	27%	14%	34%	28%	17%	33%	28%	17%	35%
Specificity	76%	71%	82%	77%	72%	81%	77%	72%	83%
OR Quartile 2	1.15	1.27	1.81	1.00	1.37	2.07	1.00	1.37	1.68
p Value	0.79	0.69	0.26	1.0	0.59	0.17	1.0	0.59	0.32

Lower limit of 95% CI	0.406	0.400	0.649	0.362	0.436	0.728	0.362	0.436	0.605
Upper limit of 95% CI	3.26	4.00	5.02	2.76	4.31	5.89	2.76	4.31	4.68
OR Quartile 3	1.23	1.03	1.86	1.22	1.17	1.87	1.22	1.17	2.07
p Value	0.65	0.95	0.18	0.65	0.75	0.17	0.65	0.75	0.11
Lower limit of 95% CI	0.503	0.389	0.757	0.507	0.445	0.758	0.507	0.445	0.839
Upper limit of 95% CI	3.01	2.75	4.57	2.96	3.07	4.60	2.96	3.07	5.11
OR Quartile 4	1.15	0.390	2.45	1.30	0.553	2.12	1.30	0.553	2.63
p Value	0.79	0.17	0.096	0.60	0.34	0.15	0.60	0.34	0.073
Lower limit of 95% CI	0.413	0.102	0.853	0.477	0.163	0.754	0.477	0.163	0.914
Upper limit of 95% CI	3.19	1.49	7.04	3.56	1.88	5.99	3.56	1.88	7.57

[0177] Example 10. Use of Tyrosine-protein kinase receptor UFO for evaluating renal status in patients admitted to the ICU: Recovery to RIFLE 0 from RIFLE I and F

[0178] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Tyrosine-protein kinase receptor UFO is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0179] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output during a period starting at 12, 24, 48, or 72 hours after sample collection or at any time within 7 days after sample collection. Two cohorts are defined to represent a “recovered” and a “non-recovered” population. “Recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0). “Non-recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is risk of injury (R), injury (I) or failure (F). If a patient dies or is placed on renal replacement therapy (RRT) within 9 days of enrollment, the patient is considered “non-recovered”.

[0180] The ability to distinguish the “recovered” and “non-recovered” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0181] Table 10.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	6.03	3.67	5.42	3.71	6.03	3.71
Average	6.95	4.61	5.98	4.75	6.82	4.74
Stdev	2.51	4.17	2.14	4.21	2.09	4.15
p (t-test)		0.051		0.29		0.18
Min	3.44	0.276	3.44	0.276	4.88	0.276
Max	10.3	20.6	10.3	20.6	10.3	20.6
n (Patient)	8	73	6	75	4	77

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	7.53	2.44	6.87	2.51	6.87	2.51
Average	8.09	2.93	7.97	3.20	7.89	3.40
Stdev	4.48	2.25	4.61	2.57	4.52	2.94
p (t-test)		1.1E-6		1.5E-5		6.4E-5
Min	0.696	0.276	0.696	0.276	0.696	0.276
Max	20.6	11.5	20.6	11.5	20.6	14.5
n (Patient)	30	51	28	53	26	55

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	3.44	4.42	4.16	4.30	3.44	4.30
Average	3.86	5.21	4.05	5.21	3.93	5.17
Stdev	2.86	4.32	2.94	4.35	3.07	4.29
p (t-test)		0.22		0.32		0.33
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	10.3	20.6	10.3	20.6	10.3	20.6
n (Patient)	11	61	10	62	9	64

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.24	0.12	0.58	0.31	0.15	0.56	0.24	0.16	0.58
SE	0.076	0.037	0.090	0.099	0.041	0.095	0.10	0.043	0.098
p Value	6.7E-4	0	0.38	0.053	0	0.54	0.0097	1.6E-15	0.44
nCohort Recovered	8	30	11	6	28	10	4	26	9
nCohort Non-recovered	73	51	61	75	53	62	77	55	64
Cutoff Quartile 2	1.99	1.99	2.09	1.99	1.99	2.09	1.99	1.99	2.12
Sensitivity	71%	61%	77%	72%	62%	76%	73%	64%	77%
Specificity	0%	3%	36%	0%	4%	30%	0%	4%	44%
Cutoff Quartile 3	3.81	3.81	4.30	3.81	3.81	4.30	3.81	3.81	4.18
Sensitivity	45%	27%	51%	47%	30%	50%	47%	31%	50%
Specificity	12%	13%	55%	17%	14%	50%	0%	12%	56%
Cutoff Quartile 4	6.29	6.29	6.33	6.29	6.29	6.33	6.29	6.29	6.32
Sensitivity	22%	4%	26%	24%	8%	26%	23%	9%	25%
Specificity	50%	40%	82%	67%	43%	80%	50%	42%	78%
OR Quartile 2	0.144	0.0534	1.92	0.195	0.0611	1.34	0.292	0.0700	2.61
p Value	0.19	0.0056	0.35	0.27	0.0082	0.69	0.42	0.012	0.19
Lower limit of 95% CI	0.00793	0.00674	0.490	0.0105	0.00770	0.308	0.0151	0.00881	0.621
Upper limit of 95% CI	2.60	0.424	7.52	3.61	0.485	5.85	5.66	0.556	11.0
OR Quartile 3	0.118	0.0582	1.24	0.175	0.0721	1.00	0.0977	0.0584	1.25
p Value	0.051	4.8E-6	0.74	0.12	2.0E-5	1.0	0.12	2.9E-5	0.76
Lower limit of 95% CI	0.0138	0.0172	0.342	0.0195	0.0215	0.263	0.00509	0.0154	0.307
Upper limit of 95% CI	1.01	0.197	4.50	1.57	0.242	3.80	1.88	0.221	5.08
OR Quartile 4	0.281	0.0272	1.60	0.632	0.0612	1.39	0.305	0.0733	1.17
p Value	0.095	9.0E-6	0.57	0.61	1.5E-5	0.69	0.25	2.1E-5	0.86

Lower limit of 95% CI	0.0631	0.00554	0.312	0.107	0.0173	0.267	0.0401	0.0220	0.220
Upper limit of 95% CI	1.25	0.134	8.21	3.74	0.217	7.25	2.32	0.245	6.20

[0182] Table 10.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	6.38	3.60	6.87	3.52	7.36	3.60
Average	6.96	4.50	7.71	4.51	8.08	4.52
Stdev	3.14	4.16	2.76	4.13	2.76	4.10
p (t-test)		0.042		0.019		0.019
Min	1.99	0.276	4.88	0.276	4.88	0.276
Max	13.5	20.6	13.5	20.6	13.5	20.6
n (Patient)	11	69	8	72	7	73

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	6.38	2.44	6.35	2.51	6.35	2.51
Average	7.72	3.01	7.58	3.36	7.58	3.36
Stdev	4.54	2.47	4.52	2.99	4.52	2.99
p (t-test)		5.4E-6		8.7E-5		8.7E-5
Min	0.696	0.276	0.696	0.276	0.696	0.276
Max	20.6	11.5	20.6	14.5	20.6	14.5
n (Patient)	31	49	28	52	28	52

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	4.30	4.30	4.88	4.18	4.30	4.18
Average	3.90	5.11	4.05	5.11	3.96	5.07
Stdev	2.62	4.35	2.67	4.38	2.76	4.32
p (t-test)		0.21		0.28		0.28
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	8.32	20.6	8.32	20.6	8.32	20.6
n (Patient)	14	54	13	55	12	57

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.26	0.14	0.55	0.19	0.17	0.53	0.17	0.17	0.55
SE	0.070	0.041	0.085	0.065	0.045	0.088	0.064	0.045	0.090
p Value	5.2E-4	0	0.55	1.7E-6	3.6E-13	0.71	3.1E-7	3.6E-13	0.61
nCohort Recovered	11	31	14	8	28	13	7	28	12
nCohort Non-recovered	69	49	54	72	52	55	73	52	57
Cutoff Quartile 2	1.90	1.90	1.90	1.90	1.90	1.90	1.90	1.90	1.99
Sensitivity	71%	61%	76%	72%	63%	76%	73%	63%	75%
Specificity	0%	3%	29%	0%	4%	31%	0%	4%	33%

Cutoff Quartile 3	3.77	3.77	4.30	3.77	3.77	4.30	3.77	3.77	4.18
Sensitivity	45%	27%	50%	44%	29%	49%	45%	29%	49%
Specificity	18%	13%	50%	0%	11%	46%	0%	11%	50%
Cutoff Quartile 4	6.30	6.30	6.30	6.30	6.30	6.30	6.30	6.30	6.29
Sensitivity	20%	6%	26%	21%	10%	25%	21%	10%	25%
Specificity	45%	45%	79%	38%	46%	77%	29%	46%	75%
OR Quartile 2	0.105	0.0526	1.26	0.151	0.0643	1.44	0.174	0.0643	1.54
p Value	0.12	0.0054	0.73	0.20	0.0095	0.59	0.24	0.0095	0.53
Lower limit of 95% CI	0.00591	0.00662	0.338	0.00831	0.00808	0.379	0.00950	0.00808	0.401
Upper limit of 95% CI	1.87	0.419	4.71	2.73	0.512	5.44	3.19	0.512	5.88
OR Quartile 3	0.181	0.0535	1.00	0.0472	0.0486	0.827	0.0551	0.0486	0.966
p Value	0.037	2.9E-6	1.0	0.038	9.7E-6	0.76	0.050	9.7E-6	0.96
Lower limit of 95% CI	0.0365	0.0157	0.309	0.00263	0.0127	0.246	0.00304	0.0127	0.278
Upper limit of 95% CI	0.901	0.182	3.24	0.849	0.186	2.78	1.00	0.186	3.35
OR Quartile 4	0.212	0.0537	1.28	0.158	0.0922	1.14	0.103	0.0922	0.977
p Value	0.022	2.7E-5	0.73	0.019	7.9E-5	0.86	0.010	7.9E-5	0.97
Lower limit of 95% CI	0.0564	0.0137	0.312	0.0338	0.0282	0.274	0.0182	0.0282	0.232
Upper limit of 95% CI	0.797	0.210	5.28	0.737	0.301	4.74	0.587	0.301	4.12

[0183] Table 10.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	6.01	2.51	6.32	2.77	6.32	2.77
Average	7.12	3.91	7.42	3.91	7.42	3.91
Stdev	3.85	3.87	3.88	3.81	3.88	3.81
p (t-test)		0.0020		0.0013		0.0013
Min	2.12	0.276	2.12	0.276	2.12	0.276
Max	20.6	20.5	20.6	20.5	20.6	20.5
n (Patient)	23	57	21	59	21	59

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.77	2.51	5.79	2.47	5.79	2.47
Average	6.84	3.39	7.02	3.34	7.02	3.34
Stdev	4.45	3.15	4.40	3.13	4.40	3.13
p (t-test)		3.6E-4		1.6E-4		1.6E-4
Min	0.696	0.276	0.696	0.276	0.696	0.276
Max	20.6	14.5	20.6	14.5	20.6	14.5
n (Patient)	34	45	33	46	33	46

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.32	3.03	5.19	3.15	5.19	3.15
Average	5.34	4.26	4.90	4.50	4.90	4.50
Stdev	3.35	4.07	2.83	4.24	2.83	4.24
p (t-test)		0.28		0.67		0.67
Min	0.366	0.398	0.366	0.398	0.366	0.398

Max	14.5	20.5	9.65	20.5	9.65	20.5
n (Patient)	22	37	20	40	20	40

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.20	0.22	0.37	0.19	0.20	0.40	0.19	0.20	0.40
SE	0.050	0.051	0.073	0.048	0.049	0.076	0.048	0.049	0.076
p Value	1.9E-9	3.4E-8	0.070	7.1E-11	5.2E-10	0.21	7.1E-11	5.2E-10	0.21
nCohort Recovered	23	34	22	21	33	20	21	33	20
nCohort Non-recovered	57	45	37	59	46	40	59	46	40
Cutoff Quartile 2	1.90	2.05	1.62	1.90	2.05	1.63	1.90	2.05	1.63
Sensitivity	65%	62%	68%	66%	61%	70%	66%	61%	70%
Specificity	0%	9%	14%	0%	6%	15%	0%	6%	15%
Cutoff Quartile 3	3.77	3.81	3.81	3.77	3.81	3.77	3.77	3.81	3.77
Sensitivity	35%	29%	41%	36%	28%	42%	36%	28%	42%
Specificity	13%	24%	36%	10%	21%	35%	10%	21%	35%
Cutoff Quartile 4	6.30	6.30	6.15	6.30	6.30	6.08	6.30	6.30	6.08
Sensitivity	16%	11%	22%	15%	11%	22%	15%	11%	22%
Specificity	52%	56%	68%	48%	55%	70%	48%	55%	70%
OR Quartile 2	0.0389	0.159	0.329	0.0448	0.100	0.412	0.0448	0.100	0.412
p Value	0.026	0.0068	0.12	0.033	0.0036	0.21	0.033	0.0036	0.21
Lower limit of 95% CI	0.00225	0.0422	0.0812	0.00258	0.0214	0.101	0.00258	0.0214	0.101
Upper limit of 95% CI	0.675	0.602	1.33	0.778	0.472	1.67	0.778	0.472	1.67
OR Quartile 3	0.0811	0.125	0.390	0.0582	0.106	0.398	0.0582	0.106	0.398
p Value	2.1E-4	6.6E-5	0.090	3.3E-4	3.0E-5	0.10	3.3E-4	3.0E-5	0.10
Lower limit of 95% CI	0.0214	0.0450	0.131	0.0123	0.0370	0.131	0.0123	0.0370	0.131
Upper limit of 95% CI	0.307	0.347	1.16	0.274	0.304	1.21	0.274	0.304	1.21
OR Quartile 4	0.205	0.158	0.591	0.164	0.146	0.677	0.164	0.146	0.677
p Value	0.0041	0.0017	0.39	0.0014	0.0011	0.53	0.0014	0.0011	0.53
Lower limit of 95% CI	0.0691	0.0501	0.180	0.0538	0.0462	0.202	0.0538	0.0462	0.202
Upper limit of 95% CI	0.605	0.500	1.94	0.498	0.464	2.27	0.498	0.464	2.27

[0184] Table 10.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.90	2.77	6.01	2.64	6.01	2.64
Average	6.65	3.65	6.83	3.62	6.83	3.62
Stdev	3.99	3.19	3.96	3.16	3.96	3.16
p (t-test)		0.0021		0.0012		0.0012
Min	0.502	0.276	0.502	0.276	0.502	0.276
Max	20.5	14.5	20.5	14.5	20.5	14.5
n (Patient)	26	53	25	54	25	54

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.58	2.65	5.67	2.51	5.67	2.77
Average	6.10	3.56	6.24	3.50	6.27	3.60
Stdev	3.92	3.19	3.89	3.17	3.94	3.20
p (t-test)		0.0034		0.0017		0.0029

Min	0.502	0.276	0.502	0.276	0.502	0.276
Max	20.5	14.5	20.5	14.5	20.5	14.5
n (Patient)	35	42	34	43	32	45

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	3.72	3.03	4.09	2.91	4.09	2.91
Average	4.05	4.06	4.18	4.00	4.18	4.00
Stdev	2.71	3.51	2.74	3.48	2.74	3.48
p (t-test)		0.99		0.85		0.85
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	9.53	14.5	9.53	14.5	9.53	14.5
n (Patient)	17	35	16	36	16	36

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.24	0.27	0.46	0.22	0.25	0.44	0.22	0.26	0.44
SE	0.054	0.057	0.085	0.052	0.055	0.086	0.052	0.056	0.086
p Value	1.1E-6	6.3E-5	0.64	5.5E-8	8.5E-6	0.50	5.5E-8	2.0E-5	0.50
nCohort Recovered	26	35	17	25	34	16	25	32	16
nCohort Non-recovered	53	42	35	54	43	36	54	45	36
Cutoff Quartile 2	1.81	2.12	1.56	1.81	2.12	1.56	1.81	2.12	1.56
Sensitivity	66%	67%	71%	67%	65%	72%	67%	67%	72%
Specificity	8%	17%	18%	8%	15%	19%	8%	16%	19%
Cutoff Quartile 3	3.72	3.81	3.36	3.72	3.81	3.36	3.72	3.81	3.36
Sensitivity	34%	31%	46%	33%	30%	44%	33%	31%	44%
Specificity	19%	29%	41%	16%	26%	38%	16%	25%	38%
Cutoff Quartile 4	6.15	6.29	5.39	6.15	6.29	5.39	6.15	6.29	5.39
Sensitivity	15%	12%	20%	15%	12%	19%	15%	13%	19%
Specificity	54%	60%	65%	52%	59%	62%	52%	59%	62%
OR Quartile 2	0.162	0.414	0.536	0.174	0.322	0.600	0.174	0.370	0.600
p Value	0.021	0.11	0.40	0.027	0.051	0.49	0.027	0.087	0.49
Lower limit of 95% CI	0.0344	0.139	0.126	0.0368	0.103	0.140	0.0368	0.119	0.140
Upper limit of 95% CI	0.764	1.23	2.28	0.821	1.00	2.56	0.821	1.16	2.56
OR Quartile 3	0.122	0.179	0.589	0.0952	0.156	0.480	0.0952	0.151	0.480
p Value	2.7E-4	6.1E-4	0.38	1.4E-4	2.8E-4	0.23	1.4E-4	2.7E-4	0.23
Lower limit of 95% CI	0.0396	0.0671	0.182	0.0284	0.0573	0.144	0.0284	0.0543	0.144
Upper limit of 95% CI	0.379	0.479	1.90	0.319	0.425	1.60	0.319	0.417	1.60
OR Quartile 4	0.207	0.203	0.458	0.188	0.188	0.402	0.188	0.225	0.402
p Value	0.0042	0.0067	0.24	0.0026	0.0046	0.17	0.0026	0.0085	0.17
Lower limit of 95% CI	0.0706	0.0640	0.126	0.0636	0.0592	0.109	0.0636	0.0740	0.109
Upper limit of 95% CI	0.609	0.642	1.67	0.558	0.597	1.49	0.558	0.684	1.49

[0185] Table 10.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.58	2.51	5.58	2.51	5.58	2.65
Average	6.47	3.34	6.43	3.65	6.38	3.80
Stdev	4.50	2.83	4.34	3.34	4.43	3.38
p (t-test)		4.0E-4		0.0024		0.0060

Min	0.366	0.276	0.502	0.276	0.502	0.276
Max	20.6	11.5	20.6	14.5	20.6	14.5
n (Patient)	41	42	37	46	35	48

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.32	2.51	5.32	2.51	5.32	2.51
Average	6.07	3.07	6.10	3.20	6.03	3.56
Stdev	4.53	2.46	4.51	2.72	4.40	3.30
p (t-test)		3.0E-4		6.8E-4		0.0059
Min	0.366	0.276	0.502	0.276	0.502	0.276
Max	20.6	11.5	20.6	11.5	20.6	14.5
n (Patient)	48	33	46	35	42	39

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.16	3.52	5.16	3.52	5.19	3.60
Average	5.76	4.53	5.74	4.56	5.76	4.57
Stdev	4.17	4.00	4.17	4.00	4.23	3.96
p (t-test)		0.21		0.22		0.23
Min	0.0344	0.398	0.366	0.398	0.366	0.398
Max	20.5	20.6	20.5	20.6	20.5	20.6
n (Patient)	31	48	31	48	30	49

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.26	0.27	0.39	0.26	0.27	0.39	0.28	0.29	0.39
SE	0.054	0.059	0.064	0.054	0.058	0.064	0.056	0.058	0.064
p Value	6.4E-6	1.2E-4	0.073	1.2E-5	9.7E-5	0.087	1.1E-4	3.2E-4	0.10
nCohort Recovered	41	48	31	37	46	31	35	42	30
nCohort Non-recovered	42	33	48	46	35	48	48	39	49
Cutoff Quartile 2	2.05	1.99	2.05	2.05	1.99	2.05	2.05	1.99	2.05
Sensitivity	60%	64%	69%	61%	63%	69%	62%	64%	69%
Specificity	10%	19%	16%	8%	17%	16%	9%	17%	17%
Cutoff Quartile 3	4.01	3.81	4.42	4.01	3.81	4.42	4.01	3.81	4.42
Sensitivity	31%	27%	40%	33%	29%	42%	35%	31%	43%
Specificity	32%	35%	35%	30%	35%	39%	31%	33%	40%
Cutoff Quartile 4	6.30	6.29	6.35	6.30	6.29	6.35	6.30	6.29	6.35
Sensitivity	12%	6%	21%	15%	9%	21%	17%	13%	20%
Specificity	61%	62%	68%	62%	63%	68%	63%	64%	67%
OR Quartile 2	0.159	0.404	0.423	0.137	0.356	0.423	0.156	0.357	0.453
p Value	0.0027	0.080	0.14	0.0032	0.049	0.14	0.0058	0.053	0.17
Lower limit of 95% CI	0.0478	0.146	0.136	0.0366	0.128	0.136	0.0417	0.126	0.146
Upper limit of 95% CI	0.529	1.11	1.32	0.514	0.993	1.32	0.585	1.01	1.41
OR Quartile 3	0.208	0.206	0.360	0.205	0.213	0.451	0.251	0.222	0.500
p Value	9.1E-4	0.0014	0.033	9.0E-4	0.0015	0.091	0.0035	0.0016	0.14
Lower limit of 95% CI	0.0823	0.0781	0.141	0.0802	0.0824	0.179	0.0995	0.0873	0.198
Upper limit of 95% CI	0.526	0.541	0.919	0.522	0.553	1.14	0.635	0.566	1.26
OR Quartile 4	0.211	0.108	0.553	0.295	0.160	0.553	0.338	0.265	0.513
p Value	0.0067	0.0047	0.26	0.022	0.0068	0.26	0.038	0.021	0.20
Lower limit of 95% CI	0.0685	0.0229	0.198	0.104	0.0425	0.198	0.122	0.0854	0.183
Upper limit of 95% CI	0.650	0.504	1.54	0.837	0.602	1.54	0.941	0.820	1.44

[0186] Table 10.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum

creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.706	0.614	0.468	0.636	0.373	0.640
Average	0.685	0.887	0.537	0.889	0.434	0.890
Stdev	0.369	0.875	0.329	0.859	0.288	0.854
p (t-test)		0.26		0.11		0.061
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	1.22	4.86	0.948	4.86	0.881	4.86
n (Patient)	8	74	5	77	4	78

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.522	0.737	0.484	0.737	0.484	0.690
Average	0.615	1.04	0.603	1.03	0.612	1.01
Stdev	0.410	0.990	0.416	0.973	0.428	0.961
p (t-test)		0.010		0.0087		0.014
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.35	4.86	2.35	4.86	2.35	4.86
n (Patient)	31	50	29	52	27	54

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.915	0.575	0.881	0.571	0.817	0.571
Average	0.880	0.870	0.842	0.872	0.829	0.863
Stdev	0.451	0.921	0.460	0.915	0.487	0.905
p (t-test)		0.96		0.88		0.88
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	1.47	4.86	1.47	4.86	1.47	4.86
n (Patient)	10	61	9	62	8	64

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	0.63	0.38	0.64	0.64	0.42	0.72	0.63	0.43
SE	0.11	0.062	0.090	0.12	0.062	0.098	0.11	0.064	0.10
p Value	0.87	0.039	0.19	0.23	0.022	0.39	0.046	0.041	0.52
nCohort Recovered	8	31	10	5	29	9	4	27	8
nCohort Non-recovered	74	50	61	77	52	62	78	54	64
Cutoff Quartile 2	0.374	0.374	0.375	0.374	0.374	0.375	0.374	0.374	0.374
Sensitivity	74%	78%	74%	75%	79%	74%	76%	78%	75%
Specificity	25%	32%	20%	40%	34%	22%	50%	33%	25%
Cutoff Quartile 3	0.614	0.636	0.636	0.614	0.636	0.593	0.614	0.636	0.584
Sensitivity	50%	56%	46%	51%	56%	47%	51%	54%	48%
Specificity	50%	61%	30%	60%	62%	33%	75%	59%	38%
Cutoff Quartile 4	1.04	1.04	0.990	1.04	1.04	0.990	1.04	1.04	0.984
Sensitivity	26%	36%	23%	27%	35%	24%	27%	33%	23%
Specificity	75%	94%	60%	100%	93%	67%	100%	93%	62%
OR Quartile 2	0.965	1.69	0.703	2.04	1.96	0.821	3.11	1.75	1.00
p Value	0.97	0.31	0.68	0.45	0.19	0.82	0.27	0.28	1.0
Lower limit of 95% CI	0.179	0.617	0.135	0.316	0.711	0.154	0.409	0.628	0.183
Upper limit of 95% CI	5.19	4.62	3.67	13.1	5.41	4.37	23.6	4.88	5.46
OR Quartile 3	1.00	2.02	0.364	1.54	2.06	0.439	3.16	1.69	0.564

p Value	1.0	0.13	0.17	0.65	0.13	0.27	0.33	0.27	0.46
Lower limit of 95% CI	0.232	0.808	0.0859	0.243	0.815	0.101	0.315	0.662	0.124
Upper limit of 95% CI	4.30	5.02	1.54	9.73	5.22	1.92	31.7	4.30	2.56
OR Quartile 4	1.04	8.16	0.447	4.19	7.15	0.638	3.37	6.25	0.510
p Value	0.97	0.0078	0.26	0.34	0.013	0.56	0.42	0.020	0.39
Lower limit of 95% CI	0.193	1.74	0.110	0.222	1.52	0.142	0.174	1.33	0.109
Upper limit of 95% CI	5.58	38.2	1.81	79.0	33.5	2.87	65.2	29.4	2.39

[0187] Table 10.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.724	0.614	0.517	0.640	0.517	0.640
Average	0.809	0.881	0.728	0.888	0.755	0.881
Stdev	0.557	0.882	0.594	0.871	0.661	0.861
p (t-test)		0.74		0.53		0.70
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.14	4.86	2.14	4.86	2.14	4.86
n (Patient)	10	70	8	72	6	74

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.567	0.644	0.522	0.644	0.545	0.643
Average	0.685	1.01	0.675	0.999	0.687	0.986
Stdev	0.486	1.000	0.498	0.981	0.502	0.975
p (t-test)		0.065		0.058		0.079
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.35	4.86	2.35	4.86	2.35	4.86
n (Patient)	31	48	29	50	28	51

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.754	0.640	0.673	0.636	0.593	0.636
Average	0.923	0.874	0.902	0.877	0.898	0.866
Stdev	0.685	0.925	0.704	0.919	0.730	0.907
p (t-test)		0.83		0.91		0.90
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	15	54	14	55	13	57

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	0.58	0.42	0.56	0.59	0.44	0.56	0.58	0.45
SE	0.097	0.065	0.081	0.10	0.065	0.084	0.12	0.066	0.087
p Value	0.87	0.23	0.32	0.55	0.15	0.50	0.61	0.24	0.59
n Cohort Recovered	10	31	15	8	29	14	6	28	13
n Cohort Non-recovered	70	48	54	72	50	55	74	51	57

Cutoff Quartile 2	0.374	0.375	0.376	0.374	0.375	0.376	0.374	0.375	0.375
Sensitivity	76%	77%	72%	76%	78%	73%	76%	76%	74%
Specificity	30%	29%	20%	38%	31%	21%	33%	29%	23%
Cutoff Quartile 3	0.614	0.636	0.643	0.614	0.636	0.636	0.614	0.636	0.614
Sensitivity	50%	52%	48%	51%	52%	49%	51%	51%	51%
Specificity	50%	55%	47%	62%	55%	50%	67%	54%	54%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	0.995
Sensitivity	24%	33%	22%	26%	34%	24%	26%	33%	25%
Specificity	70%	87%	67%	88%	90%	71%	83%	89%	69%
OR Quartile 2	1.34	1.38	0.650	1.94	1.60	0.727	1.56	1.30	0.840
p Value	0.70	0.54	0.55	0.40	0.38	0.66	0.63	0.62	0.81
Lower limit of 95% CI	0.311	0.493	0.161	0.420	0.568	0.178	0.263	0.457	0.203
Upper limit of 95% CI	5.75	3.84	2.63	8.98	4.48	2.97	9.21	3.69	3.47
OR Quartile 3	1.00	1.32	0.812	1.76	1.33	0.964	2.11	1.20	1.21
p Value	1.0	0.55	0.72	0.46	0.54	0.95	0.40	0.70	0.76
Lower limit of 95% CI	0.266	0.533	0.258	0.392	0.532	0.298	0.364	0.477	0.361
Upper limit of 95% CI	3.76	3.27	2.56	7.93	3.34	3.12	12.2	3.02	4.04
OR Quartile 4	0.748	3.38	0.571	2.51	4.46	0.774	1.73	4.17	0.733
p Value	0.70	0.049	0.38	0.40	0.028	0.70	0.63	0.036	0.64
Lower limit of 95% CI	0.174	1.01	0.164	0.289	1.18	0.208	0.190	1.10	0.195
Upper limit of 95% CI	3.22	11.3	2.00	21.8	16.9	2.88	15.7	15.8	2.75

[0188] Table 10.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.567	0.614	0.625	0.593	0.625	0.593
Average	0.692	0.915	0.725	0.894	0.725	0.894
Stdev	0.563	0.923	0.587	0.907	0.587	0.907
p (t-test)		0.21		0.37		0.37
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	21	56	18	59	18	59

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.503	0.644	0.522	0.643	0.522	0.643
Average	0.674	0.988	0.685	0.973	0.685	0.973
Stdev	0.578	0.983	0.584	0.977	0.584	0.977
p (t-test)		0.090		0.12		0.12
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	32	44	31	45	31	45

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.718	0.532	0.718	0.553	0.718	0.553
Average	0.857	0.880	0.865	0.859	0.865	0.859
Stdev	0.604	0.879	0.634	0.853	0.634	0.853

p (t-test)		0.91		0.98		0.98
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.60	2.99	4.60	2.99	4.60
n (Patient)	20	37	18	40	18	40

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.61	0.43	0.51	0.59	0.43	0.51	0.59	0.43
SE	0.073	0.065	0.079	0.078	0.066	0.080	0.078	0.066	0.080
p Value	0.53	0.094	0.34	0.89	0.16	0.36	0.89	0.16	0.36
nCohort Recovered	21	32	20	18	31	18	18	31	18
nCohort Non-recovered	56	44	37	59	45	40	59	45	40
Cutoff Quartile 2	0.374	0.374	0.389	0.374	0.374	0.379	0.374	0.374	0.379
Sensitivity	73%	80%	68%	71%	78%	70%	71%	78%	70%
Specificity	24%	31%	15%	17%	29%	17%	17%	29%	17%
Cutoff Quartile 3	0.593	0.584	0.636	0.593	0.584	0.614	0.593	0.584	0.614
Sensitivity	50%	57%	46%	49%	56%	48%	49%	56%	48%
Specificity	52%	59%	45%	50%	58%	44%	50%	58%	44%
Cutoff Quartile 4	1.00	1.01	1.07	1.00	1.01	1.06	1.00	1.01	1.06
Sensitivity	32%	36%	24%	31%	36%	25%	31%	36%	25%
Specificity	95%	91%	75%	94%	90%	72%	94%	90%	72%
OR Quartile 2	0.854	1.77	0.368	0.494	1.43	0.467	0.494	1.43	0.467
p Value	0.79	0.29	0.16	0.31	0.50	0.29	0.31	0.50	0.29
Lower limit of 95% CI	0.266	0.621	0.0900	0.127	0.503	0.114	0.127	0.503	0.114
Upper limit of 95% CI	2.74	5.03	1.50	1.93	4.08	1.92	1.93	4.08	1.92
OR Quartile 3	1.10	1.92	0.695	0.967	1.73	0.724	0.967	1.73	0.724
p Value	0.85	0.17	0.51	0.95	0.24	0.57	0.95	0.24	0.57
Lower limit of 95% CI	0.403	0.763	0.233	0.336	0.687	0.237	0.336	0.687	0.237
Upper limit of 95% CI	3.00	4.84	2.07	2.78	4.36	2.21	2.78	4.36	2.21
OR Quartile 4	9.47	5.52	0.964	7.46	5.15	0.867	7.46	5.15	0.867
p Value	0.035	0.012	0.95	0.060	0.016	0.82	0.060	0.016	0.82
Lower limit of 95% CI	1.18	1.45	0.273	0.922	1.35	0.247	0.922	1.35	0.247
Upper limit of 95% CI	76.2	21.1	3.40	60.4	19.6	3.04	60.4	19.6	3.04

[0189] Table 10.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.669	0.584	0.669	0.584	0.669	0.584
Average	0.832	0.883	0.832	0.883	0.832	0.883
Stdev	0.672	0.927	0.672	0.927	0.672	0.927
p (t-test)		0.80		0.80		0.80
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	22	52	22	52	22	52

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.567	0.614	0.567	0.614	0.656	0.584
Average	0.779	0.927	0.782	0.917	0.818	0.888
Stdev	0.650	0.999	0.663	0.980	0.671	0.967

p (t-test)		0.46		0.49		0.72
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	33	40	31	42	29	44

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.625	0.605	0.625	0.605	0.625	0.605
Average	0.752	0.880	0.752	0.880	0.752	0.880
Stdev	0.372	0.871	0.372	0.871	0.372	0.871
p (t-test)		0.49		0.49		0.49
Min	0.279	0.172	0.279	0.172	0.279	0.172
Max	1.47	4.60	1.47	4.60	1.47	4.60
n (Patient)	14	34	14	34	14	34

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	0.53	0.45	0.48	0.53	0.45	0.48	0.48	0.45
SE	0.073	0.068	0.091	0.073	0.069	0.091	0.073	0.069	0.091
p Value	0.78	0.67	0.59	0.78	0.69	0.59	0.78	0.82	0.59
nCohort Recovered	22	33	14	22	31	14	22	29	14
nCohort Non-recovered	52	40	34	52	42	34	52	44	34
Cutoff Quartile 2	0.375	0.374	0.397	0.375	0.374	0.397	0.375	0.374	0.397
Sensitivity	73%	75%	71%	73%	74%	71%	73%	70%	71%
Specificity	23%	27%	14%	23%	26%	14%	23%	21%	14%
Cutoff Quartile 3	0.614	0.593	0.614	0.614	0.593	0.614	0.614	0.593	0.614
Sensitivity	48%	50%	50%	48%	50%	50%	48%	48%	50%
Specificity	45%	52%	50%	45%	52%	50%	45%	48%	50%
Cutoff Quartile 4	1.03	1.00	1.05	1.03	1.00	1.05	1.03	1.00	1.05
Sensitivity	29%	30%	26%	29%	31%	26%	29%	30%	26%
Specificity	82%	82%	79%	82%	84%	79%	82%	83%	79%
OR Quartile 2	0.798	1.12	0.400	0.798	0.980	0.400	0.798	0.622	0.400
p Value	0.71	0.83	0.28	0.71	0.97	0.28	0.71	0.40	0.28
Lower limit of 95% CI	0.248	0.394	0.0754	0.248	0.340	0.0754	0.248	0.206	0.0754
Upper limit of 95% CI	2.57	3.21	2.12	2.57	2.83	2.12	2.57	1.88	2.12
OR Quartile 3	0.772	1.06	1.00	0.772	1.07	1.00	0.772	0.852	1.00
p Value	0.61	0.90	1.0	0.61	0.89	1.0	0.61	0.74	1.0
Lower limit of 95% CI	0.284	0.423	0.288	0.284	0.421	0.288	0.284	0.333	0.288
Upper limit of 95% CI	2.10	2.67	3.47	2.10	2.70	3.47	2.10	2.18	3.47
OR Quartile 4	1.82	1.93	1.32	1.82	2.33	1.32	1.82	2.01	1.32
p Value	0.34	0.25	0.71	0.34	0.15	0.71	0.34	0.24	0.71
Lower limit of 95% CI	0.529	0.633	0.298	0.529	0.731	0.298	0.529	0.630	0.298
Upper limit of 95% CI	6.29	5.87	5.84	6.29	7.43	5.84	6.29	6.43	5.84

[0190] Table 10.10: Comparison of marker levels and the area under the ROC curve

(AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.602	0.618	0.612	0.614	0.561	0.640
Average	0.845	0.874	0.875	0.844	0.869	0.851
Stdev	0.838	0.827	0.872	0.796	0.894	0.779

p (t-test)		0.88		0.87		0.92
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	44	40	40	44	38	46

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.561	0.644	0.602	0.643	0.539	0.644
Average	0.845	0.919	0.865	0.889	0.862	0.889
Stdev	0.847	0.836	0.860	0.821	0.897	0.781
p (t-test)		0.71		0.90		0.89
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	48	33	46	35	42	39

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.580	0.609	0.593	0.575	0.580	0.609
Average	0.753	0.906	0.746	0.909	0.739	0.910
Stdev	0.537	0.979	0.533	0.989	0.541	0.979
p (t-test)		0.38		0.35		0.33
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	30	48	31	47	30	48

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.51	0.56	0.47	0.49	0.53	0.47	0.51	0.56	0.49
SE	0.063	0.066	0.067	0.063	0.065	0.067	0.064	0.064	0.067
p Value	0.94	0.39	0.67	0.86	0.61	0.71	0.87	0.32	0.84
nCohort Recovered	44	48	30	40	46	31	38	42	30
nCohort Non-recovered	40	33	48	44	35	47	46	39	48
Cutoff Quartile 2	0.372	0.374	0.375	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	72%	79%	69%	73%	77%	70%	74%	79%	71%
Specificity	23%	29%	17%	22%	28%	19%	24%	31%	20%
Cutoff Quartile 3	0.614	0.636	0.584	0.614	0.636	0.584	0.614	0.636	0.584
Sensitivity	50%	55%	50%	50%	51%	49%	52%	54%	50%
Specificity	50%	54%	50%	50%	52%	48%	53%	55%	50%
Cutoff Quartile 4	1.04	1.04	0.995	1.04	1.04	0.995	1.04	1.04	0.995
Sensitivity	30%	30%	29%	27%	29%	30%	28%	28%	29%
Specificity	80%	79%	80%	78%	78%	81%	79%	79%	80%
OR Quartile 2	0.775	1.53	0.440	0.774	1.33	0.566	0.879	1.74	0.607
p Value	0.61	0.42	0.16	0.61	0.58	0.30	0.80	0.29	0.37
Lower limit of 95% CI	0.288	0.540	0.141	0.286	0.481	0.190	0.325	0.629	0.204
Upper limit of 95% CI	2.09	4.33	1.37	2.09	3.68	1.68	2.38	4.80	1.81
OR Quartile 3	1.00	1.42	1.00	1.00	1.16	0.898	1.21	1.41	1.00
p Value	1.0	0.44	1.0	1.0	0.75	0.82	0.66	0.44	1.0
Lower limit of 95% CI	0.425	0.582	0.402	0.425	0.479	0.363	0.513	0.589	0.402
Upper limit of 95% CI	2.35	3.45	2.49	2.35	2.78	2.23	2.87	3.39	2.49
OR Quartile 4	1.67	1.65	1.65	1.29	1.44	1.77	1.48	1.44	1.65
p Value	0.32	0.33	0.37	0.61	0.48	0.30	0.45	0.48	0.37
Lower limit of 95% CI	0.615	0.597	0.554	0.477	0.522	0.595	0.538	0.522	0.554
Upper limit of 95% CI	4.52	4.57	4.90	3.50	3.97	5.25	4.06	3.97	4.90

[0191] Example 11. Use of Tyrosine-protein kinase receptor UFO for evaluating renal status in patients admitted to the ICU: Recovery to RIFLE 0 and R from RIFLE I and F

[0192] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Tyrosine-protein kinase receptor UFO is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0193] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output during a period starting at 12, 24, 48, or 72 hours after sample collection or at any time within 7 days after sample collection. Two cohorts are defined to represent a “recovered” and a “non-recovered” population.

“Recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0) or risk of injury (R). “Non-recovered” indicates those patients whose maximum RIFLE stage during a period of 24, 48 or 72 hours is injury (I) or failure (F). If a patient dies or is placed on renal replacement therapy (RRT) within 9 days of enrollment, the patient is considered “non-recovered”.

[0194] The ability to distinguish the “recovered” and “non-recovered” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0195] Table 11.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.79	3.52	5.74	3.60	5.69	3.64
Average	6.19	4.43	5.96	4.53	5.46	4.68
Stdev	3.26	4.24	3.19	4.27	2.51	4.41
p (t-test)		0.070		0.14		0.36
Min	1.99	0.276	1.99	0.276	1.99	0.276
Max	14.5	20.6	14.5	20.6	10.3	20.6
n (Patient)	19	62	18	63	17	64

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered	Non-recovered	Recovered	Non-recovered	Recovered	Non-recovered

	Cohort	Cohort	Cohort	Cohort	Cohort	Cohort
Median	5.58	2.32	5.58	2.47	5.58	2.47
Average	6.33	2.79	6.31	3.02	6.31	3.02
Stdev	4.42	2.41	4.45	2.65	4.45	2.65
p (t-test)		2.0E-5		1.1E-4		1.1E-4
Min	0.502	0.276	0.502	0.276	0.502	0.276
Max	20.6	11.5	20.6	11.5	20.6	11.5
n (Patient)	47	34	45	36	45	36

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	4.74	4.09	4.88	4.01	4.21	4.18
Average	4.87	5.05	5.13	5.01	4.29	5.29
Stdev	3.50	4.39	3.61	4.42	2.74	4.58
p (t-test)		0.86		0.91		0.27
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	14.5	20.6	14.5	20.6	10.3	20.6
n (Patient)	20	52	21	51	20	53

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.30	0.21	0.48	0.33	0.23	0.46	0.35	0.23	0.53
SE	0.064	0.053	0.076	0.067	0.054	0.074	0.071	0.054	0.076
p Value	0.0021	6.9E-8	0.83	0.0094	9.1E-7	0.58	0.039	9.1E-7	0.73
nCohort Recovered	19	47	20	18	45	21	17	45	20
nCohort Non-recovered	62	34	52	63	36	51	64	36	53
Cutoff Quartile 2	1.99	1.99	2.09	1.99	1.99	2.09	1.99	1.99	2.12
Sensitivity	68%	56%	75%	68%	58%	75%	69%	58%	75%
Specificity	5%	13%	25%	6%	13%	24%	6%	13%	30%
Cutoff Quartile 3	3.81	3.81	4.30	3.81	3.81	4.30	3.81	3.81	4.18
Sensitivity	44%	24%	48%	44%	25%	47%	45%	25%	49%
Specificity	32%	32%	45%	33%	31%	43%	35%	31%	50%
Cutoff Quartile 4	6.29	6.29	6.33	6.29	6.29	6.33	6.29	6.29	6.32
Sensitivity	21%	6%	25%	22%	8%	24%	23%	8%	26%
Specificity	63%	62%	75%	67%	62%	71%	71%	62%	80%
OR Quartile 2	0.117	0.185	1.00	0.126	0.215	0.913	0.138	0.215	1.32
p Value	0.043	0.0025	1.0	0.052	0.0056	0.88	0.063	0.0056	0.64
Lower limit of 95% CI	0.0145	0.0622	0.304	0.0157	0.0728	0.279	0.0170	0.0728	0.421
Upper limit of 95% CI	0.937	0.552	3.29	1.02	0.638	2.99	1.11	0.638	4.14
OR Quartile 3	0.356	0.144	0.758	0.400	0.151	0.667	0.452	0.151	0.963
p Value	0.063	1.5E-4	0.60	0.10	1.6E-4	0.44	0.16	1.6E-4	0.94
Lower limit of 95% CI	0.120	0.0530	0.269	0.133	0.0563	0.239	0.149	0.0563	0.344
Upper limit of 95% CI	1.06	0.393	2.13	1.20	0.403	1.86	1.37	0.403	2.69
OR Quartile 4	0.455	0.101	1.00	0.571	0.150	0.769	0.735	0.150	1.44
p Value	0.17	0.0036	1.0	0.34	0.0050	0.65	0.61	0.0050	0.57
Lower limit of 95% CI	0.149	0.0215	0.304	0.182	0.0397	0.244	0.223	0.0397	0.410
Upper limit of 95% CI	1.39	0.472	3.29	1.80	0.564	2.42	2.42	0.564	5.03

[0196] Table 11.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.90	3.15	5.79	3.28	5.79	3.36

Average	6.37	4.17	6.20	4.28	5.83	4.46
Stdev	3.54	4.18	3.52	4.22	3.11	4.39
p (t-test)		0.022		0.046		0.13
Min	0.502	0.276	0.502	0.276	0.502	0.276
Max	14.5	20.6	14.5	20.6	13.5	20.6
n (Patient)	24	56	23	57	22	58

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.58	2.44	5.54	2.47	5.58	2.51
Average	6.41	2.81	6.32	3.02	6.34	3.08
Stdev	4.49	2.38	4.50	2.65	4.55	2.65
p (t-test)		2.1E-5		1.4E-4		1.9E-4
Min	0.502	0.276	0.502	0.276	0.502	0.276
Max	20.6	11.5	20.6	11.5	20.6	11.5
n (Patient)	45	35	44	36	43	37

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.02	3.84	5.16	3.67	4.74	4.01
Average	4.96	4.82	5.19	4.77	4.42	5.09
Stdev	3.39	4.38	3.49	4.42	2.70	4.61
p (t-test)		0.89		0.67		0.46
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	14.5	20.6	14.5	20.6	8.84	20.6
n (Patient)	22	46	23	45	22	47

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.28	0.21	0.45	0.30	0.24	0.43	0.33	0.25	0.49
SE	0.059	0.053	0.074	0.061	0.055	0.072	0.064	0.055	0.075
p Value	2.4E-4	6.3E-8	0.49	0.0014	1.4E-6	0.31	0.0071	3.8E-6	0.91
nCohort Recovered	24	45	22	23	44	23	22	43	22
nCohort Non-recovered	56	35	46	57	36	45	58	37	47
Cutoff Quartile 2	1.90	1.90	1.90	1.90	1.90	1.90	1.90	1.90	1.99
Sensitivity	66%	57%	74%	67%	58%	73%	67%	59%	74%
Specificity	4%	11%	23%	4%	11%	22%	5%	12%	27%
Cutoff Quartile 3	3.77	3.77	4.30	3.77	3.77	4.30	3.77	3.77	4.18
Sensitivity	41%	23%	46%	42%	25%	44%	43%	27%	47%
Specificity	29%	29%	41%	30%	30%	39%	32%	30%	45%
Cutoff Quartile 4	6.30	6.30	6.30	6.30	6.30	6.30	6.30	6.30	6.29
Sensitivity	16%	6%	22%	18%	8%	20%	19%	8%	23%
Specificity	54%	60%	68%	57%	61%	65%	59%	60%	73%
OR Quartile 2	0.0847	0.167	0.833	0.0909	0.179	0.764	0.0977	0.193	1.09
p Value	0.020	0.0022	0.76	0.024	0.0032	0.66	0.028	0.0047	0.88
Lower limit of 95% CI	0.0106	0.0530	0.252	0.0114	0.0572	0.232	0.0122	0.0617	0.348
Upper limit of 95% CI	0.676	0.524	2.75	0.726	0.563	2.51	0.782	0.604	3.44
OR Quartile 3	0.287	0.120	0.582	0.318	0.140	0.514	0.354	0.160	0.733
p Value	0.017	4.6E-5	0.30	0.030	1.0E-4	0.20	0.049	2.3E-4	0.55
Lower limit of 95% CI	0.103	0.0435	0.208	0.113	0.0517	0.185	0.125	0.0606	0.265
Upper limit of 95% CI	0.803	0.333	1.63	0.893	0.378	1.43	0.997	0.425	2.03
OR Quartile 4	0.226	0.0909	0.595	0.277	0.144	0.469	0.338	0.135	0.815
p Value	0.0067	0.0024	0.37	0.019	0.0043	0.19	0.048	0.0031	0.73
Lower limit of 95% CI	0.0773	0.0194	0.191	0.0948	0.0382	0.152	0.116	0.0357	0.256
Upper limit of 95% CI	0.662	0.427	1.86	0.807	0.545	1.45	0.989	0.510	2.59

[0197] Table 11.3: Comparison of marker levels and the area under the ROC curve

(AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery

starts at 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.67	2.65	5.67	2.91	5.58	3.03
Average	6.19	3.61	5.96	4.00	5.88	4.10
Stdev	4.10	3.75	3.96	4.05	3.99	4.06
p (t-test)		0.0051		0.036		0.059
Min	0.366	0.276	0.366	0.276	0.366	0.276
Max	20.6	20.5	20.6	20.5	20.6	20.5
n (Patient)	38	42	34	46	33	47

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.36	2.65	5.32	2.78	5.32	2.78
Average	6.01	3.20	6.03	3.27	6.03	3.27
Stdev	4.52	2.75	4.57	2.73	4.57	2.73
p (t-test)		0.0011		0.0014		0.0014
Min	0.366	0.276	0.366	0.276	0.366	0.276
Max	20.6	11.5	20.6	11.5	20.6	11.5
n (Patient)	47	32	46	33	46	33

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.16	2.91	4.88	3.28	4.67	3.36
Average	5.49	3.87	4.76	4.54	4.59	4.66
Stdev	3.43	4.07	2.79	4.42	2.72	4.42
p (t-test)		0.11		0.81		0.95
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	14.5	20.5	9.65	20.5	9.65	20.5
n (Patient)	29	30	25	35	24	36

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.27	0.28	0.32	0.30	0.29	0.41	0.32	0.29	0.44
SE	0.056	0.060	0.070	0.058	0.060	0.074	0.059	0.060	0.075
p Value	2.3E-5	2.7E-4	0.0095	7.0E-4	5.3E-4	0.23	0.0023	5.3E-4	0.39
nCohort Recovered	38	47	29	34	46	25	33	46	24
nCohort Non-recovered	42	32	30	46	33	35	47	33	36
Cutoff Quartile 2	1.90	2.05	1.62	1.90	2.05	1.63	1.90	2.05	1.63
Sensitivity	60%	62%	60%	63%	64%	66%	64%	64%	67%
Specificity	8%	17%	10%	9%	17%	12%	9%	17%	12%
Cutoff Quartile 3	3.77	3.81	3.81	3.77	3.81	3.77	3.77	3.81	3.77
Sensitivity	33%	28%	37%	37%	30%	43%	38%	30%	44%
Specificity	32%	36%	38%	32%	37%	40%	33%	37%	42%
Cutoff Quartile 4	6.30	6.30	6.15	6.30	6.30	6.08	6.30	6.30	6.08
Sensitivity	12%	9%	17%	15%	9%	23%	17%	9%	25%
Specificity	61%	64%	66%	62%	63%	72%	64%	63%	75%
OR Quartile 2	0.126	0.342	0.173	0.165	0.368	0.261	0.176	0.368	0.286
p Value	0.0023	0.044	0.014	0.0078	0.060	0.059	0.010	0.060	0.078
Lower limit of 95% CI	0.0333	0.120	0.0427	0.0438	0.130	0.0649	0.0468	0.130	0.0709
Upper limit of 95% CI	0.477	0.972	0.702	0.623	1.04	1.05	0.666	1.04	1.15
OR Quartile 3	0.231	0.222	0.354	0.280	0.255	0.500	0.310	0.255	0.571

p Value	0.0022	0.0024	0.054	0.0077	0.0050	0.19	0.014	0.0050	0.29
Lower limit of 95% CI	0.0903	0.0838	0.123	0.110	0.0982	0.176	0.122	0.0982	0.201
Upper limit of 95% CI	0.589	0.587	1.02	0.714	0.661	1.42	0.789	0.661	1.62
OR Quartile 4	0.207	0.183	0.380	0.290	0.171	0.762	0.359	0.171	1.00
p Value	0.0067	0.012	0.12	0.022	0.0091	0.65	0.054	0.0091	1.0
Lower limit of 95% CI	0.0664	0.0483	0.111	0.100	0.0451	0.235	0.127	0.0451	0.303
Upper limit of 95% CI	0.647	0.690	1.30	0.838	0.645	2.47	1.02	0.645	3.30

[0198] Table 11.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.54	2.44	5.49	2.47	5.49	2.47
Average	5.89	3.47	5.81	3.60	5.81	3.60
Stdev	3.78	3.32	3.79	3.38	3.79	3.38
p (t-test)		0.0039		0.0090		0.0090
Min	0.366	0.276	0.366	0.276	0.366	0.276
Max	20.5	14.5	20.5	14.5	20.5	14.5
n (Patient)	38	41	37	42	37	42

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.02	2.51	5.02	2.51	5.02	2.51
Average	5.72	3.21	5.72	3.21	5.72	3.21
Stdev	3.98	2.80	3.98	2.80	3.98	2.80
p (t-test)		0.0020		0.0020		0.0020
Min	0.366	0.276	0.366	0.276	0.366	0.276
Max	20.5	11.5	20.5	11.5	20.5	11.5
n (Patient)	46	31	46	31	46	31

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	4.09	2.91	3.72	3.03	3.72	3.03
Average	4.28	3.92	4.04	4.06	4.04	4.06
Stdev	2.74	3.56	2.59	3.60	2.59	3.60
p (t-test)		0.69		0.98		0.98
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	9.53	14.5	9.53	14.5	9.53	14.5
n (Patient)	20	32	19	33	19	33

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.27	0.28	0.42	0.29	0.28	0.45	0.29	0.28	0.45
SE	0.056	0.061	0.081	0.057	0.061	0.083	0.057	0.061	0.083
p Value	3.8E-5	4.3E-4	0.32	1.9E-4	4.3E-4	0.54	1.9E-4	4.3E-4	0.54
nCohort Recovered	38	46	20	37	46	19	37	46	19
nCohort Non-recovered	41	31	32	42	31	33	42	31	33
Cutoff Quartile 2	1.81	2.12	1.56	1.81	2.12	1.56	1.81	2.12	1.56
Sensitivity	59%	61%	69%	60%	61%	70%	60%	61%	70%

Specificity	8%	17%	15%	8%	17%	16%	8%	17%	16%
Cutoff Quartile 3	3.72	3.81	3.36	3.72	3.81	3.36	3.72	3.81	3.36
Sensitivity	32%	29%	44%	33%	29%	45%	33%	29%	45%
Specificity	32%	37%	40%	32%	37%	42%	32%	37%	42%
Cutoff Quartile 4	6.15	6.29	5.39	6.15	6.29	5.39	6.15	6.29	5.39
Sensitivity	15%	10%	19%	17%	10%	21%	17%	10%	21%
Specificity	63%	65%	65%	65%	65%	68%	65%	65%	68%
OR Quartile 2	0.121	0.333	0.388	0.130	0.333	0.431	0.130	0.333	0.431
p Value	0.0019	0.040	0.20	0.0026	0.040	0.25	0.0026	0.040	0.25
Lower limit of 95% CI	0.0319	0.117	0.0922	0.0343	0.117	0.102	0.0343	0.117	0.102
Upper limit of 95% CI	0.459	0.953	1.63	0.491	0.953	1.82	0.491	0.953	1.82
OR Quartile 3	0.214	0.240	0.519	0.240	0.240	0.606	0.240	0.240	0.606
p Value	0.0015	0.0043	0.26	0.0030	0.0043	0.39	0.0030	0.0043	0.39
Lower limit of 95% CI	0.0830	0.0900	0.167	0.0937	0.0900	0.194	0.0937	0.0900	0.194
Upper limit of 95% CI	0.554	0.639	1.61	0.615	0.639	1.89	0.615	0.639	1.89
OR Quartile 4	0.294	0.201	0.429	0.369	0.201	0.583	0.369	0.201	0.583
p Value	0.027	0.019	0.19	0.064	0.019	0.41	0.064	0.019	0.41
Lower limit of 95% CI	0.0990	0.0528	0.119	0.128	0.0528	0.163	0.128	0.0528	0.163
Upper limit of 95% CI	0.873	0.764	1.54	1.06	0.764	2.09	1.06	0.764	2.09

[0199] Table 11.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.16	2.35	5.54	2.51	5.54	2.51
Average	6.00	3.11	6.18	3.11	6.18	3.11
Stdev	4.39	2.63	4.45	2.55	4.45	2.55
p (t-test)		3.8E-4		1.9E-4		1.9E-4
Min	0.366	0.276	0.366	0.276	0.366	0.276
Max	20.6	11.5	20.6	11.5	20.6	11.5
n (Patient)	51	32	48	35	48	35

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	4.87	2.44	4.88	2.44	4.88	2.44
Average	5.57	3.02	5.66	3.01	5.66	3.01
Stdev	4.33	2.71	4.37	2.63	4.37	2.63
p (t-test)		0.0027		0.0014		0.0014
Min	0.366	0.276	0.366	0.276	0.366	0.276
Max	20.6	11.5	20.6	11.5	20.6	11.5
n (Patient)	58	23	56	25	56	25

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	5.02	3.28	5.16	3.23	5.02	3.43
Average	5.61	4.41	5.69	4.29	5.56	4.46
Stdev	3.99	4.15	4.02	4.08	4.01	4.14
p (t-test)		0.20		0.14		0.24
Min	0.0344	0.398	0.366	0.398	0.366	0.398

Max	20.5	20.6	20.5	20.6	20.5	20.6
n (Patient)	40	39	41	38	40	39

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.27	0.29	0.38	0.26	0.29	0.36	0.26	0.29	0.39
SE	0.059	0.068	0.063	0.057	0.065	0.063	0.057	0.065	0.063
p Value	8.5E-5	0.0020	0.050	1.9E-5	9.8E-4	0.029	1.9E-5	9.8E-4	0.073
nCohort Recovered	51	58	40	48	56	41	48	56	40
nCohort Non-recovered	32	23	39	35	25	38	35	25	39
Cutoff Quartile 2	2.05	1.99	2.05	2.05	1.99	2.05	2.05	1.99	2.05
Sensitivity	56%	61%	67%	57%	60%	66%	57%	60%	67%
Specificity	14%	21%	18%	12%	20%	17%	12%	20%	18%
Cutoff Quartile 3	4.01	3.81	4.42	4.01	3.81	4.42	4.01	3.81	4.42
Sensitivity	28%	22%	36%	29%	24%	37%	29%	24%	38%
Specificity	37%	40%	38%	35%	39%	39%	35%	39%	40%
Cutoff Quartile 4	6.30	6.29	6.35	6.30	6.29	6.35	6.30	6.29	6.35
Sensitivity	9%	9%	18%	9%	8%	16%	9%	8%	18%
Specificity	65%	69%	68%	62%	68%	66%	62%	68%	68%
OR Quartile 2	0.205	0.406	0.424	0.190	0.367	0.396	0.190	0.367	0.424
p Value	0.0033	0.093	0.11	0.0028	0.058	0.085	0.0028	0.058	0.11
Lower limit of 95% CI	0.0709	0.142	0.148	0.0643	0.130	0.138	0.0643	0.130	0.148
Upper limit of 95% CI	0.590	1.16	1.22	0.564	1.03	1.14	0.564	1.03	1.22
OR Quartile 3	0.232	0.183	0.336	0.219	0.204	0.373	0.219	0.204	0.417
p Value	0.0028	0.0030	0.020	0.0016	0.0034	0.034	0.0016	0.0034	0.058
Lower limit of 95% CI	0.0892	0.0594	0.135	0.0855	0.0706	0.150	0.0855	0.0706	0.169
Upper limit of 95% CI	0.605	0.560	0.839	0.563	0.592	0.928	0.563	0.592	1.03
OR Quartile 4	0.190	0.212	0.454	0.156	0.184	0.362	0.156	0.184	0.454
p Value	0.014	0.050	0.14	0.0058	0.032	0.066	0.0058	0.032	0.14
Lower limit of 95% CI	0.0507	0.0448	0.159	0.0417	0.0390	0.122	0.0417	0.0390	0.159
Upper limit of 95% CI	0.710	1.00	1.30	0.585	0.865	1.07	0.585	0.865	1.30

[0200] Table 11.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 12 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.659	0.584	0.682	0.575	0.718	0.584
Average	0.828	0.881	0.843	0.875	0.855	0.871
Stdev	0.681	0.886	0.695	0.880	0.712	0.874
p (t-test)		0.78		0.87		0.94
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	20	62	19	63	18	64

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.527	0.979	0.539	0.738	0.539	0.738
Average	0.724	1.07	0.734	1.04	0.734	1.04
Stdev	0.611	1.04	0.623	1.02	0.623	1.02
p (t-test)		0.087		0.12		0.12
Min	0.108	0.204	0.108	0.204	0.108	0.204

Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	46	35	44	37	44	37

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.682	0.571	0.659	0.567	0.682	0.567
Average	1.01	0.814	0.988	0.815	0.989	0.806
Stdev	1.06	0.771	1.04	0.778	1.07	0.764
p (t-test)		0.46		0.50		0.49
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	21	50	22	49	21	51

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.50	0.63	0.45	0.50	0.62	0.45	0.50	0.62	0.47
SE	0.075	0.063	0.074	0.076	0.063	0.073	0.077	0.063	0.074
p Value	0.97	0.045	0.46	1.00	0.063	0.48	1.0	0.063	0.66
nCohort Recovered	20	46	21	19	44	22	18	44	21
nCohort Non-recovered	62	35	50	63	37	49	64	37	51
Cutoff Quartile 2	0.374	0.374	0.375	0.374	0.374	0.375	0.374	0.374	0.374
Sensitivity	76%	80%	76%	76%	81%	76%	77%	81%	76%
Specificity	30%	30%	29%	32%	32%	27%	33%	32%	29%
Cutoff Quartile 3	0.614	0.636	0.636	0.614	0.636	0.593	0.614	0.636	0.584
Sensitivity	48%	60%	48%	48%	57%	47%	48%	57%	47%
Specificity	45%	59%	48%	42%	57%	45%	44%	57%	43%
Cutoff Quartile 4	1.04	1.04	0.990	1.04	1.04	0.990	1.04	1.04	0.984
Sensitivity	26%	40%	24%	25%	38%	24%	25%	38%	24%
Specificity	75%	87%	71%	74%	86%	73%	72%	86%	71%
OR Quartile 2	1.34	1.75	1.27	1.48	2.00	1.16	1.63	2.00	1.30
p Value	0.61	0.29	0.69	0.50	0.19	0.80	0.40	0.19	0.65
Lower limit of 95% CI	0.439	0.619	0.402	0.478	0.708	0.369	0.523	0.708	0.413
Upper limit of 95% CI	4.11	4.95	3.99	4.56	5.65	3.62	5.10	5.65	4.09
OR Quartile 3	0.767	2.13	0.839	0.661	1.73	0.737	0.752	1.73	0.667
p Value	0.61	0.098	0.74	0.43	0.22	0.55	0.59	0.22	0.44
Lower limit of 95% CI	0.279	0.871	0.302	0.235	0.714	0.269	0.263	0.714	0.239
Upper limit of 95% CI	2.11	5.22	2.33	1.86	4.17	2.02	2.15	4.17	1.86
OR Quartile 4	1.04	4.44	0.789	0.953	3.86	0.865	0.867	3.86	0.769
p Value	0.94	0.0075	0.69	0.94	0.015	0.80	0.81	0.015	0.65
Lower limit of 95% CI	0.327	1.49	0.251	0.296	1.30	0.276	0.267	1.30	0.244
Upper limit of 95% CI	3.33	13.3	2.49	3.07	11.4	2.71	2.81	11.4	2.42

[0201] Table 11.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.602	0.618	0.636	0.593	0.625	0.614
Average	0.763	0.924	0.795	0.903	0.802	0.899
Stdev	0.616	0.936	0.647	0.916	0.660	0.908
p (t-test)		0.37		0.56		0.61
Min	0.108	0.172	0.108	0.172	0.108	0.172

Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	26	54	23	57	22	58

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.544	0.738	0.555	0.691	0.561	0.644
Average	0.736	1.08	0.741	1.06	0.754	1.04
Stdev	0.614	1.07	0.620	1.06	0.621	1.05
p (t-test)		0.11		0.12		0.17
Min	0.108	0.217	0.108	0.217	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	46	33	45	34	44	35

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.656	0.609	0.659	0.575	0.682	0.575
Average	0.950	0.848	0.969	0.835	0.969	0.825
Stdev	0.981	0.813	0.996	0.807	1.02	0.791
p (t-test)		0.67		0.58		0.56
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	25	44	24	45	23	47

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	0.61	0.46	0.52	0.61	0.44	0.52	0.59	0.46
SE	0.069	0.065	0.072	0.071	0.065	0.072	0.072	0.065	0.073
p Value	0.66	0.078	0.58	0.83	0.088	0.43	0.82	0.19	0.57
nCohort Recovered	26	46	25	23	45	24	22	44	23
nCohort Non-recovered	54	33	44	57	34	45	58	35	47
Cutoff Quartile 2	0.374	0.375	0.376	0.374	0.375	0.376	0.374	0.375	0.375
Sensitivity	78%	82%	75%	77%	82%	73%	78%	80%	77%
Specificity	31%	30%	28%	30%	31%	25%	32%	30%	30%
Cutoff Quartile 3	0.614	0.636	0.643	0.614	0.636	0.636	0.614	0.636	0.614
Sensitivity	50%	58%	48%	49%	56%	49%	50%	54%	49%
Specificity	50%	57%	48%	48%	56%	50%	50%	55%	48%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	0.995
Sensitivity	28%	36%	25%	26%	35%	24%	26%	34%	26%
Specificity	81%	83%	76%	78%	82%	75%	77%	82%	74%
OR Quartile 2	1.56	1.97	1.17	1.48	2.11	0.917	1.62	1.68	1.43
p Value	0.41	0.22	0.79	0.48	0.18	0.88	0.39	0.33	0.53
Lower limit of 95% CI	0.544	0.665	0.385	0.502	0.713	0.294	0.544	0.586	0.469
Upper limit of 95% CI	4.45	5.83	3.53	4.37	6.23	2.85	4.80	4.80	4.37
OR Quartile 3	1.00	1.76	0.843	0.885	1.58	0.957	1.00	1.42	0.878
p Value	1.0	0.22	0.73	0.80	0.32	0.93	1.0	0.44	0.80
Lower limit of 95% CI	0.392	0.715	0.315	0.336	0.646	0.355	0.375	0.584	0.324
Upper limit of 95% CI	2.55	4.35	2.25	2.33	3.88	2.58	2.67	3.47	2.38
OR Quartile 4	1.62	2.71	1.06	1.29	2.52	0.971	1.19	2.35	0.971
p Value	0.41	0.060	0.93	0.67	0.081	0.96	0.77	0.11	0.96
Lower limit of 95% CI	0.515	0.958	0.336	0.406	0.893	0.308	0.373	0.833	0.311
Upper limit of 95% CI	5.06	7.69	3.31	4.07	7.13	3.06	3.77	6.62	3.03

[0202] Table 11.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 48 hours after sample collection and renal status is assessed by serum

creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.539	0.644	0.561	0.636	0.567	0.614
Average	0.668	1.02	0.698	0.966	0.710	0.952
Stdev	0.511	1.03	0.531	0.997	0.536	0.990
p (t-test)		0.062		0.14		0.17
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	36	41	32	45	31	46

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.503	0.691	0.522	0.644	0.522	0.644
Average	0.706	1.09	0.718	1.06	0.718	1.06
Stdev	0.594	1.10	0.595	1.09	0.595	1.09
p (t-test)		0.096		0.13		0.13
Min	0.108	0.217	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	2.99	4.86
n (Patient)	46	30	45	31	45	31

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.593	0.644	0.682	0.575	0.718	0.553
Average	0.771	0.963	0.816	0.890	0.838	0.875
Stdev	0.561	0.946	0.596	0.896	0.600	0.888
p (t-test)		0.36		0.71		0.85
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.60	2.99	4.60	2.99	4.60
n (Patient)	27	30	23	35	22	36

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.64	0.50	0.56	0.61	0.46	0.55	0.61	0.44
SE	0.065	0.066	0.077	0.066	0.067	0.077	0.067	0.067	0.077
p Value	0.13	0.034	0.97	0.34	0.090	0.59	0.49	0.090	0.40
nCohort Recovered	36	46	27	32	45	23	31	45	22
nCohort Non-recovered	41	30	30	45	31	35	46	31	36
Cutoff Quartile 2	0.374	0.374	0.389	0.374	0.374	0.379	0.374	0.374	0.379
Sensitivity	78%	90%	67%	78%	87%	71%	76%	87%	69%
Specificity	31%	35%	19%	31%	33%	22%	29%	33%	18%
Cutoff Quartile 3	0.593	0.584	0.636	0.593	0.584	0.614	0.593	0.584	0.614
Sensitivity	54%	60%	53%	51%	58%	49%	50%	58%	47%
Specificity	56%	57%	56%	53%	56%	48%	52%	56%	45%
Cutoff Quartile 4	1.00	1.01	1.07	1.00	1.01	1.06	1.00	1.01	1.06
Sensitivity	34%	37%	27%	31%	35%	26%	30%	35%	25%
Specificity	86%	83%	78%	84%	82%	74%	84%	82%	73%
OR Quartile 2	1.56	4.80	0.455	1.59	3.38	0.694	1.30	3.38	0.505
p Value	0.39	0.022	0.21	0.38	0.051	0.56	0.62	0.051	0.30
Lower limit of 95% CI	0.562	1.26	0.133	0.570	0.997	0.202	0.465	0.997	0.138
Upper limit of 95% CI	4.36	18.3	1.56	4.44	11.4	2.38	3.65	11.4	1.84
OR Quartile 3	1.45	1.95	1.43	1.18	1.73	0.866	1.07	1.73	0.746

p Value	0.42	0.16	0.50	0.71	0.24	0.79	0.89	0.24	0.59
Lower limit of 95% CI	0.589	0.766	0.503	0.478	0.687	0.302	0.429	0.687	0.257
Upper limit of 95% CI	3.56	4.96	4.06	2.94	4.36	2.48	2.65	4.36	2.16
OR Quartile 4	3.21	2.75	1.27	2.44	2.54	0.981	2.28	2.54	0.889
p Value	0.045	0.062	0.70	0.13	0.085	0.97	0.16	0.085	0.85
Lower limit of 95% CI	1.02	0.949	0.377	0.777	0.881	0.295	0.724	0.881	0.267
Upper limit of 95% CI	10.1	7.97	4.29	7.66	7.35	3.26	7.15	7.35	2.96

[0203] Table 11.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts at 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.612	0.614	0.656	0.593	0.656	0.593
Average	0.849	0.886	0.864	0.872	0.864	0.872
Stdev	0.892	0.827	0.901	0.821	0.901	0.821
p (t-test)		0.85		0.97		0.97
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	36	38	35	39	35	39

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.561	0.643	0.561	0.643	0.561	0.643
Average	0.815	0.927	0.815	0.927	0.815	0.927
Stdev	0.853	0.872	0.853	0.872	0.853	0.872
p (t-test)		0.60		0.60		0.60
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	44	29	44	29	44	29

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.625	0.605	0.656	0.575	0.656	0.575
Average	0.735	0.907	0.759	0.889	0.759	0.889
Stdev	0.385	0.910	0.383	0.901	0.383	0.901
p (t-test)		0.38		0.50		0.50
Min	0.200	0.172	0.200	0.172	0.200	0.172
Max	1.47	4.60	1.47	4.60	1.47	4.60
n (Patient)	18	30	17	31	17	31

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.54	0.58	0.48	0.53	0.58	0.45	0.53	0.58	0.45
SE	0.067	0.069	0.087	0.067	0.069	0.087	0.067	0.069	0.087
p Value	0.51	0.26	0.81	0.69	0.26	0.58	0.69	0.26	0.58
n Cohort Recovered	36	44	18	35	44	17	35	44	17
n Cohort Non-recovered	38	29	30	39	29	31	39	29	31

Cutoff Quartile 2	0.375	0.374	0.397	0.375	0.374	0.397	0.375	0.374	0.397
Sensitivity	82%	83%	73%	79%	83%	71%	79%	83%	71%
Specificity	33%	32%	22%	31%	32%	18%	31%	32%	18%
Cutoff Quartile 3	0.614	0.593	0.614	0.614	0.593	0.614	0.614	0.593	0.614
Sensitivity	50%	52%	50%	49%	52%	48%	49%	52%	48%
Specificity	50%	52%	50%	49%	52%	47%	49%	52%	47%
Cutoff Quartile 4	1.03	1.00	1.05	1.03	1.00	1.05	1.03	1.00	1.05
Sensitivity	32%	34%	27%	31%	34%	26%	31%	34%	26%
Specificity	81%	82%	78%	80%	82%	76%	80%	82%	76%
OR Quartile 2	2.21	2.24	0.786	1.78	2.24	0.524	1.78	2.24	0.524
p Value	0.15	0.17	0.73	0.29	0.17	0.39	0.29	0.17	0.39
Lower limit of 95% CI	0.757	0.707	0.199	0.618	0.707	0.121	0.618	0.707	0.121
Upper limit of 95% CI	6.48	7.10	3.11	5.10	7.10	2.27	5.10	7.10	2.27
OR Quartile 3	1.00	1.17	1.00	0.897	1.17	0.833	0.897	1.17	0.833
p Value	1.0	0.74	1.0	0.82	0.74	0.76	0.82	0.74	0.76
Lower limit of 95% CI	0.402	0.459	0.311	0.360	0.459	0.255	0.360	0.459	0.255
Upper limit of 95% CI	2.49	3.00	3.22	2.24	3.00	2.72	2.24	3.00	2.72
OR Quartile 4	1.91	2.37	1.27	1.78	2.37	1.13	1.78	2.37	1.13
p Value	0.24	0.12	0.73	0.29	0.12	0.86	0.29	0.12	0.86
Lower limit of 95% CI	0.655	0.802	0.322	0.609	0.802	0.285	0.609	0.802	0.285
Upper limit of 95% CI	5.59	7.00	5.03	5.19	7.00	4.49	5.19	7.00	4.49

[0204] Table 11.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “recovered” and “non-recovered” cohorts where recovery starts within 7 days after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.544	0.765	0.544	0.765	0.544	0.765
Average	0.780	1.00	0.776	0.994	0.776	0.994
Stdev	0.779	0.906	0.789	0.883	0.789	0.883
p (t-test)		0.27		0.27		0.27
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	54	30	52	32	52	32

sCr only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.567	0.860	0.561	0.981	0.561	0.981
Average	0.806	1.06	0.798	1.07	0.798	1.07
Stdev	0.782	0.965	0.786	0.945	0.786	0.945
p (t-test)		0.29		0.24		0.24
Min	0.108	0.217	0.108	0.217	0.108	0.217
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	59	22	58	23	58	23

UO only

Recovery Period Duration (hr)	24		48		72	
	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort	Recovered Cohort	Non-recovered Cohort
Median	0.539	0.646	0.527	0.669	0.522	0.647
Average	0.788	0.910	0.769	0.932	0.768	0.929
Stdev	0.817	0.860	0.802	0.879	0.814	0.864

p (t-test)		0.53		0.41		0.41
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	40	38	42	36	41	37

Recovery Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.60	0.53	0.60	0.62	0.55	0.60	0.62	0.56
SE	0.066	0.073	0.066	0.065	0.071	0.066	0.065	0.071	0.065
p Value	0.20	0.16	0.61	0.14	0.087	0.48	0.14	0.087	0.33
nCohort Recovered	54	59	40	52	58	42	52	58	41
nCohort Non-recovered	30	22	38	32	23	36	32	23	37
Cutoff Quartile 2	0.372	0.374	0.375	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	77%	82%	74%	78%	83%	72%	78%	83%	76%
Specificity	26%	29%	25%	27%	29%	24%	27%	29%	27%
Cutoff Quartile 3	0.614	0.636	0.584	0.614	0.636	0.584	0.614	0.636	0.584
Sensitivity	63%	64%	55%	62%	65%	58%	62%	65%	57%
Specificity	57%	56%	55%	58%	57%	57%	58%	57%	56%
Cutoff Quartile 4	1.04	1.04	0.995	1.04	1.04	0.995	1.04	1.04	0.995
Sensitivity	37%	36%	34%	38%	39%	36%	38%	39%	35%
Specificity	81%	80%	82%	83%	81%	83%	83%	81%	83%
OR Quartile 2	1.15	1.82	0.933	1.32	1.97	0.812	1.32	1.97	1.14
p Value	0.79	0.34	0.89	0.60	0.28	0.69	0.60	0.28	0.80
Lower limit of 95% CI	0.406	0.537	0.338	0.466	0.583	0.294	0.466	0.583	0.411
Upper limit of 95% CI	3.26	6.18	2.58	3.72	6.65	2.25	3.72	6.65	3.16
OR Quartile 3	2.33	2.22	1.51	2.27	2.47	1.87	2.27	2.47	1.68
p Value	0.071	0.12	0.37	0.075	0.077	0.17	0.075	0.077	0.26
Lower limit of 95% CI	0.930	0.810	0.618	0.922	0.908	0.758	0.922	0.908	0.684
Upper limit of 95% CI	5.83	6.09	3.69	5.61	6.75	4.60	5.61	6.75	4.11
OR Quartile 4	2.55	2.24	2.45	2.87	2.75	2.83	2.87	2.75	2.63
p Value	0.070	0.14	0.096	0.042	0.063	0.054	0.042	0.063	0.073
Lower limit of 95% CI	0.927	0.764	0.853	1.04	0.948	0.980	1.04	0.948	0.914
Upper limit of 95% CI	7.00	6.56	7.04	7.90	7.96	8.15	7.90	7.96	7.57

[0205] Example 12. Use of C-C motif chemokine 14 for evaluating renal status in patients admitted to the ICU: Persistent at RIFLE F

[0206] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. C-C motif chemokine 14 is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0207] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output. Two cohorts are defined to represent a “persistent” and a “non-persistent” population. “Persistent” indicates those patients whose minimum RIFLE stage during a period of 24, 48 or 72 hours is failure (F) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. “Non-persistent” indicates those patients who are not

persistent at failure (F) and whose minimum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0), risk of injury (R), or injury (I) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. If a patient dies after failure (F) or is placed on renal replacement therapy (RRT) at any time from sample collection to 24, 48, 72, 96 or 168 hours after sample collection, the patient is considered “persistent”.

[0208] The ability to distinguish the “persistent” and “non-persistent” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0209] Table 12.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.704	2.96	0.768	5.37	0.779	5.21
Average	1.43	3.29	1.49	4.09	1.56	3.92
Stdev	1.69	2.40	1.68	2.44	1.76	2.45
p (t-test)		1.7E-4		5.3E-6		7.5E-5
Min	0.194	0.121	0.121	0.422	0.121	0.422
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	61	22	69	14	70	13

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.801	3.80	0.812	2.87	1.03	2.16
Average	1.61	3.63	1.70	3.64	1.83	3.08
Stdev	1.80	2.57	1.87	2.68	1.98	2.66
p (t-test)		7.2E-4		0.0037		0.090
Min	0.121	0.422	0.121	0.422	0.121	0.422
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	66	14	69	11	71	9

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.704	2.87	0.768	5.53	0.768	5.53
Average	1.55	3.19	1.54	4.72	1.54	4.72
Stdev	1.81	2.32	1.75	1.99	1.75	1.99
p (t-test)		0.0027		2.9E-6		2.9E-6
Min	0.194	0.121	0.121	1.03	0.121	1.03
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	61	17	69	9	69	9

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.73	0.72	0.74	0.79	0.71	0.87	0.77	0.64	0.87
SE	0.067	0.082	0.075	0.075	0.092	0.077	0.080	0.10	0.077
p Value	5.0E-4	0.0066	0.0015	1.1E-4	0.023	1.2E-6	7.8E-4	0.17	1.2E-6
nCohort Non-persistent	61	66	61	69	69	69	70	71	69
nCohort Persistent	22	14	17	14	11	9	13	9	9
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	91%	86%	94%	93%	82%	100%	92%	78%	100%
Specificity	31%	27%	31%	29%	26%	29%	29%	25%	29%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	73%	71%	76%	79%	73%	89%	77%	67%	89%
Specificity	57%	55%	57%	55%	54%	55%	54%	52%	55%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	55%	50%	53%	64%	45%	78%	62%	33%	78%
Specificity	85%	80%	82%	83%	78%	81%	81%	76%	81%
OR Quartile 2	4.52	2.25	7.24	5.31	1.59	7.87	4.80	1.19	7.87
p Value	0.057	0.32	0.064	0.12	0.58	0.16	0.14	0.84	0.16
Lower limit of 95% CI	0.959	0.458	0.894	0.650	0.313	0.437	0.585	0.226	0.437
Upper limit of 95% CI	21.3	11.1	58.6	43.3	8.06	142	39.4	6.25	142
OR Quartile 3	3.59	3.00	4.38	4.49	3.08	9.81	3.96	2.18	9.81
p Value	0.019	0.087	0.019	0.031	0.12	0.036	0.050	0.30	0.036
Lower limit of 95% CI	1.24	0.854	1.28	1.15	0.754	1.16	1.00	0.504	1.16
Upper limit of 95% CI	10.4	10.5	15.0	17.5	12.6	82.7	15.6	9.39	82.7
OR Quartile 4	6.93	4.08	5.11	8.55	3.00	15.1	7.02	1.59	15.1
p Value	5.5E-4	0.023	0.0056	8.3E-4	0.10	0.0016	0.0026	0.54	0.0016
Lower limit of 95% CI	2.31	1.21	1.61	2.43	0.803	2.80	1.97	0.358	2.80
Upper limit of 95% CI	20.8	13.7	16.2	30.1	11.2	81.2	25.0	7.04	81.2

[0210] Table 12.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.685	2.87	0.763	5.21	0.768	4.04
Average	1.35	3.26	1.42	3.91	1.49	3.76
Stdev	1.59	2.41	1.59	2.48	1.69	2.49
p (t-test)		5.3E-5		2.5E-6		3.6E-5
Min	0.194	0.121	0.121	0.422	0.121	0.422
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	58	25	66	17	67	16

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.801	3.80	0.812	2.87	1.03	2.16
Average	1.61	3.63	1.70	3.64	1.83	3.08
Stdev	1.80	2.57	1.87	2.68	1.98	2.66
p (t-test)		7.2E-4		0.0037		0.090
Min	0.121	0.422	0.121	0.422	0.121	0.422
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	66	14	69	11	71	9

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.665	2.87	0.757	5.53	0.757	5.53
Average	1.38	3.32	1.40	4.45	1.40	4.45
Stdev	1.63	2.39	1.57	2.24	1.57	2.24
p (t-test)		1.1E-4		8.5E-8		8.5E-8
Min	0.194	0.121	0.121	0.448	0.121	0.448
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	57	21	65	13	65	13

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.74	0.72	0.76	0.78	0.71	0.85	0.76	0.64	0.85
SE	0.063	0.082	0.067	0.070	0.092	0.069	0.074	0.10	0.069
p Value	1.7E-4	0.0066	9.8E-5	6.5E-5	0.023	3.5E-7	4.5E-4	0.17	3.5E-7
nCohort Non-persistent	58	66	57	66	69	65	67	71	65
nCohort Persistent	25	14	21	17	11	13	16	9	13
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	88%	86%	90%	88%	82%	92%	88%	78%	92%
Specificity	31%	27%	32%	29%	26%	29%	28%	25%	29%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	72%	71%	76%	76%	73%	85%	75%	67%	85%
Specificity	59%	55%	60%	56%	54%	57%	55%	52%	57%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	52%	50%	52%	59%	45%	69%	56%	33%	69%
Specificity	86%	80%	84%	83%	78%	83%	82%	76%	83%
OR Quartile 2	3.30	2.25	4.38	3.03	1.59	4.96	2.77	1.19	4.96
p Value	0.078	0.32	0.063	0.17	0.58	0.14	0.20	0.84	0.14
Lower limit of 95% CI	0.874	0.458	0.921	0.632	0.313	0.602	0.574	0.226	0.602
Upper limit of 95% CI	12.5	11.1	20.9	14.6	8.06	40.8	13.4	6.25	40.8
OR Quartile 3	3.64	3.00	4.73	4.15	3.08	7.27	3.70	2.18	7.27
p Value	0.013	0.087	0.0073	0.022	0.12	0.014	0.037	0.30	0.014
Lower limit of 95% CI	1.32	0.854	1.52	1.22	0.754	1.49	1.08	0.504	1.49
Upper limit of 95% CI	10.1	10.5	14.7	14.1	12.6	35.4	12.7	9.39	35.4
OR Quartile 4	6.77	4.08	5.87	7.14	3.00	11.0	5.89	1.59	11.0
p Value	5.4E-4	0.023	0.0018	9.2E-4	0.10	4.6E-4	0.0029	0.54	4.6E-4
Lower limit of 95% CI	2.29	1.21	1.93	2.23	0.803	2.88	1.83	0.358	2.88
Upper limit of 95% CI	20.0	13.7	17.9	22.8	11.2	42.4	19.0	7.04	42.4

[0211] Table 12.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.665	2.56	0.768	4.04	0.779	2.87
Average	1.36	3.16	1.43	3.73	1.50	3.58
Stdev	1.60	2.42	1.60	2.52	1.70	2.52
p (t-test)		1.3E-4		1.0E-5		1.2E-4
Min	0.194	0.121	0.121	0.422	0.121	0.422
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	57	26	65	18	66	17

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.812	2.87	0.812	2.87	1.03	2.16
Average	1.63	3.44	1.70	3.64	1.83	3.08
Stdev	1.81	2.59	1.87	2.68	1.98	2.66
p (t-test)		0.0020		0.0037		0.090
Min	0.121	0.422	0.121	0.422	0.121	0.422
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	65	15	69	11	71	9

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.653	2.82	0.768	5.21	0.736	5.37
Average	1.40	3.20	1.42	3.95	1.41	4.18
Stdev	1.64	2.40	1.59	2.45	1.58	2.37
p (t-test)		2.8E-4		4.3E-6		7.2E-7
Min	0.194	0.121	0.121	0.448	0.121	0.448
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	56	22	63	15	64	14

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.73	0.70	0.75	0.76	0.71	0.80	0.74	0.64	0.83
SE	0.063	0.081	0.066	0.070	0.092	0.072	0.074	0.10	0.071
p Value	3.0E-4	0.011	2.0E-4	1.7E-4	0.023	2.8E-5	9.7E-4	0.17	4.5E-6
nCohort Non-persistent	57	65	56	65	69	63	66	71	64
nCohort Persistent	26	15	22	18	11	15	17	9	14
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	88%	87%	91%	89%	82%	93%	88%	78%	93%
Specificity	32%	28%	32%	29%	26%	30%	29%	25%	30%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	69%	67%	73%	72%	73%	73%	71%	67%	79%
Specificity	58%	54%	59%	55%	54%	56%	55%	52%	56%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	50%	47%	50%	56%	45%	60%	53%	33%	64%
Specificity	86%	80%	84%	83%	78%	83%	82%	76%	83%
OR Quartile 2	3.54	2.49	4.74	3.30	1.59	6.05	3.03	1.19	5.49
p Value	0.062	0.26	0.050	0.13	0.58	0.093	0.17	0.84	0.11
Lower limit of 95% CI	0.939	0.510	0.997	0.691	0.313	0.741	0.632	0.226	0.670
Upper limit of 95% CI	13.3	12.1	22.5	15.8	8.06	49.3	14.6	6.25	45.0
OR Quartile 3	3.09	2.33	3.83	3.23	3.08	3.44	2.88	2.18	4.71
p Value	0.025	0.16	0.015	0.044	0.12	0.052	0.071	0.30	0.026
Lower limit of 95% CI	1.16	0.718	1.30	1.03	0.754	0.987	0.912	0.504	1.20
Upper limit of 95% CI	8.28	7.59	11.3	10.1	12.6	12.0	9.10	9.39	18.5
OR Quartile 4	6.12	3.50	5.22	6.14	3.00	7.09	5.06	1.59	8.67
p Value	9.2E-4	0.038	0.0032	0.0017	0.10	0.0017	0.0053	0.54	8.7E-4
Lower limit of 95% CI	2.10	1.07	1.74	1.98	0.803	2.09	1.62	0.358	2.43
Upper limit of 95% CI	17.9	11.4	15.7	19.1	11.2	24.0	15.8	7.04	30.9

[0212] Table 12.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.665	2.56	0.779	2.87	0.790	2.56
Average	1.36	3.16	1.44	3.57	1.51	3.42
Stdev	1.60	2.42	1.61	2.55	1.71	2.54
p (t-test)		1.3E-4		3.7E-5		3.5E-4
Min	0.194	0.121	0.121	0.422	0.121	0.422
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	57	26	64	19	65	18

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.812	2.87	0.922	2.51	1.03	2.07
Average	1.63	3.44	1.72	3.38	1.84	2.83
Stdev	1.81	2.59	1.87	2.70	1.99	2.62
p (t-test)		0.0020		0.0098		0.16
Min	0.121	0.422	0.121	0.422	0.121	0.422
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	65	15	68	12	70	10

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.653	2.82	0.779	4.04	0.768	5.21
Average	1.40	3.20	1.43	3.74	1.42	3.95
Stdev	1.64	2.40	1.60	2.51	1.59	2.46
p (t-test)		2.8E-4		2.1E-5		4.6E-6
Min	0.194	0.121	0.121	0.448	0.121	0.448
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	56	22	62	16	63	15

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.73	0.70	0.75	0.75	0.68	0.78	0.72	0.62	0.80
SE	0.063	0.081	0.066	0.070	0.090	0.073	0.073	0.10	0.073
p Value	3.0E-4	0.011	2.0E-4	4.8E-4	0.044	1.4E-4	0.0023	0.24	4.1E-5
nCohort Non-persistent	57	65	56	64	68	62	65	70	63
nCohort Persistent	26	15	22	19	12	16	18	10	15
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	88%	87%	91%	89%	83%	94%	89%	80%	93%
Specificity	32%	28%	32%	30%	26%	31%	29%	26%	30%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	69%	67%	73%	68%	67%	69%	67%	60%	73%
Specificity	58%	54%	59%	55%	53%	55%	54%	51%	56%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	50%	47%	50%	53%	42%	56%	50%	30%	60%
Specificity	86%	80%	84%	83%	78%	82%	82%	76%	83%
OR Quartile 2	3.54	2.49	4.74	3.59	1.80	6.63	3.30	1.38	6.05
p Value	0.062	0.26	0.050	0.11	0.47	0.077	0.13	0.70	0.093
Lower limit of 95% CI	0.939	0.510	0.997	0.754	0.359	0.816	0.691	0.269	0.741
Upper limit of 95% CI	13.3	12.1	22.5	17.1	9.01	53.9	15.8	7.14	49.3
OR Quartile 3	3.09	2.33	3.83	2.61	2.25	2.67	2.33	1.59	3.44
p Value	0.025	0.16	0.015	0.083	0.22	0.100	0.13	0.50	0.052
Lower limit of 95% CI	1.16	0.718	1.30	0.883	0.619	0.830	0.781	0.412	0.987
Upper limit of 95% CI	8.28	7.59	11.3	7.74	8.18	8.60	6.97	6.12	12.0
OR Quartile 4	6.12	3.50	5.22	5.35	2.52	5.96	4.42	1.34	7.09
p Value	9.2E-4	0.038	0.0032	0.0031	0.16	0.0031	0.0091	0.70	0.0017

Lower limit of 95% CI	2.10	1.07	1.74	1.76	0.700	1.83	1.45	0.311	2.09
Upper limit of 95% CI	17.9	11.4	15.7	16.2	9.10	19.5	13.5	5.75	24.0

[0213] Table 12.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.639	2.77	0.736	2.77	0.779	2.77
Average	1.26	3.18	1.37	3.38	1.45	3.34
Stdev	1.52	2.36	1.55	2.51	1.65	2.51
p (t-test)		2.2E-5		3.2E-5		1.7E-4
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	54	29	60	23	62	21

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.801	3.80	0.812	2.87	0.922	2.51
Average	1.56	3.58	1.66	3.56	1.73	3.34
Stdev	1.75	2.56	1.82	2.66	1.89	2.65
p (t-test)		3.6E-4		0.0021		0.013
Min	0.121	0.422	0.121	0.422	0.121	0.422
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	64	16	67	13	68	12

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.639	2.82	0.717	2.82	0.704	2.87
Average	1.31	3.25	1.37	3.46	1.36	3.60
Stdev	1.56	2.36	1.55	2.50	1.54	2.48
p (t-test)		4.7E-5		3.6E-5		1.1E-5
Min	0.194	0.121	0.194	0.121	0.194	0.121
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	54	24	58	20	59	19

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.76	0.72	0.77	0.73	0.71	0.75	0.71	0.68	0.76
SE	0.059	0.077	0.062	0.066	0.086	0.069	0.070	0.091	0.069
p Value	1.4E-5	0.0037	1.7E-5	4.9E-4	0.017	2.8E-4	0.0027	0.050	1.2E-4
nCohort Non-persistent	54	64	54	60	67	58	62	68	59
nCohort Persistent	29	16	24	23	13	20	21	12	19
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	90%	88%	92%	87%	85%	90%	86%	83%	89%
Specificity	33%	28%	33%	30%	27%	31%	29%	26%	31%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	72%	69%	75%	70%	69%	70%	67%	67%	74%

Specificity	61%	55%	61%	57%	54%	57%	55%	53%	58%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	48%	50%	50%	48%	46%	50%	48%	42%	53%
Specificity	87%	81%	85%	83%	79%	83%	82%	78%	83%
OR Quartile 2	4.33	2.74	5.50	2.86	2.02	4.05	2.45	1.80	3.73
p Value	0.030	0.21	0.032	0.12	0.39	0.079	0.19	0.47	0.099
Lower limit of 95% CI	1.15	0.565	1.16	0.753	0.408	0.848	0.643	0.359	0.779
Upper limit of 95% CI	16.3	13.3	26.0	10.8	10.0	19.3	9.37	9.01	17.9
OR Quartile 3	4.12	2.66	4.71	2.99	2.61	3.08	2.43	2.25	3.81
p Value	0.0046	0.10	0.0047	0.036	0.14	0.043	0.093	0.22	0.022
Lower limit of 95% CI	1.55	0.827	1.61	1.07	0.732	1.04	0.862	0.619	1.21
Upper limit of 95% CI	11.0	8.52	13.8	8.33	9.32	9.15	6.84	8.18	12.0
OR Quartile 4	6.27	4.33	5.75	4.58	3.24	4.80	4.21	2.52	5.44
p Value	8.4E-4	0.014	0.0018	0.0050	0.063	0.0056	0.0088	0.16	0.0032
Lower limit of 95% CI	2.13	1.35	1.92	1.58	0.940	1.58	1.44	0.700	1.76
Upper limit of 95% CI	18.4	13.9	17.2	13.3	11.2	14.6	12.4	9.10	16.8

[0214] Table 12.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	231	285	233	293	235	285
Average	248	313	250	335	250	337
Stdev	111	148	108	166	107	172
p (t-test)		0.031		0.013		0.014
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	512	651	512	651	512	651
n (Patient)	61	23	68	16	69	15

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	235	307	243	307	245	312
Average	252	324	254	325	255	327
Stdev	114	154	113	166	112	174
p (t-test)		0.047		0.068		0.073
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	67	14	69	12	70	11

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	233	302	235	350	235	350
Average	248	346	252	388	252	388
Stdev	110	147	111	155	111	155
p (t-test)		0.0037		9.9E-4		9.9E-4
Min	73.7	161	73.7	177	73.7	177
Max	590	651	590	651	590	651
n (Patient)	60	17	67	10	67	10

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only

AUC	0.63	0.64	0.70	0.65	0.62	0.77	0.64	0.61	0.77
SE	0.071	0.086	0.077	0.081	0.093	0.091	0.083	0.096	0.091
p Value	0.064	0.10	0.0081	0.066	0.20	0.0030	0.085	0.25	0.0030
nCohort Non-persistent	61	67	60	68	69	67	69	70	67
nCohort Persistent	23	14	17	16	12	10	15	11	10
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	87%	86%	88%	88%	83%	100%	87%	82%	100%
Specificity	30%	27%	28%	28%	26%	28%	28%	26%	28%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	70%	71%	76%	75%	67%	90%	73%	64%	90%
Specificity	57%	54%	57%	56%	52%	55%	55%	51%	55%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	30%	36%	41%	31%	33%	50%	33%	36%	50%
Specificity	77%	76%	78%	76%	75%	78%	77%	76%	78%
OR Quartile 2	2.79	2.20	2.97	2.71	1.76	8.44	2.47	1.56	8.44
p Value	0.13	0.33	0.18	0.21	0.49	0.15	0.26	0.59	0.15
Lower limit of 95% CI	0.736	0.449	0.612	0.563	0.353	0.471	0.509	0.307	0.471
Upper limit of 95% CI	10.6	10.8	14.4	13.1	8.83	151	12.0	7.90	151
OR Quartile 3	3.08	2.90	4.25	3.80	2.18	11.1	3.37	1.85	11.1
p Value	0.031	0.096	0.021	0.033	0.24	0.026	0.055	0.36	0.026
Lower limit of 95% CI	1.11	0.828	1.24	1.11	0.601	1.33	0.977	0.498	1.33
Upper limit of 95% CI	8.56	10.2	14.6	13.0	7.92	92.6	11.6	6.90	92.6
OR Quartile 4	1.47	1.77	2.53	1.48	1.53	3.47	1.66	1.78	3.47
p Value	0.48	0.36	0.11	0.52	0.53	0.075	0.41	0.40	0.075
Lower limit of 95% CI	0.504	0.518	0.806	0.447	0.409	0.884	0.494	0.464	0.884
Upper limit of 95% CI	4.28	6.05	7.95	4.89	5.72	13.6	5.56	6.83	13.6

[0215] Table 12.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	226	293	231	302	233	298
Average	245	317	247	339	248	341
Stdev	110	145	107	162	107	167
p (t-test)		0.016		0.0061		0.0065
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	512	651	512	651	512	651
n (Patient)	60	24	67	17	68	16

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	235	307	243	307	245	312
Average	252	324	254	325	255	327
Stdev	114	154	113	166	112	174
p (t-test)		0.047		0.068		0.073
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	67	14	69	12	70	11

UO only

Persistence Period Duration (hr)	24	48	72
-------------------------------------	----	----	----

	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	226	312	231	396	231	396
Average	239	362	244	406	244	406
Stdev	100	150	102	152	102	152
p (t-test)		1.2E-4		1.5E-5		1.5E-5
Min	73.7	161	73.7	177	73.7	177
Max	493	651	512	651	512	651
n (Patient)	58	19	65	12	65	12

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	0.64	0.75	0.67	0.62	0.81	0.66	0.61	0.81
SE	0.069	0.086	0.071	0.078	0.093	0.078	0.080	0.096	0.078
p Value	0.032	0.10	4.7E-4	0.031	0.20	5.8E-5	0.041	0.25	5.8E-5
nCohort Non-persistent	60	67	58	67	69	65	68	70	65
nCohort Persistent	24	14	19	17	12	12	16	11	12
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	88%	86%	89%	88%	83%	100%	88%	82%	100%
Specificity	30%	27%	29%	28%	26%	29%	28%	26%	29%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	71%	71%	79%	76%	67%	92%	75%	64%	92%
Specificity	58%	54%	59%	57%	52%	57%	56%	51%	57%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	33%	36%	47%	35%	33%	58%	38%	36%	58%
Specificity	78%	76%	81%	78%	75%	80%	78%	76%	80%
OR Quartile 2	3.00	2.20	3.52	2.97	1.76	10.5	2.71	1.56	10.5
p Value	0.11	0.33	0.12	0.17	0.49	0.11	0.21	0.59	0.11
Lower limit of 95% CI	0.794	0.449	0.733	0.619	0.353	0.591	0.563	0.307	0.591
Upper limit of 95% CI	11.3	10.8	16.9	14.2	8.83	186	13.1	7.90	186
OR Quartile 3	3.40	2.90	5.31	4.26	2.18	14.5	3.80	1.85	14.5
p Value	0.019	0.096	0.0073	0.020	0.24	0.013	0.033	0.36	0.013
Lower limit of 95% CI	1.23	0.828	1.57	1.26	0.601	1.77	1.11	0.498	1.77
Upper limit of 95% CI	9.42	10.2	18.0	14.4	7.92	119	13.0	6.90	119
OR Quartile 4	1.81	1.77	3.85	1.89	1.53	5.60	2.12	1.78	5.60
p Value	0.27	0.36	0.018	0.28	0.53	0.0093	0.21	0.40	0.0093
Lower limit of 95% CI	0.634	0.518	1.26	0.600	0.409	1.53	0.662	0.464	1.53
Upper limit of 95% CI	5.15	6.05	11.7	5.96	5.72	20.5	6.78	6.83	20.5

[0216] Table 12.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	221	285	233	293	235	285
Average	245	315	248	333	249	334
Stdev	111	143	108	160	107	164
p (t-test)		0.017		0.0097		0.010
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	512	651	512	651	512	651
n (Patient)	59	25	66	18	67	17

sCr only

Persistence Period Duration (hr)	24	48	72
----------------------------------	----	----	----

	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	233	302	243	307	245	312
Average	252	321	254	325	255	327
Stdev	114	149	113	166	112	174
p (t-test)		0.050		0.068		0.073
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	66	15	69	12	70	11

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	221	307	231	350	233	389
Average	239	358	244	384	245	392
Stdev	101	147	104	151	103	154
p (t-test)		1.5E-4		8.3E-5		5.2E-5
Min	73.7	161	73.7	177	73.7	177
Max	493	651	512	651	512	651
n (Patient)	57	20	63	14	64	13

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	0.64	0.74	0.66	0.62	0.78	0.65	0.61	0.79
SE	0.068	0.084	0.069	0.077	0.093	0.077	0.079	0.096	0.079
p Value	0.028	0.098	4.4E-4	0.040	0.20	3.3E-4	0.053	0.25	2.7E-4
nCohort Non-persistent	59	66	57	66	69	63	67	70	64
nCohort Persistent	25	15	20	18	12	14	17	11	13
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	88%	87%	90%	89%	83%	100%	88%	82%	100%
Specificity	31%	27%	30%	29%	26%	30%	28%	26%	30%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	72%	73%	80%	72%	67%	86%	71%	64%	85%
Specificity	59%	55%	60%	56%	52%	57%	55%	51%	56%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	32%	33%	45%	33%	33%	50%	35%	36%	54%
Specificity	78%	76%	81%	77%	75%	79%	78%	76%	80%
OR Quartile 2	3.22	2.44	3.82	3.23	1.76	12.7	2.97	1.56	11.6
p Value	0.084	0.27	0.093	0.14	0.49	0.082	0.17	0.59	0.095
Lower limit of 95% CI	0.854	0.500	0.798	0.677	0.353	0.721	0.619	0.307	0.655
Upper limit of 95% CI	12.1	11.9	18.3	15.4	8.83	224	14.2	7.90	205
OR Quartile 3	3.75	3.30	5.91	3.32	2.18	8.00	2.96	1.85	7.07
p Value	0.011	0.060	0.0042	0.039	0.24	0.0098	0.064	0.36	0.016
Lower limit of 95% CI	1.36	0.952	1.75	1.06	0.601	1.65	0.938	0.498	1.45
Upper limit of 95% CI	10.4	11.4	20.0	10.4	7.92	38.8	9.34	6.90	34.5
OR Quartile 4	1.67	1.56	3.42	1.70	1.53	3.85	1.89	1.78	4.58
p Value	0.34	0.47	0.028	0.36	0.53	0.029	0.28	0.40	0.017
Lower limit of 95% CI	0.588	0.465	1.14	0.546	0.409	1.14	0.600	0.464	1.31
Upper limit of 95% CI	4.72	5.25	10.3	5.30	5.72	12.9	5.96	6.83	16.0

[0217] Table 12.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24	48	72
----------------------------------	----	----	----

	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	221	285	231	285	233	283
Average	245	315	247	330	248	331
Stdev	111	143	109	155	108	160
p (t-test)		0.017		0.010		0.011
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	512	651	512	651	512	651
n (Patient)	59	25	65	19	66	18

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	233	302	239	302	243	297
Average	252	321	254	322	255	323
Stdev	114	149	114	160	113	167
p (t-test)		0.050		0.071		0.076
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	66	15	68	13	69	12

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	221	307	226	312	231	350
Average	239	358	244	377	244	384
Stdev	101	147	105	148	104	151
p (t-test)		1.5E-4		1.2E-4		7.8E-5
Min	73.7	161	73.7	177	73.7	177
Max	493	651	512	651	512	651
n (Patient)	57	20	62	15	63	14

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	0.64	0.74	0.66	0.62	0.77	0.65	0.61	0.78
SE	0.068	0.084	0.069	0.075	0.089	0.076	0.077	0.093	0.077
p Value	0.028	0.098	4.4E-4	0.035	0.18	3.2E-4	0.047	0.23	2.8E-4
nCohort Non-persistent	59	66	57	65	68	62	66	69	63
nCohort Persistent	25	15	20	19	13	15	18	12	14
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	88%	87%	90%	89%	85%	100%	89%	83%	100%
Specificity	31%	27%	30%	29%	26%	31%	29%	26%	30%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	72%	73%	80%	74%	69%	87%	72%	67%	86%
Specificity	59%	55%	60%	57%	53%	58%	56%	52%	57%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	32%	33%	45%	32%	31%	47%	33%	33%	50%
Specificity	78%	76%	81%	77%	75%	79%	77%	75%	79%
OR Quartile 2	3.22	2.44	3.82	3.51	1.98	13.9	3.23	1.76	12.7
p Value	0.084	0.27	0.093	0.11	0.40	0.072	0.14	0.49	0.082
Lower limit of 95% CI	0.854	0.500	0.798	0.738	0.400	0.791	0.677	0.353	0.721
Upper limit of 95% CI	12.1	11.9	18.3	16.7	9.81	244	15.4	8.83	224
OR Quartile 3	3.75	3.30	5.91	3.70	2.53	9.00	3.32	2.18	8.00
p Value	0.011	0.060	0.0042	0.024	0.15	0.0061	0.039	0.24	0.0098
Lower limit of 95% CI	1.36	0.952	1.75	1.19	0.711	1.87	1.06	0.601	1.65
Upper limit of 95% CI	10.4	11.4	20.0	11.5	9.02	43.3	10.4	7.92	38.8
OR Quartile 4	1.67	1.56	3.42	1.54	1.33	3.30	1.70	1.53	3.85
p Value	0.34	0.47	0.028	0.45	0.66	0.048	0.36	0.53	0.029
Lower limit of 95% CI	0.588	0.465	1.14	0.499	0.364	1.01	0.546	0.409	1.14
Upper limit of 95% CI	4.72	5.25	10.3	4.75	4.89	10.8	5.30	5.72	12.9

[0218] Table 12.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	219	302	226	293	233	283
Average	237	327	241	335	246	328
Stdev	104	144	102	155	107	158
p (t-test)		0.0016		0.0020		0.0099
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	493	651	493	651	512	651
n (Patient)	57	27	62	22	64	20

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	233	302	239	302	243	297
Average	252	321	254	322	255	323
Stdev	114	149	114	160	113	167
p (t-test)		0.050		0.071		0.076
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	66	15	68	13	69	12

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	220	302	221	298	226	312
Average	239	352	240	366	241	371
Stdev	102	146	101	150	100	153
p (t-test)		2.3E-4		1.1E-4		8.4E-5
Min	73.7	161	73.7	161	73.7	161
Max	493	651	493	651	493	651
n (Patient)	56	21	59	18	60	17

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.69	0.64	0.74	0.68	0.62	0.75	0.65	0.61	0.75
SE	0.065	0.084	0.069	0.070	0.089	0.072	0.074	0.093	0.073
p Value	0.0031	0.098	5.7E-4	0.010	0.18	4.9E-4	0.040	0.23	5.0E-4
nCohort Non-persistent	57	66	56	62	68	59	64	69	60
nCohort Persistent	27	15	21	22	13	18	20	12	17
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	89%	87%	90%	86%	85%	94%	85%	83%	94%
Specificity	32%	27%	30%	29%	26%	31%	28%	26%	30%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	74%	73%	81%	73%	69%	83%	70%	67%	82%
Specificity	61%	55%	61%	58%	53%	59%	56%	52%	58%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	37%	33%	43%	36%	31%	44%	35%	33%	47%

Specificity	81%	76%	80%	79%	75%	80%	78%	75%	80%
OR Quartile 2	3.69	2.44	4.14	2.59	1.98	7.46	2.22	1.76	6.86
p Value	0.053	0.27	0.075	0.16	0.40	0.060	0.25	0.49	0.072
Lower limit of 95% CI	0.983	0.500	0.866	0.682	0.400	0.922	0.579	0.353	0.844
Upper limit of 95% CI	13.9	11.9	19.8	9.85	9.81	60.4	8.49	8.83	55.7
OR Quartile 3	4.55	3.30	6.57	3.69	2.53	7.29	3.00	2.18	6.53
p Value	0.0034	0.060	0.0024	0.016	0.15	0.0038	0.045	0.24	0.0064
Lower limit of 95% CI	1.65	0.952	1.95	1.27	0.711	1.90	1.02	0.601	1.70
Upper limit of 95% CI	12.5	11.4	22.1	10.7	9.02	28.0	8.80	7.92	25.2
OR Quartile 4	2.46	1.56	3.07	2.15	1.33	3.13	1.92	1.53	3.56
p Value	0.084	0.47	0.043	0.16	0.66	0.047	0.24	0.53	0.030
Lower limit of 95% CI	0.886	0.465	1.03	0.744	0.364	1.02	0.644	0.409	1.13
Upper limit of 95% CI	6.83	5.25	9.10	6.23	4.89	9.65	5.74	5.72	11.2

[0219] Example 13. Use of C-C motif chemokine 14 for evaluating renal status in patients admitted to the ICU: Persistent at RIFLE I or F

[0220] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. C-C motif chemokine 14 is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0221] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output. Two cohorts are defined to represent a “persistent” and a “non-persistent” population. “Persistent” indicates those patients whose minimum RIFLE stage during a period of 24, 48 or 72 hours is injury (I) or failure (F) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. “Non-persistent” indicates those patients who are not persistent at injury (I) or failure (F) and whose minimum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0) or risk of injury (R) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. If a patient dies after injury (I) or failure (F) or is placed on renal replacement therapy (RRT) at any time from sample collection to 24, 48, 72, 96 or 168 hours after sample collection, the patient is considered “persistent”.

[0222] The ability to distinguish the “persistent” and “non-persistent” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0223] Table 13.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where

persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.672	1.38	0.731	2.77	0.731	2.87
Average	1.36	2.40	1.38	3.06	1.38	3.35
Stdev	1.75	2.19	1.62	2.42	1.59	2.46
p (t-test)		0.020		3.4E-4		5.0E-5
Min	0.208	0.121	0.121	0.194	0.121	0.349
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	38	45	56	27	60	23

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.768	2.77	0.812	2.25	0.922	2.20
Average	1.50	3.13	1.64	3.02	1.72	2.96
Stdev	1.76	2.40	1.83	2.53	1.88	2.59
p (t-test)		0.0011		0.011		0.033
Min	0.121	0.349	0.121	0.349	0.121	0.349
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	57	23	61	19	64	16

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.790	1.15	0.790	1.19	0.790	1.19
Average	1.72	2.05	1.68	2.29	1.64	2.39
Stdev	2.05	2.04	1.95	2.15	1.92	2.19
p (t-test)		0.48		0.20		0.12
Min	0.208	0.121	0.121	0.194	0.121	0.194
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	35	43	49	29	51	27

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.66	0.71	0.56	0.71	0.67	0.59	0.74	0.64	0.60
SE	0.059	0.067	0.065	0.064	0.075	0.068	0.065	0.081	0.069
p Value	0.0074	0.0015	0.32	0.0011	0.027	0.20	2.3E-4	0.078	0.14
nCohort Non-persistent	38	57	35	56	61	49	60	64	51
nCohort Persistent	45	23	43	27	19	29	23	16	27
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	82%	87%	79%	85%	84%	79%	87%	81%	81%
Specificity	34%	30%	31%	30%	28%	29%	30%	27%	29%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	60%	70%	53%	67%	63%	55%	70%	62%	56%
Specificity	61%	58%	54%	57%	54%	53%	57%	53%	53%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	38%	43%	30%	48%	37%	34%	52%	31%	37%
Specificity	89%	82%	80%	86%	79%	80%	85%	77%	80%
OR Quartile 2	2.40	2.83	1.73	2.51	2.06	1.53	2.86	1.57	1.83
p Value	0.091	0.13	0.29	0.14	0.30	0.44	0.12	0.52	0.30
Lower limit of 95% CI	0.870	0.742	0.622	0.751	0.532	0.515	0.753	0.397	0.585

Upper limit of 95% CI	6.65	10.8	4.82	8.36	7.98	4.57	10.8	6.18	5.75
OR Quartile 3	2.30	3.14	1.37	2.67	2.02	1.39	2.99	1.89	1.41
p Value	0.064	0.030	0.50	0.045	0.19	0.48	0.036	0.27	0.48
Lower limit of 95% CI	0.952	1.12	0.558	1.02	0.700	0.553	1.07	0.613	0.551
Upper limit of 95% CI	5.56	8.82	3.34	6.96	5.83	3.50	8.33	5.82	3.59
OR Quartile 4	5.16	3.62	1.73	5.57	2.15	2.05	6.18	1.48	2.41
p Value	0.0073	0.019	0.31	0.0015	0.18	0.17	9.7E-4	0.52	0.098
Lower limit of 95% CI	1.56	1.24	0.605	1.92	0.706	0.730	2.09	0.445	0.850
Upper limit of 95% CI	17.1	10.5	4.97	16.1	6.57	5.77	18.2	4.95	6.84

[0224] Table 13.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.557	1.20	0.653	2.16	0.653	2.25
Average	1.29	2.29	1.31	2.86	1.32	3.06
Stdev	1.70	2.17	1.54	2.40	1.52	2.45
p (t-test)		0.033		5.7E-4		1.4E-4
Min	0.208	0.121	0.121	0.194	0.121	0.349
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	30	53	50	33	54	29

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.665	2.25	0.922	2.20	0.922	2.20
Average	1.50	2.89	1.63	2.84	1.70	2.88
Stdev	1.79	2.34	1.85	2.45	1.89	2.50
p (t-test)		0.0040		0.020		0.034
Min	0.121	0.349	0.121	0.349	0.121	0.349
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	53	27	58	22	62	18

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.790	1.15	0.773	1.28	0.773	1.59
Average	1.51	2.14	1.50	2.43	1.47	2.52
Stdev	1.83	2.13	1.77	2.26	1.74	2.29
p (t-test)		0.19		0.046		0.024
Min	0.208	0.121	0.121	0.194	0.121	0.194
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	29	49	44	34	46	32

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.70	0.59	0.71	0.66	0.62	0.73	0.65	0.63
SE	0.060	0.064	0.066	0.060	0.071	0.065	0.061	0.077	0.065
p Value	0.0046	0.0015	0.15	5.6E-4	0.022	0.060	1.7E-4	0.050	0.038

nCohort Non-persistent	30	53	29	50	58	44	54	62	46
nCohort Persistent	53	27	49	33	22	34	29	18	32
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	81%	89%	78%	85%	86%	79%	86%	83%	81%
Specificity	37%	32%	31%	32%	29%	30%	31%	27%	30%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	57%	63%	53%	64%	59%	56%	66%	61%	56%
Specificity	60%	57%	55%	58%	53%	55%	57%	53%	54%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	34%	41%	31%	42%	36%	35%	45%	33%	38%
Specificity	90%	83%	83%	86%	79%	82%	85%	77%	83%
OR Quartile 2	2.49	3.78	1.55	2.64	2.63	1.62	2.87	1.89	1.90
p Value	0.077	0.050	0.40	0.090	0.16	0.37	0.085	0.36	0.25
Lower limit of 95% CI	0.905	0.997	0.553	0.858	0.686	0.564	0.864	0.485	0.639
Upper limit of 95% CI	6.85	14.3	4.37	8.09	10.1	4.64	9.55	7.36	5.62
OR Quartile 3	1.96	2.22	1.39	2.42	1.66	1.52	2.56	1.79	1.53
p Value	0.15	0.10	0.48	0.056	0.32	0.36	0.049	0.29	0.36
Lower limit of 95% CI	0.787	0.856	0.553	0.978	0.614	0.618	1.00	0.613	0.617
Upper limit of 95% CI	4.86	5.74	3.50	5.97	4.48	3.74	6.53	5.22	3.79
OR Quartile 4	4.63	3.36	2.12	4.53	2.19	2.45	4.67	1.71	2.85
p Value	0.023	0.024	0.20	0.0051	0.15	0.091	0.0040	0.36	0.050
Lower limit of 95% CI	1.23	1.18	0.678	1.57	0.747	0.868	1.64	0.545	1.00
Upper limit of 95% CI	17.4	9.61	6.62	13.0	6.43	6.94	13.3	5.40	8.11

[0225] Table 13.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.557	1.19	0.653	1.99	0.653	2.16
Average	1.32	2.25	1.34	2.73	1.35	2.90
Stdev	1.72	2.16	1.56	2.39	1.54	2.45
p (t-test)		0.049		0.0020		6.3E-4
Min	0.208	0.121	0.121	0.194	0.121	0.349
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	29	54	48	35	52	31

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.739	2.20	1.03	2.16	1.03	2.16
Average	1.52	2.80	1.66	2.74	1.72	2.75
Stdev	1.80	2.35	1.86	2.45	1.90	2.49
p (t-test)		0.0077		0.035		0.061
Min	0.121	0.349	0.121	0.349	0.121	0.349
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	52	28	57	23	61	19

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.790	1.15	0.790	1.19	0.790	1.19

Average	1.51	2.14	1.52	2.38	1.49	2.47
Stdev	1.83	2.13	1.79	2.24	1.76	2.27
p (t-test)		0.19		0.063		0.035
Min	0.208	0.121	0.121	0.194	0.121	0.194
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	29	49	43	35	45	33

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	0.68	0.59	0.68	0.64	0.62	0.70	0.62	0.63
SE	0.061	0.065	0.066	0.060	0.071	0.064	0.061	0.077	0.065
p Value	0.012	0.0048	0.15	0.0025	0.051	0.069	0.0010	0.11	0.045
nCohort Non-persistent	29	52	29	48	57	43	52	61	45
nCohort Persistent	54	28	49	35	23	35	31	19	33
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	80%	86%	78%	83%	83%	80%	84%	79%	82%
Specificity	34%	31%	31%	31%	28%	30%	31%	26%	31%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	56%	61%	53%	60%	57%	54%	61%	58%	55%
Specificity	59%	56%	55%	56%	53%	53%	56%	52%	53%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	33%	39%	31%	40%	35%	34%	42%	32%	36%
Specificity	90%	83%	83%	85%	79%	81%	85%	77%	82%
OR Quartile 2	2.06	2.67	1.55	2.20	1.85	1.73	2.31	1.33	2.03
p Value	0.16	0.11	0.40	0.15	0.32	0.31	0.14	0.65	0.20
Lower limit of 95% CI	0.748	0.794	0.553	0.753	0.545	0.605	0.751	0.385	0.686
Upper limit of 95% CI	5.66	8.95	4.37	6.41	6.30	4.97	7.11	4.62	6.02
OR Quartile 3	1.77	1.95	1.39	1.93	1.44	1.37	2.00	1.52	1.37
p Value	0.22	0.16	0.48	0.15	0.46	0.50	0.13	0.43	0.49
Lower limit of 95% CI	0.710	0.765	0.553	0.796	0.545	0.558	0.806	0.536	0.557
Upper limit of 95% CI	4.41	4.96	3.50	4.67	3.83	3.34	4.94	4.29	3.38
OR Quartile 4	4.33	3.09	2.12	3.90	2.00	2.28	3.97	1.55	2.64
p Value	0.030	0.034	0.20	0.011	0.20	0.12	0.0092	0.45	0.068
Lower limit of 95% CI	1.15	1.09	0.678	1.37	0.687	0.809	1.41	0.497	0.932
Upper limit of 95% CI	16.3	8.79	6.62	11.1	5.82	6.44	11.2	4.83	7.50

[0226] Table 13.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.556	1.19	0.637	1.68	0.639	1.99
Average	1.18	2.29	1.26	2.72	1.28	2.81
Stdev	1.56	2.18	1.47	2.37	1.46	2.42
p (t-test)		0.021		9.7E-4		5.8E-4
Min	0.208	0.121	0.121	0.194	0.121	0.349
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	27	56	45	38	48	35

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.653	2.20	1.03	2.16	1.03	2.07

Average	1.50	2.74	1.65	2.67	1.74	2.58
Stdev	1.82	2.29	1.88	2.38	1.93	2.39
p (t-test)		0.0089		0.041		0.11
Min	0.121	0.349	0.121	0.349	0.121	0.349
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	50	30	55	25	58	22

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.640	1.15	0.665	1.19	0.727	1.16
Average	1.38	2.18	1.46	2.35	1.45	2.38
Stdev	1.70	2.16	1.74	2.23	1.72	2.25
p (t-test)		0.097		0.052		0.044
Min	0.208	0.121	0.121	0.194	0.121	0.194
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	27	51	39	39	40	38

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.68	0.69	0.62	0.70	0.65	0.63	0.71	0.62	0.63
SE	0.060	0.063	0.065	0.058	0.069	0.063	0.059	0.073	0.063
p Value	0.0029	0.0025	0.072	5.5E-4	0.033	0.034	3.8E-4	0.10	0.044
nCohort Non-persistent	27	50	27	45	55	39	48	58	40
nCohort Persistent	56	30	51	38	25	39	35	22	38
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	80%	87%	78%	84%	84%	82%	86%	82%	82%
Specificity	37%	32%	33%	33%	29%	33%	33%	28%	32%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	55%	60%	53%	61%	56%	54%	60%	55%	53%
Specificity	59%	56%	56%	58%	53%	54%	56%	52%	52%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	34%	40%	31%	39%	36%	33%	40%	32%	34%
Specificity	93%	84%	85%	87%	80%	82%	85%	78%	82%
OR Quartile 2	2.41	3.06	1.82	2.67	2.15	2.29	3.00	1.71	2.13
p Value	0.092	0.070	0.26	0.072	0.22	0.12	0.055	0.39	0.16
Lower limit of 95% CI	0.866	0.913	0.641	0.915	0.638	0.796	0.978	0.503	0.743
Upper limit of 95% CI	6.69	10.2	5.15	7.77	7.28	6.56	9.20	5.85	6.12
OR Quartile 3	1.80	1.91	1.41	2.10	1.42	1.36	1.93	1.29	1.23
p Value	0.21	0.17	0.48	0.099	0.47	0.50	0.15	0.62	0.65
Lower limit of 95% CI	0.711	0.761	0.551	0.871	0.549	0.559	0.796	0.480	0.505
Upper limit of 95% CI	4.58	4.79	3.59	5.05	3.67	3.32	4.67	3.44	2.99
OR Quartile 4	6.42	3.50	2.63	4.24	2.25	2.29	3.90	1.62	2.45
p Value	0.018	0.020	0.12	0.0086	0.13	0.12	0.011	0.39	0.096
Lower limit of 95% CI	1.37	1.22	0.780	1.44	0.787	0.796	1.37	0.544	0.853
Upper limit of 95% CI	30.0	10.0	8.86	12.5	6.43	6.56	11.1	4.80	7.04

[0227] Table 13.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.556	1.19	0.637	1.68	0.639	1.99

Average	1.14	2.27	1.24	2.66	1.27	2.75
Stdev	1.57	2.16	1.47	2.35	1.46	2.40
p (t-test)		0.021		0.0013		8.6E-4
Min	0.208	0.121	0.208	0.121	0.194	0.121
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	25	58	43	40	46	37

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.640	2.25	0.911	2.20	0.911	2.20
Average	1.41	2.84	1.57	2.79	1.59	2.85
Stdev	1.73	2.32	1.81	2.40	1.80	2.46
p (t-test)		0.0024		0.014		0.012
Min	0.121	0.349	0.121	0.349	0.121	0.349
Max	7.86	6.79	7.86	6.79	7.86	6.79
n (Patient)	49	31	54	26	56	24

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.715	1.14	0.790	1.14	0.790	1.14
Average	1.42	2.15	1.52	2.25	1.49	2.32
Stdev	1.72	2.15	1.77	2.22	1.73	2.25
p (t-test)		0.14		0.12		0.071
Min	0.208	0.121	0.208	0.121	0.208	0.121
Max	7.86	6.66	7.86	6.66	7.86	6.66
n (Patient)	26	52	37	41	39	39

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.68	0.71	0.60	0.69	0.67	0.59	0.70	0.66	0.60
SE	0.061	0.061	0.067	0.058	0.067	0.064	0.059	0.069	0.064
p Value	0.0027	6.8E-4	0.14	0.0012	0.014	0.16	8.9E-4	0.021	0.11
nCohort Non-persistent	25	49	26	43	54	37	46	56	39
nCohort Persistent	58	31	52	40	26	41	37	24	39
Cutoff Quartile 2	0.467	0.457	0.483	0.467	0.457	0.483	0.467	0.457	0.483
Sensitivity	79%	87%	77%	82%	85%	78%	84%	83%	79%
Specificity	36%	33%	31%	33%	30%	30%	33%	29%	31%
Cutoff Quartile 3	1.04	1.04	1.03	1.04	1.04	1.03	1.04	1.04	1.03
Sensitivity	55%	61%	52%	60%	58%	51%	59%	58%	51%
Specificity	60%	57%	54%	58%	54%	51%	57%	54%	51%
Cutoff Quartile 4	2.82	2.88	2.84	2.82	2.88	2.84	2.82	2.88	2.84
Sensitivity	34%	42%	31%	40%	38%	32%	41%	38%	33%
Specificity	96%	86%	85%	88%	81%	81%	87%	80%	82%
OR Quartile 2	2.16	3.27	1.48	2.28	2.32	1.50	2.50	2.00	1.72
p Value	0.15	0.054	0.46	0.12	0.18	0.43	0.093	0.27	0.30
Lower limit of 95% CI	0.766	0.978	0.517	0.808	0.687	0.542	0.858	0.590	0.613
Upper limit of 95% CI	6.07	11.0	4.25	6.41	7.80	4.18	7.29	6.77	4.84
OR Quartile 3	1.85	2.11	1.26	2.08	1.58	1.11	1.91	1.62	1.11
p Value	0.21	0.11	0.63	0.10	0.34	0.82	0.15	0.33	0.82
Lower limit of 95% CI	0.712	0.843	0.490	0.868	0.615	0.456	0.793	0.614	0.456
Upper limit of 95% CI	4.79	5.29	3.24	5.00	4.07	2.70	4.59	4.25	2.69
OR Quartile 4	12.6	4.33	2.44	5.07	2.75	1.99	4.55	2.45	2.29
p Value	0.016	0.0073	0.15	0.0048	0.058	0.20	0.0060	0.096	0.12
Lower limit of 95% CI	1.59	1.48	0.724	1.64	0.965	0.694	1.54	0.853	0.796
Upper limit of 95% CI	100	12.7	8.26	15.6	7.83	5.71	13.4	7.06	6.56

[0228] Table 13.6: Comparison of marker levels and the area under the ROC curve

(AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where

persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	219	302	220	302	224	302
Average	224	306	236	326	242	330
Stdev	86.6	142	94.4	155	101	157
p (t-test)		0.0024		0.0013		0.0033
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	434	651	446	651	512	651
n (Patient)	41	43	56	28	61	23

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	226	312	235	307	243	307
Average	242	322	248	317	251	313
Stdev	111	136	112	145	112	151
p (t-test)		0.0085		0.030		0.061
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	58	23	61	20	63	18

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	243	252	235	257	235	257
Average	254	284	252	301	256	297
Stdev	107	140	106	150	110	148
p (t-test)		0.28		0.098		0.17
Min	108	73.7	73.7	105	73.7	105
Max	590	651	590	651	590	651
n (Patient)	37	40	49	28	51	26

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.68	0.55	0.67	0.64	0.58	0.66	0.62	0.57
SE	0.059	0.069	0.066	0.065	0.075	0.069	0.070	0.078	0.070
p Value	0.0047	0.0094	0.43	0.0080	0.059	0.24	0.018	0.13	0.32
nCohort Non-persistent	41	58	37	56	61	49	61	63	51
nCohort Persistent	43	23	40	28	20	28	23	18	26
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	79%	87%	78%	82%	85%	82%	83%	83%	81%
Specificity	29%	29%	27%	29%	28%	29%	28%	27%	27%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	63%	70%	52%	71%	65%	57%	74%	61%	58%
Specificity	63%	57%	51%	61%	54%	53%	59%	52%	53%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	37%	39%	30%	36%	35%	32%	35%	33%	31%
Specificity	88%	79%	78%	80%	77%	78%	79%	76%	76%
OR Quartile 2	1.56	2.76	1.28	1.84	2.19	1.84	1.84	1.85	1.59
p Value	0.38	0.14	0.65	0.29	0.25	0.30	0.33	0.38	0.43
Lower limit of 95% CI	0.577	0.725	0.452	0.596	0.568	0.583	0.545	0.475	0.502

Upper limit of 95% CI	4.23	10.5	3.60	5.68	8.44	5.80	6.18	7.19	5.03
OR Quartile 3	2.92	3.02	1.17	3.86	2.19	1.51	4.08	1.73	1.53
p Value	0.018	0.035	0.74	0.0069	0.14	0.39	0.0094	0.32	0.38
Lower limit of 95% CI	1.21	1.08	0.477	1.45	0.768	0.591	1.41	0.594	0.592
Upper limit of 95% CI	7.10	8.44	2.85	10.3	6.24	3.84	11.8	5.03	3.98
OR Quartile 4	4.27	2.46	1.55	2.27	1.81	1.64	1.97	1.60	1.44
p Value	0.011	0.093	0.40	0.11	0.29	0.35	0.21	0.42	0.49
Lower limit of 95% CI	1.39	0.861	0.552	0.823	0.604	0.579	0.686	0.512	0.503
Upper limit of 95% CI	13.1	7.05	4.37	6.28	5.41	4.62	5.65	5.00	4.15

[0229] Table 13.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	215	280	215	293	221	302
Average	214	298	229	320	236	322
Stdev	82.2	136	92.0	146	100	147
p (t-test)		0.0021		7.3E-4		0.0023
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	360	651	446	651	512	651
n (Patient)	32	52	50	34	55	29

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	220	304	226	302	235	307
Average	239	316	244	317	248	316
Stdev	112	132	112	138	111	146
p (t-test)		0.0080		0.016		0.034
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	54	27	58	23	61	20

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	232	255	229	260	229	260
Average	244	286	244	304	248	302
Stdev	93.8	140	94.4	152	101	150
p (t-test)		0.15		0.034		0.064
Min	108	73.7	73.7	105	73.7	105
Max	421	651	429	651	512	651
n (Patient)	30	47	44	33	46	31

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.68	0.68	0.57	0.68	0.66	0.60	0.67	0.64	0.59
SE	0.058	0.066	0.066	0.061	0.070	0.066	0.064	0.075	0.067
p Value	0.0016	0.0066	0.29	0.0024	0.024	0.13	0.0074	0.068	0.18

nCohort Non-persistent	32	54	30	50	58	44	55	61	46
nCohort Persistent	52	27	47	34	23	33	29	20	31
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	83%	89%	79%	85%	87%	82%	86%	85%	81%
Specificity	38%	31%	30%	32%	29%	30%	31%	28%	28%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	60%	67%	53%	68%	65%	58%	69%	60%	58%
Specificity	66%	57%	53%	62%	55%	55%	60%	52%	54%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	35%	37%	30%	35%	35%	33%	34%	35%	32%
Specificity	91%	80%	80%	82%	78%	80%	80%	77%	78%
OR Quartile 2	2.87	3.68	1.59	2.73	2.76	1.89	2.80	2.19	1.64
p Value	0.042	0.055	0.39	0.079	0.14	0.26	0.093	0.25	0.38
Lower limit of 95% CI	1.04	0.972	0.556	0.891	0.725	0.630	0.842	0.568	0.547
Upper limit of 95% CI	7.90	13.9	4.52	8.36	10.5	5.65	9.29	8.44	4.92
OR Quartile 3	2.82	2.70	1.30	3.41	2.31	1.63	3.33	1.66	1.65
p Value	0.027	0.044	0.58	0.0088	0.10	0.29	0.013	0.34	0.29
Lower limit of 95% CI	1.13	1.03	0.519	1.36	0.847	0.655	1.28	0.593	0.657
Upper limit of 95% CI	7.04	7.08	3.25	8.54	6.29	4.05	8.65	4.62	4.13
OR Quartile 4	5.12	2.30	1.70	2.48	1.85	1.94	2.11	1.81	1.71
p Value	0.015	0.11	0.34	0.077	0.26	0.21	0.15	0.29	0.30
Lower limit of 95% CI	1.37	0.826	0.570	0.907	0.642	0.694	0.766	0.604	0.613
Upper limit of 95% CI	19.1	6.40	5.05	6.81	5.31	5.45	5.79	5.41	4.79

[0230] Table 13.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	219	279	219	285	221	285
Average	215	296	230	316	238	314
Stdev	83.4	135	92.7	146	102	145
p (t-test)		0.0034		0.0014		0.0059
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	360	651	446	651	512	651
n (Patient)	31	53	49	35	53	31

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	221	303	231	292	239	302
Average	241	311	245	311	249	309
Stdev	113	132	112	138	112	146
p (t-test)		0.014		0.027		0.056
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	53	28	57	24	60	21

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	232	255	235	257	235	257

Average	244	286	244	302	249	299
Stdev	93.8	140	95.5	150	102	149
p (t-test)		0.15		0.042		0.079
Min	108	73.7	73.7	105	73.7	105
Max	421	651	429	651	512	651
n (Patient)	30	47	43	34	45	32

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.66	0.57	0.67	0.64	0.60	0.65	0.62	0.58
SE	0.059	0.066	0.066	0.061	0.070	0.066	0.064	0.074	0.067
p Value	0.0030	0.012	0.29	0.0047	0.042	0.15	0.016	0.11	0.21
nCohort Non-persistent	31	53	30	49	57	43	53	60	45
nCohort Persistent	53	28	47	35	24	34	31	21	32
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	83%	89%	79%	86%	88%	82%	87%	86%	81%
Specificity	39%	32%	30%	33%	30%	30%	32%	28%	29%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	58%	64%	53%	66%	62%	56%	65%	57%	56%
Specificity	65%	57%	53%	61%	54%	53%	58%	52%	53%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	34%	36%	30%	34%	33%	32%	32%	33%	31%
Specificity	90%	79%	80%	82%	77%	79%	79%	77%	78%
OR Quartile 2	3.09	3.94	1.59	2.91	2.98	2.02	3.19	2.37	1.76
p Value	0.030	0.043	0.39	0.062	0.11	0.21	0.058	0.21	0.31
Lower limit of 95% CI	1.12	1.04	0.556	0.950	0.782	0.676	0.962	0.618	0.588
Upper limit of 95% CI	8.55	14.9	4.52	8.91	11.3	6.05	10.6	9.11	5.27
OR Quartile 3	2.56	2.35	1.30	3.03	1.99	1.46	2.56	1.43	1.47
p Value	0.044	0.077	0.58	0.016	0.17	0.41	0.044	0.49	0.41
Lower limit of 95% CI	1.02	0.913	0.519	1.23	0.748	0.590	1.02	0.523	0.591
Upper limit of 95% CI	6.41	6.04	3.25	7.47	5.28	3.60	6.41	3.88	3.66
OR Quartile 4	4.80	2.12	1.70	2.32	1.69	1.81	1.82	1.64	1.59
p Value	0.020	0.15	0.34	0.10	0.33	0.26	0.24	0.37	0.38
Lower limit of 95% CI	1.28	0.766	0.570	0.849	0.592	0.647	0.666	0.554	0.570
Upper limit of 95% CI	18.0	5.88	5.05	6.33	4.84	5.05	4.96	4.87	4.44

[0231] Table 13.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	216	277	211	285	216	283
Average	215	294	227	316	232	316
Stdev	84.8	135	91.7	143	97.1	144
p (t-test)		0.0043		9.1E-4		0.0019
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	360	651	446	651	446	651
n (Patient)	30	54	47	37	50	34

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	221	302	231	292	235	292

Average	240	308	245	307	248	304
Stdev	115	128	114	134	115	137
p (t-test)		0.016		0.032		0.064
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	51	30	55	26	57	24

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	243	252	228	260	235	257
Average	245	285	240	302	244	299
Stdev	95.4	139	96.0	145	97.6	146
p (t-test)		0.18		0.030		0.051
Min	108	73.7	73.7	105	73.7	105
Max	421	651	429	651	429	651
n (Patient)	29	48	40	37	41	36

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.66	0.57	0.68	0.64	0.61	0.67	0.62	0.59
SE	0.059	0.064	0.067	0.060	0.068	0.064	0.061	0.070	0.065
p Value	0.0036	0.012	0.33	0.0024	0.041	0.086	0.0053	0.093	0.15
nCohort Non-persistent	30	51	29	47	55	40	50	57	41
nCohort Persistent	54	30	48	37	26	37	34	24	36
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	83%	90%	79%	86%	88%	84%	88%	88%	83%
Specificity	40%	33%	31%	34%	31%	32%	34%	30%	32%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	57%	63%	52%	65%	62%	57%	65%	58%	56%
Specificity	63%	57%	52%	62%	55%	55%	60%	53%	54%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	33%	33%	29%	35%	31%	32%	32%	29%	31%
Specificity	90%	78%	79%	83%	76%	80%	80%	75%	78%
OR Quartile 2	3.33	4.50	1.71	3.30	3.43	2.49	3.86	2.98	2.32
p Value	0.021	0.026	0.32	0.036	0.070	0.10	0.027	0.11	0.13
Lower limit of 95% CI	1.20	1.19	0.598	1.08	0.905	0.831	1.17	0.782	0.776
Upper limit of 95% CI	9.27	17.0	4.89	10.1	13.0	7.45	12.8	11.3	6.95
OR Quartile 3	2.33	2.28	1.16	2.97	1.92	1.60	2.75	1.56	1.45
p Value	0.071	0.082	0.75	0.017	0.18	0.30	0.028	0.37	0.42
Lower limit of 95% CI	0.930	0.901	0.463	1.22	0.741	0.652	1.12	0.593	0.589
Upper limit of 95% CI	5.83	5.75	2.93	7.28	4.97	3.95	6.78	4.08	3.56
OR Quartile 4	4.50	1.82	1.58	2.64	1.44	1.92	1.91	1.26	1.56
p Value	0.026	0.25	0.41	0.061	0.50	0.22	0.20	0.67	0.39
Lower limit of 95% CI	1.20	0.662	0.529	0.955	0.508	0.681	0.705	0.435	0.562
Upper limit of 95% CI	16.8	5.00	4.71	7.30	4.06	5.41	5.19	3.68	4.36

[0232] Table 13.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	216	268	211	281	216	280

Average	216	291	228	309	233	310
Stdev	86.9	134	93.3	142	98.6	143
p (t-test)		0.0091		0.0024		0.0048
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	360	651	446	651	446	651
n (Patient)	28	56	45	39	48	36

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	221	302	231	292	235	292
Average	240	308	245	307	248	304
Stdev	115	128	114	134	115	137
p (t-test)		0.016		0.032		0.064
Min	73.7	89.8	73.7	89.8	73.7	89.8
Max	651	592	651	592	651	592
n (Patient)	51	30	55	26	57	24

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	248	249	239	255	239	255
Average	248	282	245	294	246	295
Stdev	95.3	139	96.4	145	97.9	146
p (t-test)		0.26		0.082		0.081
Min	108	73.7	73.7	105	73.7	105
Max	421	651	429	651	429	651
n (Patient)	28	49	38	39	40	37

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.66	0.66	0.55	0.66	0.64	0.58	0.65	0.62	0.58
SE	0.061	0.064	0.068	0.060	0.068	0.065	0.061	0.070	0.065
p Value	0.0096	0.012	0.49	0.0061	0.041	0.23	0.013	0.093	0.23
nCohort Non-persistent	28	51	28	45	55	38	48	57	40
nCohort Persistent	56	30	49	39	26	39	36	24	37
Cutoff Quartile 2	169	171	174	169	171	174	169	171	174
Sensitivity	82%	90%	78%	85%	88%	79%	86%	88%	81%
Specificity	39%	33%	29%	33%	31%	29%	33%	30%	30%
Cutoff Quartile 3	249	249	249	249	249	249	249	249	249
Sensitivity	55%	63%	51%	62%	62%	54%	61%	58%	54%
Specificity	61%	57%	50%	60%	55%	53%	58%	53%	52%
Cutoff Quartile 4	332	331	335	332	331	335	332	331	335
Sensitivity	32%	33%	29%	33%	31%	31%	31%	29%	30%
Specificity	89%	78%	79%	82%	76%	79%	79%	75%	78%
OR Quartile 2	2.98	4.50	1.38	2.75	3.43	1.58	3.10	2.98	1.84
p Value	0.036	0.026	0.55	0.063	0.070	0.39	0.048	0.11	0.26
Lower limit of 95% CI	1.07	1.19	0.479	0.945	0.905	0.554	1.01	0.782	0.633
Upper limit of 95% CI	8.26	17.0	3.99	8.00	13.0	4.50	9.49	11.3	5.33
OR Quartile 3	1.92	2.28	1.04	2.40	1.92	1.30	2.20	1.56	1.30
p Value	0.17	0.082	0.93	0.051	0.18	0.57	0.080	0.37	0.57
Lower limit of 95% CI	0.761	0.901	0.412	0.997	0.741	0.529	0.911	0.593	0.531
Upper limit of 95% CI	4.83	5.75	2.64	5.78	4.97	3.17	5.32	4.08	3.19
OR Quartile 4	3.95	1.82	1.47	2.31	1.44	1.67	1.67	1.26	1.46
p Value	0.042	0.25	0.49	0.10	0.50	0.33	0.31	0.67	0.47
Lower limit of 95% CI	1.05	0.662	0.491	0.839	0.508	0.592	0.619	0.435	0.524
Upper limit of 95% CI	14.8	5.00	4.38	6.37	4.06	4.69	4.52	3.68	4.06

[0233] Example 14. Use of C-C motif chemokine 16 for evaluating renal status in patients admitted to the ICU: Persistent at RIFLE F

[0234] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. C-C motif chemokine 16 is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0235] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output. Two cohorts are defined to represent a “persistent” and a “non-persistent” population. “Persistent” indicates those patients whose minimum RIFLE stage during a period of 24, 48 or 72 hours is failure (F) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. “Non-persistent” indicates those patients who are not persistent at failure (F) and whose minimum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0), risk of injury (R), or injury (I) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. If a patient dies after failure (F) or is placed on renal replacement therapy (RRT) at any time from sample collection to 24, 48, 72, 96 or 168 hours after sample collection, the patient is considered “persistent”.

[0236] The ability to distinguish the “persistent” and “non-persistent” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0237] Table 14.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0115	0.0419	0.0133	0.0444	0.0137	0.0427
Average	0.0200	0.195	0.0235	0.277	0.0243	0.293
Stdev	0.0260	0.627	0.0313	0.783	0.0318	0.813
p (t-test)		0.031		0.0074		0.0059

Min	4.13E-6	6.68E-6	4.13E-6	1.60E-5	4.13E-6	1.60E-5
Max	0.113	2.98	0.151	2.98	0.151	2.98
n (Patient)	61	22	69	14	70	13

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0124	0.0487	0.0142	0.0329	0.0151	0.0305
Average	0.0226	0.283	0.0258	0.335	0.0318	0.356
Stdev	0.0281	0.782	0.0326	0.884	0.0550	0.983
p (t-test)		0.0070		0.0037		0.0053
Min	4.13E-6	1.60E-5	4.13E-6	1.60E-5	4.13E-6	1.60E-5
Max	0.113	2.98	0.151	2.98	0.399	2.98
n (Patient)	66	14	69	11	71	9

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0108	0.0473	0.0133	0.0671	0.0133	0.0671
Average	0.0214	0.240	0.0232	0.420	0.0232	0.420
Stdev	0.0300	0.711	0.0307	0.966	0.0307	0.966
p (t-test)		0.017		6.4E-4		6.4E-4
Min	4.13E-6	6.68E-6	4.13E-6	0.0305	4.13E-6	0.0305
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	61	17	69	9	69	9

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.76	0.78	0.79	0.77	0.71	0.89	0.76	0.64	0.89
SE	0.065	0.077	0.070	0.077	0.092	0.073	0.082	0.10	0.073
p Value	9.3E-5	3.6E-4	3.0E-5	3.8E-4	0.021	7.2E-8	0.0017	0.17	7.2E-8
nCohort Non-persistent	61	66	61	69	69	69	70	71	69
nCohort Persistent	22	14	17	14	11	9	13	9	9
Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	86%	93%	88%	93%	91%	100%	92%	89%	100%
Specificity	28%	29%	28%	28%	28%	28%	27%	27%	28%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	82%	86%	88%	86%	82%	100%	85%	78%	100%
Specificity	61%	58%	61%	57%	55%	57%	56%	54%	57%
Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	50%	57%	59%	57%	45%	78%	54%	33%	78%
Specificity	82%	82%	82%	80%	78%	80%	79%	76%	80%
OR Quartile 2	2.45	5.26	2.90	4.94	3.80	7.34	4.47	2.92	7.34
p Value	0.19	0.12	0.19	0.14	0.22	0.18	0.16	0.33	0.18
Lower limit of 95% CI	0.641	0.642	0.598	0.604	0.455	0.407	0.544	0.342	0.407
Upper limit of 95% CI	9.35	43.0	14.0	40.4	31.7	132	36.8	25.0	132
OR Quartile 3	6.94	8.14	11.6	7.80	5.52	24.6	6.92	4.03	24.6
p Value	0.0015	0.0090	0.0021	0.010	0.037	0.029	0.016	0.096	0.029
Lower limit of 95% CI	2.09	1.69	2.42	1.62	1.11	1.38	1.43	0.782	1.38
Upper limit of 95% CI	23.0	39.3	55.2	37.5	27.4	440	33.6	20.8	440
OR Quartile 4	4.55	6.00	6.49	5.24	3.00	13.8	4.28	1.59	13.8
p Value	0.0051	0.0043	0.0017	0.0073	0.10	0.0022	0.021	0.54	0.0022
Lower limit of 95% CI	1.57	1.75	2.02	1.56	0.803	2.57	1.25	0.358	2.57
Upper limit of 95% CI	13.1	20.5	20.8	17.6	11.2	73.6	14.6	7.04	73.6

[0238] Table 14.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by

serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0112	0.0411	0.0128	0.0427	0.0133	0.0389
Average	0.0197	0.174	0.0234	0.233	0.0242	0.243
Stdev	0.0262	0.589	0.0317	0.713	0.0322	0.735
p (t-test)		0.048		0.018		0.016
Min	4.13E-6	6.68E-6	4.13E-6	1.60E-5	4.13E-6	1.60E-5
Max	0.113	2.98	0.151	2.98	0.151	2.98
n (Patient)	58	25	66	17	67	16

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0124	0.0487	0.0142	0.0329	0.0151	0.0305
Average	0.0226	0.283	0.0258	0.335	0.0318	0.356
Stdev	0.0281	0.782	0.0326	0.884	0.0550	0.983
p (t-test)		0.0070		0.0037		0.0053
Min	4.13E-6	1.60E-5	4.13E-6	1.60E-5	4.13E-6	1.60E-5
Max	0.113	2.98	0.151	2.98	0.399	2.98
n (Patient)	66	14	69	11	71	9

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.00924	0.0427	0.0124	0.0539	0.0124	0.0539
Average	0.0209	0.200	0.0229	0.300	0.0229	0.300
Stdev	0.0306	0.642	0.0313	0.811	0.0313	0.811
p (t-test)		0.037		0.0062		0.0062
Min	4.13E-6	6.68E-6	4.13E-6	0.00279	4.13E-6	0.00279
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	57	21	65	13	65	13

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.75	0.78	0.78	0.75	0.71	0.82	0.73	0.64	0.82
SE	0.063	0.077	0.065	0.073	0.092	0.074	0.076	0.10	0.074
p Value	7.4E-5	3.6E-4	1.8E-5	5.5E-4	0.021	1.0E-5	0.0022	0.17	1.0E-5
nCohort Non-persistent	58	66	57	66	69	65	67	71	65
nCohort Persistent	25	14	21	17	11	13	16	9	13
Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	88%	93%	90%	94%	91%	100%	94%	89%	100%
Specificity	29%	29%	30%	29%	28%	29%	28%	27%	29%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	80%	86%	86%	82%	82%	92%	81%	78%	92%
Specificity	62%	58%	63%	58%	55%	58%	57%	54%	58%
Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	48%	57%	52%	53%	45%	62%	50%	33%	62%
Specificity	83%	82%	82%	80%	78%	80%	79%	76%	80%
OR Quartile 2	3.04	5.26	4.04	6.47	3.80	11.3	5.94	2.92	11.3
p Value	0.10	0.12	0.080	0.080	0.22	0.098	0.095	0.33	0.098
Lower limit of 95% CI	0.802	0.642	0.845	0.800	0.455	0.641	0.732	0.342	0.641
Upper limit of 95% CI	11.5	43.0	19.3	52.3	31.7	200	48.1	25.0	200
OR Quartile 3	6.55	8.14	10.3	6.33	5.52	16.9	5.68	4.03	16.9

p Value	9.5E-4	0.0090	6.2E-4	0.0069	0.037	0.0083	0.011	0.096	0.0083
Lower limit of 95% CI	2.15	1.69	2.71	1.66	1.11	2.07	1.48	0.782	2.07
Upper limit of 95% CI	19.9	39.3	39.1	24.2	27.4	138	21.8	20.8	138
OR Quartile 4	4.43	6.00	5.17	4.59	3.00	6.40	3.79	1.59	6.40
p Value	0.0050	0.0043	0.0033	0.0082	0.10	0.0042	0.022	0.54	0.0042
Lower limit of 95% CI	1.57	1.75	1.73	1.48	0.803	1.79	1.21	0.358	1.79
Upper limit of 95% CI	12.5	20.5	15.5	14.2	11.2	22.8	11.9	7.04	22.8

[0239] Table 14.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0115	0.0381	0.0133	0.0389	0.0137	0.0352
Average	0.0201	0.168	0.0237	0.220	0.0245	0.228
Stdev	0.0263	0.578	0.0318	0.694	0.0323	0.714
p (t-test)		0.056		0.023		0.021
Min	6.68E-6	4.13E-6	4.13E-6	1.26E-5	4.13E-6	1.26E-5
Max	0.113	2.98	0.151	2.98	0.151	2.98
n (Patient)	57	26	65	18	66	17

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0133	0.0460	0.0142	0.0329	0.0151	0.0305
Average	0.0229	0.265	0.0258	0.335	0.0318	0.356
Stdev	0.0282	0.757	0.0326	0.884	0.0550	0.983
p (t-test)		0.011		0.0037		0.0053
Min	6.68E-6	4.13E-6	4.13E-6	1.60E-5	4.13E-6	1.60E-5
Max	0.113	2.98	0.151	2.98	0.399	2.98
n (Patient)	65	15	69	11	71	9

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0100	0.0419	0.0133	0.0427	0.0128	0.0483
Average	0.0213	0.190	0.0236	0.260	0.0232	0.278
Stdev	0.0308	0.628	0.0315	0.758	0.0314	0.783
p (t-test)		0.046		0.014		0.0096
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	4.13E-6	1.26E-5
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	56	22	63	15	64	14

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.72	0.72	0.74	0.72	0.71	0.73	0.70	0.64	0.78
SE	0.064	0.080	0.067	0.074	0.092	0.080	0.077	0.10	0.077
p Value	7.8E-4	0.0056	3.7E-4	0.0027	0.021	0.0044	0.0084	0.17	2.4E-4
n Cohort Non-persistent	57	65	56	65	69	63	66	71	64
n Cohort Persistent	26	15	22	18	11	15	17	9	14

Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	85%	87%	86%	89%	91%	87%	88%	89%	93%
Specificity	28%	28%	29%	28%	28%	27%	27%	27%	28%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	77%	80%	82%	78%	82%	80%	76%	78%	86%
Specificity	61%	57%	62%	57%	55%	57%	56%	54%	58%
Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	46%	53%	50%	50%	45%	53%	47%	33%	57%
Specificity	82%	82%	82%	80%	78%	79%	79%	76%	80%
OR Quartile 2	2.15	2.49	2.53	3.06	3.80	2.40	2.81	2.92	5.09
p Value	0.22	0.26	0.18	0.16	0.22	0.28	0.20	0.33	0.13
Lower limit of 95% CI	0.639	0.510	0.658	0.639	0.455	0.490	0.584	0.342	0.619
Upper limit of 95% CI	7.21	12.1	9.76	14.7	31.7	11.8	13.5	25.0	41.8
OR Quartile 3	5.30	5.29	7.50	4.62	5.52	5.33	4.15	4.03	8.22
p Value	0.0020	0.016	0.0011	0.013	0.037	0.016	0.022	0.096	0.0088
Lower limit of 95% CI	1.84	1.36	2.23	1.37	1.11	1.37	1.22	0.782	1.70
Upper limit of 95% CI	15.3	20.5	25.2	15.6	27.4	20.8	14.1	20.8	39.8
OR Quartile 4	4.03	5.05	4.60	4.00	3.00	4.40	3.30	1.59	5.23
p Value	0.0080	0.0078	0.0056	0.014	0.10	0.014	0.037	0.54	0.0079
Lower limit of 95% CI	1.44	1.53	1.56	1.32	0.803	1.35	1.08	0.358	1.54
Upper limit of 95% CI	11.3	16.6	13.5	12.1	11.2	14.4	10.1	7.04	17.7

[0240] Table 14.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0115	0.0381	0.0128	0.0427	0.0133	0.0389
Average	0.0201	0.168	0.0233	0.211	0.0241	0.219
Stdev	0.0263	0.578	0.0319	0.675	0.0324	0.694
p (t-test)		0.056		0.027		0.025
Min	6.68E-6	4.13E-6	4.13E-6	1.26E-5	4.13E-6	1.26E-5
Max	0.113	2.98	0.151	2.98	0.151	2.98
n (Patient)	57	26	64	19	65	18

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0133	0.0460	0.0137	0.0395	0.0146	0.0317
Average	0.0229	0.265	0.0254	0.311	0.0315	0.325
Stdev	0.0282	0.757	0.0326	0.847	0.0553	0.932
p (t-test)		0.011		0.0055		0.0083
Min	6.68E-6	4.13E-6	4.13E-6	1.60E-5	4.13E-6	1.60E-5
Max	0.113	2.98	0.151	2.98	0.399	2.98
n (Patient)	65	15	68	12	70	10

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0100	0.0419	0.0128	0.0471	0.0124	0.0514
Average	0.0213	0.190	0.0231	0.247	0.0228	0.263
Stdev	0.0308	0.628	0.0316	0.734	0.0315	0.757

p (t-test)		0.046		0.017		0.012
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	4.13E-6	1.26E-5
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	56	22	62	16	63	15

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.72	0.72	0.74	0.73	0.73	0.74	0.71	0.67	0.79
SE	0.064	0.080	0.067	0.071	0.088	0.076	0.074	0.099	0.073
p Value	7.8E-4	0.0056	3.7E-4	0.0010	0.0097	0.0017	0.0037	0.094	6.7E-5
nCohort Non-persistent	57	65	56	64	68	62	65	70	63
nCohort Persistent	26	15	22	19	12	16	18	10	15
Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	85%	87%	86%	89%	92%	88%	89%	90%	93%
Specificity	28%	28%	29%	28%	28%	27%	28%	27%	29%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	77%	80%	82%	79%	83%	81%	78%	80%	87%
Specificity	61%	57%	62%	58%	56%	58%	57%	54%	59%
Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	46%	53%	50%	53%	50%	56%	50%	40%	60%
Specificity	82%	82%	82%	81%	79%	81%	80%	77%	81%
OR Quartile 2	2.15	2.49	2.53	3.33	4.27	2.64	3.06	3.35	5.60
p Value	0.22	0.26	0.18	0.13	0.18	0.23	0.16	0.27	0.11
Lower limit of 95% CI	0.639	0.510	0.658	0.697	0.515	0.543	0.639	0.398	0.685
Upper limit of 95% CI	7.21	12.1	9.76	15.9	35.3	12.9	14.7	28.3	45.8
OR Quartile 3	5.30	5.29	7.50	5.14	6.33	6.00	4.62	4.75	9.25
p Value	0.0020	0.016	0.0011	0.0080	0.023	0.0094	0.013	0.059	0.0055
Lower limit of 95% CI	1.84	1.36	2.23	1.53	1.29	1.55	1.37	0.941	1.92
Upper limit of 95% CI	15.3	20.5	25.2	17.2	31.1	23.2	15.6	24.0	44.5
OR Quartile 4	4.03	5.05	4.60	4.81	3.86	5.36	4.00	2.25	6.38
p Value	0.0080	0.0078	0.0056	0.0050	0.038	0.0050	0.014	0.25	0.0027
Lower limit of 95% CI	1.44	1.53	1.56	1.61	1.08	1.66	1.32	0.565	1.90
Upper limit of 95% CI	11.3	16.6	13.5	14.4	13.8	17.3	12.1	8.97	21.4

[0241] Table 14.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0100	0.0427	0.0120	0.0460	0.0128	0.0427
Average	0.0171	0.158	0.0212	0.184	0.0225	0.196
Stdev	0.0234	0.547	0.0305	0.614	0.0311	0.643
p (t-test)		0.061		0.042		0.036
Min	6.68E-6	4.13E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6
Max	0.113	2.98	0.151	2.98	0.151	2.98
n (Patient)	54	29	60	23	62	21

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0124	0.0487	0.0133	0.0460	0.0137	0.0395
Average	0.0219	0.253	0.0245	0.294	0.0253	0.312
Stdev	0.0272	0.733	0.0320	0.813	0.0324	0.846

p (t-test)		0.012		0.0069		0.0054
Min	6.68E-6	4.13E-6	4.13E-6	1.60E-5	4.13E-6	1.60E-5
Max	0.113	2.98	0.151	2.98	0.151	2.98
n (Patient)	64	16	67	13	68	12

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.00924	0.0444	0.0116	0.0467	0.0108	0.0473
Average	0.0196	0.180	0.0216	0.206	0.0213	0.217
Stdev	0.0298	0.601	0.0311	0.658	0.0309	0.674
p (t-test)		0.052		0.034		0.027
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	4.13E-6	6.68E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	54	24	58	20	59	19

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.76	0.74	0.77	0.75	0.75	0.74	0.72	0.73	0.78
SE	0.058	0.076	0.062	0.065	0.082	0.069	0.069	0.087	0.067
p Value	6.8E-6	0.0013	1.7E-5	1.4E-4	0.0023	4.9E-4	0.0015	0.0081	2.1E-5
nCohort Non-persistent	54	64	54	60	67	58	62	68	59
nCohort Persistent	29	16	24	23	13	20	21	12	19
Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	86%	88%	88%	87%	92%	85%	86%	92%	89%
Specificity	30%	28%	30%	28%	28%	28%	27%	28%	29%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	79%	81%	83%	78%	85%	80%	76%	83%	84%
Specificity	65%	58%	65%	60%	57%	60%	58%	56%	61%
Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	52%	56%	54%	57%	54%	60%	52%	50%	63%
Specificity	87%	83%	85%	85%	81%	84%	82%	79%	85%
OR Quartile 2	2.63	2.74	2.95	2.64	4.75	2.16	2.27	4.27	3.44
p Value	0.12	0.21	0.11	0.16	0.15	0.27	0.23	0.18	0.12
Lower limit of 95% CI	0.788	0.565	0.769	0.692	0.577	0.556	0.591	0.515	0.716
Upper limit of 95% CI	8.79	13.3	11.3	10.0	39.1	8.38	8.69	35.3	16.5
OR Quartile 3	7.06	5.94	9.21	5.40	7.21	6.09	4.43	6.33	8.35
p Value	2.9E-4	0.0097	3.2E-4	0.0031	0.014	0.0036	0.0094	0.023	0.0019
Lower limit of 95% CI	2.45	1.54	2.75	1.77	1.48	1.81	1.44	1.29	2.19
Upper limit of 95% CI	20.3	22.9	30.9	16.5	35.1	20.5	13.6	31.1	31.9
OR Quartile 4	7.19	6.19	6.80	7.37	4.85	8.17	5.10	3.86	9.52
p Value	3.3E-4	0.0025	6.3E-4	3.2E-4	0.013	3.2E-4	0.0030	0.038	1.6E-4
Lower limit of 95% CI	2.45	1.90	2.26	2.48	1.39	2.61	1.74	1.08	2.95
Upper limit of 95% CI	21.1	20.2	20.4	21.8	16.9	25.6	15.0	13.8	30.7

[0242] Table 14.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	7.94	12.2	8.73	11.4	8.89	12.2
Average	10.6	15.9	11.3	15.3	11.3	15.7
Stdev	6.93	11.5	7.58	12.1	7.52	12.4

p (t-test)		0.012		0.094		0.071
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	30.8	38.9	38.9	37.2	38.9	37.2
n (Patient)	61	23	68	16	69	15

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.00	11.4	9.75	10.0	9.66	10.5
Average	11.9	13.2	12.1	12.2	12.1	12.4
Stdev	8.56	10.0	8.54	10.4	8.49	10.9
p (t-test)		0.62		0.99		0.91
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	67	14	69	12	70	11

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.23	10.7	9.56	14.2	9.56	14.2
Average	11.1	15.9	11.6	15.8	11.6	15.8
Stdev	7.07	11.9	7.66	12.9	7.66	12.9
p (t-test)		0.040		0.14		0.14
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	37.2	38.9	38.9	36.8	38.9	36.8
n (Patient)	60	17	67	10	67	10

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	0.54	0.60	0.58	0.49	0.54	0.59	0.49	0.54
SE	0.070	0.087	0.081	0.082	0.091	0.10	0.084	0.095	0.10
p Value	0.039	0.63	0.22	0.31	0.88	0.65	0.29	0.89	0.65
nCohort Non-persistent	61	67	60	68	69	67	69	70	67
nCohort Persistent	23	14	17	16	12	10	15	11	10
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	83%	79%	76%	75%	75%	60%	73%	73%	60%
Specificity	28%	25%	25%	25%	25%	22%	25%	24%	22%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	65%	57%	59%	62%	50%	60%	67%	55%	60%
Specificity	56%	51%	52%	53%	49%	51%	54%	50%	51%
Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	39%	36%	41%	38%	25%	50%	40%	27%	50%
Specificity	80%	76%	78%	78%	74%	78%	78%	74%	78%
OR Quartile 2	1.84	1.25	1.08	1.00	0.981	0.433	0.899	0.855	0.433
p Value	0.33	0.76	0.90	1.0	0.98	0.24	0.87	0.83	0.24
Lower limit of 95% CI	0.545	0.310	0.306	0.284	0.238	0.108	0.253	0.204	0.108
Upper limit of 95% CI	6.18	5.01	3.83	3.52	4.04	1.74	3.20	3.59	1.74
OR Quartile 3	2.36	1.37	1.53	1.88	0.971	1.55	2.31	1.20	1.55
p Value	0.091	0.59	0.45	0.27	0.96	0.53	0.16	0.78	0.53
Lower limit of 95% CI	0.872	0.430	0.513	0.613	0.285	0.400	0.715	0.335	0.400
Upper limit of 95% CI	6.39	4.39	4.54	5.74	3.31	5.98	7.47	4.30	5.98
OR Quartile 4	2.62	1.77	2.53	2.12	0.944	3.47	2.40	1.08	3.47
p Value	0.071	0.36	0.11	0.21	0.94	0.075	0.15	0.91	0.075
Lower limit of 95% CI	0.920	0.518	0.806	0.662	0.230	0.884	0.737	0.259	0.884
Upper limit of 95% CI	7.49	6.05	7.95	6.78	3.88	13.6	7.82	4.53	13.6

[0243] Table 14.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by

serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.17	11.5	8.89	10.5	8.94	11.4
Average	10.7	15.5	11.4	14.8	11.3	15.1
Stdev	6.97	11.4	7.61	11.9	7.56	12.2
p (t-test)		0.021		0.14		0.12
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	30.8	38.9	38.9	37.2	38.9	37.2
n (Patient)	60	24	67	17	68	16

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.00	11.4	9.75	10.0	9.66	10.5
Average	11.9	13.2	12.1	12.2	12.1	12.4
Stdev	8.56	10.0	8.54	10.4	8.49	10.9
p (t-test)		0.62		0.99		0.91
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	67	14	69	12	70	11

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.23	10.7	9.56	14.2	9.56	14.2
Average	10.7	16.5	11.3	16.8	11.3	16.8
Stdev	6.27	12.5	7.05	13.6	7.05	13.6
p (t-test)		0.0094		0.038		0.038
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	38.9	37.2	38.9	37.2
n (Patient)	58	19	65	12	65	12

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.63	0.54	0.61	0.56	0.49	0.56	0.57	0.49	0.56
SE	0.070	0.087	0.077	0.080	0.091	0.093	0.082	0.095	0.093
p Value	0.063	0.63	0.15	0.42	0.88	0.49	0.41	0.89	0.49
nCohort Non-persistent	60	67	58	67	69	65	68	70	65
nCohort Persistent	24	14	19	17	12	12	16	11	12
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	83%	79%	79%	76%	75%	67%	75%	73%	67%
Specificity	28%	25%	26%	25%	25%	23%	25%	24%	23%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	62%	57%	58%	59%	50%	58%	62%	55%	58%
Specificity	55%	51%	52%	52%	49%	51%	53%	50%	51%
Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	38%	36%	42%	35%	25%	50%	38%	27%	50%
Specificity	80%	76%	79%	78%	74%	78%	78%	74%	78%
OR Quartile 2	1.98	1.25	1.31	1.10	0.981	0.600	1.00	0.855	0.600
p Value	0.27	0.76	0.67	0.88	0.98	0.45	1.0	0.83	0.45
Lower limit of 95% CI	0.589	0.310	0.375	0.317	0.238	0.158	0.284	0.204	0.158
Upper limit of 95% CI	6.64	5.01	4.56	3.85	4.04	2.27	3.52	3.59	2.27
OR Quartile 3	2.04	1.37	1.47	1.56	0.971	1.44	1.88	1.20	1.44

p Value	0.15	0.59	0.47	0.42	0.96	0.56	0.27	0.78	0.56
Lower limit of 95% CI	0.772	0.430	0.517	0.532	0.285	0.415	0.613	0.335	0.415
Upper limit of 95% CI	5.38	4.39	4.19	4.59	3.31	5.02	5.74	4.30	5.02
OR Quartile 4	2.40	1.77	2.79	1.89	0.944	3.64	2.12	1.08	3.64
p Value	0.099	0.36	0.070	0.28	0.94	0.047	0.21	0.91	0.047
Lower limit of 95% CI	0.848	0.518	0.918	0.600	0.230	1.02	0.662	0.259	1.02
Upper limit of 95% CI	6.80	6.05	8.46	5.96	3.88	13.1	6.78	4.53	13.1

[0244] Table 14.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.41	10.7	8.73	10.6	8.89	10.7
Average	10.8	15.0	11.4	14.6	11.4	14.9
Stdev	6.95	11.4	7.67	11.6	7.61	11.9
p (t-test)		0.043		0.17		0.13
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	30.8	38.9	38.9	37.2	38.9	37.2
n (Patient)	59	25	66	18	67	17

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.37	10.5	9.75	10.0	9.66	10.5
Average	12.0	12.5	12.1	12.2	12.1	12.4
Stdev	8.55	10.0	8.54	10.4	8.49	10.9
p (t-test)		0.86		0.99		0.91
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	66	15	69	12	70	11

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.56	10.3	9.56	10.3	9.28	10.7
Average	10.9	15.8	11.4	15.4	11.3	16.4
Stdev	6.23	12.6	7.08	13.2	7.11	13.2
p (t-test)		0.024		0.12		0.050
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	38.9	37.2	38.9	37.2
n (Patient)	57	20	63	14	64	13

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.50	0.58	0.57	0.49	0.52	0.57	0.49	0.57
SE	0.069	0.083	0.076	0.078	0.091	0.087	0.080	0.095	0.090
p Value	0.14	0.96	0.32	0.38	0.88	0.77	0.37	0.89	0.45
n Cohort Non-persistent	59	66	57	66	69	63	67	70	64
n Cohort Persistent	25	15	20	18	12	14	17	11	13

Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	80%	73%	75%	78%	75%	64%	76%	73%	69%
Specificity	27%	24%	25%	26%	25%	22%	25%	24%	23%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	60%	53%	55%	61%	50%	57%	65%	55%	62%
Specificity	54%	50%	51%	53%	49%	51%	54%	50%	52%
Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	36%	33%	40%	33%	25%	43%	35%	27%	46%
Specificity	80%	76%	79%	77%	74%	78%	78%	74%	78%
OR Quartile 2	1.49	0.880	0.977	1.21	0.981	0.514	1.10	0.855	0.689
p Value	0.49	0.84	0.97	0.76	0.98	0.29	0.88	0.83	0.58
Lower limit of 95% CI	0.478	0.246	0.301	0.351	0.238	0.148	0.317	0.204	0.185
Upper limit of 95% CI	4.63	3.15	3.17	4.20	4.04	1.78	3.85	3.59	2.56
OR Quartile 3	1.78	1.14	1.27	1.77	0.971	1.38	2.13	1.20	1.70
p Value	0.24	0.82	0.65	0.29	0.96	0.59	0.18	0.78	0.39
Lower limit of 95% CI	0.688	0.372	0.455	0.612	0.285	0.428	0.705	0.335	0.503
Upper limit of 95% CI	4.60	3.51	3.52	5.14	3.31	4.43	6.43	4.30	5.77
OR Quartile 4	2.20	1.56	2.50	1.70	0.944	2.62	1.89	1.08	3.06
p Value	0.13	0.47	0.10	0.36	0.94	0.12	0.28	0.91	0.077
Lower limit of 95% CI	0.784	0.465	0.834	0.546	0.230	0.780	0.600	0.259	0.885
Upper limit of 95% CI	6.19	5.25	7.50	5.30	3.88	8.84	5.96	4.53	10.6

[0245] Table 14.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.41	10.7	8.56	10.7	8.73	11.5
Average	10.8	15.0	11.2	15.0	11.2	15.3
Stdev	6.95	11.4	7.60	11.4	7.55	11.7
p (t-test)		0.043		0.094		0.074
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	30.8	38.9	38.9	37.2	38.9	37.2
n (Patient)	59	25	65	19	66	18

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.37	10.5	9.37	10.5	9.56	11.4
Average	12.0	12.5	12.0	13.0	11.9	13.2
Stdev	8.55	10.0	8.51	10.4	8.45	10.8
p (t-test)		0.86		0.71		0.64
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	66	15	68	13	69	12

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.56	10.3	9.28	10.7	9.00	14.6
Average	10.9	15.8	11.3	15.9	11.1	16.8
Stdev	6.23	12.6	7.00	12.8	7.02	12.7

p (t-test)		0.024		0.060		0.023
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	38.9	37.2	38.9	37.2
n (Patient)	57	20	62	15	63	14

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.50	0.58	0.59	0.52	0.55	0.60	0.52	0.60
SE	0.069	0.083	0.076	0.077	0.089	0.085	0.078	0.092	0.087
p Value	0.14	0.96	0.32	0.23	0.82	0.53	0.22	0.80	0.27
nCohort Non-persistent	59	66	57	65	68	62	66	69	63
nCohort Persistent	25	15	20	19	13	15	18	12	14
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	80%	73%	75%	79%	77%	67%	78%	75%	71%
Specificity	27%	24%	25%	26%	25%	23%	26%	25%	24%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	60%	53%	55%	63%	54%	60%	67%	58%	64%
Specificity	54%	50%	51%	54%	50%	52%	55%	51%	52%
Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	36%	33%	40%	37%	31%	47%	39%	33%	50%
Specificity	80%	76%	79%	78%	75%	79%	79%	75%	79%
OR Quartile 2	1.49	0.880	0.977	1.33	1.11	0.583	1.21	0.981	0.781
p Value	0.49	0.84	0.97	0.65	0.88	0.39	0.76	0.98	0.71
Lower limit of 95% CI	0.478	0.246	0.301	0.387	0.273	0.171	0.351	0.238	0.214
Upper limit of 95% CI	4.63	3.15	3.17	4.56	4.52	1.99	4.20	4.04	2.86
OR Quartile 3	1.78	1.14	1.27	2.00	1.17	1.60	2.40	1.44	1.98
p Value	0.24	0.82	0.65	0.20	0.80	0.42	0.12	0.56	0.26
Lower limit of 95% CI	0.688	0.372	0.455	0.698	0.355	0.508	0.804	0.417	0.596
Upper limit of 95% CI	4.60	3.51	3.52	5.73	3.83	5.04	7.16	4.98	6.57
OR Quartile 4	2.20	1.56	2.50	2.12	1.33	3.30	2.36	1.53	3.85
p Value	0.13	0.47	0.10	0.18	0.66	0.048	0.13	0.53	0.029
Lower limit of 95% CI	0.784	0.465	0.834	0.705	0.364	1.01	0.774	0.409	1.14
Upper limit of 95% CI	6.19	5.25	7.50	6.41	4.89	10.8	7.22	5.72	12.9

[0246] Table 14.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.56	10.5	8.73	10.2	8.73	10.6
Average	11.0	14.4	11.4	13.9	11.3	14.5
Stdev	7.01	11.2	7.72	10.9	7.62	11.3
p (t-test)		0.096		0.24		0.16
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	30.8	38.9	38.9	37.2	38.9	37.2
n (Patient)	57	27	62	22	64	20

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.37	10.5	9.37	10.5	9.56	11.4
Average	12.0	12.5	12.0	13.0	11.9	13.2
Stdev	8.55	10.0	8.51	10.4	8.45	10.8

p (t-test)		0.86		0.71		0.64
Min	1.53	1.32	1.53	1.32	1.53	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	66	15	68	13	69	12

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	9.23	10.7	9.56	10.3	9.23	10.7
Average	10.8	15.7	11.3	14.8	11.2	15.5
Sdev	6.29	12.3	7.15	11.9	7.18	11.9
p (t-test)		0.027		0.13		0.064
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	38.9	37.2	38.9	37.2
n (Patient)	56	21	59	18	60	17

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.57	0.50	0.58	0.55	0.52	0.55	0.56	0.52	0.58
SE	0.068	0.083	0.075	0.073	0.089	0.079	0.075	0.092	0.081
p Value	0.29	0.96	0.27	0.47	0.82	0.56	0.40	0.80	0.31
nCohort Non-persistent	57	66	56	62	68	59	64	69	60
nCohort Persistent	27	15	21	22	13	18	20	12	17
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	78%	73%	76%	77%	77%	72%	75%	75%	76%
Specificity	26%	24%	25%	26%	25%	24%	25%	25%	25%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	56%	53%	57%	55%	54%	56%	60%	58%	59%
Specificity	53%	50%	52%	52%	50%	51%	53%	51%	52%
Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	33%	33%	38%	32%	31%	39%	35%	33%	41%
Specificity	79%	76%	79%	77%	75%	78%	78%	75%	78%
OR Quartile 2	1.25	0.880	1.07	1.18	1.11	0.809	1.00	0.981	1.08
p Value	0.69	0.84	0.91	0.77	0.88	0.73	1.0	0.98	0.90
Lower limit of 95% CI	0.424	0.246	0.330	0.375	0.273	0.245	0.314	0.238	0.306
Upper limit of 95% CI	3.69	3.15	3.44	3.73	4.52	2.67	3.19	4.04	3.83
OR Quartile 3	1.39	1.14	1.43	1.28	1.17	1.29	1.70	1.44	1.53
p Value	0.48	0.82	0.49	0.62	0.80	0.63	0.31	0.56	0.45
Lower limit of 95% CI	0.553	0.372	0.521	0.482	0.355	0.448	0.613	0.417	0.513
Upper limit of 95% CI	3.49	3.51	3.94	3.40	3.83	3.73	4.72	4.98	4.54
OR Quartile 4	1.88	1.56	2.26	1.60	1.33	2.25	1.92	1.53	2.53
p Value	0.23	0.47	0.14	0.39	0.66	0.16	0.24	0.53	0.11
Lower limit of 95% CI	0.674	0.465	0.760	0.545	0.364	0.727	0.644	0.409	0.806
Upper limit of 95% CI	5.21	5.25	6.70	4.70	4.89	6.97	5.74	5.72	7.95

[0247] Example 15. Use of C-C motif chemokine 16 for evaluating renal status in patients admitted to the ICU: Persistent at RIFLE I or F

[0248] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. C-C motif chemokine 16 is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0249] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output. Two cohorts are defined to represent a “persistent” and a “non-persistent” population. “Persistent” indicates those patients whose minimum RIFLE stage during a period of 24, 48 or 72 hours is injury (I) or failure (F) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. “Non-persistent” indicates those patients who are not persistent at injury (I) or failure (F) and whose minimum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0) or risk of injury (R) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. If a patient dies after injury (I) or failure (F) or is placed on renal replacement therapy (RRT) at any time from sample collection to 24, 48, 72, 96 or 168 hours after sample collection, the patient is considered “persistent”.

[0250] The ability to distinguish the “persistent” and “non-persistent” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0251] Table 15.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0100	0.0299	0.00924	0.0411	0.0100	0.0352
Average	0.0164	0.108	0.0204	0.162	0.0221	0.182
Stdev	0.0191	0.442	0.0311	0.568	0.0317	0.615
p (t-test)		0.20		0.065		0.046
Min	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6	1.60E-5
Max	0.0865	2.98	0.151	2.98	0.151	2.98
n (Patient)	38	45	56	27	60	23

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0108	0.0460	0.0133	0.0329	0.0146	0.0265
Average	0.0193	0.190	0.0239	0.211	0.0312	0.216
Stdev	0.0233	0.613	0.0316	0.676	0.0566	0.737
p (t-test)		0.038		0.032		0.046
Min	4.13E-6	1.26E-5	4.13E-6	1.26E-5	4.13E-6	1.26E-5
Max	0.106	2.98	0.151	2.98	0.399	2.98
n (Patient)	57	23	61	19	64	16

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0142	0.0170	0.0153	0.0170	0.0153	0.0170
Average	0.0264	0.104	0.0264	0.141	0.0264	0.149
Stdev	0.0352	0.453	0.0342	0.550	0.0337	0.570
p (t-test)		0.32		0.15		0.13
Min	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	35	43	49	29	51	27

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.65	0.75	0.54	0.76	0.69	0.56	0.75	0.63	0.56
SE	0.060	0.065	0.066	0.060	0.074	0.068	0.065	0.082	0.069
p Value	0.0094	1.3E-4	0.50	2.1E-5	0.0086	0.38	1.6E-4	0.12	0.43
nCohort Non-persistent	38	57	35	56	61	49	60	64	51
nCohort Persistent	45	23	43	27	19	29	23	16	27
Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	76%	91%	72%	93%	89%	76%	96%	88%	74%
Specificity	24%	32%	20%	32%	30%	24%	32%	28%	24%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	62%	74%	53%	78%	74%	52%	78%	69%	52%
Specificity	63%	60%	54%	62%	57%	51%	60%	55%	51%
Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	38%	52%	30%	48%	47%	34%	43%	38%	33%
Specificity	87%	86%	77%	84%	82%	78%	80%	78%	76%
OR Quartile 2	0.959	4.85	0.646	5.92	3.56	1.02	10.2	2.74	0.879
p Value	0.94	0.047	0.42	0.024	0.11	0.97	0.028	0.21	0.81
Lower limit of 95% CI	0.349	1.02	0.223	1.26	0.744	0.349	1.28	0.565	0.299
Upper limit of 95% CI	2.64	22.9	1.87	27.8	17.0	2.98	81.3	13.3	2.58
OR Quartile 3	2.82	4.19	1.37	5.83	3.77	1.12	5.40	2.66	1.12
p Value	0.023	0.0087	0.50	0.0011	0.023	0.81	0.0031	0.10	0.81
Lower limit of 95% CI	1.16	1.44	0.558	2.03	1.21	0.445	1.77	0.827	0.440
Upper limit of 95% CI	6.90	12.2	3.34	16.8	11.8	2.80	16.5	8.52	2.85
OR Quartile 4	4.01	6.68	1.46	4.85	4.09	1.82	3.08	2.14	1.62
p Value	0.015	7.8E-4	0.47	0.0029	0.013	0.25	0.034	0.20	0.36
Lower limit of 95% CI	1.31	2.21	0.526	1.72	1.35	0.657	1.09	0.663	0.581
Upper limit of 95% CI	12.2	20.2	4.07	13.7	12.4	5.03	8.70	6.92	4.55

[0252] Table 15.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0137	0.0182	0.0100	0.0329	0.0112	0.0305
Average	0.0175	0.0939	0.0209	0.135	0.0228	0.147
Stdev	0.0194	0.408	0.0322	0.515	0.0328	0.549
p (t-test)		0.31		0.12		0.099
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.0865	2.98	0.151	2.98	0.151	2.98
n (Patient)	30	53	50	33	54	29

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0133	0.0305	0.0137	0.0302	0.0146	0.0262
Average	0.0199	0.163	0.0245	0.184	0.0316	0.195
Stdev	0.0238	0.568	0.0322	0.630	0.0575	0.695
p (t-test)		0.069		0.056		0.068
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	4.13E-6	1.26E-5
Max	0.106	2.98	0.151	2.98	0.399	2.98
n (Patient)	53	27	58	22	62	18

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0142	0.0170	0.0147	0.0189	0.0147	0.0189
Average	0.0280	0.0933	0.0268	0.124	0.0268	0.130
Stdev	0.0374	0.425	0.0354	0.509	0.0349	0.524
p (t-test)		0.41		0.21		0.19
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	29	49	44	34	46	32

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.69	0.52	0.71	0.65	0.55	0.69	0.62	0.55
SE	0.063	0.065	0.068	0.060	0.072	0.066	0.063	0.078	0.067
p Value	0.10	0.0034	0.78	5.5E-4	0.038	0.43	0.0032	0.13	0.48
nCohort Non-persistent	30	53	29	50	58	44	54	62	46
nCohort Persistent	53	27	49	33	22	34	29	18	32
Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	75%	89%	71%	91%	86%	76%	93%	89%	75%
Specificity	23%	32%	17%	34%	29%	25%	33%	29%	24%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	57%	67%	53%	70%	68%	53%	69%	67%	53%
Specificity	60%	58%	55%	62%	57%	52%	59%	55%	52%
Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	34%	44%	29%	42%	41%	32%	38%	33%	31%
Specificity	87%	85%	76%	84%	81%	77%	80%	77%	76%
OR Quartile 2	0.936	3.78	0.521	5.15	2.63	1.08	6.75	3.27	0.943
p Value	0.90	0.050	0.26	0.015	0.16	0.88	0.015	0.14	0.91
Lower limit of 95% CI	0.327	0.997	0.166	1.37	0.686	0.381	1.44	0.682	0.330
Upper limit of 95% CI	2.68	14.3	1.64	19.3	10.1	3.08	31.6	15.7	2.69
OR Quartile 3	1.96	2.82	1.39	3.75	2.83	1.23	3.23	2.43	1.24
p Value	0.15	0.036	0.48	0.0057	0.049	0.65	0.016	0.11	0.65
Lower limit of 95% CI	0.787	1.07	0.553	1.47	1.00	0.503	1.24	0.808	0.501
Upper limit of 95% CI	4.86	7.43	3.50	9.57	7.98	3.02	8.41	7.30	3.05
OR Quartile 4	3.34	4.50	1.26	3.87	2.96	1.63	2.39	1.71	1.45
p Value	0.048	0.0058	0.67	0.0096	0.048	0.34	0.088	0.36	0.47
Lower limit of 95% CI	1.01	1.55	0.439	1.39	1.01	0.594	0.878	0.545	0.527
Upper limit of 95% CI	11.1	13.1	3.60	10.8	8.66	4.45	6.50	5.40	3.97

[0253] Table 15.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0142	0.0177	0.0112	0.0305	0.0124	0.0299
Average	0.0179	0.0923	0.0216	0.128	0.0235	0.138
Stdev	0.0197	0.405	0.0327	0.500	0.0332	0.532
p (t-test)		0.33		0.15		0.12
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.0865	2.98	0.151	2.98	0.151	2.98
n (Patient)	29	54	48	35	52	31

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0137	0.0302	0.0142	0.0299	0.0151	0.0225
Average	0.0202	0.158	0.0248	0.176	0.0320	0.185
Stdev	0.0240	0.558	0.0324	0.616	0.0579	0.677
p (t-test)		0.079		0.066		0.081
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	4.13E-6	1.26E-5
Max	0.106	2.98	0.151	2.98	0.399	2.98
n (Patient)	52	28	57	23	61	19

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0142	0.0170	0.0153	0.0170	0.0153	0.0170
Average	0.0280	0.0933	0.0274	0.120	0.0274	0.126
Stdev	0.0374	0.425	0.0356	0.502	0.0351	0.517
p (t-test)		0.41		0.23		0.21
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	29	49	43	35	45	33

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.68	0.52	0.68	0.64	0.54	0.66	0.60	0.53
SE	0.064	0.065	0.068	0.060	0.071	0.066	0.064	0.077	0.067
p Value	0.13	0.0060	0.78	0.0029	0.057	0.57	0.013	0.17	0.63
nCohort Non-persistent	29	52	29	48	57	43	52	61	45
nCohort Persistent	54	28	49	35	23	35	31	19	33
Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	76%	89%	71%	89%	87%	74%	90%	89%	73%
Specificity	24%	33%	17%	33%	30%	23%	33%	30%	22%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	56%	64%	53%	66%	65%	51%	65%	63%	52%
Specificity	59%	58%	55%	60%	56%	51%	58%	54%	51%
Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	33%	43%	29%	40%	39%	31%	35%	32%	30%
Specificity	86%	85%	76%	83%	81%	77%	79%	77%	76%
OR Quartile 2	1.00	4.05	0.521	3.88	2.83	0.875	4.53	3.56	0.762
p Value	0.99	0.039	0.26	0.027	0.13	0.80	0.025	0.11	0.61
Lower limit of 95% CI	0.349	1.07	0.166	1.16	0.742	0.310	1.21	0.744	0.269
Upper limit of 95% CI	2.88	15.3	1.64	12.9	10.8	2.47	17.0	17.0	2.15
OR Quartile 3	1.77	2.45	1.39	2.93	2.40	1.11	2.48	2.02	1.11
p Value	0.22	0.064	0.48	0.020	0.088	0.82	0.053	0.19	0.82
Lower limit of 95% CI	0.710	0.950	0.553	1.18	0.879	0.454	0.989	0.700	0.452
Upper limit of 95% CI	4.41	6.34	3.50	7.24	6.56	2.71	6.21	5.83	2.73
OR Quartile 4	3.12	4.12	1.26	3.33	2.69	1.51	2.05	1.55	1.34
p Value	0.062	0.0089	0.67	0.020	0.069	0.42	0.16	0.45	0.56
Lower limit of 95% CI	0.944	1.43	0.439	1.21	0.927	0.554	0.760	0.497	0.491

Upper limit of 95% CI	10.4	11.9	3.60	9.21	7.80	4.13	5.53	4.83	3.68
-----------------------	------	------	------	------	------	------	------	------	------

[0254] Table 15.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0142	0.0177	0.0108	0.0302	0.0100	0.0305
Average	0.0155	0.0908	0.0208	0.120	0.0213	0.128
Stdev	0.0151	0.397	0.0322	0.481	0.0328	0.500
p (t-test)		0.33		0.17		0.14
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.0518	2.98	0.151	2.98	0.151	2.98
n (Patient)	27	56	45	38	48	35

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0125	0.0302	0.0142	0.0299	0.0146	0.0262
Average	0.0199	0.149	0.0247	0.164	0.0318	0.164
Stdev	0.0243	0.540	0.0329	0.591	0.0593	0.629
p (t-test)		0.094		0.083		0.11
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	4.13E-6	1.26E-5
Max	0.106	2.98	0.151	2.98	0.399	2.98
n (Patient)	50	30	55	25	58	22

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0142	0.0170	0.0153	0.0170	0.0147	0.0189
Average	0.0264	0.0916	0.0263	0.112	0.0257	0.115
Stdev	0.0370	0.416	0.0357	0.475	0.0354	0.481
p (t-test)		0.42		0.27		0.25
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	27	51	39	39	40	38

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.68	0.54	0.68	0.64	0.56	0.70	0.62	0.57
SE	0.064	0.063	0.068	0.059	0.069	0.065	0.059	0.073	0.065
p Value	0.061	0.0041	0.55	0.0020	0.045	0.37	8.8E-4	0.089	0.27
nCohort Non-persistent	27	50	27	45	55	39	48	58	40
nCohort Persistent	56	30	51	38	25	39	35	22	38
Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	77%	90%	73%	89%	88%	77%	91%	91%	76%
Specificity	26%	34%	19%	36%	31%	26%	35%	31%	25%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	55%	63%	53%	63%	64%	51%	66%	64%	53%
Specificity	59%	58%	56%	60%	56%	51%	60%	55%	52%

Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	34%	40%	29%	39%	36%	33%	40%	32%	34%
Specificity	89%	84%	78%	84%	80%	79%	83%	78%	80%
OR Quartile 2	1.16	4.64	0.601	4.69	3.28	1.15	5.85	4.50	1.07
p Value	0.79	0.024	0.38	0.012	0.081	0.79	0.0089	0.058	0.89
Lower limit of 95% CI	0.401	1.23	0.190	1.41	0.863	0.408	1.56	0.949	0.381
Upper limit of 95% CI	3.34	17.5	1.90	15.6	12.5	3.24	22.0	21.3	3.02
OR Quartile 3	1.80	2.39	1.41	2.57	2.30	1.11	2.93	2.15	1.23
p Value	0.21	0.067	0.48	0.037	0.095	0.82	0.020	0.14	0.65
Lower limit of 95% CI	0.711	0.940	0.551	1.06	0.866	0.456	1.18	0.784	0.505
Upper limit of 95% CI	4.58	6.05	3.59	6.25	6.09	2.69	7.24	5.92	2.99
OR Quartile 4	4.11	3.50	1.46	3.54	2.25	1.94	3.33	1.62	2.08
p Value	0.036	0.020	0.50	0.017	0.13	0.21	0.020	0.39	0.16
Lower limit of 95% CI	1.10	1.22	0.491	1.26	0.787	0.696	1.21	0.544	0.747
Upper limit of 95% CI	15.4	10.0	4.33	9.98	6.43	5.39	9.21	4.80	5.79

[0255] Table 15.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0142	0.0177	0.0108	0.0262	0.0100	0.0299
Average	0.0159	0.0880	0.0213	0.115	0.0218	0.122
Stdev	0.0154	0.391	0.0328	0.469	0.0334	0.487
p (t-test)		0.36		0.20		0.17
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.0518	2.98	0.151	2.98	0.151	2.98
n (Patient)	25	58	43	40	46	37

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0108	0.0305	0.0129	0.0302	0.0129	0.0302
Average	0.0185	0.147	0.0236	0.161	0.0243	0.171
Stdev	0.0225	0.531	0.0321	0.580	0.0327	0.603
p (t-test)		0.094		0.084		0.071
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	4.13E-6	1.26E-5
Max	0.106	2.98	0.151	2.98	0.151	2.98
n (Patient)	49	31	54	26	56	24

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.0147	0.0163	0.0157	0.0151	0.0153	0.0170
Average	0.0274	0.0898	0.0277	0.106	0.0264	0.112
Stdev	0.0373	0.413	0.0361	0.464	0.0356	0.475
p (t-test)		0.45		0.31		0.27
Min	6.68E-6	4.13E-6	6.68E-6	4.13E-6	6.68E-6	4.13E-6
Max	0.151	2.98	0.151	2.98	0.151	2.98
n (Patient)	26	52	37	41	39	39

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.70	0.52	0.67	0.66	0.52	0.68	0.67	0.55
SE	0.066	0.062	0.069	0.060	0.067	0.066	0.060	0.069	0.065
p Value	0.11	0.0011	0.80	0.0055	0.018	0.80	0.0028	0.013	0.44
nCohort Non-persistent	25	49	26	43	54	37	46	56	39
nCohort Persistent	58	31	52	40	26	41	37	24	39
Cutoff Quartile 2	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202	0.00202	0.00161	0.00202
Sensitivity	76%	90%	71%	88%	88%	73%	89%	92%	74%
Specificity	24%	35%	15%	35%	31%	22%	35%	32%	23%
Cutoff Quartile 3	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155	0.0157	0.0165	0.0155
Sensitivity	55%	65%	52%	62%	65%	49%	65%	67%	51%
Specificity	60%	59%	54%	60%	57%	49%	61%	57%	51%
Cutoff Quartile 4	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427	0.0427	0.0435	0.0427
Sensitivity	33%	42%	29%	38%	38%	32%	38%	38%	33%
Specificity	88%	86%	77%	84%	81%	78%	83%	80%	79%
OR Quartile 2	0.992	4.96	0.448	3.75	3.52	0.752	4.40	5.21	0.870
p Value	0.99	0.018	0.20	0.022	0.064	0.59	0.016	0.037	0.79
Lower limit of 95% CI	0.331	1.31	0.132	1.21	0.929	0.265	1.32	1.10	0.309
Upper limit of 95% CI	2.97	18.7	1.52	11.6	13.4	2.14	14.6	24.6	2.45
OR Quartile 3	1.85	2.64	1.26	2.55	2.55	0.902	2.87	2.67	1.11
p Value	0.21	0.041	0.63	0.038	0.059	0.82	0.021	0.055	0.82
Lower limit of 95% CI	0.712	1.04	0.490	1.05	0.964	0.371	1.17	0.981	0.456
Upper limit of 95% CI	4.79	6.69	3.24	6.18	6.73	2.20	7.05	7.25	2.69
OR Quartile 4	3.57	4.33	1.35	3.09	2.75	1.68	2.89	2.45	1.94
p Value	0.060	0.0073	0.59	0.032	0.058	0.32	0.040	0.096	0.21
Lower limit of 95% CI	0.950	1.48	0.453	1.10	0.965	0.605	1.05	0.853	0.696
Upper limit of 95% CI	13.4	12.7	4.03	8.66	7.83	4.68	7.95	7.06	5.39

[0256] Table 15.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	7.72	10.6	8.48	10.6	8.56	10.5
Average	10.3	13.8	10.8	14.6	10.9	15.2
Stdev	7.18	9.68	6.82	11.3	6.79	12.0
p (t-test)		0.067		0.059		0.040
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	41	43	56	28	61	23

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.48	12.0	9.00	10.6	9.75	10.0
Average	11.6	13.4	12.1	12.3	12.3	11.6
Stdev	8.72	8.96	8.75	9.05	8.71	9.21
p (t-test)		0.43		0.93		0.78
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	58	23	61	20	63	18

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.41	10.5	8.89	11.3	8.89	11.3
Average	11.3	13.0	11.2	13.8	11.2	14.0
Stdev	8.07	8.97	7.59	9.90	7.48	10.2
p (t-test)		0.37		0.20		0.18
Min	2.64	1.32	1.62	1.32	1.62	1.32
Max	37.2	38.9	37.2	38.9	37.2	38.9
n (Patient)	37	40	49	28	51	26

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.58	0.57	0.59	0.52	0.57	0.59	0.49	0.57
SE	0.061	0.072	0.065	0.067	0.075	0.069	0.072	0.078	0.070
p Value	0.043	0.25	0.27	0.21	0.74	0.30	0.23	0.87	0.34
nCohort Non-persistent	41	58	37	56	61	49	61	63	51
nCohort Persistent	43	23	40	28	20	28	23	18	26
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	81%	83%	80%	79%	80%	79%	78%	78%	77%
Specificity	32%	28%	30%	27%	26%	27%	26%	25%	25%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	58%	61%	57%	57%	55%	61%	57%	50%	62%
Specificity	59%	53%	57%	54%	51%	55%	52%	49%	55%
Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	33%	35%	30%	36%	25%	36%	39%	22%	35%
Specificity	83%	78%	78%	80%	74%	80%	80%	73%	78%
OR Quartile 2	2.03	1.81	1.69	1.34	1.42	1.32	1.28	1.19	1.14
p Value	0.17	0.34	0.32	0.59	0.58	0.62	0.67	0.78	0.82
Lower limit of 95% CI	0.739	0.533	0.594	0.456	0.414	0.439	0.408	0.342	0.376
Upper limit of 95% CI	5.58	6.14	4.82	3.95	4.89	3.99	4.02	4.15	3.46
OR Quartile 3	1.96	1.79	1.78	1.54	1.26	1.90	1.43	0.969	1.95
p Value	0.13	0.25	0.21	0.36	0.65	0.18	0.46	0.95	0.18
Lower limit of 95% CI	0.823	0.668	0.720	0.617	0.458	0.738	0.546	0.340	0.743
Upper limit of 95% CI	4.67	4.78	4.38	3.84	3.48	4.88	3.77	2.76	5.11
OR Quartile 4	2.34	1.85	1.55	2.27	0.938	2.17	2.62	0.773	1.93
p Value	0.11	0.26	0.40	0.11	0.91	0.14	0.071	0.68	0.22
Lower limit of 95% CI	0.834	0.642	0.552	0.823	0.293	0.766	0.920	0.223	0.675
Upper limit of 95% CI	6.59	5.31	4.37	6.28	3.00	6.13	7.49	2.68	5.49

[0257] Table 15.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	7.83	10.5	8.78	10.2	9.00	9.91
Average	10.3	13.2	11.1	13.5	11.1	13.8
Stdev	7.46	9.25	6.97	10.7	6.92	11.2
p (t-test)		0.15		0.21		0.18
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	32	52	50	34	55	29

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.48	12.0	9.37	10.5	9.75	10.0
Average	11.6	13.2	12.3	11.8	12.3	11.6
Stdev	8.75	8.88	8.82	8.84	8.78	8.95
p (t-test)		0.46		0.82		0.75
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	54	27	58	23	61	20

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.17	10.6	8.73	12.0	8.73	12.0
Average	10.6	13.2	10.6	14.2	10.7	14.3
Stdev	6.96	9.33	6.57	10.4	6.49	10.6
p (t-test)		0.19		0.071		0.065
Min	2.64	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	30	47	44	33	46	31

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.57	0.58	0.54	0.49	0.58	0.54	0.48	0.58
SE	0.062	0.069	0.066	0.065	0.072	0.066	0.067	0.075	0.067
p Value	0.092	0.32	0.21	0.53	0.90	0.22	0.60	0.81	0.25
nCohort Non-persistent	32	54	30	50	58	44	55	61	46
nCohort Persistent	52	27	47	34	23	33	29	20	31
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	79%	78%	79%	76%	74%	79%	76%	75%	77%
Specificity	31%	26%	30%	26%	24%	27%	25%	25%	26%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	56%	59%	57%	53%	52%	61%	52%	50%	61%
Specificity	59%	54%	60%	52%	50%	57%	51%	49%	57%
Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	31%	37%	30%	32%	26%	36%	34%	25%	35%
Specificity	84%	80%	80%	80%	74%	82%	80%	74%	80%
OR Quartile 2	1.69	1.22	1.59	1.14	0.902	1.39	1.07	0.978	1.21
p Value	0.30	0.72	0.39	0.80	0.85	0.54	0.89	0.97	0.73
Lower limit of 95% CI	0.623	0.411	0.556	0.414	0.298	0.480	0.378	0.304	0.416
Upper limit of 95% CI	4.61	3.65	4.52	3.15	2.73	4.05	3.05	3.15	3.52
OR Quartile 3	1.84	1.69	2.02	1.22	1.09	2.02	1.11	0.968	2.06
p Value	0.18	0.27	0.14	0.66	0.86	0.13	0.82	0.95	0.13
Lower limit of 95% CI	0.755	0.662	0.798	0.509	0.415	0.808	0.452	0.352	0.813
Upper limit of 95% CI	4.50	4.30	5.14	2.92	2.87	5.07	2.73	2.66	5.21
OR Quartile 4	2.40	2.30	1.70	1.91	1.01	2.57	2.11	0.938	2.26
p Value	0.13	0.11	0.34	0.20	0.98	0.076	0.15	0.91	0.12
Lower limit of 95% CI	0.782	0.826	0.570	0.705	0.337	0.905	0.766	0.293	0.803
Upper limit of 95% CI	7.37	6.40	5.05	5.19	3.04	7.30	5.79	3.00	6.37

[0258] Table 15.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	7.72	10.6	8.56	10.5	8.56	10.5
Average	10.1	13.2	11.0	13.6	11.1	13.8
Stdev	7.51	9.17	7.00	10.5	7.02	10.9
p (t-test)		0.12		0.18		0.16
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	31	53	49	35	53	31

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.41	12.1	9.00	10.6	9.37	10.5
Average	11.5	13.3	12.2	11.9	12.2	11.8
Stdev	8.82	8.73	8.88	8.69	8.84	8.77
p (t-test)		0.40		0.90		0.84
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	38.9	37.2	38.9	37.2	38.9	37.2
n (Patient)	53	28	57	24	60	21

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.17	10.6	8.56	11.4	8.56	11.4
Average	10.6	13.2	10.6	14.1	10.7	14.2
Stdev	6.96	9.33	6.65	10.2	6.56	10.5
p (t-test)		0.19		0.078		0.073
Min	2.64	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	30	47	43	34	45	32

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.58	0.58	0.55	0.51	0.59	0.55	0.50	0.58
SE	0.062	0.068	0.066	0.064	0.071	0.066	0.066	0.074	0.067
p Value	0.055	0.23	0.21	0.42	0.93	0.19	0.43	0.98	0.22
nCohort Non-persistent	31	53	30	49	57	43	53	60	45
nCohort Persistent	53	28	47	35	24	34	31	21	32
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	79%	79%	79%	77%	75%	79%	77%	76%	78%
Specificity	32%	26%	30%	27%	25%	28%	26%	25%	27%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	57%	61%	57%	54%	54%	62%	55%	52%	62%
Specificity	61%	55%	60%	53%	51%	58%	53%	50%	58%
Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	30%	39%	30%	31%	29%	35%	32%	29%	34%
Specificity	84%	81%	80%	80%	75%	81%	79%	75%	80%
OR Quartile 2	1.82	1.32	1.59	1.22	0.977	1.49	1.23	1.07	1.30
p Value	0.24	0.62	0.39	0.70	0.97	0.46	0.70	0.91	0.63
Lower limit of 95% CI	0.666	0.443	0.556	0.443	0.324	0.514	0.435	0.334	0.447
Upper limit of 95% CI	4.96	3.91	4.52	3.35	2.94	4.33	3.48	3.41	3.78
OR Quartile 3	2.07	1.87	2.02	1.34	1.22	2.24	1.36	1.10	2.28
p Value	0.12	0.19	0.14	0.51	0.68	0.085	0.50	0.85	0.082
Lower limit of 95% CI	0.836	0.736	0.798	0.562	0.470	0.895	0.559	0.407	0.901
Upper limit of 95% CI	5.10	4.74	5.14	3.20	3.18	5.63	3.31	2.97	5.77
OR Quartile 4	2.25	2.78	1.70	1.79	1.26	2.39	1.82	1.20	2.10
p Value	0.16	0.050	0.34	0.25	0.67	0.10	0.24	0.75	0.16
Lower limit of 95% CI	0.732	0.999	0.570	0.660	0.435	0.842	0.666	0.394	0.746

Upper limit of 95% CI	6.91	7.75	5.05	4.84	3.68	6.76	4.96	3.65	5.88
-----------------------	------	------	------	------	------	------	------	------	------

[0259] Table 15.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	7.83	10.5	8.56	10.5	8.78	10.2
Average	10.3	13.1	11.1	13.3	11.0	13.6
Stdev	7.60	9.14	7.11	10.3	6.99	10.6
p (t-test)		0.16		0.25		0.18
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	30	54	47	37	50	34

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.41	12.1	9.00	10.6	9.00	10.6
Average	11.1	13.9	11.8	12.7	11.7	13.1
Stdev	8.06	9.76	8.23	9.97	8.17	10.2
p (t-test)		0.17		0.67		0.52
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	36.8	38.9	36.8	38.9	36.8	38.9
n (Patient)	51	30	55	26	57	24

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.41	10.5	8.48	10.8	8.56	11.4
Average	10.7	13.0	10.5	14.0	10.5	14.1
Stdev	7.03	9.29	6.59	10.0	6.51	10.1
p (t-test)		0.25		0.069		0.063
Min	2.64	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	29	48	40	37	41	36

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.59	0.57	0.54	0.52	0.59	0.55	0.53	0.59
SE	0.063	0.067	0.067	0.064	0.069	0.065	0.065	0.071	0.065
p Value	0.096	0.18	0.32	0.51	0.81	0.15	0.46	0.66	0.18
nCohort Non-persistent	30	51	29	47	55	40	50	57	41
nCohort Persistent	54	30	48	37	26	37	34	24	36
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	78%	77%	77%	76%	73%	78%	76%	75%	78%
Specificity	30%	25%	28%	26%	24%	28%	26%	25%	27%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	56%	60%	56%	54%	54%	62%	53%	54%	61%
Specificity	60%	55%	59%	53%	51%	60%	52%	51%	59%

Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	30%	40%	29%	30%	31%	35%	32%	33%	36%
Specificity	83%	82%	79%	79%	76%	82%	80%	77%	83%
OR Quartile 2	1.50	1.12	1.28	1.07	0.840	1.38	1.14	0.977	1.28
p Value	0.43	0.83	0.65	0.90	0.75	0.55	0.80	0.97	0.64
Lower limit of 95% CI	0.546	0.391	0.445	0.394	0.289	0.483	0.414	0.324	0.451
Upper limit of 95% CI	4.12	3.23	3.69	2.89	2.44	3.91	3.15	2.94	3.65
OR Quartile 3	1.88	1.83	1.82	1.34	1.21	2.46	1.22	1.22	2.22
p Value	0.17	0.20	0.21	0.51	0.69	0.054	0.66	0.68	0.087
Lower limit of 95% CI	0.757	0.731	0.716	0.564	0.475	0.985	0.509	0.470	0.890
Upper limit of 95% CI	4.64	4.56	4.63	3.17	3.08	6.17	2.92	3.18	5.53
OR Quartile 4	2.11	3.11	1.58	1.57	1.44	2.55	1.91	1.69	2.75
p Value	0.19	0.030	0.41	0.38	0.50	0.083	0.20	0.33	0.062
Lower limit of 95% CI	0.684	1.12	0.529	0.580	0.508	0.886	0.705	0.592	0.951
Upper limit of 95% CI	6.48	8.68	4.71	4.22	4.06	7.36	5.19	4.84	7.93

[0260] Table 15.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	7.83	10.5	8.41	10.5	8.48	10.2
Average	10.3	13.0	11.1	13.2	11.0	13.5
Stdev	7.83	9.00	7.25	10.1	7.12	10.3
p (t-test)		0.18		0.27		0.19
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	28	56	45	39	48	36

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.41	12.1	9.00	10.6	9.00	10.6
Average	11.1	13.9	11.8	12.7	11.7	13.1
Stdev	8.06	9.76	8.23	9.97	8.17	10.2
p (t-test)		0.17		0.67		0.52
Min	1.62	1.32	1.62	1.32	1.62	1.32
Max	36.8	38.9	36.8	38.9	36.8	38.9
n (Patient)	51	30	55	26	57	24

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	8.48	10.4	8.48	10.7	8.48	10.7
Average	10.8	12.9	10.6	13.7	10.5	13.9
Stdev	7.12	9.23	6.74	9.82	6.58	10.0
p (t-test)		0.31		0.11		0.077
Min	2.64	1.32	1.62	1.32	1.62	1.32
Max	30.8	38.9	30.8	38.9	30.8	38.9
n (Patient)	28	49	38	39	40	37

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.59	0.56	0.55	0.52	0.58	0.55	0.53	0.59
SE	0.064	0.067	0.068	0.063	0.069	0.065	0.064	0.071	0.065
p Value	0.083	0.18	0.39	0.43	0.81	0.20	0.39	0.66	0.19
nCohort Non-persistent	28	51	28	45	55	38	48	57	40
nCohort Persistent	56	30	49	39	26	39	36	24	37
Cutoff Quartile 2	6.19	6.19	6.24	6.19	6.19	6.24	6.19	6.19	6.24
Sensitivity	79%	77%	78%	77%	73%	79%	78%	75%	78%
Specificity	32%	25%	29%	27%	24%	29%	27%	25%	28%
Cutoff Quartile 3	9.66	9.75	9.75	9.66	9.75	9.75	9.66	9.75	9.75
Sensitivity	55%	60%	55%	54%	54%	59%	53%	54%	59%
Specificity	61%	55%	57%	53%	51%	58%	52%	51%	57%
Cutoff Quartile 4	16.0	15.9	15.9	16.0	15.9	15.9	16.0	15.9	15.9
Sensitivity	29%	40%	29%	28%	31%	33%	31%	33%	35%
Specificity	82%	82%	79%	78%	76%	82%	79%	77%	82%
OR Quartile 2	1.74	1.12	1.38	1.21	0.840	1.58	1.30	0.977	1.38
p Value	0.29	0.83	0.55	0.70	0.75	0.39	0.61	0.97	0.55
Lower limit of 95% CI	0.628	0.391	0.479	0.448	0.289	0.554	0.473	0.324	0.483
Upper limit of 95% CI	4.81	3.23	3.99	3.28	2.44	4.50	3.57	2.94	3.91
OR Quartile 3	1.92	1.83	1.64	1.33	1.21	1.98	1.21	1.22	1.98
p Value	0.17	0.20	0.30	0.51	0.69	0.14	0.66	0.68	0.14
Lower limit of 95% CI	0.761	0.731	0.641	0.564	0.475	0.798	0.511	0.470	0.801
Upper limit of 95% CI	4.83	4.56	4.17	3.15	3.08	4.89	2.89	3.18	4.92
OR Quartile 4	1.84	3.11	1.47	1.38	1.44	2.21	1.67	1.69	2.55
p Value	0.29	0.030	0.49	0.53	0.50	0.14	0.31	0.33	0.083
Lower limit of 95% CI	0.596	1.12	0.491	0.511	0.508	0.770	0.619	0.592	0.886
Upper limit of 95% CI	5.68	8.68	4.38	3.70	4.06	6.37	4.52	4.84	7.36

[0261] Example 16. Use of Tyrosine-protein kinase receptor UFO for evaluating renal status in patients admitted to the ICU: Persistent at RIFLE F

[0262] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 (± 0.5) and 8 (± 1) hours after contrast administration (if applicable); at 12 (± 1), 24 (± 2), and 48 (± 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Tyrosine-protein kinase receptor UFO is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0263] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output. Two cohorts are defined to represent a “persistent” and a “non-persistent” population. “Persistent” indicates those patients whose minimum RIFLE stage during a period of 24, 48 or 72 hours is failure (F) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. “Non-persistent” indicates those patients who are not persistent at failure (F) and whose minimum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0), risk of injury (R), or injury (I) where the persistence

period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. If a patient dies after failure (F) or is placed on renal replacement therapy (RRT) at any time from sample collection to 24, 48, 72, 96 or 168 hours after sample collection, the patient is considered “persistent”.

[0264] The ability to distinguish the “persistent” and “non-persistent” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0265] Table 16.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.87	1.89	4.87	1.22	4.85	1.16
Average	5.74	2.51	5.59	1.43	5.54	1.35
Stdev	4.27	2.28	4.12	1.09	4.10	1.09
p (t-test)		0.0011		3.5E-4		4.8E-4
Min	0.432	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.53	20.6	4.01	20.6	4.01
n (Patient)	61	22	69	14	70	13

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.83	1.52	4.60	1.45	4.45	1.45
Average	5.45	2.17	5.30	2.25	5.20	2.35
Stdev	4.22	2.35	4.20	2.57	4.18	2.85
p (t-test)		0.0062		0.022		0.051
Min	0.432	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.11	20.6	9.11	20.6	9.11
n (Patient)	66	14	69	11	71	9

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.87	2.78	4.87	1.29	4.87	1.29
Average	5.64	2.97	5.51	1.60	5.51	1.60
Stdev	4.36	2.35	4.19	1.13	4.19	1.13
p (t-test)		0.018		0.0071		0.0071
Min	0.366	0.489	0.366	0.489	0.366	0.489
Max	20.6	9.53	20.6	4.01	20.6	4.01
n (Patient)	61	17	69	9	69	9

Persistence Period Duration (hr)	24	48	72
-------------------------------------	----	----	----

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.22	0.20	0.29	0.12	0.22	0.16	0.11	0.23	0.16
SE	0.063	0.075	0.077	0.061	0.086	0.085	0.062	0.096	0.085
p Value	1.4E-5	7.6E-5	0.0067	5.3E-10	0.0013	7.5E-5	3.0E-10	0.0058	7.5E-5
nCohort Non-persistent	61	66	61	69	69	69	70	71	69
nCohort Persistent	22	14	17	14	11	9	13	9	9
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	50%	43%	53%	29%	45%	22%	23%	44%	22%
Specificity	16%	18%	20%	16%	20%	19%	16%	21%	19%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	23%	14%	18%	7%	18%	0%	8%	22%	0%
Specificity	39%	42%	41%	41%	45%	43%	41%	46%	43%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36
Sensitivity	5%	7%	6%	0%	9%	0%	0%	11%	0%
Specificity	67%	71%	69%	70%	72%	71%	70%	73%	71%
OR Quartile 2	0.196	0.167	0.276	0.0759	0.212	0.0663	0.0559	0.214	0.0663
p Value	0.0030	0.0043	0.027	1.4E-4	0.022	0.0016	8.9E-5	0.035	0.0016
Lower limit of 95% CI	0.0668	0.0487	0.0879	0.0201	0.0564	0.0123	0.0132	0.0511	0.0123
Upper limit of 95% CI	0.575	0.570	0.864	0.286	0.797	0.357	0.237	0.898	0.357
OR Quartile 3	0.191	0.123	0.149	0.0525	0.181	0.0406	0.0589	0.248	0.0406
p Value	0.0038	0.0090	0.0056	0.0057	0.037	0.029	0.0081	0.096	0.029
Lower limit of 95% CI	0.0621	0.0254	0.0387	0.00650	0.0365	0.00227	0.00726	0.0482	0.00227
Upper limit of 95% CI	0.586	0.593	0.572	0.425	0.901	0.726	0.479	1.28	0.726
OR Quartile 4	0.0976	0.190	0.138	0.0778	0.263	0.127	0.0853	0.342	0.127
p Value	0.028	0.12	0.064	0.081	0.22	0.16	0.092	0.33	0.16
Lower limit of 95% CI	0.0122	0.0232	0.0171	0.00443	0.0315	0.00706	0.00485	0.0401	0.00706
Upper limit of 95% CI	0.778	1.56	1.12	1.36	2.20	2.29	1.50	2.92	2.29

[0266] Table 16.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.88	2.19	4.87	1.29	4.87	1.22
Average	5.79	2.79	5.62	2.02	5.58	2.00
Stdev	4.29	2.58	4.14	2.25	4.12	2.32
p (t-test)		0.0017		8.9E-4		0.0013
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.53	20.6	9.11	20.6	9.11
n (Patient)	58	25	66	17	67	16

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.83	1.52	4.60	1.45	4.45	1.45
Average	5.45	2.17	5.30	2.25	5.20	2.35
Stdev	4.22	2.35	4.20	2.57	4.18	2.85
p (t-test)		0.0062		0.022		0.051
Min	0.432	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.11	20.6	9.11	20.6	9.11
n (Patient)	66	14	69	11	71	9

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.88	2.78	4.87	1.29	4.87	1.29
Average	5.77	3.10	5.62	2.25	5.62	2.25
Stdev	4.38	2.67	4.20	2.49	4.20	2.49
p (t-test)		0.011		0.0067		0.0067
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	20.6	9.53	20.6	9.11	20.6	9.11
n (Patient)	57	21	65	13	65	13

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.24	0.20	0.28	0.17	0.22	0.20	0.17	0.23	0.20
SE	0.062	0.075	0.070	0.065	0.086	0.077	0.066	0.096	0.077
p Value	3.7E-5	7.6E-5	0.0021	3.7E-7	0.0013	1.2E-4	5.6E-7	0.0058	1.2E-4
nCohort Non-persistent	58	66	57	66	69	65	67	71	65
nCohort Persistent	25	14	21	17	11	13	16	9	13
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	52%	43%	52%	35%	45%	31%	31%	44%	31%
Specificity	16%	18%	18%	15%	20%	17%	15%	21%	17%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	28%	14%	24%	18%	18%	15%	19%	22%	15%
Specificity	40%	42%	40%	41%	45%	43%	42%	46%	43%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36
Sensitivity	8%	7%	10%	6%	9%	8%	6%	11%	8%
Specificity	67%	71%	68%	70%	72%	71%	70%	73%	71%
OR Quartile 2	0.199	0.167	0.234	0.0974	0.212	0.0905	0.0797	0.214	0.0905
p Value	0.0028	0.0043	0.0093	1.4E-4	0.022	4.6E-4	7.6E-5	0.035	4.6E-4
Lower limit of 95% CI	0.0690	0.0487	0.0783	0.0293	0.0564	0.0236	0.0228	0.0511	0.0236
Upper limit of 95% CI	0.574	0.570	0.700	0.324	0.797	0.347	0.279	0.898	0.347
OR Quartile 3	0.256	0.123	0.211	0.148	0.181	0.138	0.166	0.248	0.138
p Value	0.0087	0.0090	0.0073	0.0053	0.037	0.014	0.0089	0.096	0.014
Lower limit of 95% CI	0.0922	0.0254	0.0679	0.0388	0.0365	0.0282	0.0431	0.0482	0.0282
Upper limit of 95% CI	0.708	0.593	0.658	0.567	0.901	0.671	0.637	1.28	0.671
OR Quartile 4	0.178	0.190	0.228	0.144	0.263	0.202	0.157	0.342	0.202
p Value	0.029	0.12	0.063	0.069	0.22	0.14	0.082	0.33	0.14
Lower limit of 95% CI	0.0381	0.0232	0.0479	0.0178	0.0315	0.0245	0.0194	0.0401	0.0245
Upper limit of 95% CI	0.837	1.56	1.09	1.16	2.20	1.66	1.27	2.92	1.66

[0267] Table 16.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.88	2.32	4.87	1.37	4.87	1.29
Average	5.83	2.81	5.66	2.08	5.61	2.06
Stdev	4.32	2.53	4.16	2.20	4.14	2.26
p (t-test)		0.0014		7.2E-4		0.0010
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.53	20.6	9.11	20.6	9.11
n (Patient)	57	26	65	18	66	17

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.84	1.59	4.60	1.45	4.45	1.45
Average	5.49	2.24	5.30	2.25	5.20	2.35
Stdev	4.24	2.29	4.20	2.57	4.18	2.85
p (t-test)		0.0055		0.022		0.051
Min	0.432	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.11	20.6	9.11	20.6	9.11
n (Patient)	65	15	69	11	71	9

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.02	2.91	4.88	1.59	4.88	1.44
Average	5.82	3.11	5.70	2.37	5.66	2.30
Stdev	4.41	2.60	4.24	2.33	4.22	2.40
p (t-test)		0.0087		0.0045		0.0054
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	20.6	9.53	20.6	9.11	20.6	9.11
n (Patient)	56	22	63	15	64	14

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.24	0.21	0.28	0.18	0.22	0.21	0.18	0.23	0.21
SE	0.061	0.074	0.069	0.064	0.086	0.074	0.065	0.096	0.076
p Value	2.9E-5	8.7E-5	0.0016	4.2E-7	0.0013	1.0E-4	6.8E-7	0.0058	1.1E-4
nCohort Non-persistent	57	65	56	65	69	63	66	71	64
nCohort Persistent	26	15	22	18	11	15	17	9	14
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	54%	47%	55%	39%	45%	40%	35%	44%	36%
Specificity	16%	18%	18%	15%	20%	17%	15%	21%	17%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	27%	13%	23%	17%	18%	13%	18%	22%	14%
Specificity	39%	42%	39%	40%	45%	41%	41%	46%	42%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36
Sensitivity	8%	7%	9%	6%	9%	7%	6%	11%	7%
Specificity	67%	71%	68%	69%	72%	70%	70%	73%	70%
OR Quartile 2	0.219	0.198	0.261	0.116	0.212	0.141	0.0974	0.214	0.115
p Value	0.0045	0.0078	0.015	2.8E-4	0.022	0.0017	1.4E-4	0.035	8.7E-4
Lower limit of 95% CI	0.0766	0.0601	0.0884	0.0362	0.0564	0.0416	0.0293	0.0511	0.0323
Upper limit of 95% CI	0.625	0.653	0.770	0.370	0.797	0.478	0.324	0.898	0.411
OR Quartile 3	0.232	0.109	0.190	0.133	0.181	0.108	0.148	0.248	0.122
p Value	0.0048	0.0057	0.0041	0.0031	0.037	0.0055	0.0053	0.096	0.0088
Lower limit of 95% CI	0.0837	0.0228	0.0613	0.0351	0.0365	0.0225	0.0388	0.0482	0.0251
Upper limit of 95% CI	0.641	0.525	0.590	0.507	0.901	0.520	0.567	1.28	0.589
OR Quartile 4	0.167	0.173	0.211	0.132	0.263	0.165	0.144	0.342	0.182
p Value	0.023	0.10	0.050	0.057	0.22	0.093	0.069	0.33	0.11
Lower limit of 95% CI	0.0356	0.0212	0.0445	0.0165	0.0315	0.0203	0.0178	0.0401	0.0222
Upper limit of 95% CI	0.781	1.41	1.00	1.06	2.20	1.35	1.16	2.92	1.49

[0268] Table 16.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.88	2.32	4.88	1.45	4.87	1.37
Average	5.83	2.81	5.69	2.16	5.64	2.15
Stdev	4.32	2.53	4.18	2.17	4.17	2.23
p (t-test)		0.0014		6.8E-4		9.9E-4
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.53	20.6	9.11	20.6	9.11
n (Patient)	57	26	64	19	65	18

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.84	1.59	4.71	1.82	4.53	1.82
Average	5.49	2.24	5.32	2.36	5.22	2.48
Stdev	4.24	2.29	4.23	2.49	4.21	2.72
p (t-test)		0.0055		0.022		0.049
Min	0.432	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.11	20.6	9.11	20.6	9.11
n (Patient)	65	15	68	12	70	10

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.02	2.91	5.02	1.59	4.88	1.59
Average	5.82	3.11	5.73	2.45	5.69	2.39
Stdev	4.41	2.60	4.27	2.27	4.25	2.34
p (t-test)		0.0087		0.0041		0.0050
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	20.6	9.53	20.6	9.11	20.6	9.11
n (Patient)	56	22	62	16	63	15

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.24	0.21	0.28	0.19	0.24	0.22	0.19	0.25	0.22
SE	0.061	0.074	0.069	0.063	0.084	0.073	0.065	0.093	0.074
p Value	2.9E-5	8.7E-5	0.0016	7.4E-7	0.0019	1.2E-4	1.3E-6	0.0081	1.4E-4
nCohort Non-persistent	57	65	56	64	68	62	65	70	63
nCohort Persistent	26	15	22	19	12	16	18	10	15
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	54%	47%	55%	42%	50%	44%	39%	50%	40%
Specificity	16%	18%	18%	16%	21%	18%	15%	21%	17%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	27%	13%	23%	16%	17%	12%	17%	20%	13%
Specificity	39%	42%	39%	39%	44%	40%	40%	46%	41%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36
Sensitivity	8%	7%	9%	5%	8%	6%	6%	10%	7%
Specificity	67%	71%	68%	69%	72%	69%	69%	73%	70%
OR Quartile 2	0.219	0.198	0.261	0.135	0.259	0.168	0.116	0.273	0.141
p Value	0.0045	0.0078	0.015	5.3E-4	0.038	0.0031	2.8E-4	0.062	0.0017
Lower limit of 95% CI	0.0766	0.0601	0.0884	0.0434	0.0724	0.0514	0.0362	0.0697	0.0416
Upper limit of 95% CI	0.625	0.653	0.770	0.418	0.928	0.548	0.370	1.07	0.478
OR Quartile 3	0.232	0.109	0.190	0.120	0.158	0.0965	0.133	0.211	0.108
p Value	0.0048	0.0057	0.0041	0.0018	0.023	0.0034	0.0031	0.059	0.0055
Lower limit of 95% CI	0.0837	0.0228	0.0613	0.0317	0.0321	0.0202	0.0351	0.0417	0.0225
Upper limit of 95% CI	0.641	0.525	0.590	0.455	0.776	0.462	0.507	1.06	0.520
OR Quartile 4	0.167	0.173	0.211	0.122	0.234	0.151	0.132	0.298	0.165
p Value	0.023	0.10	0.050	0.048	0.18	0.077	0.057	0.27	0.093
Lower limit of 95% CI	0.0356	0.0212	0.0445	0.0152	0.0283	0.0186	0.0165	0.0354	0.0203
Upper limit of 95% CI	0.781	1.41	1.00	0.980	1.94	1.23	1.06	2.52	1.35

[0269] Table 16.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.37	2.19	5.26	1.59	5.02	1.59
Average	6.03	2.75	5.90	2.23	5.77	2.28
Stdev	4.34	2.44	4.23	2.04	4.22	2.12
p (t-test)		3.2E-4		1.5E-4		5.0E-4
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.53	20.6	9.11	20.6	9.11
n (Patient)	54	29	60	23	62	21

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.85	1.89	4.82	2.19	4.71	1.82
Average	5.51	2.36	5.34	2.50	5.30	2.51
Stdev	4.28	2.26	4.26	2.43	4.24	2.54
p (t-test)		0.0058		0.023		0.031
Min	0.432	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.11	20.6	9.11	20.6	9.11
n (Patient)	64	16	67	13	68	12

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.37	2.91	5.42	1.59	5.36	1.59
Average	5.93	3.09	5.95	2.47	5.90	2.42
Stdev	4.44	2.52	4.31	2.11	4.29	2.16
p (t-test)		0.0045		8.9E-4		0.0011
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	20.6	9.53	20.6	9.11	20.6	9.11
n (Patient)	54	24	58	20	59	19

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.22	0.23	0.27	0.18	0.26	0.21	0.20	0.26	0.21
SE	0.057	0.073	0.066	0.058	0.083	0.065	0.062	0.086	0.066
p Value	1.3E-6	1.8E-4	6.3E-4	2.9E-8	0.0033	6.2E-6	7.4E-7	0.0047	8.1E-6
nCohort Non-persistent	54	64	54	60	67	58	62	68	59
nCohort Persistent	29	16	24	23	13	20	21	12	19
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	52%	50%	54%	43%	54%	45%	43%	50%	42%
Specificity	13%	19%	17%	13%	21%	16%	15%	21%	15%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	28%	19%	21%	17%	23%	10%	19%	25%	11%
Specificity	37%	42%	37%	37%	45%	36%	39%	46%	37%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36

Sensitivity	7%	6%	8%	4%	8%	5%	5%	8%	5%
Specificity	65%	70%	67%	67%	72%	67%	68%	72%	68%
OR Quartile 2	0.160	0.231	0.236	0.118	0.308	0.150	0.127	0.259	0.131
p Value	8.4E-4	0.014	0.0086	1.7E-4	0.063	0.0010	3.0E-4	0.038	5.6E-4
Lower limit of 95% CI	0.0543	0.0721	0.0806	0.0390	0.0892	0.0485	0.0417	0.0724	0.0413
Upper limit of 95% CI	0.469	0.739	0.693	0.359	1.06	0.466	0.389	0.928	0.415
OR Quartile 3	0.224	0.168	0.155	0.122	0.243	0.0631	0.149	0.279	0.0700
p Value	0.0029	0.0097	0.0012	5.8E-4	0.044	5.0E-4	0.0019	0.072	8.1E-4
Lower limit of 95% CI	0.0838	0.0437	0.0500	0.0367	0.0614	0.0133	0.0446	0.0695	0.0147
Upper limit of 95% CI	0.599	0.650	0.479	0.404	0.964	0.299	0.495	1.12	0.332
OR Quartile 4	0.136	0.158	0.182	0.0909	0.211	0.108	0.105	0.234	0.117
p Value	0.011	0.084	0.032	0.023	0.15	0.036	0.034	0.18	0.044
Lower limit of 95% CI	0.0292	0.0194	0.0384	0.0114	0.0256	0.0134	0.0131	0.0283	0.0145
Upper limit of 95% CI	0.637	1.28	0.860	0.724	1.73	0.869	0.839	1.94	0.942

[0270] Table 16.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.555	0.791	0.544	1.03	0.532	1.07
Average	0.769	1.10	0.765	1.26	0.761	1.31
Stdev	0.751	1.01	0.736	1.12	0.731	1.14
p (t-test)		0.11		0.032		0.020
Min	0.108	0.172	0.108	0.249	0.108	0.249
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	61	23	68	16	69	15

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.567	0.990	0.567	1.03	0.561	1.07
Average	0.860	0.948	0.853	1.00	0.848	1.05
Stdev	0.892	0.617	0.882	0.637	0.877	0.647
p (t-test)		0.73		0.58		0.47
Min	0.108	0.217	0.108	0.217	0.108	0.217
Max	4.86	2.58	4.86	2.58	4.86	2.58
n (Patient)	67	14	69	12	70	11

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.544	0.979	0.555	1.02	0.555	1.02
Average	0.748	1.21	0.758	1.47	0.758	1.47
Stdev	0.734	1.13	0.720	1.36	0.720	1.36
p (t-test)		0.047		0.013		0.013
Min	0.108	0.172	0.108	0.249	0.108	0.249
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	60	17	67	10	67	10

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.61	0.62	0.64	0.68	0.65	0.68	0.70	0.67	0.68
SE	0.071	0.087	0.080	0.080	0.092	0.099	0.081	0.095	0.099
p Value	0.12	0.18	0.086	0.022	0.100	0.067	0.015	0.070	0.067
nCohort Non-persistent	61	67	60	68	69	67	69	70	67
nCohort Persistent	23	14	17	16	12	10	15	11	10
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	78%	86%	76%	88%	92%	80%	87%	91%	80%
Specificity	26%	27%	25%	28%	28%	25%	28%	27%	25%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	61%	64%	65%	69%	67%	70%	73%	73%	70%
Specificity	54%	52%	53%	54%	52%	52%	55%	53%	52%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	39%	43%	47%	50%	50%	60%	53%	55%	60%
Specificity	80%	78%	80%	81%	78%	79%	81%	79%	79%
OR Quartile 2	1.28	2.20	1.08	2.71	4.18	1.36	2.47	3.73	1.36
p Value	0.67	0.33	0.90	0.21	0.18	0.71	0.26	0.22	0.71
Lower limit of 95% CI	0.408	0.449	0.306	0.563	0.505	0.263	0.509	0.446	0.263
Upper limit of 95% CI	4.02	10.8	3.83	13.1	34.6	7.04	12.0	31.1	7.04
OR Quartile 3	1.83	1.97	2.10	2.63	2.18	2.55	3.37	2.99	2.55
p Value	0.22	0.27	0.19	0.10	0.24	0.20	0.055	0.13	0.20
Lower limit of 95% CI	0.690	0.597	0.686	0.823	0.601	0.608	0.977	0.732	0.608
Upper limit of 95% CI	4.87	6.50	6.40	8.38	7.92	10.7	11.6	12.2	10.7
OR Quartile 4	2.62	2.60	3.56	4.23	3.60	5.68	4.92	4.40	5.68
p Value	0.071	0.12	0.030	0.014	0.048	0.015	0.0081	0.027	0.015
Lower limit of 95% CI	0.920	0.780	1.13	1.34	1.01	1.41	1.51	1.18	1.41
Upper limit of 95% CI	7.49	8.67	11.2	13.4	12.8	22.9	16.0	16.4	22.9

[0271] Table 16.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.561	0.787	0.555	1.00	0.544	1.03
Average	0.778	1.06	0.773	1.20	0.769	1.24
Stdev	0.754	1.01	0.739	1.11	0.734	1.13
p (t-test)		0.16		0.061		0.041
Min	0.108	0.172	0.108	0.217	0.108	0.217
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	60	24	67	17	68	16

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.567	0.990	0.567	1.03	0.561	1.07
Average	0.860	0.948	0.853	1.00	0.848	1.05
Stdev	0.892	0.617	0.882	0.637	0.877	0.647
p (t-test)		0.73		0.58		0.47
Min	0.108	0.217	0.108	0.217	0.108	0.217
Max	4.86	2.58	4.86	2.58	4.86	2.58
n (Patient)	67	14	69	12	70	11

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.544	0.791	0.555	0.896	0.555	0.896
Average	0.759	1.13	0.768	1.29	0.768	1.29
Stdev	0.744	1.10	0.728	1.29	0.728	1.29
p (t-test)		0.10		0.049		0.049
Min	0.108	0.172	0.108	0.217	0.108	0.217
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	58	19	65	12	65	12

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.62	0.60	0.64	0.65	0.62	0.66	0.67	0.62
SE	0.071	0.087	0.077	0.079	0.092	0.093	0.081	0.095	0.093
p Value	0.24	0.18	0.20	0.071	0.100	0.21	0.054	0.070	0.21
nCohort Non-persistent	60	67	58	67	69	65	68	70	65
nCohort Persistent	24	14	19	17	12	12	16	11	12
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	75%	86%	74%	82%	92%	75%	81%	91%	75%
Specificity	25%	27%	24%	27%	28%	25%	26%	27%	25%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	58%	64%	63%	65%	67%	67%	69%	73%	67%
Specificity	53%	52%	53%	54%	52%	52%	54%	53%	52%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	38%	43%	42%	47%	50%	50%	50%	55%	50%
Specificity	80%	78%	79%	81%	78%	78%	81%	79%	78%
OR Quartile 2	1.00	2.20	0.891	1.71	4.18	0.980	1.56	3.73	0.980
p Value	1.0	0.33	0.85	0.44	0.18	0.98	0.52	0.22	0.98
Lower limit of 95% CI	0.335	0.449	0.272	0.440	0.505	0.236	0.398	0.446	0.236
Upper limit of 95% CI	2.98	10.8	2.91	6.67	34.6	4.07	6.12	31.1	4.07
OR Quartile 3	1.60	1.97	1.97	2.13	2.18	2.19	2.63	2.99	2.19
p Value	0.34	0.27	0.21	0.18	0.24	0.23	0.10	0.13	0.23
Lower limit of 95% CI	0.614	0.597	0.678	0.705	0.601	0.601	0.823	0.732	0.601
Upper limit of 95% CI	4.17	6.50	5.71	6.43	7.92	8.01	8.38	12.2	8.01
OR Quartile 4	2.40	2.60	2.79	3.69	3.60	3.64	4.23	4.40	3.64
p Value	0.099	0.12	0.070	0.023	0.048	0.047	0.014	0.027	0.047
Lower limit of 95% CI	0.848	0.780	0.918	1.19	1.01	1.02	1.34	1.18	1.02
Upper limit of 95% CI	6.80	8.67	8.46	11.4	12.8	13.1	13.4	16.4	13.1

[0272] Table 16.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.567	0.783	0.544	1.03	0.532	1.07
Average	0.783	1.04	0.754	1.24	0.750	1.29
Stdev	0.760	0.993	0.728	1.10	0.723	1.11
p (t-test)		0.21		0.027		0.017
Min	0.108	0.172	0.108	0.217	0.108	0.217
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	59	25	66	18	67	17

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.580	0.979	0.567	1.03	0.561	1.07
Average	0.866	0.918	0.853	1.00	0.848	1.05
Stdev	0.898	0.607	0.882	0.637	0.877	0.647
p (t-test)		0.83		0.58		0.47
Min	0.108	0.217	0.108	0.217	0.108	0.217
Max	4.86	2.58	4.86	2.58	4.86	2.58
n (Patient)	66	15	69	12	70	11

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.555	0.787	0.555	0.896	0.544	1.00
Average	0.763	1.10	0.753	1.29	0.749	1.35
Stdev	0.749	1.08	0.721	1.23	0.716	1.25
p (t-test)		0.13		0.033		0.019
Min	0.108	0.172	0.108	0.217	0.108	0.217
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	57	20	63	14	64	13

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.60	0.59	0.67	0.65	0.63	0.68	0.67	0.65
SE	0.070	0.084	0.076	0.076	0.092	0.087	0.078	0.095	0.089
p Value	0.27	0.23	0.24	0.030	0.100	0.13	0.022	0.070	0.100
nCohort Non-persistent	59	66	57	66	69	63	67	70	64
nCohort Persistent	25	15	20	18	12	14	17	11	13
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	76%	87%	75%	83%	92%	79%	82%	91%	77%
Specificity	25%	27%	25%	27%	28%	25%	27%	27%	25%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	56%	60%	60%	67%	67%	64%	71%	73%	69%
Specificity	53%	52%	53%	55%	52%	52%	55%	53%	53%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	36%	40%	40%	50%	50%	50%	53%	55%	54%
Specificity	80%	77%	79%	82%	78%	79%	82%	79%	80%
OR Quartile 2	1.08	2.44	0.977	1.88	4.18	1.25	1.71	3.73	1.11
p Value	0.89	0.27	0.97	0.36	0.18	0.76	0.44	0.22	0.88
Lower limit of 95% CI	0.363	0.500	0.301	0.485	0.505	0.309	0.440	0.446	0.272
Upper limit of 95% CI	3.21	11.9	3.17	7.25	34.6	5.05	6.67	31.1	4.55
OR Quartile 3	1.41	1.59	1.67	2.40	2.18	1.98	2.96	2.99	2.55
p Value	0.47	0.42	0.33	0.12	0.24	0.26	0.064	0.13	0.15
Lower limit of 95% CI	0.550	0.510	0.592	0.804	0.601	0.596	0.938	0.732	0.712
Upper limit of 95% CI	3.61	4.98	4.69	7.16	7.92	6.57	9.34	12.2	9.14
OR Quartile 4	2.20	2.27	2.50	4.50	3.60	3.85	5.16	4.40	4.58
p Value	0.13	0.18	0.10	0.0082	0.048	0.029	0.0048	0.027	0.017
Lower limit of 95% CI	0.784	0.695	0.834	1.47	1.01	1.14	1.65	1.18	1.31
Upper limit of 95% CI	6.19	7.40	7.50	13.7	12.8	12.9	16.1	16.4	16.0

[0273] Table 16.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.567	0.783	0.532	1.00	0.527	1.03
Average	0.783	1.04	0.751	1.23	0.747	1.27
Stdev	0.760	0.993	0.733	1.07	0.728	1.08
p (t-test)		0.21		0.027		0.018
Min	0.108	0.172	0.108	0.217	0.108	0.217
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	59	25	65	19	66	18

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.580	0.979	0.561	1.00	0.555	1.03
Average	0.866	0.918	0.851	1.000	0.846	1.04
Stdev	0.898	0.607	0.889	0.610	0.883	0.617
p (t-test)		0.83		0.57		0.46
Min	0.108	0.217	0.108	0.217	0.108	0.217
Max	4.86	2.58	4.86	2.58	4.86	2.58
n (Patient)	66	15	68	13	69	12

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.555	0.787	0.544	0.979	0.532	0.990
Average	0.763	1.10	0.749	1.27	0.745	1.32
Stdev	0.749	1.08	0.726	1.19	0.721	1.21
p (t-test)		0.13		0.034		0.021
Min	0.108	0.172	0.108	0.217	0.108	0.217
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	57	20	62	15	63	14

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.60	0.59	0.67	0.66	0.64	0.69	0.68	0.66
SE	0.070	0.084	0.076	0.075	0.088	0.084	0.076	0.091	0.086
p Value	0.27	0.23	0.24	0.020	0.071	0.088	0.014	0.049	0.065
nCohort Non-persistent	59	66	57	65	68	62	66	69	63
nCohort Persistent	25	15	20	19	13	15	18	12	14
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	76%	87%	75%	84%	92%	80%	83%	92%	79%
Specificity	25%	27%	25%	28%	28%	26%	27%	28%	25%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	56%	60%	60%	68%	69%	67%	72%	75%	71%
Specificity	53%	52%	53%	55%	53%	53%	56%	54%	54%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	36%	40%	40%	47%	46%	47%	50%	50%	50%
Specificity	80%	77%	79%	82%	78%	79%	82%	78%	79%
OR Quartile 2	1.08	2.44	0.977	2.04	4.65	1.39	1.88	4.18	1.25
p Value	0.89	0.27	0.97	0.30	0.15	0.64	0.36	0.18	0.76
Lower limit of 95% CI	0.363	0.500	0.301	0.531	0.565	0.348	0.485	0.505	0.309
Upper limit of 95% CI	3.21	11.9	3.17	7.86	38.3	5.57	7.25	34.6	5.05
OR Quartile 3	1.41	1.59	1.67	2.69	2.53	2.28	3.32	3.47	2.93
p Value	0.47	0.42	0.33	0.074	0.15	0.17	0.039	0.079	0.095
Lower limit of 95% CI	0.550	0.510	0.592	0.910	0.711	0.697	1.06	0.864	0.831
Upper limit of 95% CI	3.61	4.98	4.69	7.95	9.02	7.43	10.4	13.9	10.3
OR Quartile 4	2.20	2.27	2.50	3.97	3.03	3.30	4.50	3.60	3.85
p Value	0.13	0.18	0.10	0.014	0.078	0.048	0.0082	0.048	0.029
Lower limit of 95% CI	0.784	0.695	0.834	1.33	0.884	1.01	1.47	1.01	1.14

Upper limit of 95% CI	6.19	7.40	7.50	11.9	10.4	10.8	13.7	12.8	12.9
-----------------------	------	------	------	------	------	------	------	------	------

[0274] Table 16.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.555	0.791	0.527	1.02	0.527	1.02
Average	0.773	1.04	0.746	1.18	0.749	1.21
Stdev	0.771	0.955	0.746	1.01	0.737	1.05
p (t-test)		0.17		0.038		0.030
Min	0.108	0.172	0.108	0.217	0.108	0.217
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	57	27	62	22	64	20

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.580	0.979	0.561	1.00	0.555	1.03
Average	0.866	0.918	0.851	1.000	0.846	1.04
Stdev	0.898	0.607	0.889	0.610	0.883	0.617
p (t-test)		0.83		0.57		0.46
Min	0.108	0.217	0.108	0.217	0.108	0.217
Max	4.86	2.58	4.86	2.58	4.86	2.58
n (Patient)	66	15	68	13	69	12

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.544	0.791	0.532	0.990	0.527	1.00
Average	0.758	1.10	0.745	1.20	0.740	1.24
Stdev	0.755	1.05	0.740	1.10	0.734	1.12
p (t-test)		0.12		0.048		0.032
Min	0.108	0.172	0.108	0.217	0.108	0.217
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	56	21	59	18	60	17

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.60	0.60	0.61	0.67	0.66	0.65	0.67	0.68	0.66
SE	0.068	0.084	0.075	0.070	0.088	0.078	0.073	0.091	0.079
p Value	0.13	0.23	0.16	0.015	0.071	0.063	0.023	0.049	0.047
nCohort Non-persistent	57	66	56	62	68	59	64	69	60
nCohort Persistent	27	15	21	22	13	18	20	12	17
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	78%	87%	76%	82%	92%	78%	80%	92%	76%
Specificity	26%	27%	25%	27%	28%	25%	27%	28%	25%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	59%	60%	62%	68%	69%	67%	70%	75%	71%
Specificity	54%	52%	54%	56%	53%	54%	56%	54%	55%

Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	37%	40%	43%	45%	46%	50%	45%	50%	53%
Specificity	81%	77%	80%	82%	78%	81%	81%	78%	82%
OR Quartile 2	1.25	2.44	1.07	1.70	4.65	1.19	1.45	4.18	1.08
p Value	0.69	0.27	0.91	0.39	0.15	0.78	0.56	0.18	0.90
Lower limit of 95% CI	0.424	0.500	0.330	0.503	0.565	0.340	0.424	0.505	0.306
Upper limit of 95% CI	3.69	11.9	3.44	5.75	38.3	4.19	4.94	34.6	3.83
OR Quartile 3	1.73	1.59	1.88	2.78	2.53	2.37	3.00	3.47	2.93
p Value	0.24	0.42	0.23	0.051	0.15	0.13	0.045	0.079	0.069
Lower limit of 95% CI	0.686	0.510	0.672	0.994	0.711	0.784	1.02	0.864	0.919
Upper limit of 95% CI	4.39	4.98	5.23	7.77	9.02	7.16	8.80	13.9	9.36
OR Quartile 4	2.46	2.27	3.07	3.86	3.03	4.36	3.55	3.60	5.01
p Value	0.084	0.18	0.043	0.013	0.078	0.011	0.022	0.048	0.0063
Lower limit of 95% CI	0.886	0.695	1.03	1.34	0.884	1.41	1.20	1.01	1.58
Upper limit of 95% CI	6.83	7.40	9.10	11.2	10.4	13.5	10.5	12.8	15.9

[0275] Example 17. Use of Tyrosine-protein kinase receptor UFO for evaluating renal status in patients admitted to the ICU: Persistent at RIFLE I or F

[0276] Patients from the intensive care unit (ICU) are enrolled in the following study. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) are collected from each patient at enrollment, 4 ($\pm$ 0.5) and 8 ($\pm$ 1) hours after contrast administration (if applicable); at 12 ($\pm$ 1), 24 ($\pm$ 2), and 48 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Tyrosine-protein kinase receptor UFO is measured in the earliest samples collected while the patients were in RIFLE I or F by standard immunoassay methods using commercially available assay reagents.

[0277] Kidney status is assessed by RIFLE criteria based on serum creatinine, urine output, or both serum creatinine and urine output. Two cohorts are defined to represent a “persistent” and a “non-persistent” population. “Persistent” indicates those patients whose minimum RIFLE stage during a period of 24, 48 or 72 hours is injury (I) or failure (F) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. “Non-persistent” indicates those patients who are not persistent at injury (I) or failure (F) and whose minimum RIFLE stage during a period of 24, 48 or 72 hours is non-injury (RIFLE 0) or risk of injury (R) where the persistence period can start from the time of sample collection to 24, 48, 72, 96 or 168 hours after sample collection. If a patient dies after injury (I) or failure (F) or is placed on renal replacement therapy (RRT) at any time from sample collection to 24, 48, 72, 96 or 168 hours after sample collection, the patient is considered “persistent”.

[0278] The ability to distinguish the “persistent” and “non-persistent” cohorts is determined using receiver operating characteristic (ROC) analysis.

[0279] Table 17.1: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.79	2.78	5.32	2.16	4.88	1.59
Average	6.32	3.68	6.03	2.52	5.86	2.34
Stdev	4.29	3.52	4.37	1.91	4.28	1.92
p (t-test)		0.0028		1.5E-4		3.0E-4
Min	0.432	0.276	0.366	0.276	0.366	0.276
Max	20.5	20.6	20.6	7.34	20.6	7.34
n (Patient)	38	45	56	27	60	23

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.16	1.64	4.87	2.19	4.85	1.89
Average	5.94	2.24	5.66	2.38	5.54	2.24
Stdev	4.32	1.98	4.32	2.13	4.26	2.20
p (t-test)		1.7E-4		0.0021		0.0038
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.11	20.6	9.11	20.6	9.11
n (Patient)	57	23	61	19	64	16

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.84	4.01	4.84	2.78	4.84	2.78
Average	5.51	4.69	5.39	4.48	5.41	4.39
Stdev	4.46	3.90	3.96	4.46	3.99	4.43
p (t-test)		0.39		0.35		0.31
Min	0.366	0.489	0.366	0.489	0.366	0.489
Max	20.5	20.6	20.5	20.6	20.5	20.6
n (Patient)	35	43	49	29	51	27

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.28	0.19	0.45	0.22	0.22	0.40	0.21	0.21	0.40
SE	0.056	0.058	0.065	0.058	0.068	0.068	0.061	0.072	0.069
p Value	1.1E-4	7.0E-8	0.44	9.9E-7	4.6E-5	0.15	1.5E-6	6.7E-5	0.13
nCohort Non-persistent	38	57	35	56	61	49	60	64	51
nCohort Persistent	45	23	43	27	19	29	23	16	27
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	67%	48%	74%	52%	53%	62%	48%	50%	63%
Specificity	16%	14%	26%	14%	18%	18%	15%	19%	20%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	38%	13%	47%	26%	16%	41%	22%	12%	41%
Specificity	34%	35%	46%	38%	39%	45%	38%	41%	45%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36
Sensitivity	11%	4%	16%	4%	5%	17%	4%	6%	15%

Specificity	58%	67%	63%	64%	69%	69%	67%	70%	69%
OR Quartile 2	0.375	0.150	1.01	0.179	0.244	0.368	0.162	0.231	0.415
p Value	0.072	7.8E-4	0.99	0.0015	0.013	0.060	9.7E-4	0.014	0.098
Lower limit of 95% CI	0.129	0.0494	0.362	0.0620	0.0804	0.130	0.0548	0.0721	0.146
Upper limit of 95% CI	1.09	0.453	2.80	0.520	0.743	1.04	0.477	0.739	1.18
OR Quartile 3	0.316	0.0811	0.732	0.210	0.122	0.575	0.173	0.0977	0.565
p Value	0.012	2.1E-4	0.50	0.0026	0.0020	0.24	0.0021	0.0036	0.24
Lower limit of 95% CI	0.128	0.0214	0.299	0.0760	0.0320	0.227	0.0564	0.0205	0.219
Upper limit of 95% CI	0.778	0.307	1.79	0.580	0.463	1.46	0.529	0.467	1.45
OR Quartile 4	0.172	0.0909	0.329	0.0692	0.123	0.472	0.0909	0.158	0.380
p Value	0.0023	0.024	0.040	0.011	0.049	0.20	0.023	0.084	0.12
Lower limit of 95% CI	0.0555	0.0114	0.114	0.00873	0.0153	0.151	0.0114	0.0194	0.113
Upper limit of 95% CI	0.533	0.726	0.951	0.549	0.988	1.48	0.724	1.28	1.28

[0280] Table 17.2: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.90	3.03	5.54	2.19	5.02	2.16
Average	6.86	3.77	6.24	2.83	6.04	2.73
Stdev	4.39	3.47	4.46	2.25	4.37	2.32
p (t-test)		6.7E-4		1.1E-4		2.8E-4
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.5	20.6	20.6	9.11	20.6	9.11
n (Patient)	30	53	50	33	54	29

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.49	1.64	5.02	2.32	4.87	1.89
Average	6.21	2.27	5.79	2.47	5.62	2.31
Stdev	4.35	1.91	4.38	2.04	4.29	2.15
p (t-test)		2.5E-5		0.0010		0.0023
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.6	9.11	20.6	9.11	20.6	9.11
n (Patient)	53	27	58	22	62	18

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.88	4.01	4.88	3.03	4.88	3.03
Average	5.74	4.65	5.60	4.35	5.60	4.27
Stdev	4.61	3.84	3.99	4.31	4.02	4.27
p (t-test)		0.26		0.19		0.16
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	20.5	20.6	20.5	20.6	20.5	20.6
n (Patient)	29	49	44	34	46	32

Persistence Period Duration (hr)	24	48	72
-------------------------------------	----	----	----

	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.25	0.17	0.43	0.23	0.23	0.37	0.23	0.22	0.37
SE	0.053	0.053	0.066	0.055	0.064	0.064	0.058	0.069	0.065
p Value	4.1E-6	3.6E-10	0.27	1.1E-6	1.9E-5	0.047	3.6E-6	3.9E-5	0.042
nCohort Non-persistent	30	53	29	50	58	44	54	62	46
nCohort Persistent	53	27	49	33	22	34	29	18	32
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	66%	48%	73%	55%	55%	62%	52%	50%	62%
Specificity	10%	11%	24%	12%	17%	16%	13%	18%	17%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	40%	15%	47%	30%	18%	41%	28%	17%	41%
Specificity	30%	32%	45%	36%	38%	43%	37%	40%	43%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36
Sensitivity	13%	4%	18%	6%	5%	18%	7%	6%	16%
Specificity	53%	64%	62%	62%	67%	68%	65%	69%	67%
OR Quartile 2	0.216	0.119	0.881	0.164	0.250	0.306	0.160	0.216	0.351
p Value	0.023	2.4E-4	0.82	0.0012	0.012	0.029	8.4E-4	0.0078	0.050
Lower limit of 95% CI	0.0576	0.0380	0.305	0.0548	0.0848	0.106	0.0543	0.0696	0.123
Upper limit of 95% CI	0.810	0.369	2.55	0.489	0.737	0.885	0.469	0.668	0.998
OR Quartile 3	0.281	0.0821	0.719	0.245	0.136	0.532	0.224	0.135	0.526
p Value	0.0093	5.0E-5	0.48	0.0033	0.0012	0.17	0.0029	0.0034	0.17
Lower limit of 95% CI	0.108	0.0245	0.286	0.0955	0.0406	0.215	0.0838	0.0354	0.211
Upper limit of 95% CI	0.731	0.275	1.81	0.626	0.454	1.32	0.599	0.516	1.31
OR Quartile 4	0.174	0.0688	0.368	0.105	0.0977	0.459	0.136	0.133	0.383
p Value	0.0014	0.011	0.060	0.0042	0.028	0.16	0.011	0.058	0.098
Lower limit of 95% CI	0.0596	0.00864	0.130	0.0226	0.0122	0.155	0.0292	0.0165	0.123
Upper limit of 95% CI	0.507	0.548	1.04	0.491	0.782	1.36	0.637	1.07	1.19

[0281] Table 17.3: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.79	3.15	5.54	2.44	5.02	2.19
Average	6.74	3.89	6.22	3.05	6.02	2.99
Stdev	4.42	3.55	4.49	2.52	4.39	2.62
p (t-test)		0.0020		3.1E-4		8.0E-4
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.5	20.6	20.6	10.3	20.6	10.3
n (Patient)	29	54	48	35	52	31

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.42	1.92	4.88	2.44	4.87	2.19
Average	6.13	2.56	5.71	2.81	5.55	2.74
Stdev	4.35	2.42	4.37	2.58	4.28	2.78
p (t-test)		1.4E-4		0.0040		0.0090
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.6	10.3	20.6	10.3	20.6	10.3
n (Patient)	52	28	57	23	61	19

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.88	4.01	4.88	3.03	4.88	3.03
Average	5.74	4.65	5.66	4.32	5.66	4.23
Stdev	4.61	3.84	4.01	4.25	4.04	4.21
p (t-test)		0.26		0.16		0.13
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	20.5	20.6	20.5	20.6	20.5	20.6
n (Patient)	29	49	43	35	45	33

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.27	0.20	0.43	0.25	0.26	0.37	0.26	0.26	0.36
SE	0.055	0.055	0.066	0.056	0.066	0.064	0.058	0.071	0.064
p Value	3.9E-5	4.9E-8	0.27	8.7E-6	2.4E-4	0.036	3.0E-5	5.8E-4	0.032
nCohort Non-persistent	29	52	29	48	57	43	52	61	45
nCohort Persistent	54	28	49	35	23	35	31	19	33
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	67%	50%	73%	57%	57%	63%	55%	53%	64%
Specificity	10%	12%	24%	12%	18%	16%	13%	18%	18%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	41%	18%	47%	31%	22%	40%	29%	21%	39%
Specificity	31%	33%	45%	35%	39%	42%	37%	41%	42%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36
Sensitivity	15%	7%	18%	9%	9%	17%	10%	11%	15%
Specificity	55%	65%	62%	62%	68%	67%	65%	70%	67%
OR Quartile 2	0.231	0.130	0.881	0.190	0.277	0.329	0.189	0.244	0.378
p Value	0.030	4.0E-4	0.82	0.0028	0.019	0.040	0.0022	0.013	0.068
Lower limit of 95% CI	0.0615	0.0422	0.305	0.0643	0.0948	0.114	0.0651	0.0804	0.133
Upper limit of 95% CI	0.866	0.403	2.55	0.564	0.807	0.951	0.548	0.743	1.07
OR Quartile 3	0.309	0.106	0.719	0.251	0.175	0.480	0.236	0.185	0.475
p Value	0.016	9.3E-5	0.48	0.0035	0.0024	0.11	0.0031	0.0065	0.11
Lower limit of 95% CI	0.119	0.0342	0.286	0.0995	0.0567	0.194	0.0903	0.0549	0.190
Upper limit of 95% CI	0.805	0.326	1.81	0.635	0.538	1.19	0.615	0.624	1.19
OR Quartile 4	0.214	0.145	0.368	0.156	0.206	0.429	0.202	0.281	0.357
p Value	0.0040	0.015	0.060	0.0058	0.047	0.13	0.018	0.11	0.076
Lower limit of 95% CI	0.0750	0.0309	0.130	0.0417	0.0436	0.145	0.0540	0.0588	0.115
Upper limit of 95% CI	0.611	0.683	1.04	0.585	0.976	1.27	0.758	1.34	1.11

[0282] Table 17.4: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.79	3.36	5.58	2.47	5.32	2.44
Average	6.66	4.03	6.24	3.29	6.09	3.23
Stdev	4.46	3.63	4.53	2.79	4.43	2.88
p (t-test)		0.0053		7.7E-4		0.0012
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.5	20.6	20.6	11.5	20.6	11.5
n (Patient)	27	56	45	38	48	35

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.32	2.32	4.87	2.51	4.85	2.47
Average	6.04	2.95	5.61	3.26	5.48	3.30
Stdev	4.37	2.88	4.38	3.05	4.32	3.22
p (t-test)		9.4E-4		0.018		0.035
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.6	11.5	20.6	11.5	20.6	11.5
n (Patient)	50	30	55	25	58	22

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.88	4.18	5.16	3.28	5.02	3.44
Average	5.58	4.78	5.68	4.43	5.60	4.49
Stdev	4.64	3.88	4.06	4.20	4.04	4.24
p (t-test)		0.42		0.19		0.24
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	20.5	20.6	20.5	20.6	20.5	20.6
n (Patient)	27	51	39	39	40	38

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.29	0.24	0.45	0.27	0.30	0.38	0.27	0.31	0.39
SE	0.057	0.058	0.068	0.056	0.067	0.063	0.057	0.070	0.064
p Value	2.4E-4	6.1E-6	0.45	3.9E-5	0.0033	0.050	5.3E-5	0.0079	0.073
nCohort Non-persistent	27	50	27	45	55	39	48	58	40
nCohort Persistent	56	30	51	38	25	39	35	22	38
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	68%	53%	75%	61%	60%	67%	57%	59%	66%
Specificity	11%	12%	26%	13%	18%	18%	12%	19%	18%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	43%	23%	47%	34%	28%	38%	31%	27%	39%
Specificity	33%	34%	44%	36%	40%	38%	35%	41%	40%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36
Sensitivity	16%	10%	20%	11%	12%	18%	11%	14%	18%
Specificity	56%	66%	63%	62%	69%	67%	65%	71%	68%
OR Quartile 2	0.264	0.156	1.02	0.236	0.333	0.438	0.190	0.338	0.408
p Value	0.049	0.0011	0.97	0.0086	0.041	0.12	0.0028	0.048	0.096
Lower limit of 95% CI	0.0702	0.0511	0.352	0.0803	0.116	0.152	0.0643	0.116	0.142
Upper limit of 95% CI	0.993	0.475	2.97	0.693	0.956	1.26	0.564	0.989	1.17
OR Quartile 3	0.375	0.157	0.711	0.287	0.259	0.391	0.251	0.265	0.435
p Value	0.045	4.2E-4	0.48	0.0069	0.0099	0.043	0.0035	0.015	0.072
Lower limit of 95% CI	0.144	0.0560	0.279	0.116	0.0929	0.157	0.0995	0.0904	0.175
Upper limit of 95% CI	0.979	0.439	1.82	0.710	0.724	0.973	0.635	0.775	1.08
OR Quartile 4	0.239	0.216	0.415	0.194	0.305	0.437	0.235	0.381	0.469
p Value	0.0071	0.024	0.098	0.0073	0.081	0.12	0.018	0.16	0.16
Lower limit of 95% CI	0.0845	0.0571	0.146	0.0584	0.0802	0.152	0.0710	0.0995	0.163
Upper limit of 95% CI	0.678	0.814	1.18	0.642	1.16	1.26	0.779	1.46	1.35

[0283] Table 17.5: Comparison of marker levels and the area under the ROC curve (AUC) in urine samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.79	3.36	5.69	2.47	5.54	2.44
Average	6.78	4.07	6.42	3.24	6.25	3.18
Stdev	4.50	3.64	4.55	2.73	4.45	2.82
p (t-test)		0.0048		2.6E-4		4.6E-4
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.5	20.6	20.6	11.5	20.6	11.5
n (Patient)	25	58	43	40	46	37

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	5.49	2.44	4.88	2.65	4.87	2.47
Average	6.07	2.99	5.64	3.30	5.58	3.24
Stdev	4.41	2.84	4.42	3.00	4.35	3.11
p (t-test)		8.7E-4		0.017		0.020
Min	0.502	0.276	0.366	0.276	0.366	0.276
Max	20.6	11.5	20.6	11.5	20.6	11.5
n (Patient)	49	31	54	26	56	24

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	4.74	4.30	5.16	3.43	5.16	3.43
Average	5.46	4.85	5.65	4.52	5.65	4.46
Stdev	4.69	3.89	4.12	4.15	4.08	4.19
p (t-test)		0.55		0.23		0.21
Min	0.366	0.398	0.366	0.398	0.366	0.398
Max	20.5	20.6	20.5	20.6	20.5	20.6
n (Patient)	26	52	37	41	39	39

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.28	0.24	0.47	0.25	0.31	0.39	0.25	0.30	0.38
SE	0.057	0.058	0.069	0.054	0.066	0.064	0.055	0.067	0.063
p Value	1.6E-4	7.9E-6	0.64	4.3E-6	0.0039	0.077	7.0E-6	0.0036	0.059
nCohort Non-persistent	25	49	26	43	54	37	46	56	39
nCohort Persistent	58	31	52	40	26	41	37	24	39
Cutoff Quartile 2	2.05	1.90	2.02	2.05	1.90	2.02	2.05	1.90	2.02
Sensitivity	67%	55%	75%	60%	62%	68%	57%	58%	67%
Specificity	8%	12%	27%	12%	19%	19%	11%	18%	18%
Cutoff Quartile 3	4.01	3.91	4.44	4.01	3.91	4.44	4.01	3.91	4.44
Sensitivity	43%	26%	48%	32%	31%	39%	30%	29%	38%
Specificity	32%	35%	46%	33%	41%	38%	33%	41%	38%
Cutoff Quartile 4	6.30	6.30	6.36	6.30	6.30	6.36	6.30	6.30	6.36
Sensitivity	17%	10%	21%	10%	12%	20%	11%	12%	18%
Specificity	56%	65%	65%	60%	69%	68%	63%	70%	67%
OR Quartile 2	0.178	0.169	1.11	0.197	0.364	0.503	0.160	0.304	0.438
p Value	0.029	0.0017	0.85	0.0048	0.058	0.20	0.0015	0.028	0.12
Lower limit of 95% CI	0.0381	0.0559	0.379	0.0640	0.128	0.175	0.0515	0.105	0.152
Upper limit of 95% CI	0.837	0.514	3.22	0.609	1.04	1.44	0.497	0.880	1.26
OR Quartile 3	0.357	0.185	0.794	0.232	0.306	0.390	0.205	0.287	0.391
p Value	0.041	9.0E-4	0.63	0.0019	0.019	0.043	9.0E-4	0.017	0.043
Lower limit of 95% CI	0.133	0.0682	0.309	0.0927	0.113	0.156	0.0802	0.103	0.157
Upper limit of 95% CI	0.958	0.501	2.04	0.583	0.826	0.972	0.522	0.803	0.973
OR Quartile 4	0.265	0.202	0.507	0.170	0.284	0.505	0.207	0.328	0.437
p Value	0.013	0.018	0.20	0.0038	0.064	0.20	0.0099	0.10	0.12
Lower limit of 95% CI	0.0934	0.0534	0.178	0.0512	0.0748	0.179	0.0624	0.0861	0.152

Upper limit of 95% CI	0.752	0.761	1.44	0.564	1.08	1.42	0.685	1.25	1.26
-----------------------	-------	-------	------	-------	------	------	-------	------	------

[0284] Table 17.6: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 24 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.555	0.647	0.505	0.980	0.532	0.791
Average	0.738	0.974	0.686	1.21	0.783	1.06
Stdev	0.602	1.01	0.546	1.17	0.768	0.990
p (t-test)		0.20		0.0066		0.18
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	4.86	4.60
n (Patient)	41	43	56	28	61	23

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.527	1.00	0.522	1.03	0.532	1.03
Average	0.771	1.14	0.767	1.21	0.835	1.01
Stdev	0.767	0.996	0.759	1.03	0.908	0.599
p (t-test)		0.080		0.044		0.43
Min	0.108	0.217	0.108	0.217	0.108	0.217
Max	4.60	4.86	4.60	4.86	4.86	2.58
n (Patient)	58	23	61	20	63	18

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.555	0.669	0.522	0.713	0.532	0.713
Average	0.830	0.869	0.800	0.937	0.802	0.945
Stdev	0.899	0.816	0.816	0.918	0.802	0.950
p (t-test)		0.84		0.50		0.49
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	37	40	49	28	51	26

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.56	0.67	0.54	0.66	0.71	0.56	0.61	0.68	0.55
SE	0.063	0.070	0.066	0.065	0.071	0.069	0.071	0.076	0.070
p Value	0.31	0.015	0.50	0.011	0.0030	0.36	0.11	0.019	0.49
nCohort Non-persistent	41	58	37	56	61	49	61	63	51
nCohort Persistent	43	23	40	28	20	28	23	18	26
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	77%	87%	75%	82%	95%	75%	83%	94%	73%
Specificity	27%	29%	24%	29%	31%	24%	28%	30%	24%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	53%	65%	55%	64%	70%	61%	61%	67%	62%
Specificity	54%	55%	54%	57%	56%	55%	54%	54%	55%

Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	30%	48%	30%	43%	50%	36%	39%	50%	35%
Specificity	80%	83%	78%	84%	82%	80%	80%	81%	78%
OR Quartile 2	1.21	2.76	0.964	1.84	8.60	0.973	1.84	7.34	0.835
p Value	0.71	0.14	0.95	0.29	0.043	0.96	0.33	0.061	0.74
Lower limit of 95% CI	0.450	0.725	0.342	0.596	1.07	0.332	0.545	0.910	0.283
Upper limit of 95% CI	3.25	10.5	2.72	5.68	69.0	2.85	6.18	59.2	2.46
OR Quartile 3	1.33	2.31	1.44	2.40	2.94	1.90	1.83	2.34	1.95
p Value	0.51	0.10	0.43	0.067	0.051	0.18	0.22	0.13	0.18
Lower limit of 95% CI	0.565	0.847	0.586	0.940	0.996	0.738	0.690	0.782	0.743
Upper limit of 95% CI	3.14	6.29	3.53	6.12	8.67	4.88	4.87	7.03	5.11
OR Quartile 4	1.79	4.40	1.55	3.92	4.55	2.17	2.62	4.25	1.93
p Value	0.26	0.0064	0.40	0.0096	0.0066	0.14	0.071	0.011	0.22
Lower limit of 95% CI	0.651	1.52	0.552	1.39	1.52	0.766	0.920	1.39	0.675
Upper limit of 95% CI	4.91	12.8	4.37	11.0	13.6	6.13	7.49	13.0	5.49

[0285] Table 17.7: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 48 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.561	0.645	0.479	0.980	0.522	0.791
Average	0.759	0.920	0.669	1.14	0.778	1.01
Stdev	0.649	0.936	0.561	1.08	0.800	0.901
p (t-test)		0.40		0.011		0.23
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	4.86	4.60
n (Patient)	32	52	50	34	55	29

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.527	1.00	0.503	1.04	0.522	1.05
Average	0.769	1.09	0.758	1.17	0.825	1.03
Stdev	0.789	0.936	0.774	0.970	0.920	0.569
p (t-test)		0.11		0.048		0.35
Min	0.108	0.217	0.108	0.217	0.108	0.217
Max	4.60	4.86	4.60	4.86	4.86	2.58
n (Patient)	54	27	58	23	61	20

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.561	0.644	0.507	0.691	0.527	0.691
Average	0.840	0.857	0.780	0.944	0.782	0.951
Stdev	0.938	0.802	0.821	0.895	0.805	0.921
p (t-test)		0.93		0.41		0.40
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	30	47	44	33	46	31

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.67	0.53	0.68	0.72	0.57	0.63	0.70	0.56
SE	0.064	0.066	0.068	0.061	0.067	0.066	0.066	0.072	0.067
p Value	0.43	0.0093	0.70	0.0035	8.2E-4	0.27	0.052	0.0043	0.37
nCohort Non-persistent	32	54	30	50	58	44	55	61	46
nCohort Persistent	52	27	47	34	23	33	29	20	31
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	77%	89%	74%	82%	96%	76%	83%	95%	74%
Specificity	28%	31%	23%	30%	33%	25%	29%	31%	24%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	52%	63%	53%	65%	70%	61%	62%	70%	61%
Specificity	53%	56%	53%	60%	57%	57%	56%	56%	57%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	29%	44%	30%	41%	48%	36%	38%	50%	35%
Specificity	81%	83%	80%	86%	83%	82%	82%	82%	80%
OR Quartile 2	1.30	3.68	0.888	2.00	10.7	1.04	1.97	8.60	0.904
p Value	0.60	0.055	0.83	0.20	0.025	0.94	0.24	0.043	0.85
Lower limit of 95% CI	0.477	0.972	0.304	0.687	1.34	0.365	0.639	1.07	0.316
Upper limit of 95% CI	3.56	13.9	2.59	5.83	85.6	2.97	6.07	69.0	2.59
OR Quartile 3	1.22	2.13	1.30	2.75	3.02	2.02	2.11	2.94	2.06
p Value	0.65	0.12	0.58	0.028	0.035	0.13	0.11	0.051	0.13
Lower limit of 95% CI	0.507	0.824	0.519	1.12	1.08	0.808	0.842	0.996	0.813
Upper limit of 95% CI	2.96	5.48	3.25	6.78	8.44	5.07	5.30	8.67	5.21
OR Quartile 4	1.76	4.00	1.70	4.30	4.40	2.57	2.75	4.55	2.26
p Value	0.30	0.0092	0.34	0.0065	0.0064	0.076	0.051	0.0066	0.12
Lower limit of 95% CI	0.602	1.41	0.570	1.50	1.52	0.905	0.996	1.52	0.803
Upper limit of 95% CI	5.13	11.4	5.05	12.3	12.8	7.30	7.60	13.6	6.37

[0286] Table 17.8: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 72 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.567	0.643	0.474	0.979	0.484	0.791
Average	0.767	0.913	0.672	1.12	0.760	1.03
Stdev	0.658	0.929	0.566	1.07	0.796	0.893
p (t-test)		0.44		0.015		0.16
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	4.86	4.60
n (Patient)	31	53	49	35	53	31

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.522	0.991	0.484	1.02	0.505	1.04
Average	0.774	1.07	0.762	1.14	0.830	1.01
Stdev	0.796	0.924	0.780	0.957	0.927	0.565
p (t-test)		0.14		0.065		0.42
Min	0.108	0.217	0.108	0.217	0.108	0.217
Max	4.60	4.86	4.60	4.86	4.86	2.58
n (Patient)	53	28	57	24	60	21

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.561	0.644	0.492	0.713	0.522	0.713
Average	0.840	0.857	0.751	0.975	0.755	0.984
Stdev	0.938	0.802	0.808	0.900	0.792	0.925
p (t-test)		0.93		0.26		0.25
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	30	47	43	34	45	32

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.55	0.67	0.53	0.67	0.71	0.60	0.64	0.69	0.58
SE	0.065	0.065	0.068	0.061	0.066	0.066	0.064	0.071	0.067
p Value	0.45	0.012	0.70	0.0042	0.0012	0.15	0.026	0.0061	0.22
nCohort Non-persistent	31	53	30	49	57	43	53	60	45
nCohort Persistent	53	28	47	35	24	34	31	21	32
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	77%	89%	74%	83%	96%	76%	84%	95%	75%
Specificity	29%	32%	23%	31%	33%	26%	30%	32%	24%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	51%	61%	53%	63%	67%	62%	61%	67%	62%
Specificity	52%	55%	53%	59%	56%	58%	57%	55%	58%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	28%	43%	30%	40%	46%	38%	39%	48%	38%
Specificity	81%	83%	80%	86%	82%	84%	83%	82%	82%
OR Quartile 2	1.40	3.94	0.888	2.13	11.5	1.12	2.25	9.27	0.971
p Value	0.51	0.043	0.83	0.16	0.021	0.84	0.16	0.036	0.96
Lower limit of 95% CI	0.510	1.04	0.304	0.732	1.44	0.392	0.732	1.16	0.340
Upper limit of 95% CI	3.83	14.9	2.59	6.21	91.7	3.18	6.91	74.2	2.77
OR Quartile 3	1.11	1.87	1.30	2.45	2.56	2.24	2.07	2.44	2.28
p Value	0.82	0.19	0.58	0.048	0.065	0.085	0.12	0.092	0.082
Lower limit of 95% CI	0.456	0.736	0.519	1.01	0.945	0.895	0.836	0.864	0.901
Upper limit of 95% CI	2.69	4.74	3.25	5.98	6.94	5.63	5.10	6.92	5.77
OR Quartile 4	1.64	3.67	1.70	4.00	3.98	3.18	3.09	4.05	2.78
p Value	0.36	0.014	0.34	0.0095	0.010	0.033	0.030	0.011	0.056
Lower limit of 95% CI	0.563	1.30	0.570	1.40	1.39	1.10	1.12	1.38	0.974
Upper limit of 95% CI	4.81	10.3	5.05	11.4	11.4	9.23	8.55	11.9	7.91

[0287] Table 17.9: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 96 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.602	0.618	0.484	0.791	0.479	0.885
Average	0.781	0.902	0.689	1.07	0.757	1.01
Stdev	0.664	0.924	0.572	1.06	0.815	0.861
p (t-test)		0.53		0.036		0.18
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	4.86	4.60
n (Patient)	30	54	47	37	50	34

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.555	0.980	0.522	0.991	0.522	0.991
Average	0.794	1.01	0.781	1.07	0.848	0.941
Stdev	0.805	0.916	0.788	0.950	0.945	0.569
p (t-test)		0.27		0.15		0.65
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.60	4.86	4.60	4.86	4.86	2.58
n (Patient)	51	30	55	26	57	24

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.567	0.644	0.507	0.691	0.492	0.713
Average	0.858	0.846	0.770	0.936	0.756	0.957
Stdev	0.950	0.797	0.830	0.877	0.824	0.881
p (t-test)		0.95		0.40		0.31
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	29	48	40	37	41	36

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.53	0.62	0.51	0.63	0.66	0.56	0.65	0.64	0.59
SE	0.066	0.066	0.068	0.062	0.067	0.066	0.062	0.070	0.065
p Value	0.62	0.078	0.92	0.031	0.019	0.32	0.019	0.042	0.18
nCohort Non-persistent	30	51	29	47	55	40	50	57	41
nCohort Persistent	54	30	48	37	26	37	34	24	36
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	76%	83%	73%	78%	88%	73%	82%	88%	75%
Specificity	27%	29%	21%	28%	31%	22%	30%	30%	24%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	50%	57%	52%	59%	62%	59%	62%	62%	61%
Specificity	50%	53%	52%	57%	55%	57%	58%	54%	59%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	28%	40%	29%	38%	42%	35%	38%	42%	36%
Specificity	80%	82%	79%	85%	82%	82%	84%	81%	83%
OR Quartile 2	1.15	2.08	0.702	1.39	3.43	0.784	2.00	2.98	0.968
p Value	0.79	0.20	0.53	0.53	0.070	0.65	0.20	0.11	0.95
Lower limit of 95% CI	0.413	0.671	0.234	0.505	0.905	0.278	0.687	0.782	0.343
Upper limit of 95% CI	3.19	6.47	2.11	3.81	13.0	2.21	5.83	11.3	2.73
OR Quartile 3	1.00	1.47	1.16	1.98	1.92	1.98	2.23	1.99	2.22
p Value	1.0	0.40	0.75	0.13	0.18	0.14	0.078	0.17	0.087
Lower limit of 95% CI	0.410	0.594	0.463	0.826	0.741	0.801	0.915	0.748	0.890
Upper limit of 95% CI	2.44	3.65	2.93	4.75	4.97	4.92	5.44	5.28	5.53
OR Quartile 4	1.54	3.11	1.58	3.48	3.30	2.55	3.25	2.99	2.75
p Value	0.43	0.030	0.41	0.019	0.024	0.083	0.024	0.040	0.062
Lower limit of 95% CI	0.525	1.12	0.529	1.23	1.17	0.886	1.17	1.05	0.951
Upper limit of 95% CI	4.51	8.68	4.71	9.86	9.31	7.36	9.06	8.49	7.93

[0288] Table 17.10: Comparison of marker levels and the area under the ROC curve (AUC) in EDTA samples for the “persistent” and “non-persistent” cohorts where persistence starts within 168 hours after sample collection and renal status is assessed by serum creatinine (sCr) only, urine output (UO) only, or serum creatinine or urine output RIFLE criteria.

sCr or UO

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.602	0.618	0.484	0.738	0.479	0.765
Average	0.802	0.887	0.698	1.04	0.768	0.980
Stdev	0.682	0.910	0.582	1.04	0.830	0.845
p (t-test)		0.66		0.059		0.25
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	2.99	4.86	2.99	4.86	4.86	4.60
n (Patient)	28	56	45	39	48	36

sCr only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.555	0.980	0.522	0.991	0.522	0.991
Average	0.794	1.01	0.781	1.07	0.848	0.941
Stdev	0.805	0.916	0.788	0.950	0.945	0.569
p (t-test)		0.27		0.15		0.65
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.60	4.86	4.60	4.86	4.86	2.58
n (Patient)	51	30	55	26	57	24

UO only

Persistence Period Duration (hr)	24		48		72	
	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort	Non-persistent Cohort	Persistent Cohort
Median	0.580	0.643	0.539	0.647	0.507	0.691
Average	0.876	0.835	0.793	0.905	0.767	0.940
Stdev	0.962	0.792	0.845	0.865	0.832	0.875
p (t-test)		0.84		0.57		0.38
Min	0.108	0.172	0.108	0.172	0.108	0.172
Max	4.86	4.60	4.86	4.60	4.86	4.60
n (Patient)	28	49	38	39	40	37

Persistence Period Duration (hr)	24			48			72		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.52	0.62	0.49	0.62	0.66	0.53	0.63	0.64	0.57
SE	0.067	0.066	0.069	0.062	0.067	0.066	0.062	0.070	0.066
p Value	0.79	0.078	0.87	0.057	0.019	0.65	0.037	0.042	0.28
nCohort Non-persistent	28	51	28	45	55	38	48	57	40
nCohort Persistent	56	30	49	39	26	39	36	24	37
Cutoff Quartile 2	0.372	0.374	0.374	0.372	0.374	0.374	0.372	0.374	0.374
Sensitivity	75%	83%	71%	77%	88%	69%	81%	88%	73%
Specificity	25%	29%	18%	27%	31%	18%	29%	30%	22%
Cutoff Quartile 3	0.614	0.636	0.593	0.614	0.636	0.593	0.614	0.636	0.593
Sensitivity	50%	57%	51%	59%	62%	56%	61%	62%	59%
Specificity	50%	53%	50%	58%	55%	55%	58%	54%	57%
Cutoff Quartile 4	1.04	1.04	1.00	1.04	1.04	1.00	1.04	1.04	1.00
Sensitivity	27%	40%	29%	36%	42%	33%	36%	42%	35%
Specificity	79%	82%	79%	84%	82%	82%	83%	81%	82%
OR Quartile 2	1.00	2.08	0.543	1.21	3.43	0.508	1.71	2.98	0.784
p Value	1.0	0.20	0.30	0.70	0.070	0.21	0.31	0.11	0.65
Lower limit of 95% CI	0.351	0.671	0.172	0.448	0.905	0.175	0.607	0.782	0.278
Upper limit of 95% CI	2.85	6.47	1.71	3.28	13.0	1.47	4.80	11.3	2.21
OR Quartile 3	1.00	1.47	1.04	1.97	1.92	1.60	2.20	1.99	1.98
p Value	1.0	0.40	0.93	0.13	0.18	0.31	0.080	0.17	0.14
Lower limit of 95% CI	0.404	0.594	0.412	0.824	0.741	0.650	0.911	0.748	0.801
Upper limit of 95% CI	2.48	3.65	2.64	4.70	4.97	3.93	5.32	5.28	4.92
OR Quartile 4	1.34	3.11	1.47	3.04	3.30	2.21	2.83	2.99	2.55
p Value	0.59	0.030	0.49	0.036	0.024	0.14	0.046	0.040	0.083
Lower limit of 95% CI	0.456	1.12	0.491	1.08	1.17	0.770	1.02	1.05	0.886

Upper limit of 95% CI	3.95	8.68	4.38	8.59	9.31	6.37	7.83	8.49	7.36
-----------------------	------	------	------	------	------	------	------	------	------

[0289] Example 18. AKI Biomarkers in ICU patients

[0290] Patients from the intensive care unit (ICU) are enrolled in the following study. Each patient is classified by kidney status as non-injury (0), risk of injury (R), injury (I), and failure (F) according to the maximum stage reached within 7 days of enrollment as determined by the RIFLE criteria. EDTA anti-coagulated blood samples (10 mL) and urine samples (50 mL) are collected from each patient at enrollment, at 12 ($\pm$ 1), 24 ($\pm$ 2), 36 ($\pm$ 2), 48 ($\pm$ 2), 60 ($\pm$ 2), 72 ($\pm$ 2), and 84 ($\pm$ 2) hours after enrollment, and thereafter daily up to day 7 while the subject is hospitalized. C-C motif chemokine 14, C-C motif chemokine 16, and Tyrosine-protein kinase receptor UFO are measured by standard immunoassay methods using commercially available assay reagents in the urine samples and the plasma component of the blood samples collected.

[0291] Two cohorts are defined to represent a “diseased” and a “normal” population. While these terms are used for convenience, “diseased” and “normal” simply represent two cohorts for comparison (say RIFLE 0 vs RIFLE R, I and F; RIFLE 0 vs RIFLE R; RIFLE 0 and R vs RIFLE I and F; etc.). The time “prior max stage” represents the time at which a sample is collected, relative to the time a particular patient reaches the lowest disease stage as defined for that cohort, binned into three groups which are $\pm$ 12 hours. For example, “24 hr prior” which uses 0 vs R, I, F as the two cohorts would mean 24 hr ($\pm$ 12 hours) prior to reaching stage R (or I if no sample at R, or F if no sample at R or I).

[0292] A receiver operating characteristic (ROC) curve is generated for each biomarker and the area under the ROC curve (AUC) is determined. Patients in Cohort 2 are also separated according to the reason for adjudication to cohort 2 as being based on serum creatinine measurements (sCr), being based on urine output (UO), or being based on either serum creatinine measurements or urine output. Using the same example discussed above (0 vs R, I, F), for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of urine output; for those patients adjudicated to stage R, I, or F on the basis of urine output alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements; and for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements or urine output, the stage 0 cohort contains only patients in stage 0 for both

serum creatinine measurements and urine output. Also, in the data for patients adjudicated on the basis of serum creatinine measurements or urine output, the adjudication method which yielded the most severe RIFLE stage is used.

[0293] The ability to distinguish cohort 1 from Cohort 2 is determined using ROC analysis. SE is the standard error of the AUC, n is the number of sample or individual patients (“pts,” as indicated). Standard errors are calculated as described in Hanley, J. A., and McNeil, B.J., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 143: 29-36; p values are calculated with a two-tailed Z-test. An AUC < 0.5 is indicative of a negative going marker for the comparison, and an AUC > 0.5 is indicative of a positive going marker for the comparison.

[0294] Various biomarker threshold (or “cutoff”) concentrations are selected, and the associated sensitivity and specificity for distinguishing cohort 1 from cohort 2 are determined. OR is the odds ratio calculated for the particular cutoff concentration, and 95% CI is the confidence interval for the odds ratio.

Table 18.1: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.

C-C motif chemokine 14

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.368	0.472	0.368	0.381	0.368	0.387
Average	0.696	1.03	0.696	0.784	0.696	0.959
Stdev	1.07	1.45	1.07	1.46	1.07	1.72
p(t-test)		1.7E-4		0.41		0.082
Min	0.00865	2.08E-6	0.00865	0.000797	0.00865	0.0465
Max	8.80	8.57	8.80	10.4	8.80	9.42
n (Samp)	528	287	528	152	528	67
n (Patient)	137	287	137	152	137	67

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.414	0.781	0.414	0.481	0.414	0.519
Average	0.758	1.68	0.758	1.40	0.758	1.43
Stdev	1.07	2.15	1.07	2.10	1.07	2.40
p(t-test)		2.8E-14		4.3E-6		1.1E-4
Min	0.00229	2.08E-6	0.00229	0.000797	0.00229	0.0516
Max	8.80	8.78	8.80	10.4	8.80	9.42
n (Samp)	1187	109	1187	74	1187	45
n (Patient)	315	109	315	74	315	45

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.403	0.461	0.403	0.372	0.403	0.387
Average	0.880	1.09	0.880	0.778	0.880	1.13
Stdev	1.42	1.54	1.42	1.32	1.42	2.03
p(t-test)		0.046		0.43		0.18

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Min	2.08E-6	0.0157	2.08E-6	0.0404	2.08E-6	0.00229
Max	10.4	7.28	10.4	9.26	10.4	9.39
n (Samp)	685	261	685	147	685	69
n (Patient)	172	261	172	147	172	69

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.59	0.65	0.56	0.51	0.59	0.48	0.53	0.58	0.50
SE	0.021	0.030	0.021	0.027	0.036	0.026	0.038	0.045	0.037
p	2.8E-5	7.6E-7	0.0061	0.63	0.010	0.56	0.42	0.087	0.89
nCohort 1	528	1187	685	528	1187	685	528	1187	685
nCohort 2	287	109	261	152	74	147	67	45	69
Cutoff 1	0.302	0.375	0.300	0.256	0.355	0.253	0.272	0.334	0.272
Sens 1	70%	71%	70%	70%	70%	70%	70%	71%	71%
Spec 1	41%	45%	38%	35%	43%	32%	38%	40%	35%
Cutoff 2	0.241	0.297	0.239	0.196	0.268	0.179	0.222	0.234	0.172
Sens 2	80%	81%	80%	80%	81%	80%	81%	80%	81%
Spec 2	31%	35%	29%	23%	31%	20%	28%	25%	18%
Cutoff 3	0.146	0.163	0.151	0.143	0.199	0.119	0.104	0.168	0.0781
Sens 3	90%	91%	90%	90%	91%	90%	91%	91%	91%
Spec 3	15%	15%	15%	15%	20%	11%	9%	16%	6%
Cutoff 4	0.592	0.668	0.648	0.592	0.668	0.648	0.592	0.668	0.648
Sens 4	41%	51%	37%	29%	38%	31%	34%	36%	29%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.869	0.983	0.977	0.869	0.983	0.977	0.869	0.983	0.977
Sens 5	31%	40%	28%	18%	32%	16%	22%	27%	23%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1.32	1.60	1.97	1.32	1.60	1.97	1.32	1.60	1.97
Sens 6	21%	31%	15%	10%	20%	7%	16%	22%	16%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.5	1.4	1.5	1.1	1.3	1.1	1.5	0.59	1.6
p Value	0.055	0.39	0.048	0.60	0.56	0.80	0.27	0.32	0.17
95% CI of	0.99	0.68	1.0	0.69	0.58	0.64	0.72	0.21	0.81
OR Quart2	2.3	2.7	2.3	1.9	2.7	1.8	3.2	1.6	3.3
OR Quart 3	1.7	1.6	1.4	1.1	1.8	1.1	1.5	1.5	1.2
p Value	0.015	0.18	0.16	0.79	0.11	0.70	0.27	0.31	0.70
95% CI of	1.1	0.81	0.89	0.64	0.87	0.67	0.72	0.67	0.55
OR Quart3	2.6	3.1	2.1	1.8	3.7	1.8	3.2	3.5	2.4
OR Quart 4	2.5	3.8	1.9	1.2	2.3	1.1	1.2	1.4	1.2
p Value	2.0E-5	1.0E-5	0.0032	0.44	0.023	0.80	0.57	0.41	0.58
95% CI of	1.6	2.1	1.2	0.74	1.1	0.64	0.58	0.62	0.59
OR Quart4	3.8	7.0	2.8	2.0	4.6	1.8	2.7	3.2	2.6

Table 18.2: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.

C-C motif chemokine 14

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.397	0.741	0.397	0.475	0.397	0.374
Average	0.777	1.57	0.777	1.04	0.777	1.03
Stdev	1.22	1.99	1.22	1.60	1.22	1.76
p(t-test)		1.4E-12		0.026		0.098
Min	2.08E-6	0.0110	2.08E-6	0.0184	2.08E-6	0.00229
Max	10.4	9.06	10.4	9.26	10.4	9.39
n (Samp)	970	183	970	133	970	76
n (Patient)	249	183	249	133	249	76

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.441	1.19	0.441	0.673	0.441	0.565
Average	0.837	2.39	0.837	1.94	0.837	1.51
Stdev	1.22	2.49	1.22	2.48	1.22	2.26

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
p(t-test)		5.3E-19		3.9E-9		0.0019
Min	2.08E-6	0.000562	2.08E-6	0.0926	2.08E-6	0.0516
Max	10.4	8.81	10.4	9.07	10.4	9.06
n (Samp)	1464	59	1464	49	1464	34
n (Patient)	380	59	380	49	380	34

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.428	0.657	0.428	0.464	0.428	0.411
Average	0.992	1.38	0.992	1.01	0.992	1.00
Stdev	1.59	1.78	1.59	1.51	1.59	1.69
p(t-test)		0.0057		0.91		0.96
Min	2.08E-6	0.0110	2.08E-6	0.0184	2.08E-6	0.00229
Max	10.4	9.06	10.4	9.26	10.4	9.39
n (Samp)	1113	156	1113	118	1113	67
n (Patient)	274	156	274	118	274	67

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.67	0.73	0.62	0.55	0.69	0.52	0.50	0.58	0.49
SE	0.023	0.038	0.025	0.027	0.043	0.028	0.034	0.052	0.037
p	2.6E-13	7.5E-10	1.8E-6	0.062	1.4E-5	0.52	0.92	0.13	0.72
nCohort 1	970	1464	1113	970	1464	1113	970	1464	1113
nCohort 2	183	59	156	133	49	118	76	34	67
Cutoff 1	0.434	0.512	0.415	0.280	0.558	0.280	0.251	0.372	0.275
Sens 1	70%	71%	71%	71%	71%	70%	71%	71%	70%
Spec 1	54%	57%	49%	36%	61%	33%	30%	43%	32%
Cutoff 2	0.326	0.386	0.315	0.219	0.401	0.216	0.196	0.253	0.211
Sens 2	80%	81%	80%	80%	82%	81%	80%	82%	81%
Spec 2	41%	45%	37%	25%	46%	22%	22%	27%	21%
Cutoff 3	0.230	0.307	0.216	0.140	0.220	0.134	0.170	0.185	0.170
Sens 3	90%	92%	90%	90%	92%	91%	91%	91%	91%
Spec 3	26%	35%	22%	13%	21%	11%	18%	17%	16%
Cutoff 4	0.639	0.742	0.754	0.639	0.742	0.754	0.639	0.742	0.754
Sens 4	54%	66%	46%	34%	47%	33%	29%	38%	25%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.927	1.08	1.13	0.927	1.08	1.13	0.927	1.08	1.13
Sens 5	41%	54%	35%	25%	41%	21%	22%	26%	21%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	1.59	1.82	2.64	1.59	1.82	2.64	1.59	1.82	2.64
Sens 6	27%	41%	16%	18%	27%	9%	16%	21%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.6	2.8	1.2	1.00	1.4	1.1	1.3	2.0	0.93
p Value	0.089	0.081	0.47	0.99	0.56	0.69	0.42	0.20	0.85
95% CI of	0.93	0.88	0.70	0.58	0.44	0.65	0.68	0.68	0.45
OR Quart2	2.9	8.9	2.2	1.7	4.5	1.9	2.5	6.0	1.9
OR Quart 3	2.6	2.0	2.2	1.3	2.9	1.0	0.88	1.6	1.3
p Value	5.1E-4	0.26	0.0040	0.30	0.045	0.90	0.72	0.41	0.49
95% CI of	1.5	0.60	1.3	0.78	1.0	0.60	0.44	0.52	0.64
OR Quart3	4.5	6.8	3.7	2.2	8.0	1.8	1.8	5.0	2.5
OR Quart 4	4.9	9.8	2.9	1.4	4.8	1.2	1.1	2.2	1.0
p Value	1.5E-9	1.8E-5	4.0E-5	0.25	0.0016	0.42	0.87	0.14	1.0
95% CI of	2.9	3.5	1.7	0.81	1.8	0.73	0.54	0.77	0.49
OR Quart4	8.1	28	4.8	2.3	13	2.1	2.1	6.5	2.0

Table 18.3: Comparison of marker levels in urine samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).

C-C motif chemokine 14

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.462	0.657	0.795	1.45	0.461	0.664
Average	0.689	1.43	0.801	2.27	0.890	1.42

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Stdev	0.724	1.84	0.595	2.38	1.33	1.82
p(t-test)		0.0085		0.0064		0.066
Min	2.08E-6	0.0157	2.08E-6	0.110	0.0313	0.0157
Max	3.38	8.57	2.51	8.78	7.84	8.08
n (Samp)	46	126	22	38	49	115
n (Patient)	46	126	22	38	49	115

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.63	0.69	0.61
SE	0.046	0.068	0.046
p	0.0046	0.0042	0.017
nCohort 1	46	22	49
nCohort 2	126	38	115
Cutoff 1	0.384	0.518	0.370
Sens 1	71%	71%	70%
Spec 1	43%	32%	39%
Cutoff 2	0.309	0.435	0.291
Sens 2	80%	82%	80%
Spec 2	35%	32%	33%
Cutoff 3	0.224	0.302	0.214
Sens 3	90%	92%	90%
Spec 3	22%	27%	20%
Cutoff 4	0.754	0.977	0.708
Sens 4	45%	61%	49%
Spec 4	72%	73%	71%
Cutoff 5	0.977	1.10	1.09
Sens 5	38%	58%	35%
Spec 5	80%	82%	82%
Cutoff 6	1.42	1.42	2.81
Sens 6	27%	50%	16%
Spec 6	91%	91%	92%
OR Quart 2	1.7	0.77	1.1
p Value	0.25	0.72	0.82
95% CI of	0.69	0.18	0.45
OR Quart2	4.3	3.2	2.7
OR Quart 3	1.2	1.3	2.0
p Value	0.65	0.71	0.16
95% CI of	0.50	0.31	0.77
OR Quart3	3.0	5.6	5.1
OR Quart 4	4.5	12	2.6
p Value	0.0084	0.030	0.056
95% CI of	1.5	1.3	0.98
OR Quart4	14	120	7.1

Table 18.4: Comparison of the maximum marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values in urine samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.

C-C motif chemokine 14

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.616	3.05	0.616	1.84	0.616	0.853
Average	1.09	3.78	1.09	3.30	1.09	2.63
Stdev	1.41	2.90	1.41	2.99	1.41	3.10
p(t-test)		1.7E-14		8.0E-10		1.5E-4
Min	0.0409	0.110	0.0409	0.110	0.0409	0.185
Max	8.80	9.39	8.80	9.39	8.80	9.39
n (Samp)	137	47	137	39	137	23
n (Patient)	137	47	137	39	137	23

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.670	4.44	0.670	2.70	0.670	1.35
Average	1.21	4.51	1.21	4.06	1.21	3.05
Stdev	1.43	3.20	1.43	3.21	1.43	3.35
p(t-test)		1.8E-21		7.8E-16		2.6E-6
Min	0.0409	0.284	0.0409	0.240	0.0409	0.185
Max	8.80	9.39	8.80	9.39	8.80	9.39
n (Samp)	315	28	315	25	315	18
n (Patient)	315	28	315	25	315	18

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.619	2.57	0.619	1.67	0.619	0.686
Average	1.32	3.21	1.32	2.75	1.32	1.79
Stdev	1.84	2.50	1.84	2.71	1.84	2.17
p(t-test)		1.2E-6		5.8E-4		0.37
Min	0.000797	0.110	0.000797	0.110	0.000797	0.221
Max	10.4	8.88	10.4	8.88	10.4	6.68
n (Samp)	172	32	172	27	172	14
n (Patient)	172	32	172	27	172	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.82	0.82	0.77	0.77	0.79	0.70	0.62	0.61	0.57
SE	0.040	0.050	0.051	0.047	0.055	0.059	0.066	0.072	0.083
p	2.4E-15	1.3E-10	1.1E-7	1.9E-8	7.9E-8	9.4E-4	0.067	0.13	0.42
nCohort 1	137	315	172	137	315	172	137	315	172
nCohort 2	47	28	32	39	25	27	23	18	14
Cutoff 1	1.79	1.92	1.33	0.937	1.66	0.677	0.606	0.590	0.606
Sens 1	70%	71%	72%	72%	72%	70%	74%	72%	71%
Spec 1	87%	85%	77%	69%	81%	55%	50%	44%	49%
Cutoff 2	0.891	0.851	0.891	0.590	0.851	0.556	0.350	0.350	0.352
Sens 2	81%	82%	81%	82%	80%	81%	83%	83%	86%
Spec 2	66%	59%	62%	49%	59%	44%	21%	19%	20%
Cutoff 3	0.495	0.502	0.456	0.495	0.506	0.398	0.216	0.211	0.270
Sens 3	91%	93%	91%	92%	92%	93%	91%	94%	93%
Spec 3	39%	35%	34%	39%	35%	27%	9%	6%	14%
Cutoff 4	0.971	1.20	1.13	0.971	1.20	1.13	0.971	1.20	1.13
Sens 4	77%	79%	72%	69%	72%	59%	43%	50%	36%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	1.38	1.62	1.58	1.38	1.62	1.58	1.38	1.62	1.58
Sens 5	72%	79%	69%	62%	72%	52%	43%	50%	36%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	2.31	2.86	3.08	2.31	2.86	3.08	2.31	2.86	3.08
Sens 6	60%	54%	44%	44%	44%	33%	30%	33%	21%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	1.7	1.5	1.0	2.2	4.1	3.2	0.30	0.59	0.98
p Value	0.46	0.66	1.0	0.30	0.21	0.17	0.15	0.47	0.98
95% CI of	0.39	0.24	0.19	0.50	0.45	0.61	0.056	0.14	0.19
OR Quart2	7.8	9.2	5.2	9.2	38	17	1.6	2.5	5.1
OR Quart 3	3.5	0.49	1.7	2.6	2.0	2.0	0.81	0.19	1.0
p Value	0.076	0.56	0.47	0.19	0.57	0.42	0.75	0.13	1.0
95% CI of	0.88	0.043	0.39	0.62	0.18	0.36	0.23	0.022	0.19
OR Quart3	14	5.5	7.7	11	23	12	2.9	1.7	5.2
OR Quart 4	27	14	11	15	23	10	1.9	1.9	1.7
p Value	9.9E-7	4.5E-4	2.5E-4	5.4E-5	0.0027	0.0033	0.27	0.28	0.48
95% CI of	7.2	3.2	3.1	4.0	2.9	2.2	0.61	0.60	0.38
OR Quart4	100	63	41	56	170	47	5.8	5.8	7.6

Table 18.5: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.

C-C motif chemokine 16

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.17E-6	0.000221	8.17E-6	9.29E-6	8.17E-6	7.11E-6
Average	0.00491	0.0120	0.00491	0.00833	0.00491	0.0161
Stdev	0.0138	0.0577	0.0138	0.0354	0.0138	0.0894
p(t-test)		0.0071		0.073		0.0082
Min	2.10E-6	1.99E-6	2.10E-6	2.10E-6	2.10E-6	2.10E-6
Max	0.158	0.692	0.158	0.372	0.158	0.718
n (Samp)	528	287	528	152	528	67
n (Patient)	137	287	137	152	137	67

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.61E-6	0.00158	8.61E-6	1.41E-5	8.61E-6	8.17E-6
Average	0.00464	0.0263	0.00464	0.0143	0.00464	0.0311
Stdev	0.0130	0.0954	0.0130	0.0315	0.0130	0.115
p(t-test)		1.3E-12		5.7E-8		7.3E-12
Min	1.99E-6	1.99E-6	1.99E-6	2.10E-6	1.99E-6	2.10E-6
Max	0.187	0.692	0.187	0.156	0.187	0.718
n (Samp)	1187	109	1187	74	1187	45
n (Patient)	315	109	315	74	315	45

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.52E-6	0.000224	8.52E-6	9.29E-6	8.52E-6	7.11E-6
Average	0.0100	0.0260	0.0100	0.0602	0.0100	0.0843
Stdev	0.0547	0.286	0.0547	0.631	0.0547	0.501
p(t-test)		0.16		0.041		2.4E-4
Min	1.99E-6	1.99E-6	1.99E-6	1.99E-6	1.99E-6	2.10E-6
Max	0.819	4.61	0.819	7.64	0.819	4.05
n (Samp)	685	261	685	147	685	69
n (Patient)	172	261	172	147	172	69

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.58	0.61	0.57	0.51	0.58	0.50	0.45	0.52	0.47
SE	0.021	0.030	0.021	0.027	0.036	0.026	0.038	0.044	0.037
p	4.0E-4	3.9E-4	0.0018	0.61	0.017	0.95	0.20	0.72	0.45
nCohort 1	528	1187	685	528	1187	685	528	1187	685
nCohort 2	287	109	261	152	74	147	67	45	69
Cutoff 1	7.11E-6	7.11E-6	7.11E-6	5.32E-6	7.11E-6	5.28E-6	4.12E-6	5.28E-6	4.50E-6
Sens 1	70%	72%	70%	71%	72%	73%	72%	71%	72%
Spec 1	42%	39%	40%	34%	39%	29%	22%	28%	24%
Cutoff 2	4.27E-6	4.98E-6	4.27E-6	3.90E-6	4.98E-6	3.90E-6	3.61E-6	3.61E-6	3.90E-6
Sens 2	81%	81%	80%	83%	81%	81%	81%	80%	83%
Spec 2	22%	25%	22%	19%	25%	19%	16%	16%	19%
Cutoff 3	2.97E-6	3.45E-6	2.97E-6	2.55E-6	3.59E-6	2.35E-6	2.35E-6	2.55E-6	2.55E-6
Sens 3	91%	91%	91%	91%	92%	93%	93%	93%	91%
Spec 3	12%	13%	12%	9%	13%	5%	6%	9%	9%
Cutoff 4	0.000773	0.00151	0.00176	0.000773	0.00151	0.00176	0.000773	0.00151	0.00176
Sens 4	43%	50%	40%	33%	41%	33%	25%	33%	28%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.00616	0.00593	0.00690	0.00616	0.00593	0.00690	0.00616	0.00593	0.00690
Sens 5	25%	34%	26%	18%	27%	20%	16%	29%	20%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.0149	0.0144	0.0169	0.0149	0.0144	0.0169	0.0149	0.0144	0.0169
Sens 6	16%	23%	16%	9%	20%	8%	10%	20%	9%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	1.0	0.90	0.90	1.1	1.1	0.97	0.84	1.1	0.94
p Value	0.85	0.74	0.65	0.69	0.85	0.90	0.68	0.83	0.86
95% CI of	0.68	0.47	0.59	0.66	0.51	0.58	0.38	0.48	0.45
OR Quart2	1.6	1.7	1.4	1.9	2.3	1.6	1.9	2.5	2.0
OR Quart 3	1.5	1.3	1.4	1.2	1.5	1.1	1.4	0.63	1.2
p Value	0.065	0.45	0.100	0.51	0.29	0.61	0.36	0.34	0.59
95% CI of	0.98	0.69	0.94	0.71	0.72	0.69	0.68	0.24	0.60
OR Quart3	2.2	2.3	2.1	2.0	2.9	1.9	2.9	1.6	2.4
OR Quart 4	1.8	2.2	1.5	1.1	1.8	1.0	1.7	1.4	1.2
p Value	0.0062	0.0045	0.035	0.60	0.074	1.0	0.15	0.42	0.58
95% CI of	1.2	1.3	1.0	0.69	0.94	0.60	0.83	0.62	0.60
OR Quart4	2.7	3.8	2.3	1.9	3.6	1.7	3.4	3.1	2.4

Table 18.6: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.

C-C motif chemokine 16

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.17E-6	0.000773	8.17E-6	1.41E-5	8.17E-6	1.31E-5
Average	0.00545	0.0233	0.00545	0.0173	0.00545	0.0149
Stdev	0.0252	0.0828	0.0252	0.0629	0.0252	0.0828
p(t-test)		4.3E-8		6.5E-5		0.016
Min	2.10E-6	1.99E-6	2.10E-6	2.10E-6	2.10E-6	2.10E-6
Max	0.649	0.692	0.649	0.568	0.649	0.718
n (Samp)	971	183	971	133	971	76
n (Patient)	249	183	249	133	249	76

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.61E-6	0.00462	8.61E-6	0.00430	8.61E-6	0.00293
Average	0.00567	0.0566	0.00567	0.0292	0.00567	0.0157
Stdev	0.0227	0.137	0.0227	0.0838	0.0227	0.0483
p(t-test)		2.9E-27		2.0E-9		0.014
Min	1.99E-6	1.99E-6	1.99E-6	1.99E-6	1.99E-6	2.10E-6
Max	0.649	0.692	0.649	0.568	0.649	0.278
n (Samp)	1465	59	1465	49	1465	34
n (Patient)	380	59	380	49	380	34

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	8.61E-6	0.000636	8.61E-6	1.36E-5	8.61E-6	1.31E-5
Average	0.0532	0.0122	0.0532	0.0124	0.0532	0.0179
Stdev	0.513	0.0322	0.513	0.0418	0.513	0.0913
p(t-test)		0.32		0.39		0.57
Min	1.99E-6	1.99E-6	1.99E-6	1.99E-6	1.99E-6	2.10E-6
Max	8.98	0.278	8.98	0.372	8.98	0.718
n (Samp)	1113	156	1113	118	1113	67
n (Patient)	274	156	274	118	274	67

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.62	0.66	0.60	0.58	0.66	0.54	0.53	0.60	0.51
SE	0.024	0.039	0.025	0.027	0.043	0.028	0.035	0.052	0.037
p	1.5E-7	6.8E-5	1.7E-4	0.0024	3.3E-4	0.12	0.37	0.066	0.71
nCohort 1	971	1465	1113	971	1465	1113	971	1465	1113
nCohort 2	183	59	156	133	49	118	76	34	67
Cutoff 1	8.17E-6	8.61E-6	8.17E-6	7.08E-6	8.61E-6	7.08E-6	4.50E-6	6.48E-6	5.28E-6
Sens 1	71%	73%	71%	71%	73%	70%	72%	71%	72%
Spec 1	50%	51%	48%	37%	51%	36%	24%	34%	29%
Cutoff 2	5.28E-6	4.12E-6	5.32E-6	4.27E-6	5.28E-6	4.27E-6	3.90E-6	3.90E-6	3.90E-6
Sens 2	81%	85%	81%	82%	82%	81%	82%	82%	82%
Spec 2	30%	20%	32%	22%	27%	22%	19%	18%	19%
Cutoff 3	3.45E-6	3.45E-6	3.45E-6	2.35E-6	2.35E-6	2.35E-6	2.55E-6	2.55E-6	2.97E-6
Sens 3	95%	93%	96%	95%	94%	94%	91%	91%	91%
Spec 3	14%	12%	13%	6%	6%	6%	10%	9%	12%
Cutoff 4	0.000688	0.00170	0.00215	0.000688	0.00170	0.00215	0.000688	0.00170	0.00215
Sens 4	51%	59%	42%	43%	55%	37%	39%	59%	31%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.00482	0.00610	0.00746	0.00482	0.00610	0.00746	0.00482	0.00610	0.00746
Sens 5	37%	44%	30%	33%	43%	26%	26%	35%	19%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.0142	0.0154	0.0187	0.0142	0.0154	0.0187	0.0142	0.0154	0.0187
Sens 6	25%	34%	16%	20%	33%	13%	9%	15%	7%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.71	0.33	1.2	0.96	0.62	1.1	0.48	0.49	0.69
p Value	0.21	0.054	0.49	0.89	0.40	0.79	0.051	0.25	0.34

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
95% CI of OR Quart2	0.41	0.10	0.70	0.54	0.20	0.62	0.23	0.15	0.33
OR Quart 3	1.2	1.0	2.1	1.7	1.9	1.9	1.0	1.7	1.5
p Value	1.5	0.91	1.7	1.2	1.4	0.91	0.85	0.87	1.2
95% CI of OR Quart3	0.077	0.83	0.044	0.58	0.49	0.76	0.62	0.79	0.61
OR Quart 4	0.96	0.40	1.0	0.68	0.55	0.51	0.45	0.31	0.61
p Value	2.5	2.1	2.8	2.0	3.5	1.6	1.6	2.4	2.3
95% CI of OR Quart4	2.6	2.8	2.2	2.0	3.3	1.6	1.1	1.9	1.1
OR Quart2	2.2E-5	0.0028	0.0017	0.0073	0.0042	0.072	0.77	0.15	0.86
p Value	1.7	1.4	1.3	1.2	1.5	0.96	0.60	0.80	0.54
95% CI of OR Quart4	4.1	5.6	3.6	3.3	7.3	2.7	2.0	4.6	2.1

Table 18.7: Comparison of marker levels in urine samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).

C-C motif chemokine 16

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	1.12E-5	0.00172	1.12E-5	0.00400	8.61E-6	0.00209
Average	0.00367	0.0217	0.00331	0.0527	0.190	0.0113
Stdev	0.00820	0.0855	0.00546	0.150	1.28	0.0224
p(t-test)		0.15		0.13		0.14
Min	2.10E-6	1.99E-6	2.10E-6	1.99E-6	2.10E-6	1.99E-6
Max	0.0462	0.692	0.0177	0.692	8.98	0.139
n (Samp)	46	126	22	38	49	115
n (Patient)	46	126	22	38	49	115

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.61	0.64	0.62
SE	0.047	0.072	0.046
p	0.016	0.057	0.0092
nCohort 1	46	22	49
nCohort 2	126	38	115
Cutoff 1	8.52E-6	8.61E-6	8.52E-6
Sens 1	71%	74%	72%
Spec 1	46%	45%	45%
Cutoff 2	5.32E-6	3.61E-6	6.48E-6
Sens 2	80%	82%	81%
Spec 2	26%	14%	31%
Cutoff 3	3.45E-6	2.35E-6	3.45E-6
Sens 3	92%	92%	93%
Spec 3	20%	9%	16%
Cutoff 4	0.00307	0.00307	0.00264
Sens 4	42%	50%	46%
Spec 4	72%	73%	71%
Cutoff 5	0.00473	0.00603	0.00473
Sens 5	36%	42%	36%
Spec 5	80%	82%	82%
Cutoff 6	0.00979	0.0130	0.0232
Sens 6	27%	32%	14%
Spec 6	91%	91%	92%
OR Quart 2	0.65	1.0	0.90
p Value	0.36	1.0	0.82
95% CI of OR Quart2	0.26	0.24	0.37
OR Quart3	1.6	4.2	2.2
OR Quart 3	1.1	1.8	1.6
p Value	0.81	0.46	0.34
95% CI of OR Quart3	0.43	0.40	0.62
OR Quart 4	2.9	7.7	4.0
p Value	2.0	3.5	2.8
95% CI of OR Quart4	0.20	0.13	0.050
OR Quart4	0.70	0.69	1.00
	5.7	18	7.9

Table 18.8: Comparison of the maximum marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values in urine samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.

C-C motif chemokine 16

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00380	0.0234	0.00380	0.0177	0.00380	0.0116
Average	0.0110	0.185	0.0110	0.112	0.0110	0.100
Stdev	0.0202	0.611	0.0202	0.220	0.0202	0.204
p(t-test)		9.7E-4		2.8E-7		1.2E-6
Min	3.61E-6	1.99E-6	3.61E-6	2.10E-6	3.61E-6	5.32E-6
Max	0.158	4.05	0.158	0.819	0.158	0.718
n (Samp)	137	47	137	39	137	23
n (Patient)	137	47	137	39	137	23

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00380	0.0324	0.00380	0.0235	0.00380	0.0186
Average	0.0104	0.293	0.0104	0.164	0.0104	0.131
Stdev	0.0198	0.778	0.0198	0.262	0.0198	0.225
p(t-test)		2.6E-10		1.5E-21		7.0E-18
Min	2.35E-6	1.99E-6	2.35E-6	3.61E-6	2.35E-6	5.32E-6
Max	0.187	4.05	0.187	0.819	0.187	0.718
n (Samp)	315	28	315	25	315	18
n (Patient)	315	28	315	25	315	18

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	0.00373	0.0167	0.00373	0.00910	0.00373	0.00519
Average	0.0174	0.0349	0.0174	0.0310	0.0174	0.0149
Stdev	0.0667	0.0446	0.0667	0.0465	0.0667	0.0208
p(t-test)		0.16		0.31		0.89
Min	2.10E-6	8.74E-6	2.10E-6	2.10E-6	2.10E-6	7.08E-6
Max	0.819	0.197	0.819	0.197	0.819	0.0703
n (Samp)	172	32	172	27	172	14
n (Patient)	172	32	172	27	172	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.74	0.76	0.73	0.72	0.79	0.65	0.67	0.75	0.58
SE	0.045	0.054	0.053	0.050	0.055	0.061	0.065	0.068	0.083
p	1.4E-7	1.4E-6	1.9E-5	1.3E-5	1.5E-7	0.011	0.0092	1.7E-4	0.34
nCohort 1	137	315	172	137	315	172	137	315	172
nCohort 2	47	28	32	39	25	27	23	18	14
Cutoff 1	0.00712	0.0100	0.00589	0.00589	0.0100	0.00406	0.00473	0.00746	0.00214
Sens 1	70%	71%	72%	72%	72%	70%	74%	72%	71%
Spec 1	57%	69%	56%	54%	69%	52%	53%	59%	42%
Cutoff 2	0.00422	0.00593	0.00417	0.00260	0.00746	0.00171	0.00214	0.00523	0.000619
Sens 2	81%	82%	81%	82%	80%	81%	83%	83%	86%
Spec 2	52%	57%	52%	43%	59%	41%	42%	55%	38%
Cutoff 3	0.000619	3.59E-6	0.00214	0.000519	0.00260	0.000519	1.36E-5	0.00260	1.36E-5
Sens 3	91%	93%	91%	92%	92%	93%	91%	94%	93%
Spec 3	38%	1%	42%	37%	44%	37%	28%	44%	29%
Cutoff 4	0.0119	0.0115	0.0120	0.0119	0.0115	0.0120	0.0119	0.0115	0.0120
Sens 4	60%	68%	56%	54%	64%	44%	48%	61%	36%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	0.0167	0.0162	0.0162	0.0167	0.0162	0.0162	0.0167	0.0162	0.0162
Sens 5	55%	57%	50%	51%	56%	41%	43%	50%	29%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	0.0267	0.0235	0.0282	0.0267	0.0235	0.0282	0.0267	0.0235	0.0282
Sens 6	43%	50%	34%	41%	48%	30%	30%	44%	14%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	2.9	0.65	9.3	4.0	3.1	3.8	2.7	1.0	5.4
p Value	0.091	0.64	0.039	0.046	0.34	0.11	0.25	1.0	0.13
95% CI of	0.84	0.11	1.1	1.0	0.31	0.75	0.49	0.062	0.60
OR Quart2	10	4.0	77	16	30	19	15	16	48
OR Quart 3	2.2	2.4	8.0	2.2	6.4	3.2	3.4	6.4	3.1
p Value	0.22	0.21	0.057	0.30	0.090	0.17	0.15	0.089	0.33
95% CI of	0.62	0.60	0.94	0.50	0.75	0.61	0.63	0.75	0.31
OR Quart3	7.9	9.7	67	9.2	54	17	18	54	31
OR Quart 4	12	6.2	23	11	18	7.4	6.3	11	5.4
p Value	2.7E-5	0.0048	0.0030	2.8E-4	0.0057	0.012	0.023	0.023	0.13
95% CI of	3.8	1.7	2.9	3.1	2.3	1.6	1.3	1.4	0.60
OR Quart4	41	22	180	42	140	35	31	89	48

Table 18.9: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.

Tyrosine-protein kinase receptor UFO

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	4.93	4.61	4.93	4.08	4.93	3.89
Average	5.64	5.61	5.64	5.03	5.64	4.88
Stdev	4.24	4.64	4.24	4.13	4.24	4.05
p(t-test)		0.93		0.11		0.16
Min	0.0189	0.00291	0.0189	0.00439	0.0189	0.133
Max	31.0	28.6	31.0	24.8	31.0	17.0
n (Samp)	528	287	528	152	528	67
n (Patient)	137	287	137	152	137	67

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5.51	2.52	5.51	3.54	5.51	4.09
Average	6.27	3.44	6.27	5.29	6.27	5.23
Stdev	4.55	3.26	4.55	5.23	4.55	4.50
p(t-test)		3.1E-10		0.077		0.13
Min	0.00291	0.00597	0.00291	0.00439	0.00291	0.133
Max	31.0	16.8	31.0	28.6	31.0	17.8
n (Samp)	1187	109	1187	74	1187	45
n (Patient)	315	109	315	74	315	45

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	4.14	5.16	4.14	4.36	4.14	4.01
Average	5.01	5.93	5.01	5.28	5.01	4.89
Stdev	4.12	4.64	4.12	4.10	4.12	4.23
p(t-test)		0.0031		0.48		0.82
Min	0.00439	0.00291	0.00439	0.111	0.00439	0.0794
Max	31.0	28.6	31.0	24.8	31.0	17.0
n (Samp)	685	261	685	147	685	69
n (Patient)	172	261	172	147	172	69

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.48	0.29	0.56	0.45	0.40	0.52	0.43	0.42	0.48
SE	0.021	0.029	0.021	0.027	0.036	0.026	0.038	0.045	0.037
p	0.43	2.7E-13	0.0055	0.042	0.0043	0.36	0.077	0.072	0.58
nCohort 1	528	1187	685	528	1187	685	528	1187	685
nCohort 2	287	109	261	152	74	147	67	45	69
Cutoff 1	2.65	1.32	2.82	2.54	2.57	2.83	2.44	1.83	2.21
Sens 1	70%	71%	70%	70%	70%	70%	70%	71%	71%
Spec 1	24%	10%	36%	23%	21%	36%	22%	15%	27%
Cutoff 2	1.71	0.689	1.96	1.85	2.08	1.81	1.71	1.53	1.40
Sens 2	80%	81%	80%	80%	81%	80%	81%	80%	81%
Spec 2	16%	5%	25%	17%	17%	23%	16%	12%	18%

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
Cutoff 3	0.673	0.418	1.14	0.955	0.905	1.18	0.706	0.374	0.396
Sens 3	90%	91%	90%	90%	91%	90%	91%	91%	91%
Spec 3	6%	4%	15%	9%	7%	16%	7%	3%	7%
Cutoff 4	6.86	7.65	6.28	6.86	7.65	6.28	6.86	7.65	6.28
Sens 4	30%	12%	37%	23%	19%	33%	22%	24%	25%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	8.46	9.56	7.65	8.46	9.56	7.65	8.46	9.56	7.65
Sens 5	21%	6%	28%	15%	16%	19%	12%	16%	17%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	10.7	12.3	10.1	10.7	12.3	10.1	10.7	12.3	10.1
Sens 6	15%	2%	17%	10%	12%	12%	9%	13%	12%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.84	2.5	0.93	1.0	0.63	1.2	1.4	1.0	1.3
p Value	0.40	0.044	0.73	0.89	0.30	0.60	0.43	1.0	0.46
95% CI of	0.56	1.0	0.61	0.60	0.27	0.68	0.63	0.39	0.64
OR Quart2	1.3	6.1	1.4	1.8	1.5	1.9	3.0	2.6	2.7
OR Quart 3	0.82	4.0	1.2	1.5	1.6	1.3	1.5	1.1	1.1
p Value	0.35	0.0015	0.47	0.15	0.17	0.30	0.33	0.82	0.71
95% CI of	0.55	1.7	0.77	0.87	0.81	0.79	0.68	0.45	0.55
OR Quart3	1.2	9.2	1.8	2.5	3.2	2.2	3.2	2.8	2.4
OR Quart 4	1.2	10	1.5	1.7	2.2	1.3	2.0	1.9	1.2
p Value	0.39	1.5E-8	0.037	0.040	0.020	0.36	0.069	0.11	0.57
95% CI of	0.80	4.5	1.0	1.0	1.1	0.76	0.95	0.85	0.60
OR Quart4	1.8	22	2.3	2.9	4.2	2.1	4.2	4.4	2.5

Table 18.10: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.

Tyrosine-protein kinase receptor UFO

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	4.56	4.92	4.56	4.61	4.56	4.72
Average	5.46	5.96	5.46	5.44	5.46	5.81
Stdev	4.29	5.18	4.29	4.04	4.29	4.51
p(t-test)		0.16		0.97		0.50
Min	0.00439	0.00597	0.00439	0.00291	0.00439	0.0794
Max	31.0	28.6	31.0	24.1	31.0	20.8
n (Samp)	971	183	971	133	971	76
n (Patient)	249	183	249	133	249	76

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	5.16	1.80	5.16	2.64	5.16	3.62
Average	5.98	2.79	5.98	4.17	5.98	4.45
Stdev	4.54	3.12	4.54	4.09	4.54	3.90
p(t-test)		1.0E-7		0.0058		0.052
Min	0.00291	4.21E-6	0.00291	0.00597	0.00291	0.0794
Max	31.0	16.8	31.0	17.2	31.0	19.1
n (Samp)	1465	59	1465	49	1465	34
n (Patient)	380	59	380	49	380	34

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	4.12	5.64	4.12	5.06	4.12	4.95
Average	5.14	6.50	5.14	5.82	5.14	5.80
Stdev	4.28	5.32	4.28	4.15	4.28	4.36
p(t-test)		3.4E-4		0.10		0.22
Min	0.00439	0.00597	0.00439	0.00291	0.00439	0.133
Max	31.0	28.6	31.0	24.1	31.0	20.8
n (Samp)	1113	156	1113	118	1113	67
n (Patient)	274	156	274	118	274	67

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.51	0.25	0.57	0.51	0.36	0.56	0.52	0.39	0.55
SE	0.023	0.037	0.025	0.027	0.043	0.029	0.035	0.052	0.037
p	0.78	3.0E-11	0.0082	0.82	8.1E-4	0.028	0.61	0.034	0.18
nCohort 1	971	1465	1113	971	1465	1113	971	1465	1113
nCohort 2	183	59	156	133	49	118	76	34	67
Cutoff 1	2.08	0.889	2.72	2.84	1.47	3.25	2.71	2.02	2.71
Sens 1	70%	71%	71%	71%	71%	70%	71%	71%	70%
Spec 1	22%	8%	34%	31%	14%	40%	29%	19%	34%
Cutoff 2	1.46	0.464	1.74	2.38	0.745	2.53	2.18	1.53	1.90
Sens 2	80%	81%	80%	80%	82%	81%	80%	82%	81%
Spec 2	16%	5%	22%	25%	7%	31%	23%	14%	24%
Cutoff 3	0.773	0.258	0.800	1.19	0.374	1.37	1.40	0.776	1.34
Sens 3	90%	92%	90%	90%	92%	91%	91%	91%	91%
Spec 3	8%	3%	11%	13%	4%	18%	15%	7%	17%
Cutoff 4	6.78	7.40	6.47	6.78	7.40	6.47	6.78	7.40	6.47
Sens 4	33%	8%	39%	30%	24%	33%	29%	15%	31%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	8.40	9.18	7.95	8.40	9.18	7.95	8.40	9.18	7.95
Sens 5	27%	3%	33%	20%	14%	25%	21%	6%	22%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	10.7	12.1	10.5	10.7	12.1	10.5	10.7	12.1	10.5
Sens 6	19%	2%	22%	10%	8%	13%	14%	6%	16%
Spec 6	90%	90%	90%	90%	90%	90%	90%	90%	90%
OR Quart 2	0.49	2.7	0.78	1.5	0.30	1.3	0.94	2.4	1.0
p Value	0.0028	0.14	0.35	0.15	0.065	0.36	0.86	0.22	1.0
95% CI of	0.30	0.71	0.46	0.87	0.081	0.72	0.48	0.61	0.47
OR Quart2	0.78	10	1.3	2.5	1.1	2.4	1.8	9.2	2.1
OR Quart 3	0.65	3.0	1.1	1.3	1.3	1.9	1.00	3.7	1.5
p Value	0.059	0.097	0.80	0.34	0.53	0.028	0.99	0.044	0.23
95% CI of	0.42	0.82	0.65	0.76	0.57	1.1	0.51	1.0	0.77
OR Quart3	1.0	11	1.7	2.2	3.0	3.4	1.9	14	3.1
OR Quart 4	0.95	14	1.7	1.3	2.4	1.9	1.1	4.5	1.3
p Value	0.82	1.0E-5	0.019	0.34	0.024	0.028	0.88	0.020	0.47
95% CI of	0.63	4.4	1.1	0.76	1.1	1.1	0.55	1.3	0.64
OR Quart4	1.4	47	2.7	2.2	5.1	3.4	2.0	16	2.7

Table 18.11: Comparison of marker levels in urine samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).

Tyrosine-protein kinase receptor UFO

	sCr or UO		sCr only		UO only	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	4.17	5.43	3.72	2.10	3.89	5.61
Average	5.53	6.10	3.89	3.74	5.94	6.18
Stdev	5.31	4.95	2.93	3.82	5.68	4.75
p(t-test)		0.52		0.88		0.78
Min	0.296	0.00597	0.296	0.00597	0.476	0.00597
Max	28.2	28.6	10.4	16.8	28.2	28.6
n (Samp)	46	126	22	38	49	115
n (Patient)	46	126	22	38	49	115

	At Enrollment		
	sCr or UO	sCr only	UO only
AUC	0.55	0.45	0.54
SE	0.049	0.077	0.049
p	0.34	0.53	0.40
nCohort 1	46	22	49
nCohort 2	126	38	115
Cutoff 1	2.74	1.22	2.78
Sens 1	71%	71%	70%
Spec 1	41%	32%	39%
Cutoff 2	1.90	0.679	2.13
Sens 2	80%	82%	80%

	At Enrollment		
	sCr or UO	sCr only	UO only
Spec 2	35%	23%	33%
Cutoff 3	0.762	0.367	0.925
Sens 3	90%	92%	90%
Spec 3	17%	5%	12%
Cutoff 4	7.39	5.55	7.88
Sens 4	31%	29%	31%
Spec 4	72%	73%	71%
Cutoff 5	8.90	7.20	9.59
Sens 5	25%	21%	23%
Spec 5	80%	82%	82%
Cutoff 6	12.3	7.39	12.3
Sens 6	11%	18%	10%
Spec 6	91%	91%	92%
OR Quart 2	2.2	0.44	1.5
p Value	0.10	0.28	0.35
95% CI of	0.86	0.10	0.62
OR Quart2	5.8	1.9	3.9
OR Quart 3	1.7	9.3	2.0
p Value	0.25	0.054	0.16
95% CI of	0.69	0.96	0.77
OR Quart3	4.3	91	5.1
OR Quart 4	2.0	1.0	1.7
p Value	0.16	1.0	0.24
95% CI of	0.76	0.23	0.69
OR Quart4	5.0	4.3	4.4

Table 18.12: Comparison of the maximum marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values in urine samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.

Tyrosine-protein kinase receptor UFO

sCr or UO	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7.82	4.27	7.82	3.85	7.82	4.27
Average	8.83	6.59	8.83	5.68	8.83	6.05
Stdev	4.43	6.52	4.43	6.12	4.43	5.32
p(t-test)		0.0093		4.5E-4		0.0077
Min	2.71	0.341	2.71	0.142	2.71	0.157
Max	31.0	28.6	31.0	28.6	31.0	22.1
n (Samp)	137	47	137	39	137	23
n (Patient)	137	47	137	39	137	23

sCr only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7.87	4.98	7.87	4.27	7.87	4.98
Average	9.08	5.84	9.08	5.51	9.08	5.95
Stdev	4.98	5.09	4.98	4.85	4.98	4.98
p(t-test)		0.0011		6.1E-4		0.0099
Min	0.794	0.367	0.794	0.367	0.794	0.367
Max	31.0	22.1	31.0	22.1	31.0	22.1
n (Samp)	315	28	315	25	315	18
n (Patient)	315	28	315	25	315	18

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Median	7.10	3.79	7.10	3.50	7.10	4.84
Average	8.03	7.10	8.03	6.11	8.03	7.25
Stdev	4.59	7.62	4.59	7.40	4.59	7.14
p(t-test)		0.35		0.067		0.56
Min	0.611	0.341	0.611	0.142	0.611	0.157

UO only	0hr prior to AKI stage		24hr prior to AKI stage		48hr prior to AKI stage	
	Cohort 1	Cohort 2	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Max	31.0	28.6	31.0	28.6	31.0	25.5
n (Samp)	172	32	172	27	172	14
n (Patient)	172	32	172	27	172	14

	0hr prior to AKI stage			24hr prior to AKI stage			48hr prior to AKI stage		
	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only	sCr or UO	sCr only	UO only
AUC	0.31	0.28	0.36	0.25	0.27	0.30	0.27	0.28	0.37
SE	0.047	0.056	0.056	0.049	0.059	0.059	0.063	0.070	0.083
p	4.3E-5	1.3E-4	0.016	3.0E-7	6.2E-5	1.0E-3	1.9E-4	0.0016	0.13
nCohort 1	137	315	172	137	315	172	137	315	172
nCohort 2	47	28	32	39	25	27	23	18	14
Cutoff 1	2.03	2.99	1.90	1.96	2.27	1.63	3.13	3.62	3.18
Sens 1	70%	71%	72%	72%	72%	70%	74%	72%	71%
Spec 1	0%	7%	5%	0%	3%	3%	3%	11%	12%
Cutoff 2	1.22	1.03	1.19	1.13	1.96	1.02	1.96	3.10	1.90
Sens 2	81%	82%	81%	82%	80%	81%	83%	83%	86%
Spec 2	0%	0%	2%	0%	3%	1%	0%	7%	5%
Cutoff 3	0.585	0.794	0.370	0.367	0.401	0.341	0.472	0.367	1.63
Sens 3	91%	93%	91%	92%	92%	93%	91%	94%	93%
Spec 3	0%	0%	0%	0%	0%	0%	0%	0%	3%
Cutoff 4	10.4	11.1	9.35	10.4	11.1	9.35	10.4	11.1	9.35
Sens 4	21%	14%	25%	13%	12%	15%	13%	11%	21%
Spec 4	70%	70%	70%	70%	70%	70%	70%	70%	70%
Cutoff 5	11.8	12.9	11.4	11.8	12.9	11.4	11.8	12.9	11.4
Sens 5	19%	7%	25%	13%	4%	15%	13%	6%	21%
Spec 5	80%	80%	80%	80%	80%	80%	80%	80%	80%
Cutoff 6	14.4	15.8	14.0	14.4	15.8	14.0	14.4	15.8	14.0
Sens 6	15%	7%	19%	8%	4%	11%	9%	6%	14%
Spec 6	91%	90%	90%	91%	90%	90%	91%	90%	90%
OR Quart 2	0.44	0.49	0.34	1.2	0.66	1.0	0.65	0.50	0.33
p Value	0.17	0.41	0.12	0.75	0.65	1.0	0.65	0.57	0.34
95% CI of	0.14	0.087	0.084	0.35	0.11	0.24	0.10	0.044	0.033
OR Quart2	1.4	2.7	1.3	4.4	4.0	4.2	4.1	5.6	3.3
OR Quart 3	0.76	2.1	0.46	1.2	2.5	0.73	2.2	3.2	1.0
p Value	0.60	0.24	0.23	0.75	0.20	0.70	0.30	0.16	1.0
95% CI of	0.27	0.61	0.13	0.35	0.61	0.16	0.50	0.63	0.19
OR Quart3	2.1	7.3	1.6	4.4	9.8	3.5	9.4	16	5.2
OR Quart 4	3.9	4.0	2.7	7.8	4.9	5.6	5.3	5.0	2.6
p Value	0.0032	0.018	0.042	2.6E-4	0.016	0.0044	0.016	0.044	0.18
95% CI of	1.6	1.3	1.0	2.6	1.4	1.7	1.4	1.0	0.64
OR Quart4	9.7	13	7.0	23	18	18	21	24	11

[0295] While the invention has been described and exemplified in sufficient detail for those skilled in this art to make and use it, various alternatives, modifications, and improvements should be apparent without departing from the spirit and scope of the invention. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Modifications therein and other uses will occur to those skilled in the art. These modifications are encompassed within the spirit of the invention and are defined by the scope of the claims.

[0296] It will be readily apparent to a person skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

[0297] All patents and publications mentioned in the specification are indicative of the levels of those of ordinary skill in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

[0298] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[0299] Other embodiments are set forth within the following claims.

We claim:

1. A method for evaluating renal status in a subject, comprising:
performing an assay method configured to detect C-C motif chemokine 16, an assay method configured to detect C-C motif chemokine 14, and/or an assay method configured to detect Tyrosine-protein kinase receptor UFO on a body fluid sample obtained from the subject to provide one or more assay result(s); and
correlating the assay result(s) to the renal status of the subject.
2. A method according to claim 1, wherein said correlation step comprises correlating the assay result(s) to one or more of risk stratification, diagnosis, staging, prognosis, classifying and monitoring of the renal status of the subject.
3. A method according to claim 1, wherein said correlating step comprises assigning a likelihood of one or more future changes in renal status to the subject based on the assay result(s).
4. A method according to claim 3, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF).
5. A method according to one of claims 1-4, wherein said assay result(s) comprise a measured concentration of C-C motif chemokine 16, a measured concentration of C-C motif chemokine 14, and/or a measured concentration of Tyrosine-protein kinase receptor UFO.
6. A method according to one of claims 1-5, wherein said correlating step comprises combining a plurality of assay results using a function that converts the plurality of assay results into a single composite result.
7. A method according to claim 3, wherein said one or more future changes in renal status comprise a clinical outcome related to a renal injury suffered by the subject.
8. A method according to claim 3, wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within 30 days of the time at which the body fluid sample is obtained from the subject.
9. A method according to claim 8, wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within a

period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours.

10. A method according to one of claims 1-5, wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.

11. A method according to one of claims 1-5, wherein the subject is selected for evaluation of renal status based on an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, injury to renal function, reduced renal function, or ARF, or based on undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery, or based on exposure to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.

12. A method according to one of claims 1-5, wherein said correlating step comprises assigning a diagnosis of the occurrence or nonoccurrence of one or more of an injury to renal function, reduced renal function, or ARF to the subject based on the assay result.

13. A method according to one of claims 1-5, wherein said correlating step comprises assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF based on the assay result.

14. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of an injury to renal function in said subject.

15. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of reduced renal function in said subject.

16. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of acute renal failure in said subject.

17. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of a need for renal replacement therapy in said subject.

18. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of a need for renal transplantation in said subject.
19. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of an injury to renal function in said subject.
20. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of reduced renal function in said subject.
21. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of acute renal failure in said subject.
22. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal replacement therapy in said subject.
23. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal transplantation in said subject.
24. A method according to one of claims 1-5, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 72 hours of the time at which the body fluid sample is obtained.
25. A method according to one of claims 1-5, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 48 hours of the time at which the body fluid sample is obtained.
26. A method according to one of claims 1-5, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 24 hours of the time at which the body fluid sample is obtained.

27. A method according to one of claims 1-5, wherein the subject is in RIFLE stage 0 or R.
28. A method according to claim 27, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 72 hours.
29. A method according to claim 28, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.
30. A method according to claim 28, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.
31. A method according to claim 27, wherein the subject is in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.
32. A method according to claim 31, wherein the subject is in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.
33. A method according to claim 27, wherein the subject is in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.
34. A method according to claim 33, wherein the subject is in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.
35. A method according to one of claims 1-5, wherein the subject is in RIFLE stage 0, R, or I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.
36. A method according to claim 35, wherein the subject is in RIFLE stage I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.
37. A method according to claim 28, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 48 hours.

38. A method according to claim 29, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.
39. A method according to claim 30, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
40. A method according to claim 31, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.
41. A method according to claim 32, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
42. A method according to claim 33, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.
43. A method according to claim 34, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
44. A method according to claim 35, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
45. A method according to claim 36, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.
46. A method according to claim 28, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 24 hours.
47. A method according to claim 29, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.
48. A method according to claim 30, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.
49. A method according to claim 31, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.
50. A method according to claim 32, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.
51. A method according to claim 33, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.

52. A method according to claim 34, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.
53. A method according to claim 35, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.
54. A method according to claim 36, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.
55. A method according to one of claims 1-5, wherein the subject is not in acute renal failure.
56. A method according to one of claims 1-5, wherein the subject has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.
57. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained.
58. A method according to one of claims 1-5, wherein the subject has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.
59. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.
60. A method according to one of claims 1-5, wherein the subject has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.
61. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained.

62. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

63. A method according to one of claims 1-5, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

64. A method according to claim 63, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

65. A method according to claim 63, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

66. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 1.5-fold or greater increase in serum creatinine.

67. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

68. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience an increase of 0.3 mg/dL or greater in serum creatinine.

69. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 1.5-fold or greater increase in serum creatinine.
70. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.
71. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience an increase of 0.3 mg/dL or greater in serum creatinine.
72. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 1.5-fold or greater increase in serum creatinine.
73. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.
74. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience an increase of 0.3 mg/dL or greater in serum creatinine.
75. A method according to one of claims 1-5, wherein the subject has not experienced a 2-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.
76. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained.
77. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 2-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 2 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

78. A method according to one of claims 1-5, wherein the subject has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

79. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained.

80. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

81. A method according to one of claims 1-5, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 12 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

82. A method according to claim 81, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

83. A method according to claim 81, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

84. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 2-fold or greater increase in serum creatinine.

85. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.
86. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 2-fold or greater increase in serum creatinine.
87. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.
88. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 2-fold or greater increase in serum creatinine.
89. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.
90. A method according to one of claims 1-5, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.
91. A method according to claim 90, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.
92. A method according to claim 90, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.
93. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 3-fold or greater increase in serum creatinine.

94. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

95. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 3-fold or greater increase in serum creatinine.

96. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

97. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 3-fold or greater increase in serum creatinine.

98. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

99. A method according to one of claims 1-98, wherein the body fluid sample is a urine sample.

100. A method according to one of claims 1-98, wherein the body fluid sample is a blood, serum, or plasma sample.

101. A method according to one of claims 1-100, wherein the assay method comprises introducing the body fluid sample obtained from the subject into an assay instrument which (i) contacts the body fluid sample with one or more reagents which specifically bind for detection one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO; (ii) generates one or more assay results indicative of one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO in the urine sample, and (iii) uses the assay result(s) to assign the subject to a predetermined subpopulation of individuals having a known predisposition of a current or future acute renal injury or current or future acute renal failure.

102. A method according to claim 101, further comprising treating the subject based on the predetermined subpopulation of individuals to which the patient is assigned, wherein the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.

103. A method according to claim 101 or 102, wherein the subject does not have a current acute renal injury or acute renal failure, and the assay result is used to assign the subject to a predetermined subpopulation of individuals having a known predisposition of a future acute renal injury or future acute renal failure.

104. A method according to claim 103, wherein the future acute renal injury or future acute renal failure is within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours

105. A method according to claim 101 or 102, wherein the subject has a current acute renal injury or acute renal failure, and the assay result is used to assign the subject to a predetermined subpopulation of individuals having a known predisposition of future recovery from acute renal injury or acute renal failure.

106. A method according to claim 105, wherein the future recovery from acute renal injury or acute renal failure is within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours

107. A method according to claim 101 or 102, wherein the assay result is used to assign the subject to a predetermined subpopulation of individuals having a known predisposition of future persistence of an acute renal injury or acute renal failure.

108. A method according to claim 107, wherein the future persistence is over a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours.

109. A method according to claim 107 or 108, wherein the subject has an acute renal injury or acute renal failure at the time the body fluid sample is obtained.

110. Measurement of one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO for the evaluation of renal injury, particularly acute renal injury.

111. A kit, comprising:

reagents for performing one or more assays configured to detect one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO, and

a device which contains one or more encoded calibration curves for correlating results from performing said assay(s) to a concentration of one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO, wherein the concentration range of said calibration curve(s) comprise a normal concentration of one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO and a threshold concentration of one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO that indicates acute renal injury in a human.